

TEXTBOOK OF
DIABETES
by
**INDIAN
NATUROPATHS**

Healing the Root, Not Just Managing the Levels

Dr Vijay Raghavan | Dr Mandala Sathwik
Dr Jyoti Kumari Srivastava | Dr Pratibha Kumari



BlueRose ONE^{.com}
S t o r i e s M a t t e r

New Delhi • London

BLUEROSE PUBLISHERS

India | U.K.

Copyright © Dr Vijay Raghavan, Dr Mandala Sathwik,
Dr Jyoti Kumari Srivastava, Dr Pratibha Kumari 2026

All rights reserved by author. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of the author. Although every precaution has been taken to verify the accuracy of the information contained herein, the publisher assumes no responsibility for any errors or omissions. No liability is assumed for damages that may result from the use of information contained within.

BlueRose Publishers takes no responsibility for any damages, losses, or liabilities that may arise from the use or misuse of the information, products, or services provided in this publication.



BlueRoseONE[®]
S T O R I E S M A T T E R
New Delhi • London

For permissions requests or inquiries regarding this publication,
please contact:

BLUEROSE PUBLISHERS
www.BlueRoseONE.com
info@bluerosepublishers.com
+91 8882 898 898
+4407342408967

ISBN: 978-81-6744-366-3

Cover Design: Deepak Katheria
Typesetting: Manisha Rawat

First Edition: September 2026

Disclaimer

The contents of this book should **not** be considered a substitute for professional medical advice, diagnosis, treatment, or prescription. Readers are strongly advised to consult a qualified healthcare professional before making any decision related to diet, medication, lifestyle modification, or treatment of diabetes or any other medical condition.

The authors and publisher have made every effort to ensure the accuracy of the information presented at the time of publication; however, no guarantee is made regarding completeness, accuracy, or applicability in every individual case. The authors and publisher shall not be held responsible for any loss, injury, or adverse outcome arising from the use or misuse of the information contained in this book.

Healthcare knowledge and medical guidance continue to evolve. Readers are encouraged to use this book as a guide for understanding and discussion, not as a replacement for individualised medical care.

Prologue

For most of human history, what we now call “diabetes” was a death sentence wrapped in mystery. Ancient physicians in India, China, Greece, and the Middle East described a wasting illness marked by sweet urine and unquenchable thirst. They could recognise it; they could rarely change its course.

As the 20th century progressed, the story changed. Type 1 diabetes remained rare. Type 2 diabetes exploded.

The world urbanised. Diets shifted toward white flour, sugar, industrial oils, and ultra-processed products. Movement declined, sleep eroded, stress climbed. The body’s ancient metabolic machinery—designed for wild plants, occasional animal foods, fasting and feasting, and constant low-level movement—was dropped into a world of elevators, screens, and supermarkets.

Allopathic medicine did what it knows best: it fought. It developed sulfonylureas, biguanides, thiazolidinediones, DPP-4 inhibitors, GLP-1 agonists, SGLT2 inhibitors, statins, ACE inhibitors, stents, lasers, dialysis units, and transplant programs. It launched large trials and demonstrated that tighter control of glucose and blood pressure can delay blindness, kidney failure, and amputations.

In other words, allopathy perfected a combative model of diabetes care:

- Identify the biochemical enemy (high glucose, high blood pressure, high LDL).
- Attack with increasingly sophisticated drugs and procedures.
- Hold the line as long as possible.

This combative allopathic approach is often acutely curative (saving a life in ketoacidosis, stabilising a heart attack, treating severe infection), and sometimes partially curative (resolving a specific

complication, removing a gangrenous foot, opening a blocked artery). It is also frequently heroic. Many lives in intensive care units, operating theatres, and emergency rooms testify to that.

What it has not done is stop the tide. Each year, more people become diabetic. Each year, more live longer with more pills, more procedures, and more hidden suffering.

Somewhere along the way, the system quietly lowered its ambitions. It stopped asking, with any seriousness:

- ✓ Why are we getting so sick in the first place? And what would it mean to actually restore health, not just manage disease?

That is where this book takes a different path.

Two Ways of Seeing Diabetes: Pathogenesis vs Salutogenesis

Allopathic medicine, by design, is pathogenesis-focused: it studies how disease develops and how to combat it. This focus has given us insulin, antibiotics, and life-saving surgeries. But when pathogenesis is the only lens, the conversation shrinks to:

- What drug blocks this pathway?
- What procedure corrects this lesion?
- What number (HbA1c, LDL, BP) can we push into target?

Naturopathy brings a different, complementary lens: salutogenesis—the science of how health is created and sustained.

Salutogenesis does not ask, “What drug fights this disease?” It asks:

- What conditions allow this person to remain healthy despite risk?
- What food patterns, movement, relationships, sleep rhythms, emotional supports, and environments generate resilience?
- How can we build those conditions, deliberately, even in a modern world?

From a naturopathic viewpoint, type 2 diabetes is not merely a localised β -cell failure or isolated insulin resistance. It is a system-level breakdown of health-creating forces:

- Food has shifted from whole to ultra-processed.
- Movement has shifted from continuous to sporadic.
- Stress has shifted from acute to chronic.
- Sleep has shifted from rhythmic to chaotic.
- Social and environmental toxins (chemical, emotional, informational) have multiplied.

In this paradigm, drugs are **supporting actors**. The main characters are food, movement, sleep, stress physiology, microbiome ecology, and the web of meaning and connection in which a person lives. Diabetes cannot be “cured” by biochemistry alone if **everyday life** remains essentially toxic to the body’s regulatory systems.

Allopathy and Naturopathy: Enemies or Allies?

This book does not preach a childish war between “modern medicine” and “naturopathic medicine.” It proposes a **division of labour**:

Allopathy is at its best when it is **combative and acutely curative**:

- Stabilising crises,
- Preventing imminent organ loss,
- Correcting structural problems,
- Providing time.

Naturopathy is at its best when it is **preventive, curative in the deeper sense, and health-restorative**:

- Rebuilding nutrient status and mitochondrial function,
- Healing the gut and lowering inflammatory load,
- Reversing insulin resistance at its roots,
- Normalising weight, cholesterol, and blood pressure through lifestyle rather than lifelong polypharmacy,

- Re-establishing salutogenic conditions so that **health emerges** rather than disease being continually suppressed.

Viewed this way, ignoring naturopathic tools in diabetes care is not “scientific restraint.” It is **clinical myopia**.

What This Book Attempts

This textbook is not neutral. It is an **intervention**.

It has three explicit aims:

1. **To expose the limits and unintended harms of a drug-first, number-chasing model of diabetes care.**

We will look unflinchingly at side-effect profiles, overtreatment trials, and the ways in which “good control” on paper can coexist with deep biological distress.

2. **To synthesise modern biomedical science with the principles of naturopathy.**

Each chapter will show how mechanisms we now understand—insulin signalling, lipotoxicity, oxidative stress, incretin biology, microbiome shifts—map directly onto traditional naturopathic insights about food, fasting, movement, sleep, stress, and environment.

3. **To offer clinicians and serious patients a practical roadmap for:**

- Preventing type 2 diabetes in high-risk individuals,
- Inducing remission or deep medication reduction in established type 2 diabetes,
- Supporting people with type 1 and advanced type 2 to live with fewer complications and better quality of life through intensive lifestyle and naturopathic care.

You will notice a deliberate stylistic choice: we use strong language—about “toxic food environments,” “pharmacological

whips,” and “metabolic sabotage.” This is intentional. The current crisis is not neutral; it does not deserve neutral language.

At the same time, we honour what allopathic medicine has truly achieved and continues to achieve. If you have type 1 diabetes, insulin is not optional. If you are in diabetic ketoacidosis or septic shock, you need an ICU, not a salad and a meditation app. The cure-seeking mistake has never been the existence of these tools; it has been using them as the primary answer to a lifestyle-driven condition, while the causes remain untouched.

Your Role as Reader

Whether you are a clinician, a student, or a person living with diabetes, this book invites you into a different relationship with the disease:

- ✓ Not as a lifelong sentence to escalating medication,
- ✓ But as a complex, often reversible response to a mismatched way of living.

As you move through the chapters, you will see:

How allopathic drugs for diabetes work—and where they fail.

How naturopathic strategies—food patterns, herbal medicines, nutraceuticals, movement, sleep, stress work, environmental clean-up—map to real biological mechanisms and real outcome data.

How can an integrated protocol be built that uses the best of both worlds without pretending they are equivalent?

Most of all, you will be asked to shift your central question from:

“How do we fight this disease more aggressively?”

to:

“How do we rebuild a life and an internal environment in which health, not diabetes, is the natural outcome?”

That is the essence of Naturopathy. That is the promise of naturopathic, restorative diabetes care. And that is the journey this book is asking you to join—for the next few hundred pages, and, more importantly, for the rest of your professional and personal life.

Contents

1. Allopathic Concept of Diabetes	1
2. Anti-Diabetic Medications and Their Broader Biological Effects	18
3. Naturopathic Concept of Diabetes	73
4. Metabolism of Glucose: The Crucial Role of Minerals	85
5. Sugar and Health: A Naturopath's Viewpoint	95
6. Sugar and Cancer	105
7. Diabetic Nephropathy	114
8. Heating of Food and AGE Products in Diabetes	123
9. Artificial Sweeteners and Diabetes: Helpful Substitutes or Metabolic Distractions?	133
10. Healthy Sweeteners: Realistic Expectations	143
11. Refined Foods	150
12. Why a High-Carb Diet Can Be Disastrous to Metabolic Health?	158
13. HFCS – High Fructose Corn Syrup: Cheap Sweetness, expensive Metabolism	164
14. Trans Fats, Vegetable Oils, Margarine, and Vanaspati: Industrial Fats in a Metabolically Vulnerable Population	172
15. Soft Drinks, Sweetened Beverages, and Juices: Liquid Sugar in Disguise	180
16. Commercial Pasteurised Dairy Products: Industrial Milk vs. Real Food	186
17. Raw Organic Grass-Fed Dairy and Diabetes	196

18. Energy and Protein Bars and Diabetes: Ultra-Processed “Health Foods” in Clinical Disguise	204
19. Genetically Modified Soy and Diabetes: Industrial Ingredient or Real Food?	212
20. Animal Products and Farm-Raised Fish: When “Protein” Becomes a Metabolic Trap.....	221
21. Butter, Coconut Oil, and Hemp Oil: Natural Fats vs Industrial Chemistry.....	228
22. Oils in Your Kitchen: Stop Frying Your Metabolism.....	237
23. Organic Dark Leafy Greens: The Missing Pharmacology in Diabetes Care	245
24. Sprouted Grains: What Industrial Diabetes Care Forgot to Tell You About Wheat and Rice.....	254
25. Herbal Medicines for Diabetes Management.....	262
26. Nutraceuticals for Diabetes Management: Filling the Gaps Conventional Care Ignores.....	273
27. Scientific and Curative Treatment of Diabetes: From Lifelong “Management” to Genuine Remission.....	284
28. Diabetes Eating Plan: Food as First-Line, Not Afterthought ...	296
29. The Diabetes Protocol: Naturopathic Framework.....	308
30. 30 Day Diabetes Protocol—Take the Challenge.....	316
Epilogue.....	325

Allopathic Concept of Diabetes

The Nature and Types of Diabetes

Definition

The Indian Council of Medical Research (ICMR) defines diabetes mellitus as:

“A syndrome of multiple aetiologies characterised by chronic hyperglycaemia with disturbances of carbohydrate, fat, and protein metabolism resulting from defects in insulin secretion, insulin action, or both. This disorder is often associated with long-term complications involving organs such as the eyes, kidneys, nerves, heart, and blood vessels.”

(ICMR, 2018)

This definition reflects the dominant allopathic view: diabetes is framed primarily as a biochemical disorder (hyperglycaemia) to be “managed” numerically, largely with drugs, rather than as a complex disturbance of lifestyle, environment, stress biology, and whole-person physiology. As a result, the mainstream system often chases blood glucose targets while leaving the deeper metabolic distress that fuels diabetes only partially addressed.

Classification

According to the ADA and the World Health Organization (WHO), diabetes is classified into four major types (ADA, 2024; WHO, 2019):

1. *Type 1 diabetes*

Type 1 diabetes is primarily due to autoimmune-mediated destruction of pancreatic beta cells, resulting in absolute insulin deficiency and thus requiring insulin for good health and survival. While type 1 diabetes is also on the increase, the actual number of people with type 1 diabetes in India is, relatively speaking, still small.

2. *Type 2 diabetes*

Type 2 diabetes accounts for over 90–95% of all diabetes cases and is characterised by insulin resistance and/or abnormal insulin secretion. The global “epidemic” of diabetes is driven largely by type 2 disease, closely linked with rapid urbanisation, physical inactivity, ultra-processed food environments, chronic stress, and environmental toxins. Yet allopathic practice typically responds not with deep lifestyle restructuring but with progressive drug layering.

3. *Slowly Evolving Immune-Mediated Diabetes*

A slowly progressive form of immune-mediated diabetes is recognised, most often in adults who initially appear to have type 2 diabetes but, on closer testing, show pancreatic autoimmunity.

This has commonly been labelled “latent autoimmune diabetes in adults” (LADA). The term “latent” was used to distinguish this slower onset from rapid-onset type 1 diabetes in adults, but these patients actually have overt diabetes with a gradual autoimmune β -cell failure, not a hidden disease (Ravikumar et al., 2023; Tuomi et al., 2014). A similar phenotype has been described in children and adolescents presenting as type 2 diabetes but with islet autoantibodies; this is termed “latent autoimmune diabetes in youth” (LADY) (Dabelea et al., 2014).

4. *Gestational diabetes mellitus (GDM)*

Glucose intolerance first recognised during pregnancy, associated with adverse maternal and fetal outcomes and increased future risk of type 2 diabetes for both mother and child. Standard care again leans quickly toward pharmacologic control of glycaemia, while broader nutrition, sleep, stress, and toxin-exposure patterns often receive cursory attention.

5. *Other specific types*

This group includes monogenic diabetes (e.g., MODY), pancreatic diabetes (e.g., chronic pancreatitis, cystic fibrosis), endocrinopathies, and drug- or chemical-induced diabetes (e.g., glucocorticoids, certain antipsychotics). Ironically, some medications used within the same allopathic model can themselves induce or worsen diabetes.

In subsequent chapters, we will examine how naturopathic and integrative approaches conceptualise these same diabetes subtypes, and how intensive lifestyle-based strategies may modify risk and progression.

Differentiating Type 1 and Type 2 Diabetes (Clinical Features)

Feature	Type 1 diabetes	Type 2 diabetes
Age at diagnosis	Often childhood/adolescence; can occur in adults	Usually post-pubertal; most common in mid-to late life
Family history (first-degree)	Less common	Common
Ketosis at diagnosis	Common, especially in younger patients	Rare
Markers of insulin resistance	Typically absent	Common (central obesity, hypertension, dyslipidaemia)

C-peptide	Low/absent β -cell reserve	Preserved (at least early in disease)
Pancreatic autoantibodies	Often present	Usually absent

(ADA, 2024; Ravikumar et al., 2023)

This table reflects how allopathic medicine classifies patients for drug decision-making. It does not, by itself, engage with upstream determinants such as dietary patterns, sleep, psychosocial stress, microbiome disruption, and environmental exposures that are central to a naturopathic understanding of metabolic disease.

In subsequent chapters, we will explore how naturopathic frameworks differentiate and address these clinical patterns using food, movement, stress modulation, and natural agents as primary tools rather than afterthoughts.

Diagnostic Criteria for Diabetes and Prediabetes

Diagnostic thresholds are largely aligned across ADA and WHO (ADA, 2024; WHO, 2019):

Diabetes (any one test on two separate occasions, or with classic symptoms):

- Fasting plasma glucose (FPG) ≥ 126 mg/dL (7.0 mmol/L)
- 2-h plasma glucose ≥ 200 mg/dL (11.1 mmol/L) during 75 g OGTT
- Random plasma glucose ≥ 200 mg/dL (11.1 mmol/L) with symptoms
- HbA1c $\geq 6.5\%$ (using a standardized assay)

Prediabetes

- Impaired fasting glucose (IFG): FPG 100–125 mg/dL (5.6–6.9 mmol/L)

- Impaired glucose tolerance (IGT): 2-h OGTT 140–199 mg/dL (7.8–11.0 mmol/L)
- HbA1c 5.7–6.4%

These cut-offs are operational, based on risk of microvascular complications; they do not identify a sharp biological threshold. Yet, in the allopathic model, they are treated as rigid switches that trigger a cascade of drug prescriptions. A person can cross a numerical line by a single point and suddenly be labelled “diabetic,” frequently funnelled into life-long pharmacotherapy, even when intensive, supervised lifestyle and naturopathic interventions might reverse or significantly improve the underlying process (Zhang et al., 2023; Goldenberg et al., 2021).

Later chapters will examine how naturopathic practice uses these numbers as guides—not dictators—within a broader vision of metabolic restoration rather than life-long dependence on glucose-lowering drugs.

Monitoring and Follow-up in Conventional Care

Standard allopathic diabetes care emphasises (ADA, 2024; ICMR, 2018):

- **Glycaemic monitoring:** FPG and postprandial or random glucose; HbA1c every 3–12 months depending on control.
- **Complication screening:** Annual or more frequent assessment for retinopathy, nephropathy, neuropathy, peripheral vascular disease, and coronary artery disease.
- **Risk factor modification:** Blood pressure, lipids, smoking cessation, weight management, and foot care.

(ADA, 2024; ICMR, 2018)

These practices have unquestionably helped reduce rates of blindness, renal failure, and amputations in many settings (UKPDS Group, 1998; ADVANCE Collaborative Group, 2008). However, they are embedded in a framework that is overwhelmingly

medication-centric. Diet, movement, sleep, stress, environmental toxicity, community support, and mind-body practices are typically relegated to brief counselling notes, while prescriptions receive the bulk of clinical time and financial incentive.

The result is a system that monitors biochemical fallout while tolerating the very conditions that generate it—a chronic “management” paradigm rather than a genuine healing model.

In forthcoming chapters, we will contrast this surveillance-heavy, drug-centred approach with naturopathic models that prioritise early, intensive lifestyle transformation, therapeutic nutrition, and natural agents to reduce or sometimes even withdraw medications under professional supervision.

Allopathic Pharmacotherapy of Type 2 Diabetes: Benefits and Limitations

Conventional (“allopathic”) management of type 2 diabetes is dominated by oral glucose-lowering drugs and insulin. These agents can reduce blood glucose and HbA1c and lower the risk of some complications, especially microvascular endpoints. At the same time, they bring substantial side-effect profiles, polypharmacy, and a creeping normalisation of life-long drug dependence—even when some individuals could achieve marked improvement or remission through intensive lifestyle and integrative care.

Major Drug Classes and Key Adverse Effects

Below is a more evidence-aligned summary of common antidiabetic drug classes and important adverse effects with long-term use. Not all side effects are equally frequent or severe, but they are clinically relevant and often under-discussed with patients.

Class	Examples	Key disadvantages / serious adverse effects (selected)
Alpha-glucosidase inhibitors	Acarbose, Miglitol, Voglibose	Flatulence, diarrhoea, abdominal discomfort (Zhong et al., 2005); rare hepatotoxicity (Zhang et al., 2016); poor tolerability leads to discontinuation in many patients.
Biguanides	Metformin	Gastrointestinal intolerance (nausea, diarrhoea); risk of vitamin B12 deficiency (Hurley-Kim et al., 2023); rare but serious lactic acidosis , particularly in advanced kidney or liver disease and severe heart failure (sendil et al., 2020).
Sulfonylureas	Gliclazide, Glibenclamide (glyburide), Glimepiride	Hypoglycaemia (sometimes severe) (Douros et al., 2017).; weight gain (Azoulay & Suissa et al., 2017); risk of cardiovascular events debated in older agents; requires caution in older adults and those with kidney impairment (Holman et al., 2008;
Meglitinides	Repaglinide, Nateglinide	Hypoglycaemia risk (though generally less than older sulfonylureas); weight gain; frequent dosing burden; asymptomatic hepatotoxicity (NCBI, 2026).
Thiazolidinediones (TZDs)	Pioglitazone, Rosiglitazone	Weight gain , fluid retention (Vallon et al., 2009) and heart failure risk (Nissen & Wolski, 2007); bone fractures (especially in women) (Kaku & Hashiramoto et al., 2011); concerns about bladder cancer with pioglitazone (data mixed); possible macular oedema (Ferwana et al., 2013).
DPP-4 inhibitors	Sitagliptin, Saxagliptin, Alogliptin, Linagliptin	Generally, weight-neutral with modest HbA1c reduction; rare pancreatitis ; possible joint pain; saxagliptin and alogliptin linked to increased risk of heart failure hospitalisation in some trials (Scirica et al., 2013; Zannad et al., 2015).
GLP-1 receptor agonists	Exenatide, Liraglutide, Semaglutide	Nausea, vomiting (Alhazmi and le Roux et al., 2026), diarrhoea; risk of gallbladder disease (He et al., 2022).

SGLT2 inhibitors	Dapagliflozin, Canagliflozin, Empagliflozin	Genital mycotic and urinary infections; volume depletion, hypotension; euglycaemic ketoacidosis ; rare Fournier's gangrene; initial signal for fractures and amputations with canagliflozin (Unnikrishnan et al., 2018; Neal et al., 2017).
Insulin (all types)	Human insulin, analogues	Hypoglycaemia (potentially severe or fatal); weight gain (Carlson et al., 1993); injection-site problems; adherence burden; some observational signals of increased cancer risk at high doses (Colmers et al., 2012), though causality is uncertain and confounded by severity of disease

Large trials confirm that several of these drugs reduce microvascular complications and, for some newer agents (GLP-1 receptor agonists, SGLT2 inhibitors), also reduce certain cardiovascular and kidney outcomes in high-risk patients (Zinman et al., 2015; Marso et al., 2016; Perkovic et al., 2019). The problem is not that these medicines exist, but that they are frequently deployed as the default, life-long solution in a system that invests far less energy and resources into dismantling the root causes of insulin resistance.

Two key realities are often glossed over:

1. **They do not cure diabetes.** Most people require progressive intensification of therapy over time, suggesting that the underlying metabolic disease often progresses despite tighter glucose control (Holman et al., 2008).
2. **Over-intensive pharmacologic control can cause harm.** In the ACCORD trial, aggressive HbA1c targets achieved through multiple drugs and insulin were associated with higher mortality, likely related to hypoglycaemia, weight gain, and complex interactions in high-risk patients (ACCORD Study Group, 2008).

From a naturopathic and integrative perspective, this is a loud warning: chasing ever-lower glucose with ever-more drugs, while

leaving diet, movement, sleep, stress and toxic exposures insufficiently transformed, can be self-defeating.

In the chapters ahead, we will present naturopathic strategies—including therapeutic nutrition, movement, stress modulation, botanicals, and mind-body practices—that aim to reduce drug burden safely, always under professional supervision and without abrupt discontinuation of necessary medications.

Insulin in Type 2 Diabetes: Essential Tool or Escalating Trap?

Insulin is non-negotiable and life-saving in type 1 diabetes and in specific acute or advanced scenarios in type 2 diabetes. In these situations, withholding insulin is dangerous. However, in typical type 2 diabetes, chronic reliance on escalating insulin doses can:

- Promote weight gain, thereby worsening insulin resistance.
- Increase hypoglycaemia risk, leading to falls, arrhythmias, cognitive impairment, and fear of physical activity or flexible eating.
- Be associated, in observational data, with higher cardiovascular events and mortality compared with some non-insulin regimens, although confounding by disease severity is substantial (Currie et al., 2013).

Insulin is not inherently “toxic”; the deeper issue is a therapeutic culture that uses higher and higher doses of insulin to compensate for an insufficiently changed lifestyle. This creates a vicious cycle: more insulin → more weight gain → more resistance → more insulin.

A naturopathic orientation, in contrast, treats insulin as a critical safety tool when needed, but works aggressively on nutrition, movement, stress, and other root causes to reduce insulin doses where medically possible and safe.

Later chapters will outline structured, supervised naturopathic and lifestyle programs designed to improve insulin sensitivity and, in

appropriate cases, allow careful tapering of insulin under medical guidance.

Allopathic Diet for Type 2 Diabetes: Scientific or Self-Defeating?

Conventional dietary advice (e.g., ICMR, ADA) has typically recommended:

- **High-carbohydrate intake** ($\approx 45\text{--}65\%$ of energy), preferentially from whole grains, legumes, fruits, and vegetables.
- Low saturated fat, moderate protein, and controlled total calories.

This approach has **some evidence** supporting cardiovascular benefits and flexibility (ADA, 2024; ICMR, 2018). Yet, for many insulin-resistant individuals, routinely prescribing high carbohydrate loads while simultaneously escalating glucose-lowering drugs is biologically contradictory.

Several limitations are increasingly recognised:

1. **High carbohydrate loads can drive medication dependence.** In insulin-resistant people, large carbohydrate intakes often demand more insulin or other medications simply to keep glucose within target ranges.
2. **Lower-carbohydrate approaches can outperform standard advice for some outcomes.** Randomised trials show that low-carbohydrate and low-carbohydrate–ketogenic diets can produce greater reductions in HbA1c, weight, and medication use—and, in some cases, remission of type 2 diabetes—compared with traditional high-carbohydrate, low-fat diets (Feinman et al., 2015; Goldenberg et al., 2021).
3. **A narrow focus on "calories in–calories out" misses food quality and metabolic signals.** Focusing solely on calories and glycaemic index may overlook ultra-processing, sugar-sweetened beverages, refined grains, food

addiction-like patterns, micronutrient density, and the hormonal regulation of appetite.

In practice, many standard diet plans:

- Fail to adequately eliminate ultra-processed foods, refined sugars, and industrial snack products that drive metabolic chaos.
- Leave patients chronically hungry and demoralised, with weight and glucose only controlled by ever-increasing pharmacotherapy rather than sustainable metabolic healing.

Thus, although conventional dietary guidance is presented as “scientific,” it frequently underutilises more intensive, whole-food, low-glycaemic, Mediterranean-style, or time-restricted eating strategies that have demonstrated the capacity to reduce medication needs and, for some, to induce remission (Lean et al., 2018; ADA, 2024).

A naturopathic stance insists that food is not a minor adjunct but the primary medicine in type 2 diabetes—precisely the opposite of the current pharmacocentric status quo.

Subsequent chapters will detail naturopathic nutritional strategies—including low-glycaemic, plant-rich, anti-inflammatory patterns, structured carbohydrate restriction, and mindful eating—along with evidence on their effects on glycaemia, weight, medication use, and quality of life.

From a critical, integrative standpoint, the central problem is not that allopathic treatments exist, but that they are **too often treated as the primary solution**, while their **side effects and the possibility of remission through non-pharmacological means are under-emphasised**. This justifies a serious re-examination of how diabetes is managed in clinical practice.

A naturopathic and integrative approach aims to:

- Use medications judiciously, particularly for acute safety and clearly defined indications.

- Prioritise root-cause interventions—food, movement, sleep, stress, environment, connection—from the very beginning.
- Seek, wherever medically possible, to reduce drug burden and dependency under professional supervision.

In the chapters that follow, we will systematically explore naturopathic approaches to diabetes—including therapeutic nutrition, botanicals, physical medicine, mind-body therapies, and environmental detoxification—alongside their current scientific evidence, clinical limitations, and integration with necessary conventional care.

References

1. ACCORD Study Group. (2008). Effects of intensive glucose lowering in type 2 diabetes. *New England Journal of Medicine*, 358(24), 2545–2559.
<https://doi.org/10.1056/NEJMoa0802743>
2. ADVANCE Collaborative Group. (2008). Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. *New England Journal of Medicine*, 358(24), 2560–2572. <https://doi.org/10.1056/NEJMoa0802987>
3. Alhazmi A and le Roux CW (2026) Do no harm: managing nausea and vomiting in GLP-1 based obesity therapies. *Front. Endocrinol.* 17:1788698.
<https://doi.org/10.3389/fendo.2026.1788698>
4. American Diabetes Association. (2024). 2. Classification and diagnosis of diabetes: Standards of care in diabetes—2024. *Diabetes Care*, 47(Suppl. 1), S16–S33.
<https://doi.org/10.2337/dc24-S002>
5. American Diabetes Association. (2024). 3. Prevention or delay of type 2 diabetes and associated comorbidities: Standards of care in diabetes—2024. *Diabetes Care*, 47(Suppl. 1), S34–S46. <https://doi.org/10.2337/dc24-S003>

6. American Diabetes Association. (2024). 9. Pharmacologic approaches to glycemic treatment: Standards of care in diabetes—2024. *Diabetes Care*, 47(Suppl. 1), S144–S169. <https://doi.org/10.2337/dc24-S009>
7. Azoulay, L., & Suissa, S. (2017). Sulfonylureas and the risks of cardiovascular events and death: A Methodological Meta-Regression Analysis of the observational studies. *Diabetes Care*, 40(5), 706–714. <https://doi.org/10.2337/dc16-1943>
8. Carlson, M. G., & Campbell, P. J. (1993). Intensive insulin therapy and weight gain in IDDM. *Diabetes*, 42(12), 1700–1707. <https://doi.org/10.2337/diab.42.12.1700>
9. Colmers, I. N., Bowker, S. L., Tjosvold, L. A., & Johnson, J. A. (2012). Insulin use and cancer risk in patients with type 2 diabetes: a systematic review and meta-analysis of observational studies. *Diabetes & metabolism*, 38(6), 485–506. <https://doi.org/10.1016/j.diabet.2012.08.011>
10. Currie, C. J., Peters, J. R., Tynan, A., Evans, M., Heine, R. J., Bracco, O. L., Zagar, T., & Poole, C. D. (2010). Survival as a function of HbA1c in people with type 2 diabetes: A retrospective cohort study. *The Lancet*, 375(9713), 481–489. [https://doi.org/10.1016/S0140-6736\(09\)61969-3](https://doi.org/10.1016/S0140-6736(09)61969-3)
11. Dabelea, D., Pihoker, C., Talton, J. W., D’Agostino, R. B., Jr., Fujimoto, W., Klingensmith, G. J., Lawrence, J. M., Linder, B., Marcovina, S. M., Mayer-Davis, E. J., Imperatore, G., & Dolan, L. M. (2011). Etiological approach to characterization of diabetes type: The SEARCH for Diabetes in Youth Study. *Diabetes Care*, 34(7), 1628–1633. <https://doi.org/10.2337/dc10-2324>
12. Douros, A., Yin, H., Yu, O. H. Y., Filion, K. B., Azoulay, L., & Suissa, S. (2017). Pharmacologic differences of sulfonylureas and the risk of adverse cardiovascular and hypoglycemic events. *Diabetes Care*, 40(11), 1506–1513. <https://doi.org/10.2337/dc17-0595>

13. Feinman, R. D., Pogozelski, W. K., Astrup, A., Bernstein, R. K., Fine, E. J., Westman, E. C., Accurso, A., Frassetto, L., Gower, B. A., McFarlane, S. I., Nielsen, J. V., Krarup, T., Saslow, L., Roth, K. S., Vernon, M. C., Volek, J. S., Wilshire, G. B., Dahlqvist, A., Sundberg, R., ... Worm, N. (2015). Dietary carbohydrate restriction as the first approach in diabetes management: Critical review and evidence base. *Nutrition*, 31(1), 1–13.
<https://doi.org/10.1016/j.nut.2014.06.011>
14. Ferwana, M., Firwana, B., Hasan, R., Al-Mallah, M. H., Kim, S., Montori, V. M., & Murad, M. H. (2013). Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies. *Diabetic medicine : a journal of the British Diabetic Association*, 30(9), 1026–1032.
<https://doi.org/10.1111/dme.12144>
15. GISED (Groupe d'Investigation et de Suivi des Effets des Doses d'Insuline). (2012). Insulin therapy and cancer risk in type 2 diabetes: A review of observational studies. *Diabetes & Metabolism*, 38(6), 485–492.
<https://doi.org/10.1016/j.diabet.2012.06.004>
16. Goldenberg, J. Z., Day, A., Brinkworth, G. D., Sato, J., Yamada, S., Jönsson, T., Beardsley, J., Johnson, J. A., & Thabane, L. (2021). Efficacy and safety of low and very low carbohydrate diets for type 2 diabetes remission: Systematic review and meta-analysis of published and unpublished randomized trial data. *BMJ*, 372, m4743.
<https://doi.org/10.1136/bmj.m4743>
17. He, L., Wang, J., Ping, F., Yang, N., Huang, J., Li, Y., Xu, L., Li, W., & Zhang, H. (2022). Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials. *JAMA internal medicine*, 182(5), 513–519.
<https://doi.org/10.1001/jamainternmed.2022.0338>

18. Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008). 10-year follow-up of intensive glucose control in type 2 diabetes. *New England Journal of Medicine*, 359(15), 1577–1589.
<https://doi.org/10.1056/NEJMoa0806470>
19. Hurley-Kim, K., Vu, C. H., Dao, N. M., Tran, L. C., McBane, S., Lee, J., & Sepassi, A. (2023). Effect of metformin use on vitamin B12 deficiency over Time (EMBER): a Real-World Evidence Database study. *Endocrine Practice*, 29(11), 862–867.
<https://doi.org/10.1016/j.eprac.2023.06.013>
20. Indian Council of Medical Research. (2018). *ICMR guidelines for management of type 2 diabetes*. New Delhi: ICMR. <https://medibulletin.com/wp-content/uploads/2018/05/ICMR.diabetesGuidelines.2018.pdf>
21. Kaku, K., & Hashiramoto, M. (2011). Thiazolidinediones and bone fractures. *Journal of diabetes investigation*, 2(5), 354–355. <https://doi.org/10.1111/j.2040-1124.2011.00142.x>
22. Lean, M. E. J., Leslie, W. S., Barnes, A. C., Brosnahan, N., Thom, G., McCombie, L., Peters, C., Zhyzhneuskaya, S., Al-Mrabeh, A., Hollingsworth, K. G., Rodrigues, A. M., Rehackova, L., Adamson, A., Sniehotta, F. F., Mathers, J. C., Ross, H., McIlvenna, Y., Stefanetti, R., Trenell, M., ... Taylor, R. (2018). Primary care-led weight management for remission of type 2 diabetes (DiRECT): An open-label, cluster-randomised trial. *The Lancet*, 391(10120), 541–551.
[https://doi.org/10.1016/S0140-6736\(17\)33102-1](https://doi.org/10.1016/S0140-6736(17)33102-1)
23. Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., Woo, V., Hansen, O., Holst, A. G., Pettersson, J., & Vilsbøll, T. (2016). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. *New England Journal of Medicine*, 375(19), 1834–1844.
<https://doi.org/10.1056/nejmoa1607141>

24. National Center for Biotechnology Information (2026). PubChem Compound Summary for CID 65981, Repaglinide. Retrieved July 31, 2026 from <https://pubchem.ncbi.nlm.nih.gov/compound/Repaglinide>.
25. Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondur, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017). Canagliflozin and cardiovascular and renal events in type 2 diabetes. *New England Journal of Medicine*, 377(7), 644–657. <https://doi.org/10.1056/NEJMoa1611925>
26. Nissen, S. E., & Wolski, K. (2007). Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. *New England Journal of Medicine*, 356(24), 2457–2471. <https://doi.org/10.1056/NEJMoa072761>
27. Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., Cannon, C. P., Capuano, G., Chu, P.-L., de Zeeuw, D., Greene, T., Levin, A., Pollock, C., Wheeler, D. C., Yavin, Y., ... Mahaffey, K. W. (2019). Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. *New England Journal of Medicine*, 380(24), 2295–2306. <https://doi.org/10.1056/NEJMoa1811744>
28. Ravikumar, V., Ahmed, A., & Anjankar, A. (2023). A Review on Latent Autoimmune Diabetes in Adults. *Cureus*, 15(10), e47915. <https://doi.org/10.7759/cureus.47915>
29. Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., Cavender, M. A., Udell, J. A., Desai, N. R., Mosenson, O., McGuire, D. K., Ray, K. K., Leiter, L. A., Raz, I., & SAVOR-TIMI 53 Steering Committee and Investigators. (2013). Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. *New England Journal of Medicine*, 369(14), 1317–1326. <https://doi.org/10.1056/NEJMoa1307684>

30. Sendil, S., Yarlagadda, K., Lawal, H., Nookala, V., & Shingala, H. (2020). Metformin Associated Lactic Acidosis in the Intensive Care Unit: A Rare Condition Mimicking Sepsis. *Cureus*, 12(7), e9119.
<https://doi.org/10.7759/cureus.9119>
31. Tuomi, T., Santoro, N., Caprio, S., Cai, M., Weng, J., & Groop, L. (2014). The many faces of diabetes: A disease with increasing heterogeneity. *The Lancet*, 383(9922), 1084–1094.
[https://doi.org/10.1016/S0140-6736\(13\)62219-9](https://doi.org/10.1016/S0140-6736(13)62219-9)
32. UK Prospective Diabetes Study (UKPDS) Group. (1998). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). *The Lancet*, 352(9131), 837–853.
[https://doi.org/10.1016/S0140-6736\(98\)07019-6](https://doi.org/10.1016/S0140-6736(98)07019-6)
33. Unnikrishnan, A. G., Kalra, S., Purandare, V., & Vasnawala, H. (2018). Genital Infections with Sodium Glucose Cotransporter-2 Inhibitors: Occurrence and Management in Patients with Type 2 Diabetes Mellitus. *Indian journal of endocrinology and metabolism*, 22(6), 837–842.
https://doi.org/10.4103/ijem.IJEM_159_17
34. Vallon, V., Hummler, E., Rieg, T., Pochynyuk, O., Bugaj, V., Schroth, J., Dechenes, G., Rossier, B., Cunard, R., & Stockand, J. (2009). Thiazolidinedione-induced fluid retention is independent of collecting duct alphaENaC activity. *Journal of the American Society of Nephrology : JASN*, 20(4), 721–729.
<https://doi.org/10.1681/ASN.2008040415>
35. World Health Organization. (2019). *Classification of diabetes mellitus*. Geneva: WHO.
<https://www.who.int/publications/i/item/classification-of-diabetes-mellitus>
36. Zannad, F., Cannon, C. P., Cushman, W. C., Bakris, G. L., Menon, V., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer,

- S., & Wilson, C. (2015). Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: A multicentre, randomised, double-blind trial. *The Lancet*, 385(9982), 2067–2076.
[https://doi.org/10.1016/S0140-6736\(14\)62225-X](https://doi.org/10.1016/S0140-6736(14)62225-X)
37. Zhang, L., Chen, Q., Li, L. et al. Alpha-glucosidase inhibitors and hepatotoxicity in type 2 diabetes: a systematic review and meta-analysis. *Sci Rep* 6, 32649 (2016).
<https://doi.org/10.1038/srep32649>
38. Zhang, Y., Yang, Y., Huang, Q., Zhang, Q., Li, M., & Wu, Y. (2023). The effectiveness of lifestyle interventions for diabetes remission on patients with type 2 diabetes mellitus: A systematic review and meta-analysis. *Worldviews on evidence-based nursing*, 20(1), 64–78.
<https://doi.org/10.1111/wvn.12608>
39. Zhong, L., Yang, J., Syed, J. N., Zhang, Y., Tian, Y., & Fu, X. (2024). Alpha-Glucosidase Inhibitors in Aging and Aging-Related Diseases: Clinical Applications and Relevant Mechanisms. *Aging and disease*, 16(6), 3505–3519.
<https://doi.org/10.14336/AD.2024.1477>
40. Zinman, B., et al. (2015) Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. *The New England Journal of Medicine*, 373, 2117-2128.
<https://doi.org/10.1056/NEJMoa1504720>

Anti-Diabetic Medications and Their Broader Biological Effects

i) Metformin: Chronic, Low-Grade Mitochondrial Poisoning in the Name of “Control”

Metformin is enthroned as the unquestioned first-line oral drug for type 2 diabetes in virtually every allopathic guideline. It is marketed to clinicians and patients as almost benign— “safe,” “well tolerated,” and “protective.” Yet its primary target is not some peripheral, disposable pathway; it is the mitochondrion, the very engine of cellular life. The cornerstone of modern diabetes pharmacotherapy is, in plain mechanistic terms, chronic, low-grade interference with cellular respiration.

Mitochondrial Mechanism: Controlled Respiratory Poisoning as Therapy

Metformin is a positively charged small molecule, avidly taken up into cells and then concentrated into mitochondria due to the strong negative potential across the inner mitochondrial membrane. Experimental work suggests intramitochondrial levels can reach ~1,000-fold higher than extracellular concentrations, as predicted by the Nernst equation (Bridges et al., 2014).

At these concentrations, metformin:

- **Partially inhibits respiratory Complex I (NADH : ubiquinone oxidoreductase)**, reducing electron flux, proton pumping, and oxygen consumption (Bridges et al., 2014; Andrzejewski et al., 2018).

- **Suppresses oxidative phosphorylation and ATP synthesis**, raising AMP/ATP and ADP/ATP ratios and signalling “energy stress” in hepatocytes.
- **Secondarily activates AMP-activated protein kinase (AMPK)** and related AMP-sensitive pathways, damping gluconeogenic gene expression and hepatic glucose production (Foretz et al., 2019; LaMoia, & Shulman, 2021).
- **Alters mitochondrial redox balance**, including effects on the mitochondrial glycerol-3-phosphate dehydrogenase (mGPD) shuttle, constraining gluconeogenesis from specific substrates and increasing lactate generation (Madiraju et al., 2014).

This is not a subtle vitamin-like modulation. Functionally, metformin behaves as a **“gentle respiratory poison”**: electron transport is not abolished, but deliberately blunted. Long-term therapy, therefore, amounts to controlled, systemic dampening of mitochondrial energy metabolism in the liver and other tissues.

Allopathic practice treats this as routine “management” of hyperglycaemia; a naturopathic lens asks the obvious question: why has medicine normalised lifelong, population-level mitochondrial inhibition instead of urgently rebuilding metabolic health at its roots?

Clinical Toxicity: Lactic Acidosis and B12 Deficiency as Predictable Consequences

Allopathic discourse often reassures patients that serious adverse events with metformin are “rare,” implying they are almost irrelevant. Mechanistically, they are the logical extension of chronic mitochondrial interference in vulnerable contexts.

Metformin-Associated Lactic Acidosis (MALA)

Metformin-associated lactic acidosis (MALA) is infrequent but can be **catastrophic and fatal**. Risk skyrockets when the drug’s mitochondrial inhibition collides with:

- Advanced kidney dysfunction
- Liver failure
- Sepsis, hypoxia, or decompensated heart failure
- Any condition with hypoperfusion or impaired lactate clearance

(DeFronzo et al., 2015; Inzucchi et al., 2014).

In other words: in precisely the multi-morbid, fragile patients who populate diabetes clinics, metformin’s “gentle” inhibition of respiration can tip into full-blown metabolic collapse.

Vitamin B12 Deficiency and Neuropathy

Metformin **consistently lowers vitamin B12 levels** in a dose- and duration-dependent fashion (de Jager et al., 2010; ADA, 2024). Clinically, this can translate into:

- Peripheral neuropathy
- Macrocytic anaemia
- Cognitive symptoms

All in a population already prone to neuropathy. Routine allopathic practice often fails to screen aggressively for B12 deficiency, allowing preventable nerve damage to accumulate while “glucose control” is celebrated.

These are not random side notes; they reflect exactly what you would expect when systemic mitochondrial metabolism is chronically manipulated.

A naturopathic, root-cause-oriented paradigm would never accept silent B12 depletion and mitochondrial stress as an acceptable collateral cost of ignoring intensive nutrition and lifestyle reform.

Metformin and Cancer: Double-Edged Metabolic Stress

Allopathic discourse often reassures patients that serious adverse events with metformin are “rare,” implying they are almost

irrelevant. Mechanistically, they are the logical extension of chronic mitochondrial interference in vulnerable contexts.

Embryogenesis and Development: Animal Alarms vs. Human Data

Animal and In Vitro Evidence: Development Under Mitochondrial Siege

Developmental biology models repeatedly show that when you inhibit mitochondrial function during critical windows, embryos suffer:

- Mouse and in vitro studies report dose-dependent impairment of early embryonic development, and early developmental arrest with metformin exposure (Nayak et al. 2020).
- Zebrafish and other aquatic models display reduced hatching, morphological abnormalities, and altered developmental gene expression after metformin exposure (Lin et al., 2025).

These findings are mechanistically consistent with complex I inhibition, ATP depletion, and aberrant AMPK activation interfering with tightly choreographed developmental programs (Faure et al., 2018; Salomäki et al., 2013).

Human Pregnancy Data: No Major Malformations, but Metabolic Reprogramming?

Human data are more reassuring on **structural malformations**:

- Most observational and trial data do not show an increased rate of major congenital anomalies with first-trimester metformin exposure (Rowan et al., 2008; Cassina et al., 2014; Gui et al., 2013).
- Metformin is routinely used in gestational diabetes and PCOS, often perceived as a safer oral alternative to insulin.

However, emerging signals challenge the notion of harmlessness:

- Some cohorts show differences in birth weight or growth patterns.

- Evidence suggests in utero metformin exposure may alter offspring adiposity and metabolic risk later in life (Hanem et al., 2019; Salomäki et al., 2013).

In other words, even when gross anatomy appears unaffected, **fetal energy metabolism and long-term metabolic programming are being edited by a mitochondria-active drug.**

A naturopathic framework demands respect for such subtle, long-horizon effects, prioritising preconception and pregnancy care based on nutrition, stress regulation, toxin reduction, and safe, natural agents—not reflexive reliance on systemic respiratory inhibitors unless clearly necessary and carefully monitored.

Rethinking Routine, Lifelong Metformin Use

Metformin does:

- Lower HbA1c
- Reduce microvascular complications in some settings
- Carry a comparatively favourable short-term risk profile vs. many other agents

It remains first-line in major guidelines (UKPDS Group, 1998; ADA, 2024). But an honest, whole-person reading of the evidence shows:

- Its **core mechanism is deliberate mitochondrial respiratory inhibition**—a chronic, low-grade “poisoning” of cellular energy production, harnessed for gluconeogenesis control.
- It carries **real and mechanistically coherent risks**: lactic acidosis in vulnerable states, B12 deficiency, gastrointestinal distress, and potential developmental and epigenetic programming effects.
- It is being explored as a **cancer and “longevity” drug** precisely because it exerts broad, stressful pressure on bioenergetic and growth pathways.

From a critical, naturopathic standpoint, metformin perfectly symbolises the deeper failure of allopathic diabetes care:

- Instead of aggressively transforming **diet, physical activity, sleep, stress, microbiome, and environmental toxicity** in a structured, supervised way, the system normalises life-long interference with mitochondrial respiration to manipulate a single number—blood glucose.
- Metformin becomes a pharmacologic crutch that enables the continuation of disease-promoting lifestyles, while its systemic metabolic consequences are downplayed.

Used short-term, strategically, and in tandem with intensive lifestyle and naturopathic interventions, metformin can be a useful tool. Used reflexively, indefinitely, and as the **centrepiece** of therapy, it deserves serious re-examination.

In the chapters to come, we will explore naturopathic and integrative approaches to diabetes—built on food as medicine, movement, stress modulation, botanical and nutritional therapeutics, and environmental clean-up—that aim to restore metabolic health and reduce drug dependence safely under professional supervision.

References:

1. American Diabetes Association. (2024). Standards of medical care in diabetes—2024. *Diabetes Care*, 47(Suppl. 1). <https://doi.org/10.2337/dc24-SINT>
2. Andrzejewski, S., Gravel, S.-P., Pollak, M., & St-Pierre, J. (2014). Metformin directly acts on mitochondria to alter cellular bioenergetics. *Cancer & Metabolism*, 2, 12. <https://doi.org/10.1186/2049-3002-2-12>
3. Nayak, G., Salian, S. R., Agarwal, P., Suresh Poojary, P., Rao, A., Kumari, S., Kalthur, S. G., Shreya, A. B., Mutalik, S., Adiga, S. K., & Kalthur, G. (2020). Antidiabetic drug metformin affects the developmental competence of cleavage-stage embryos. *Journal of assisted reproduction and*

- genetics, 37(5), 1227–1238. <https://doi.org/10.1007/s10815-020-01709-6>
4. Bridges, H. R., Jones, A. J. Y., Pollak, M. N., & Hirst, J. (2014). Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria. *Biochemical Journal*, 462(3), 475–487. <https://doi.org/10.1042/bj20140620>
 5. Cassina, M., Donà, M., Di Gianantonio, E., & Clementi, M. (2014). First-trimester exposure to metformin and risk of birth defects: A systematic review and meta-analysis. *Human Reproduction Update*, 20(5), 656–669. <https://doi.org/10.1093/humupd/dmu022>
 6. de Jager, J., Kooy, A., Lehert, P., Wulffelé, M. G., van der Kolk, J., Bets, D., ... Stehouwer, C. D. A. (2010). Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: Randomised placebo controlled trial. *BMJ*, 340, c2181. <https://doi.org/10.1136/bmj.c2181>
 7. DeFronzo, R., Fleming, G. A., Chen, K., & Bicsak, T. A. (2015). Metformin-associated lactic acidosis: Current perspectives on causes and risk. *Metabolism*, 65(2), 20–29. <https://doi.org/10.1016/j.metabol.2015.10.014>
 8. Foretz, M., Guigas, B., & Viollet, B. (2019). Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus. *Nature Reviews Endocrinology*, 15(10), 569–589. <https://doi.org/10.1038/s41574-019-0242-2>
 9. Lin, Z., Liu, M., Chen, F., Zhao, C., Liu, Y., & Sun, H. (2025). Lethal toxicity of metformin on zebrafish during early embryonic development by multi-omics analysis. *Scientific reports*, 15(1), 11309. <https://doi.org/10.1038/s41598-025-95816-y>
 10. Gui, J., Liu, Q., Feng, L., & Li, X. (2013). Metformin vs insulin in the management of gestational diabetes: A

- meta-analysis. PLoS ONE, 8(5), e64585.
<https://doi.org/10.1371/journal.pone.0064585>
11. Hanem, L. G. E., Salvesen, Ø., Juliusson, P. B., Carlsen, S. M., Nossun, M. C. F., Vaage, M. Ø., Ødegård, R., & Vanky, E. (2019). Intrauterine metformin exposure and offspring cardiometabolic risk factors (PedMet study): a 5–10 year follow-up of the PregMet randomised controlled trial. *The Lancet Child & Adolescent Health*, 3(3), 166–174.
[https://doi.org/10.1016/s2352-4642\(18\)30385-7](https://doi.org/10.1016/s2352-4642(18)30385-7)
 12. Inzucchi, S. E., Lipska, K. J., Mayo, H., Bailey, C. J., & McGuire, D. K. (2014). Metformin in patients with type 2 diabetes and kidney disease: A systematic review. *JAMA*, 312(24), 2668–2675.
<https://doi.org/10.1001/jama.2014.15298>
 13. Madiraju, A. K., Erion, D. M., Rahimi, Y., Zhang, X. M., Braddock, D. T., Albright, R. A., ... Shulman, G. I. (2014). Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. *Nature*, 510(7506), 542–546. <https://doi.org/10.1038/nature13270>
 14. LaMoia, T. E., & Shulman, G. I. (2021). Cellular and Molecular Mechanisms of Metformin Action. *Endocrine reviews*, 42(1), 77–96.
<https://doi.org/10.1210/endrev/bnaa023>
 15. Rowan, J. A., Hague, W. M., Gao, W., Battin, M. R., & Moore, M. P. (2008). Metformin versus insulin for the treatment of gestational diabetes. *New England Journal of Medicine*, 358(19), 2003–2015.
<https://doi.org/10.1056/NEJMoa0707193>
 16. Salomäki, H., Heinäniemi, M., Vähätalo, L. H., Ailanen, L., Hanhineva, K., Hyötyläinen, T., ... Poutanen, M. (2013). Prenatal metformin exposure in mice programs the metabolic phenotype of the offspring during a high fat diet at adulthood. *PLoS ONE*, 8(2), e56594.
<https://doi.org/10.1371/journal.pone.0056594>

17. Faure, M., Bertoldo, M. J., Khoueiry, R., Bongrani, A., Brion, F., Giulivi, C., Dupont, J., & Froment, P. (2018). Metformin in Reproductive Biology. *Frontiers in endocrinology*, 9, 675.
<https://doi.org/10.3389/fendo.2018.00675>
18. UK Prospective Diabetes Study (UKPDS) Group. (1998). Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). *Lancet*, 352(9131), 854–865.
[https://doi.org/10.1016/S0140-6736\(98\)07037-8](https://doi.org/10.1016/S0140-6736(98)07037-8)

ii) Sulfonylureas: Forcing a Failing Pancreas – From Weed Killer Chemistry to Human Metabolic Overdrive

Sulfonylureas (SUs) are among the oldest oral glucose-lowering drugs still pushed in allopathic algorithms for type 2 diabetes. They are powerful insulin secretagogues—and that power cuts both ways. Short-term HbA1c numbers look “better,” but the real price tag includes recurrent hypoglycaemia, weight gain, β -cell burnout, and troubling cardiovascular signals. In an era of rising evidence for lifestyle- and naturopathic-based remission, clinging to sulfonylureas as routine long-term therapy looks less like science and more like therapeutic inertia.

A Chemical Class with Two Faces: Herbicides and Antidiabetic Drugs

The sulfonylurea scaffold is not some gentle “sugar pill” chemistry. It underpins:

- **Agricultural sulfonylurea herbicides** that kill plants by inhibiting acetolactate synthase (ALS), a key enzyme for branched-chain amino acid synthesis, arresting protein production and growth (Brown, 1990; Baylis, 2000). ALS does not exist in animals, which limits direct mammalian toxicity at field doses—but the concept is clear: these are

potent bioactive molecules designed to shut down living systems.

- **Antidiabetic sulfonylureas** (e.g., glibenclamide/glyburide, glipizide, gliclazide, glimepiride), which target a completely different protein in humans: the sulfonylurea receptor-1 (SUR1) subunit of ATP-sensitive K^+ (K_{ATP}) channels on pancreatic β cells.

The same chemical backbone, lethal to weeds and aggressively stimulatory to human β cells, should immediately dispel any illusion of benignity. This is hard, industrial-grade pharmacology.

Mechanism in Humans: Whipping the β Cell, Regardless of Glucose Reality

Antidiabetic sulfonylureas lower glucose not by improving insulin sensitivity, but by **forcing insulin out of β cells**, whether or not the body's tissues are willing or able to respond:

- They bind to **SUR1** on β -cell K_{ATP} channels, **close the channel**, depolarise the cell membrane, open voltage-gated Ca^{2+} channels, and trigger insulin exocytosis (Meyer et al., 1999; ADA, 2024).
- This mechanism is **not glucose-dependent**: unlike incretin-based therapies, sulfonylureas can drive insulin secretion even when blood glucose is low, laying the groundwork for severe hypoglycaemia.

Short-term consequences:

- HbA1c falls, clinicians celebrate “good control.”

Long-term biological fallout:

- **Weight gain** via persistent hyperinsulinaemia and reduced glycosuria.
- **β -cell exhaustion (“secondary failure”)** as already stressed cells are pushed harder until they fail, forcing escalation to more medications or insulin.

- **Recurrent hypoglycaemia**, especially in older adults, those with kidney impairment, irregular meals, or polypharmacy.

From a naturopathic, root-cause view, this is perverse: instead of reducing the toxic load (ultra-processed foods, sedentarism, chronic stress), the system whips the failing β cell to cover up a lifestyle and environment it refuses to seriously confront.

Adverse Effects in Adults: Cheap HbA1c, Expensive Biology

Acute and Chronic Metabolic Risks

- **Hypoglycaemia** is the signature toxicity. It can be severe, prolonged, and life-threatening—particularly with long-acting agents like glyburide/glibenclamide and chlorpropamide, and in patients with renal or hepatic dysfunction (Nathan et al., 2009).
- **Weight gain** is the rule, not the exception, during sustained therapy due to persistent insulin elevation and decreased glycosuria (Inzucchi et al., 2015).

In practice, patients are told to “watch for hypos” and “eat regularly,” effectively binding them to a rigid eating schedule and often to excess calorie intake just to avoid drug-induced collapse.

Durability: The Myth of Long-Term Control

Many patients on sulfonylureas experience declining benefit:

- Progressive β -cell dysfunction leads to classic “**secondary failure**” and the need for additional agents or insulin, especially after years of high-dose therapy (Inzucchi et al., 2015; ADA, 2024).

So the very drugs touted as potent “secretagogues” contribute to faster burnout of the tissue they stimulate. This is the opposite of regenerative medicine.

Cardiovascular Signals: Hypoglycaemia and Heart Risk

Observational data, while imperfect, consistently raise red flags:

- Compared with continuing metformin, **adding or switching to sulfonylureas** has been associated with higher risks of myocardial infarction, severe hypoglycaemia, and all-cause mortality (Azoulay & Suissa, 2017; Douros et al., 2018).
- Early trials with first-generation sulfonylureas showed worse post-myocardial-infarction outcomes, imprinting long-standing caution in those with coronary disease.

Even with residual confounding, it is hard to honestly frame sulfonylureas as a “safe, long-term default” in an era where other agents (e.g., SGLT2 inhibitors, GLP-1 receptor agonists) have demonstrated **cardiovascular and renal benefits**.

Hepatic, Dermatologic, Electrolyte Effects

Though less common, additional toxicities remind us that sulfonylureas are not “weak” drugs:

- **Cholestatic jaundice, hepatitis, and even hepatic failure** have been reported.
- **Skin reactions** (rash, pruritus, photosensitivity) can be persistent and distressing.
- **Hyponatraemia**, classically with chlorpropamide, has also been seen sporadically with newer agents.

All of this is accepted as an “acceptable” price because the drugs are cheap and lower HbA1c—again, the number eclipses whole-person health.

Pregnancy: Fetal Hyperinsulinism as the Silent Trade-Off

Human Pregnancy (Antidiabetic Sulfonylureas)

Modern clinical data are revealing:

- **Placental transfer is real:** glyburide/glibenclamide reaches umbilical cord blood at ~70% of maternal levels (Hebert et al., 2009).

- First-trimester exposure has **not** been consistently linked to major structural malformations compared with insulin; maternal hyperglycaemia itself remains the primary teratogen (Diav-Citrin et al., 2018).
- However, in **late pregnancy**, glyburide (vs. insulin) is associated with higher rates of:
 - Neonatal hypoglycaemia
 - Large-for-gestational-age/macrosomia
 - Respiratory distress and NICU admission
 - Birth trauma

(Balsells et al., 2015).

Mechanistically, the story is blunt:

- Sulfonylureas cross the placenta, **close fetal β -cell K_{ATP} channels** via SUR1, and **force chronic fetal hyperinsulinism**.
- This drives excessive fetal growth and sets up neonates for **postnatal hypoglycaemia**, despite the absence of a strong structural malformation signal (Hebert et al., 2009; Jacobson et al., 2015).

Unsurprisingly, many guidelines now discourage glyburide for gestational diabetes when insulin or metformin is available, because **neonatal outcomes are worse** even when maternal HbA1c looks similar (Jiang et al., 2025).

From a naturopathic vantage, this is unacceptable: rather than truly optimising maternal nutrition, movement, stress, and micronutrients, the system medicates the fetus into hyperinsulinism and then reacts to the predictable neonatal fallout.

Sulfonylureas in Children: High-Risk in Small Bodies

In children and adolescents, sulfonylureas reproduce the same pattern—only more precariously:

- Side-effect profiles mirror adults: **hypoglycaemia and weight gain** are most frequent; gastrointestinal upset, rash, and rare hepatic injury also occur.
- Toddlers are acutely vulnerable: **accidental ingestion of a single glyburide tablet** can cause severe, prolonged hypoglycaemia requiring ICU-level care (Rath et al, 2008).

The very property that makes these drugs “effective”—strong, long-lasting insulin release—makes them remarkably unforgiving in dosing errors, especially in small children.

Rethinking Sulfonylureas: Bridging Tool, Not Lifestyle Substitute

Sulfonylureas can:

- Provide **rapid, inexpensive HbA1c reduction**.
- Serve as **short-term bridging agents** where resources severely limit access to safer, more physiologically aligned therapies.

But from a critical, naturopathic, root-cause standpoint:

- They **do not repair insulin resistance**; they merely force a struggling pancreas to over-secrete.
- They are tied to **hypoglycaemia, weight gain, β -cell exhaustion**, and **uncertain cardiovascular safety**, and frequently fail over time.
- In pregnancy, they impose **fetal hyperinsulinism and neonatal complications**, even when gross teratogenicity is not obvious.

Used sparingly and temporarily, under close supervision, they may have a constrained role. Used reflexively and indefinitely as a cornerstone of allopathic practice, they epitomise a system that chases glucose numbers with hard-hitting drugs while refusing to commit to the far more powerful—yet less profitable—work of transforming **diet, physical activity, sleep, stress biology, environmental load, and community support**.

In subsequent chapters, we will shift from this drug-centric paradigm to naturopathic and integrative approaches for diabetes—focusing on food as medicine, movement, mind-body therapies, botanicals, and environmental interventions aimed at restoring metabolic function and reducing or even withdrawing medications safely under professional guidance.

References:

1. American Diabetes Association. (2024). Standards of medical care in diabetes—2024. *Diabetes Care*, 47(Suppl. 1). <https://doi.org/10.2337/dc24-SINT>
2. Azoulay, L., & Suissa, S. (2017). Sulfonylureas and the risks of cardiovascular events and death: A Methodological Meta-Regression Analysis of the observational studies. *Diabetes Care*, 40(5), 706–714. <https://doi.org/10.2337/dc16-1943>
3. Balsells, M., García-Patterson, A., Gich, I., & Corcoy, R. (2015). Glibenclamide, metformin, and insulin for the treatment of gestational diabetes: A systematic review and meta-analysis. *BMJ*, 350, h102. <https://doi.org/10.1136/bmj.h102>
4. Baylis, A. D. (2000). Why glyphosate is a global herbicide: Strengths, weaknesses and prospects. *Pest Management Science*, 56(4), 299–308. (Includes discussion of ALS-inhibitor sulfonylureas.) [https://doi.org/10.1002/\(SICI\)1526-4998\(200004\)56:4<299::AID-PS144>3.0.CO;2-K](https://doi.org/10.1002/(SICI)1526-4998(200004)56:4<299::AID-PS144>3.0.CO;2-K)
5. Brown, H. M. (1990). Mode of action, crop selectivity, and soil relations of the sulfonylurea herbicides. *Pesticide Science*, 29(3), 263–281. <https://doi.org/10.1002/ps.2780290304>
6. Jiang W, Zhang H, Liu X, Xie J and Liu J (2025) Efficacy of glyburide vs. metformin in preventing neonatal birth obesity in pregnancies complicated by gestational diabetes mellitus: a

- systematic review and meta-analysis. *Front. Pediatr.* 13:1604572. <https://doi.org/10.3389/fped.2025.1604572>
7. Diav-Citrin, O., Steinmetz-Shoob, S., Shechtman, S., & Ornoy, A. (2018). In-utero exposure to metformin for type 2 diabetes or polycystic ovary syndrome: A prospective comparative observational study. *Reproductive Toxicology*, 80, 85–91. <https://doi.org/10.1016/j.reprotox.2018.05.007>
 8. Douros, A., Dell’Aniello, S., Yu, O. H. Y., Fillion, K. B., Azoulay, L., & Suissa, S. (2018). Sulfonylureas as second-line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: Population based cohort study. *BMJ*, 362, k2693. <https://doi.org/10.1136/bmj.k2693>
Full text: <https://www.bmj.com/content/362/bmj.k2693>
 9. Hebert, M. F., Ma, X., Naraharisetti, S. B., Krudys, K. M., Umans, J. G., Hankins, G. D., Caritis, S. N., Miodovnik, M., Mattison, D. R., Unadkat, J. D., Kelly, E. J., Blough, D., Cobelli, C., Ahmed, M. S., Snodgrass, W. R., Carr, D. B., Easterling, T. R., Vicini, P., & Obstetric-Fetal Pharmacology Research Unit Network (2009). Are we optimizing gestational diabetes treatment with glyburide? The pharmacologic basis for better clinical practice. *Clinical pharmacology and therapeutics*, 85(6), 607–614. <https://doi.org/10.1038/clpt.2009.5>
 10. Inzucchi, S.E., Bergenstal, R.M., Buse, J.B. et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetologia* 58, 429–442 (2015). <https://doi.org/10.1007/s00125-014-3460-0>
 11. Meyer, M., Chudziak, F., Schwanstecher, C., Schwanstecher, M., & Panten, U. (1999). Structural requirements of sulphonylureas and analogues for interaction with sulphonylurea receptor subtypes. *British journal of*

pharmacology, 128(1), 27–34.

<https://doi.org/10.1038/sj.bjp.0702763>

12. Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009). Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. *Diabetes Care*, 32(1), 193–203.
<https://doi.org/10.2337/dc08-9025>
13. Rath, S., Bar-Zeev, N., Anderson, K., Fahy, R., & Roseby, R. (2008). Octreotide in children with hypoglycaemia due to sulfonylurea ingestion. *Journal of paediatrics and child health*, 44(6), 383–384. <https://doi.org/10.1111/j.1440-1754.2008.01339.x>

(iii) Meglitinides: “Rapid-Fire” β -Cell Whips with Little Long-Term Payoff

Meglitinides (repaglinide, nateglinide) were marketed as clever, short-acting alternatives to sulfonylureas— “meal-time” drugs for post-prandial spikes. Strip away the branding and you see the same pattern: **they force the β -cell to dump more insulin into an already insulin-resistant body**, adding hypoglycaemia and weight gain without changing the toxic metabolic terrain that created the problem.

Mechanism: Fast, Cleverly Packaged—But Still Non-Physiological

Meglitinides are rapid-onset insulin secretagogues. Mechanistically, they are **mini-sulfonylureas in disguise**:

- They bind the **SUR1 subunit** of the pancreatic β -cell ATP-sensitive K^+ (K_{ATP}) channel at sites that overlap, but are not identical to, classic sulfonylureas (Dictionary of Toxicology, 2024)

- Binding **closes K_{ATP}**, depolarises the membrane, opens voltage-gated Ca^{2+} channels, and triggers insulin exocytosis—especially when dosed before meals (Dictionary of Toxicology, 2024).

They are sold as “more physiological” because of their shorter duration of action. In reality, they still **override the body’s glucose-dependent control** and coerce β cells to respond on command.

Key pharmacodynamic differences:

- **Nateglinide**
 - Extremely rapid on–off kinetics at SUR1 (receptor half-life $\sim$ 2 seconds).
 - Roughly **1,000-fold selectivity for pancreatic SUR1 over cardiovascular SUR2**, yielding a short insulin pulse and somewhat lower off-meal hypoglycaemia risk.
- **Repaglinide**
 - Slower dissociation ($\approx$ 3 minutes), less SUR1-specific.
 - Longer-lasting effect, with **higher hypoglycaemia risk**, especially in renal impairment or with interacting drugs (Hatorp, 2002).

Despite these nuances, the fundamental reality remains: **no improvement in insulin sensitivity, no correction of diet, sleep, or stress—just more insulin forced out of a tired pancreas.**

Clinical Risks: Hypoglycaemia, Weight Gain, No Outcome Advantage

Short-Term Metabolic Risks

Meglitinides reproduce the classic secretagogue toxicities:

- **Hypoglycaemia** is the key immediate risk, heightened by:
 - Missed or delayed meals after dosing
 - Higher doses

- Renal impairment
- Concomitant CYP inhibitors:
 - Repaglinide: CYP3A4/2C8 inhibitors (e.g., gemfibrozil)
 - Nateglinide: CYP3A4/2C9 inhibitors

(Hatorp, 2002).

- **Weight gain** is modest but consistent, driven by chronic insulin stimulation and reduced glycosuria (Dankner, 2018).

So patients get **more drugs, more rigid meal timing, more hypos, more weight**—all in service of a prettier HbA1c printout.

Long-Term Efficacy and Safety: No Real Win

- HbA1c reduction is comparable to low-dose sulfonylureas, but there is **no evidence** that meglitinides:
 - Improve cardiovascular or renal outcomes
 - Offer durable glycaemic control beyond a few years
 - Slow progression to insulin dependence

(Inzucchi et al., 2015).

- Observational data do **not** show cardiovascular advantages over other secretagogues and clearly **not over metformin** (Zaccardi et al., 2020; Inzucchi et al., 2015).

Functionally, meglitinides are just **another way to squeeze insulin out of failing β cells**, while the true drivers—processed food, inactivity, chronic stress, circadian disruption, environmental toxins—are barely touched.

From a naturopathic angle, they epitomise the allopathic reflex: tweak the lab number with more pharmacologic pressure, ignore the fire that’s causing the smoke.

Pregnancy and Fetal Considerations: Insufficient Data, Animal Signals

Human data in pregnancy are very limited:

- Product labels for repaglinide and nateglinide advise **avoiding use in pregnancy** unless benefits clearly outweigh risks, with **insulin recommended as standard** (U.S. FDA, 2013; U.S. FDA, 2016).

Practical Implications: Why Reach for a Short-Acting Secretagogue at All?

For non-pregnant adults, if meglitinides are used at all, basic safeguards are non-negotiable:

- **Tie dosing strictly to meals** (skip the dose if a meal is skipped).
- **Adjust for renal function and drug interactions.**
- Position them as **second- or third-line add-ons**, not foundational therapy.

From a critical, root-cause perspective:

- Meglitinides **do nothing to reverse insulin resistance** or repair the metabolic terrain.
- They **increase treatment complexity** (multiple pre-meal doses), magnify hypoglycaemia and weight gain risks, and **offer no proven cardiovascular or renal benefit.**
- In an era where certain SGLT2 inhibitors and GLP-1 receptor agonists improve prognosis, and where structured nutritional programs can induce **remission of type 2 diabetes**, leaning on short-acting secretagogues is therapeutically lazy and biologically shortsighted.

Used **rarely**, in carefully chosen patients with very specific post-prandial patterns who truly cannot use other options, meglitinides may serve as a niche tool. Used broadly and long term, they are yet another example of allopathic diabetes care **pushing the pancreas harder instead of changing the patient's world.**

In the upcoming chapters, we will pivot from this “more secretagogue, more complexity” paradigm to naturopathic strategies

that target the roots of insulin resistance—therapeutic nutrition, movement, stress modulation, microbiome-supportive practices, botanicals, and environmental clean-up—aiming to reduce or even withdraw drugs safely under expert supervision.

References:

- Dankner, R. (2018). Diabetes. In Elsevier eBooks.
<https://doi.org/10.1016/b978-0-12-801238-3.65040-7>
- Dictionary of Toxicology (p. 605). (2024).
https://doi.org/10.1007/978-981-99-9283-6_1653
- Hatorp, V. (2002). Clinical pharmacokinetics and pharmacodynamics of repaglinide. *Clinical Pharmacokinetics*, 41(7), 471–483.
<https://doi.org/10.2165/00003088-200241070-00002>
- Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015). Management of hyperglycaemia in type 2 diabetes, 2015: A patient-centred approach. *Diabetologia*, 58(3), 429–442.
<https://doi.org/10.1007/s00125-014-3460-0>
- U.S. Food and Drug Administration. (2013). *Prandin (repaglinide): Label information*.
<https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process>
- U.S. Food and Drug Administration. (2016). *Starlix (nateglinide): Label information*.
<https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process>
- Zaccardi, F., Kloecker, D. E., Buse, J. B., Mathieu, C., Khunti, K., & Davies, M. J. (2020). Use of metformin and cardiovascular effects of new classes of Glucose-Lowering Agents: A Meta-analysis of cardiovascular outcome trials in

Type 2 diabetes. Diabetes Care, 44(2), e32–e34.

<https://doi.org/10.2337/dc20-2080>

(iv) GLP-1 Receptor Agonists: Powerful Metabolic Re-Programming with a Heavy Biological Price Tag

GLP-1 receptor agonists (GLP-1RAs—liraglutide, semaglutide, dulaglutide, exenatide, etc.) are the current darlings of allopathic diabetes and obesity management. They cut glucose, shed kilos, and lower cardiovascular events in high-risk patients. But they do this by **hard-wiring hormonal signalling across the gut, pancreas, brain, biliary tree, and cardiovascular system**, and they show **consistent embryo–fetal toxicity in animals at exposures overlapping clinical use**. Treating them as casual “weight-loss shots” rather than potent endocrine drugs is reckless.

Mechanism: Aggressive Pharmacologic Hijacking of the Incretin Axis

GLP-1RAs are synthetic mimetics of the gut hormone glucagon-like peptide-1:

- They activate the **GLP-1 receptor (GLP-1R)**, a Gs-coupled GPCR expressed on pancreatic β -cells, α -cells, gut, brain, and cardiovascular tissues (Drucker, 2018; Nauck & Meier, 2019).
- On **β -cells**, GLP-1R activation:
 - Stimulates adenylate cyclase $\rightarrow$ increases cAMP
 - Activates PKA and Epac
 - **Amplifies Ca^{2+} -triggered insulin exocytosis in a glucose-dependent manner**
- On **α -cells**, GLP-1RAs suppress glucagon secretion $\rightarrow$ reduce hepatic glucose output.
- In the **gut and CNS**, they slow gastric emptying and drive satiety, sharply cutting energy intake and body weight.

Clinically, this looks miraculous: lower glucose, less appetite, weight loss. Biologically, it is **deep, multi-organ endocrine re-programming** maintained indefinitely by injections or high-dose oral therapy. These are not cosmetic agents; they are system-level signal hijackers.

Human Adverse Effects: GI Distress, Pancreatic and Biliary Signals, Endocrine Unknowns

Common and Dose-Limiting Toxicity

- **Gastrointestinal symptoms**—nausea, vomiting, diarrhoea, early satiety, abdominal pain—are the leading adverse effects and a major reason for discontinuation (Marso et al., 2016; Davies et al., 2015).
- **Delayed gastric emptying** can cause bloating, reflux, and problematic absorption of other oral drugs; emerging data and case series point toward **drug-induced gastroparesis** in some susceptible patients, especially with long-acting formulations and aggressive dosing (Drucker, 2018).
- Severe vomiting/diarrhoea can provoke **dehydration and acute kidney injury**, especially in older adults, those with pre-existing CKD, or on diuretics (Meier et al., 2026).

This is not a “mild” side-effect profile; it is a controlled, chronic disruption of gut motility and appetite signalling.

Pancreas and Gallbladder

- **Acute pancreatitis** has been reported. Large CV-outcome trials and meta-analyses do not show a dramatic class-wide excess, but the **signal is persistent enough** that all labels carry pancreatitis warnings (Drucker, 2018; Monami et al., 2014).
- GLP-1RAs are associated with **higher rates of gallbladder disease and cholelithiasis**, likely from rapid weight loss and altered biliary motility (He et al., 2022).

Thyroid and Long-Term Central Effects

- In rodents, GLP-1RAs consistently cause **C-cell hyperplasia and medullary thyroid carcinoma**. Human data have not confirmed this risk, but the entire class is **contraindicated** in patients with personal/family history of medullary thyroid carcinoma or MEN2 (Marso et al., 2016).
- Chronic manipulation of **brain appetite and reward pathways** by GLP-1RAs raises unresolved questions about long-term effects on mood, food reward, and eating behaviour.

So yes, GLP-1RAs deliver big cardiometabolic wins for some—but they do so by pulling multiple heavy hormonal levers, with substantial, non-trivial side-effect burdens.

Cardiovascular and Renal Outcomes: Real Gains, Still Not Root-Cause Therapy

Several GLP-1RAs have **genuine outcome data**:

- **Liraglutide (LEADER)**: reduced major adverse cardiovascular events (MACE) and all-cause mortality vs placebo in high-risk type 2 diabetes (Marso et al., 2016).
- **Semaglutide (SUSTAIN-6)** and **dulaglutide (REWIND)** similarly reduced MACE (Marso et al., 2016; Gerstein et al., 2019).
- Trials show **reduced progression of albuminuria** and modest slowing of eGFR decline.

But:

- Benefits are shown mainly in **high-cardiovascular-risk populations on top of intensive background therapy**.
- GLP-1RAs **do not cure diabetes or obesity**; they demand chronic administration at high cost.

- **Stopping therapy typically leads to weight regain and glycaemic relapse**, exposing the truth: the underlying lifestyle and environmental drivers are still intact.

From a naturopathic standpoint, GLP-1RAs can be **valuable adjuncts in carefully selected high-risk patients**—but using them as a mass “lifestyle substitute” is a textbook example of allopathic overreach: powerful hormones first, deep behaviour and environment change later, if ever.

Pregnancy and Embryo–Fetal Toxicity: Animal Evidence Too Loud to Ignore

Human Pregnancy Guidance: Labels Are (Rightly) Restrictive

- Human pregnancy data are sparse and largely uncontrolled.
- Product labels for semaglutide, liraglutide, and similar agents **advise against use in pregnancy and in women planning conception**, and recommend discontinuation well in advance of pregnancy, with insulin-based regimens preferred for glycaemic control (EMA, 2023; ADAPPC, 2024).

Given this, the casual, off-label spread of GLP-1RAs among **women of reproductive age without strict contraception or pregnancy planning** is deeply concerning. We are deploying potent incretin mimetics directly into the most vulnerable stages of human development.

From a naturopathic and precautionary perspective, this is indefensible when powerful non-drug strategies exist to improve glucose, weight, and fertility before conception.

Rethinking GLP-1RAs: High-Impact Tools, Not Lifestyle Replacement

GLP-1RAs demonstrate that pharmacology can dramatically modulate metabolism: lower glucose, less weight, better CV outcomes. They also prove:

- This comes at the cost of **chronic administration of a powerful hormonal analogue**.
- Side effects range from **persistent GI distress to pancreatitis signals, gallbladder disease, and strong embryo–fetal toxicity in animals**.
- None of this addresses the **root causes** of type 2 diabetes and obesity: ultra-processed, hyperpalatable diets; sedentarism; sleep and circadian disruption; chronic psychosocial stress; endocrine-disrupting chemicals; and a fractured food environment.

Used judiciously, GLP-1RAs can be **life-changing and sometimes life-saving** for very high-risk patients who cannot or will not achieve adequate lifestyle change in time. Used as a broad, first-line “solution” for lifestyle-driven disease, they embody the allopathic pattern: normalise long-term endocrine manipulation, marginalise the profound healing potential of **naturopathic interventions—therapeutic nutrition, movement, stress work, botanical and nutrient therapies, and environmental detoxification**.

In the following chapters, we will examine naturopathic strategies that aim to deliver sustained weight loss, glycaemic improvement, and cardiovascular risk reduction without chronic reliance on potent hormone mimetics—focusing instead on changing the terrain in which diabetes and obesity arise.

References:

1. American Diabetes Association Professional Practice Committee (2024). 15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes-2024. Diabetes care, 47(Suppl 1), S282–S294. <https://doi.org/10.2337/dc24-S015>
2. Davies, M. J., Bergenstal, R., Bode, B., Kushner, R. F., Lewin, A., Skjøth, T. V., Andreasen, A. H., Jensen, C. B., & DeFronzo, R. A. (2015). Efficacy of liraglutide for weight

- loss among patients with type 2 diabetes: The SCALE diabetes randomized clinical trial. *JAMA*, 314(7), 687–699. <https://doi.org/10.1001/jama.2015.9676>
3. Drucker, D. J. (2018). Mechanisms of action and therapeutic application of glucagon-like peptide-1. *Cell Metabolism*, 27(4), 740–756. <https://doi.org/10.1016/j.cmet.2018.03.001>
 4. European Medicines Agency. (2023). *Ozempic (semaglutide): Summary of product characteristics*. EMA. <https://www.ema.europa.eu/en/medicines/human/EPAR/ozempic>
 5. Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Botros, F. T., Riddle, M. C., Rydén, L., Xavier, D., Atisso, C. M., Dyal, L., Hall, S., Rao-Melacini, P., & Yusuf, S. (2019). Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): A double-blind, randomised placebo-controlled trial. *The Lancet*, 394(10193), 121–130. [https://doi.org/10.1016/S0140-6736\(19\)31149-3](https://doi.org/10.1016/S0140-6736(19)31149-3)
 6. He L, Wang J, Ping F, et al. Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials. *JAMA Intern Med*. 2022;182(5):513–519. <https://doi.org/doi:10.1001/jamainternmed.2022.0338>
 7. Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., Woo, V., Hansen, O. H., Holst, A. G., Pettersson, J., & Home, P. D. (2016). Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). *New England Journal of Medicine*, 375(19), 1834–1844. <https://doi.org/10.1056/NEJMoa1607141>
 8. Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., Steinberg, W. M.,

- Stockner, M., Zinman, B., & Bergenstal, R. M. (2016). Liraglutide and cardiovascular outcomes in type 2 diabetes (LEADER). *New England Journal of Medicine*, 375(4), 311–322. <https://doi.org/10.1056/NEJMoa1603827>
9. Meier, M., Cummings, J., Abdelsaid, M., Feliciano, J., Eusebe, J., Stirn, H., & Coucha, M. (2026). Glucagon-Like peptide-1 receptor Agonists in Chronic Kidney Disease: Mechanisms and clinical Perspectives. *Kidney Medicine*, 8(4), 101282. <https://doi.org/10.1016/j.xkme.2026.101282>
 10. Monami, M., Dicembrini, I., Nardini, C., Fiordelli, I., & Mannucci, E. (2014). Glucagon-like peptide-1 receptor agonists and pancreatitis: a meta-analysis of randomized clinical trials. *Diabetes research and clinical practice*, 103(2), 269–275. <https://doi.org/10.1016/j.diabres.2014.01.010>
 11. Nauck, M. A., & Meier, J. J. (2018). Incretin hormones: Their role in health and disease. *Diabetes, obesity & metabolism*, 20 Suppl 1, 5–21. <https://doi.org/10.1111/dom.13129>

(v) DPP-4 Inhibitors: “Gentle” Tinkering With a Deep Enzyme

Dipeptidyl peptidase-4 (DPP-4) inhibitors (sitagliptin, linagliptin, saxagliptin, alogliptin, etc.) are marketed as the safe, quiet background drugs of diabetes care—oral, “well tolerated,” weight-neutral, and low risk for hypoglycaemia. Underneath that calm image, they deliver **small HbA1c changes**, no clear cardiovascular or renal protection, and **chronic inhibition of a ubiquitous protease** involved not only in incretin metabolism but also in immune and inflammatory signalling. They are a classic example of pharmacologic fine-tuning of numbers rather than transformation of biology.

Mechanism: Subtle but Persistent Amplification of Incretin Signalling

DPP-4 is a widely expressed serine protease that rapidly inactivates the incretin hormones GLP-1 and GIP:

- **DPP-4 inhibitors block this degradation**, raising active GLP-1 and GIP levels and prolonging their actions (Nauck & Meier, 2018).
- This **enhances glucose-dependent insulin secretion** from β -cells and suppresses glucagon release from α -cells, improving fasting and post-prandial glycaemia (Scheen, 2010).
- Because their action is **glucose-dependent**, intrinsic hypoglycaemia risk is low when they are not combined with insulin or sulfonylureas.

Mechanistically, they are “gentler” than sulfonylureas or meglitinides—no blunt β -cell whipping. But they still entail **lifelong manipulation of incretin and immune signalling** rather than removal of the dietary, environmental, and behavioural pressures that create insulin resistance in the first place.

Human Adverse Effects: Mild on Paper, But Not Zero

Short-Term Tolerability

DPP-4 inhibitors are generally easy to prescribe and to take:

- Common adverse effects: **nasopharyngitis/upper respiratory symptoms, headaches, mild GI upset, arthralgia** (Scheen, 2010; Jones & Jones, 2022).
- Rare but important reactions:
 - **Hypersensitivity/angioedema**, occasionally serious.
 - **Bullous pemphigoid**, particularly with vildagliptin and linagliptin, requiring drug withdrawal (Dours et al., 2019).

Hypoglycaemia is uncommon unless a DPP-4 inhibitor is stacked on top of insulin or insulin secretagogues—part of why these drugs are popular in risk-averse, guideline-driven practice.

Cardiovascular and Heart Failure Signals

Large cardiovascular outcome trials show:

- **Neutral MACE (major adverse cardiovascular events)** for sitagliptin, saxagliptin, and alogliptin (Scirica et al., 2013; White et al., 2013; Zannad et al., 2015).
- **Increased heart failure hospitalisation with saxagliptin** (SAVOR-TIMI 53) and a weaker, non-significant trend with alogliptin; sitagliptin did not show this effect (Scirica et al., 2013; Zannad et al., 2015).

So overall, DPP-4 inhibitors are not glaringly harmful—but unlike GLP-1RAs or SGLT2 inhibitors, they also **do not deliver cardiovascular or renal protection**. For a lifelong enzyme inhibitor, “neutral” is underwhelming.

Pregnancy and Embryo–Fetal Risk: Partial Reassurance, Not a Green Light

Across the class, animal data are **relatively reassuring at modest multiples** of human exposure—but they still show that at high, toxic exposures, fetal alterations emerge. That is entirely compatible with the biology of a **systemic protease inhibitor** that touches incretin, immune, and cytokine pathways. The absence of obvious malformations at moderate doses does not constitute proof of long-term developmental safety in humans.

A naturopathic, precautionary outlook keeps DPP-4 inhibitors **well away from routine pregnancy care** in favour of intensive lifestyle measures and, when needed, carefully titrated insulin.

Critical Appraisal: Why Use DPP-4 Inhibitors at All?

Clinically, DPP-4 inhibitors are tempting because they are:

- Oral, once-daily, **weight-neutral**, and easy to combine with metformin.
- Associated with **low hypoglycaemia risk** when used alone.

But:

- Their **HbA1c reduction is modest**, usually around 0.5–0.7% (Scheen, 2010; Inzucchi et al., 2015).
- They lack proven **cardiovascular or renal benefit**, especially when compared with GLP-1RAs and SGLT2 inhibitors (Zannad et al., 2015; Kristensen et al., 2019).
- They require **lifelong inhibition of DPP-4**, a protease involved not only in incretin breakdown but also in **T-cell activation, chemokine processing, and cytokine regulation** (Mulvihill & Drucker, 2014). The full implications of chronically suppressing this enzyme across decades remain uncertain.

From a root-cause, naturopathic standpoint, DPP-4 inhibitors are the epitome of **biochemical micro-management**: they gently smooth glucose excursions without changing what patients actually eat, how they move, how they sleep, or how their bodies handle stress and environmental insults. For someone unwilling or unable to make lifestyle changes, they can be a modestly helpful add-on. For broad, population-level, long-term use, they offer **limited benefit in exchange for chronic enzyme interference and ongoing cost**.

Practical Implications: Small Tool, Not a Pillar

In adults, a cautious, critical approach would see DPP-4 inhibitors used:

- As **add-on to metformin** when GLP-1RAs and SGLT2 inhibitors are unavailable, unaffordable, or contraindicated.
- With care in people at **high heart-failure risk**, avoiding saxagliptin when possible.

In pregnancy or pre-conception:

- **Insulin remains the standard** for pharmacologic glycaemic control.
- DPP-4 inhibitors should be **avoided** unless maternal benefit clearly outweighs poorly defined fetal risks.

Viewed through an integrative lens, DPP-4 inhibitors are at best **second- or third-line, modest tools**, not foundations of diabetes care. The real foundation should be **naturopathic, lifestyle-centred work**: restructuring food environments, rebuilding movement patterns, normalising sleep and circadian rhythm, clearing toxic exposures, and harnessing botanicals and nutrients that support, rather than suppress, human physiology.

In the next chapters, we will leave behind this narrow enzymatic tinkering and focus on naturopathic strategies that can substantially improve or even reverse metabolic dysfunction without chronic, system-wide protease inhibition.

References:

1. Douros, A., Rouette, J., Yin, H., Yu, O. H. Y., Filion, K. B., & Azoulay, L. (2019). Dipeptidyl peptidase-4 inhibitors and the risk of bullous pemphigoid: Population-based cohort study. *Diabetes Care*, 42(9), 1496–1503.
<https://doi.org/10.2337/dc19-0409>
2. Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015). Management of hyperglycemia in type 2 diabetes, 2015: A patient-centered approach. *Diabetes Care*, 38(1), 140–149.
<https://doi.org/10.2337/dc14-2441>
3. Jones, L., & Jones, A. M. (2022). Suspected adverse drug reactions of the type 2 antidiabetic drug class dipeptidyl-peptidase IV inhibitors (DPP4i): Can polypharmacology help explain? *Pharmacology Research &*

Perspectives, 10(6), e01029.

<https://doi.org/10.1002/prp2.1029>

4. Kristensen, S. L., Rørth, R., Jhund, P. S., Docherty, K. F., Sattar, N., Preiss, D., Køber, L., Petrie, M. C., & McMurray, J. J. V. (2019). Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A systematic review and meta-analysis. *The Lancet Diabetes & Endocrinology*, 7(10), 776–785.
[https://doi.org/10.1016/S2213-8587\(19\)30249-9](https://doi.org/10.1016/S2213-8587(19)30249-9)
5. Mulvihill, E. E., & Drucker, D. J. (2014). Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors. *Endocrine Reviews*, 35(6), 992–1019.
<https://doi.org/10.1210/er.2014-1035>
6. Nauck, M. A., & Meier, J. J. (2018). Incretin hormones: Their role in health and disease. *Diabetes, obesity & metabolism*, 20 Suppl 1, 5–21.
<https://doi.org/10.1111/dom.13129>
7. Scheen, A.J. Dipeptidylpeptidase-4 Inhibitors (Gliptins). *Clin Pharmacokinet* 49, 573–588 (2010).
<https://doi.org/10.2165/11532980-000000000-00000>
8. Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., Cavender, M. A., Udell, J. A., Desai, N. R., Mosenzon, O., McGuire, D. K., Ray, K. K., Leiter, L. A., Raz, I., & SAVOR-TIMI 53 Steering Committee and Investigators. (2013). Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. *New England Journal of Medicine*, 369(14), 1317–1326. <https://doi.org/10.1056/NEJMoa1307684>
9. White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., Wilson, C., Cushman, W. C., Zannad, F., & EXAMINE Investigators. (2013). Alogliptin after acute coronary syndrome in patients with type 2

diabetes (EXAMINE). *New England Journal of Medicine*, 369(14), 1327–1335.

<https://doi.org/10.1056/NEJMoal305889>

10. Zannad, F., Cannon, C. P., Cushman, W. C., Bakris, G. L., Menon, V., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., Wilson, C., & EXAMINE Investigators. (2015). Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE. *The Lancet*, 385(9982), 2067–2076.

[https://doi.org/10.1016/S0140-6736\(14\)62225-X](https://doi.org/10.1016/S0140-6736(14)62225-X)

(vi) Thiazolidinediones: Nuclear-Level Metabolic Rewiring With a Heavy Systemic Bill

Thiazolidinediones (TZDs; pioglitazone, rosiglitazone) were sold as the sophisticated answer to insulin resistance—“insulin sensitizers” that finally go beyond brute-force insulin secretion. Mechanistically, they do hit a core defect. But they do it by **reprogramming nuclear transcription across multiple organs**, trading some glycaemic improvement for fluid overload, heart failure, fractures, weight gain, and worrying cancer and liver signals. This is not gentle tuning; it is genome-level coercion in the service of HbA1c.

Mechanism: Forcing Insulin Sensitivity by Rewriting Gene Expression

TZDs are **selective PPAR-γ agonists**:

- They heterodimerize with RXR and bind to **PPAR response elements (PPREs)** in DNA, upregulating gene networks that:
 - Increase **GLUT4 expression** and insulin signalling
 - Raise **adiponectin** and promote **adipogenesis**
 - Shift fatty acids out of ectopic depots (liver, muscle, visceral fat) into **subcutaneous adipose tissue**
 - Suppress inflammatory signalling and hepatic gluconeogenesis

(Lehmann et al., 1995; Yki-Järvinen, 2004).

System-wide consequences:

- Improved insulin sensitivity in muscle and liver
- Increased total fat mass, particularly subcutaneous
- Enhanced **renal sodium reabsorption** and increased vascular permeability → oedema and higher heart-failure risk (Nesto et al., 2003)

This is full-scale **transcriptional reprogramming** to force a more insulin-sensitive phenotype. From a naturopathic view, it's the opposite of working with physiology: we override the body's adaptive signalling, rather than removing the toxic lifestyle inputs that made those adaptations necessary.

Human Adverse Effects: Oedema, Heart Failure, Fractures, Weight Gain

Early / Short-Term Risks

- **Fluid retention and oedema** are common, often dose-related and amplified by concomitant insulin (Dormandy et al., 2005; Nesto et al., 2003).
- **Heart failure decompensation:**
 - TZDs increase incident and worsening **heart failure**, especially in patients with LV dysfunction or on insulin (Nesto et al., 2003; Lincoff et al., 2007).
 - They are **contraindicated in NYHA class III–IV heart failure**.
- **Weight gain and anaemia/hemodilution** are frequent, reflecting both fluid retention and increased adiposity.

The “insulin sensitizer” label obscures the clinical reality: a substantial subset of patients end up heavier, more fluid-overloaded, and closer to heart-failure admissions.

Long-Term Risks

- **Bone fractures**
 - TZDs increase peripheral fractures, particularly in women and likely in men, via PPAR- γ -driven shifts from osteoblastogenesis to adipogenesis in bone marrow (Kahn et al., 2008; Bilezikian, 2008).
 - The trade-off becomes: better glucose vs more brittle bones.
- **Macular oedema**
 - Case reports and observational data link TZDs to **diabetic macular oedema**, sometimes reversible after stopping the drug (Idris et al., 2012).
 - Again, vascular permeability modulation has consequences beyond the intended targets.
- **Cardiovascular signals**
 - **Rosiglitazone** was associated with an increased risk of myocardial infarction in meta-analyses, prompting major regulatory restrictions and long-lasting distrust (Nissen & Wolski, 2007).
 - **Pioglitazone** showed mixed results: some benefit on composite CV endpoints in high-risk patients (PROactive), but **more heart-failure events** (Dormandy et al., 2005; Lincoff et al., 2007).
- **Bladder cancer (pioglitazone)**
 - Observational studies raised concerns of increased bladder-cancer risk, particularly with long duration and high cumulative dose (Ferwana et al., 2013). Later work is mixed, but the signal has not vanished.
- **Hepatotoxicity**
 - Less catastrophic than troglitazone (withdrawn), but **rare serious liver injury** still occurs, mandating evaluation

and discontinuation if hepatic symptoms appear (NIDDK, 2012).

Taken together, TZDs exchange some insulin resistance improvement for **fluid overload, skeletal fragility, uncertain carcinogenesis, and liver stress**—a high systemic price for a chronic, lifestyle-driven disease.

Pregnancy and Development: “Clean” Organogenesis, Late-Gestation Damage

Human pregnancy data are scarce. But given:

- The known **heart-failure and fluid-retention risks** in mothers
- The **developmental toxicity** at higher exposures in multiple species

Current guidance rightly steers away from TZDs in pregnancy, favouring **insulin-based regimens** where pharmacotherapy is necessary.

For a naturopathic, preconception-focused strategy, TZDs make little sense: they add systemic stress at a time when the priority should be optimising terrain—diet, micronutrients, toxin exposure, weight, and metabolic resilience—before and during gestation.

Critical Appraisal: Deep Intervention, Modest Payoff

On a conceptual level, TZDs come closest among glucose-lowering drugs to engaging a root abnormality—**insulin resistance**. But in practice:

- Their **HbA1c reduction** is moderate (~0.8–1.0%).
- They do **not cure diabetes**, nor do they remove the need for additional agents.
- They impose serious systemic liabilities: **oedema, heart failure, fractures, weight gain, possible bladder cancer, macular oedema, and occasional liver injury**.

Meanwhile, we now have:

- **GLP-1RAs** that reduce weight and improve MACE in high-risk patients.
- **SGLT2 inhibitors** that robustly protect against heart failure and CKD progression.
- Growing evidence for **intensive lifestyle and naturopathic interventions** that can markedly improve or remit insulin resistance without rewriting nuclear receptor signalling across the body.

Within this evolving landscape, routine, long-term TZD use looks increasingly like an aggressive genomic workaround to avoid confronting diet, inactivity, sleep disruption, psychosocial stress, and environmental toxins.

TZDs therefore exemplify a certain style of allopathic thinking: **pull powerful molecular levers to fix lab values while leaving the patient's world—the real source of metabolic injury—largely intact.**

In the chapters ahead, we will contrast this nuclear-reprogramming approach with naturopathic strategies that improve insulin sensitivity through whole-foods nutrition, structured movement, sleep and stress optimisation, targeted botanicals, and toxin reduction—approaches designed to work with, rather than override, the body's adaptive biology.

References:

1. Bilezikian, J.P. Combination anabolic and antiresorptive therapy for osteoporosis: Opening the anabolic window. *Curr Osteoporos Rep* 6, 24–30 (2008).
<https://doi.org/10.1007/s11914-008-0005-9>
2. Dormandy, J. A., Charbonnel, B., Eckland, D. J. A., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., Standl, E., Wilcox, R. G., Wilhelmsen, L., Betteridge, J., Birkeland, K., Golay, A., Heine, R. J., Korányi, L., Laakso, M., ...

- PROactive Investigators. (2005). Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study. *The Lancet*, 366(9493), 1279–1289.
[https://doi.org/10.1016/S0140-6736\(05\)67528-9](https://doi.org/10.1016/S0140-6736(05)67528-9)
3. Ferwana, M., Firwana, B., Hasan, R., Al-Meshari, A., Ahlawat, S., Kim, S., Montori, V., & Murad, M. H. (2013). Pioglitazone and risk of bladder cancer: A meta-analysis of controlled studies. *Diabetic Medicine*, 30(9), 1026–1032.
<https://doi.org/10.1111/dme.12144>
 4. Idris I, Warren G, Donnelly R. Association Between Thiazolidinedione Treatment and Risk of Macular Edema Among Patients With Type 2 Diabetes. *Arch Intern Med*. 2012;172(13):1005–1011.
<https://doi.org/10.1001/archinternmed.2012.1938>
 5. Kahn, S. E., Zinman, B., Lachin, J. M., Haffner, S. M., Herman, W. H., Holman, R. R., Kravitz, B. G., Yu, D., Heise, M. A., Freed, M. I., & Viberti, G. (2008). Rosiglitazone-associated fractures in type 2 diabetes: An analysis from A Diabetes Outcome Progression Trial (ADOPT). *Diabetes Care*, 31(5), 845–851.
<https://doi.org/10.2337/dc07-2270>
 6. Lehmann, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkison, W. O., Willson, T. M., & Kliewer, S. A. (1995). An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPAR γ). *Journal of Biological Chemistry*, 270(22), 12953–12956.
<https://doi.org/10.1074/jbc.270.22.12953>
 7. Lincoff, A. M., Wolski, K., Nicholls, S. J., & Nissen, S. E. (2007). Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis of randomized trials. *JAMA*, 298(10), 1180–1188.
<https://doi.org/10.1001/jama.298.10.1180>
 8. National Institute of Diabetes and Digestive and Kidney Diseases. (2012). *Pioglitazone, rosiglitazone, and other*

thiazolidinediones. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury.

<https://www.ncbi.nlm.nih.gov/books/NBK548327/>

9. Nesto, R. W., Bell, D., Bonow, R. O., Fonseca, V., Grundy, S. M., Horton, E. S., Le Winter, M., Porte, D., Semenkovich, C. F., Smith, S., Young, L. H., & Kahn, R. (2003). Thiazolidinedione use, fluid retention, and congestive heart failure. *Circulation*, 108(23), 2941–2948.
<https://doi.org/10.1161/01.CIR.0000103683.99399.7E>
10. Nissen, S. E., & Wolski, K. (2007). Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes: A meta-analysis of randomized trials. *New England Journal of Medicine*, 356(24), 2457–2471.
<https://doi.org/10.1056/NEJMoa072761>
11. Yki-Järvinen, H. (2004). Thiazolidinediones. *New England Journal of Medicine*, 351(11), 1106–1118.
<https://doi.org/10.1056/NEJMr041001>

(vii) SGLT2 Inhibitors: Cardio-Renal “Game Changers” That Push the Kidney into Chronic Glucosuria

SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin, etc.) are hailed as revolutionary in type 2 diabetes, heart failure, and chronic kidney disease. They **do** reduce heart-failure hospitalisations and slow CKD progression—something most glucose-lowering drugs never achieved. But they achieve this by **forcing the kidney to chronically waste glucose and sodium**, resetting glomerular haemodynamics via pharmacologic stress, and they carry real risks: genital infections, volume depletion, euglycaemic ketoacidosis, and rare necrotising infections, plus clear signals of developmental renal toxicity in juvenile animals. Once again, powerful pharmacology substitutes for serious work on food, movement, sleep, and environment.

Mechanism: Induced Glucosuria and a Haemodynamic “Reset”

In healthy kidneys, **SGLT2 in the S1/S2 proximal tubule reabsorbs ≈90% of filtered glucose:**

- After glomerular filtration, SGLT2 inhibitors are secreted into the tubular lumen and bind **SGLT2 on the apical membrane** of proximal tubular cells.
- This **reduces glucose and sodium reabsorption**; downstream SGLT1 picks up some of the slack, so maximal blockade yields ≈40–50% reduction in total glucose reabsorption and sustained glucosuria (Zhang et al., 2025; Heerspink et al., 2016).
- Reduced proximal Na⁺–glucose uptake increases **distal NaCl delivery**, amplifying tubuloglomerular feedback, constricting the afferent arteriole, and **lowering intraglomerular pressure**—a central mechanism for renal protection (Zhang et al., 2025b; Vallon, 2024).
- SGLT2 inhibitors also modulate **NHE3**, adding to natriuresis and blood-pressure reductions (Heerspink et al., 2016).

In practical terms, these drugs **force the kidney into chronic osmotic diuresis and natriuresis** and “reset” glomerular haemodynamics through sustained tubular and vascular signals. That reset is beneficial in over-pressured diabetic glomeruli—but it is still an imposed, pharmacologic state, not a restoration of normal physiology.

Human Adverse Effects: Genital Infections, Volume Loss, Ketoacidosis, and Rare Necrosis

Common / Short-Term Effects

- **Genital mycotic infections** (vulvovaginal candidiasis, balanitis) are frequent, driven by glucosuria and a glucose-rich perineal environment—especially in women and

uncircumcised men (Nyirjesy & Sobel, 2013; Unnikrishnan et al., 2019).

- **Polyuria and volume depletion** can cause dizziness, orthostatic hypotension, and transient creatinine rises, particularly in older adults, those on diuretics, or with low baseline BP (Chan et al., 2022; Li & Guan., 2026).
- **UTIs** may increase modestly; data are mixed.

Serious but Less Common Risks

- **Euglycaemic diabetic ketoacidosis (DKA)**
 - Reported in both type 1 and type 2 diabetes, often triggered by low-carb diets, illness, surgery, fasting, or overly aggressive insulin reduction (Peters et al., 2015).
 - DKA can occur with near-normal glucose, delaying recognition and treatment.
- **Necrotising fasciitis of the perineum (Fournier's gangrene)**
 - Rare but devastating; cases have been reported with multiple SGLT2 inhibitors, prompting FDA class-wide warnings.
- **Amputation signal (canagliflozin)**
 - The CANVAS Program showed a **higher risk of lower-limb amputation**, mostly at toe or forefoot level (Neal et al., 2017).
- **Bone effects**
 - Data are mixed: some studies suggest small increases in fracture risk with specific agents, others appear neutral (Zinman et al., 2015; Neal et al., 2017).

So while SGLT2 inhibitors are often described as “well tolerated,” they bring a recognisable syndrome: more genital infections, more volume-related issues, and a non-trivial risk of life-threatening ketoacidosis and rare necrotising infections.

Long-Term Benefits: Strong Cardio-Renal Outcomes, Still Not a Cure

SGLT2 inhibitors are unique among glucose-lowering drugs for the **strength of their outcome data**:

- **Empagliflozin (EMPA-REG OUTCOME)**: reduced **cardiovascular death, all-cause mortality, and heart-failure hospitalisation** in high-risk type 2 diabetes (Zinman et al., 2015).
- **Canagliflozin (CANVAS, CREDENCE)**: lowered composite CV outcomes and **markedly slowed CKD progression** in diabetic kidney disease (Neal et al., 2017; Perkovic et al., 2019).
- **Dapagliflozin (DAPA-HF, DAPA-CKD)** and **empagliflozin** in HFrEF/CKD, with and without diabetes, consistently reduced heart-failure hospitalisations and improved renal endpoints (McMurray et al., 2019; Heerspink et al., 2020).

These results are real—and a sharp contrast to many “me-too” glucose drugs. But:

- Benefits are **additive to standard therapies**, not substitutes for lifestyle transformation.
- The price is **lifelong renal glucose and sodium manipulation**, with the side-effect profile above.
- As soon as the drug stops, the old terrain—ultra-processed food, inactivity, poor sleep, chronic stress—reasserts itself.

From a naturopathic perspective, SGLT2 inhibitors are **high-impact adjuncts**, not excuses to avoid the more difficult work of dismantling the metabolic drivers of heart failure and CKD.

Pregnancy and Development:

Mechanistically, this is exactly what you would expect: **blocking the main renal glucose transporter in a developing kidney** alters

tubular physiology and structure, sometimes in ways that are not fully reversible.

Human Guidance

For a drug class that “protects” adult kidneys by inhibiting SGLT2, the same target becomes a **liability** in nephrogenesis. A naturopathic, preconception-centred approach avoids these agents when building a healthy pregnancy and instead prioritises metabolic healing through nutrition, movement, stress reduction, and toxin avoidance well before conception.

Critical Appraisal: High-Leverage Tools, Still Not Root-Cause Medicine

Among modern diabetes drugs, SGLT2 inhibitors arguably offer the **strongest hard-outcome benefits**, especially for heart failure and CKD. Yet:

- They enforce **chronic glucosuria and natriuresis**, with a predictable cluster of genital infections, volume issues, ketoacidosis risk, and rare necrotising infections.
- They demand **behavioural vigilance**: hydration, sick-day rules, peri-operative holds, careful insulin adjustments, and meticulous genital hygiene.
- They do **nothing to change** the underlying reality of ultra-processed, high-sugar diets, sedentary living, sleep disruption, psychosocial stress, and environmental toxicants.

Used wisely—especially in people with diabetes plus heart failure or CKD—they can be **genuinely life-prolonging**. Used as a broad, first-line patch for lifestyle-driven disease, they become yet another sophisticated pharmacologic workaround that allows the metabolic environment to remain fundamentally unchanged, locking patients into long-term dependence on a powerful renal modulator.

In later chapters, we will examine how naturopathic interventions—nutrient-dense, low-toxicity diets; structured movement; sleep and

stress work; botanicals and micronutrients supportive of vascular and renal health—can be integrated alongside or, in some cases, ahead of SGLT2 inhibitors to reduce drug burden and target root causes.

References:

1. Chan, Y., Chao, T., Chen, S., Kao, Y., Huang, C., & Chu, P. (2022). Association of acute increases in serum creatinine with subsequent outcomes in patients with type 2 diabetes mellitus treated with sodium–glucose cotransporter 2 inhibitor or dipeptidyl peptidase-4 inhibitor. *European Heart Journal - Quality of Care and Clinical Outcomes*, 9(4), 397–407. <https://doi.org/10.1093/ehjqcco/qcac040>
2. Heerspink, H. J. L., Perkins, B. A., Fitchett, D. H., Husain, M., & Cherney, D. Z. I. (2016). Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: Cardiovascular and kidney effects, potential mechanisms, and clinical applications. *Circulation*, 134(10), 752–772. <https://doi.org/10.1161/CIRCULATIONAHA.116.021887>
3. Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F. F., Lindberg, M., McMurray, J. J. V., Rossing, P., Sjöström, C. D., Toto, R. D., Langkilde, A. M., & Wheeler, D. C. (2020). Dapagliflozin in patients with chronic kidney disease. *New England Journal of Medicine*, 383(15), 1436–1446. <https://doi.org/10.1056/NEJMoa2024816>
4. Li, H., Guan, Z. Signal mining of adverse drug events related to hypovolemia caused by SGLT2 inhibitors based on FAERS database. *Int J Diabetes Dev Ctries* 46, 323–333 (2026). <https://doi.org/10.1007/s13410-025-01516-8>
5. McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohávek, J., Böhm, M.,

- Chiang, C.-E., Chopra, V. K., de Boer, R. A., Desai, A. S., Diez, M., Drozd, J., Dukát, A., ... DAPA-HF Trial Committees and Investigators. (2019). Dapagliflozin in patients with heart failure and reduced ejection fraction. *New England Journal of Medicine*, 381(21), 1995–2008.
<https://doi.org/10.1056/NEJMoa1911303>
6. Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erond, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017). Canagliflozin and cardiovascular and renal events in type 2 diabetes (CANVAS). *New England Journal of Medicine*, 377(7), 644–657.
<https://doi.org/10.1056/NEJMoa1611925>
 7. Nyirjesy, P., & Sobel, J. D. (2013). Genital mycotic infections in patients with diabetes. *Postgraduate medicine*, 125(3), 33–46. <https://doi.org/10.3810/pgm.2013.05.2650>
 8. Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., Cannon, C. P., Capuano, G., Chu, P. L., de Zeeuw, D., Greene, T., Levin, A., Pollock, C., Wheeler, D. C., Yavin, Y., Zhang, H., ... CREDENCE Trial Investigators (2019). Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. *The New England journal of medicine*, 380(24), 2295–2306.
<https://doi.org/10.1056/NEJMoa1811744>
 9. Peters, A. L., Buschur, E. O., Buse, J. B., Cohan, P., Diner, J. C., & Hirsch, I. B. (2015). Euglycemic diabetic ketoacidosis: A potential complication of treatment with sodium–glucose cotransporter 2 inhibition. *Diabetes Care*, 38(9), 1687–1693.
<https://doi.org/10.2337/dc15-0843>
 10. Unnikrishnan, A. G., Kalra, S., Purandare, V., & Vasawala, H. (2018). Genital Infections with Sodium Glucose Cotransporter-2 Inhibitors: Occurrence and Management in Patients with Type 2 Diabetes Mellitus. *Indian journal of*

- endocrinology and metabolism, 22(6), 837–842.
https://doi.org/10.4103/ijem.IJEM_159_17
11. Vallon, V. (2024). State-of-the-Art-Review: Mechanisms of action of SGLT2 inhibitors and clinical implications. *American Journal of Hypertension*, 37(11), 841–852.
<https://doi.org/10.1093/ajh/hpae092>
 12. Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., Bhatt, D. L., Leiter, L. A., McGuire, D. K., Wilding, J. P. H., Ruff, C. T., Gause-Nilsson, I., Fredriksson, M., Johansson, P. A., Langkilde, A. M., & Sabatine, M. S. (2019). Dapagliflozin and cardiovascular outcomes in type 2 diabetes (DECLARE–TIMI 58). *New England Journal of Medicine*, 380(4), 347–357.
<https://doi.org/10.1056/NEJMoa1812389>
 13. Zhang, Z., Li, Y., Gu, H. F., & Li, N. (2025). Pharmacological mechanisms and clinical applications between SGLT1 and SGLT2 inhibitors in type 2 diabetes and diabetic kidney disease: An analytic review. *Biomedicine & Pharmacotherapy*, 193, 118837.
<https://doi.org/10.1016/j.biopha.2025.118837>
 14. Zhang, Z., Li, Y., Gu, H. F., & Li, N. (2025b). Pharmacological mechanisms and clinical applications between SGLT1 and SGLT2 inhibitors in type 2 diabetes and diabetic kidney disease: An analytic review. *Biomedicine & Pharmacotherapy*, 193, 118837.
<https://doi.org/10.1016/j.biopha.2025.118837>
 15. Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Inzucchi, S. E. (2015). Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes (EMPA-REG OUTCOME). *New England Journal of Medicine*, 373(22), 2117–2128.
<https://doi.org/10.1056/NEJMoa1504720>

(viii) Insulin: Life-Saving Hormone, Blunt Force Drug

Insulin is unlike any other diabetes treatment. As a hormone, it is **physiologically essential** and absolutely life-saving—especially for type 1 diabetes and certain critical states in type 2. Without it, many patients would simply die. Yet in allopathic practice, insulin is also deployed as a **blunt pharmacologic weapon**, often in escalating doses to compensate for uncorrected insulin resistance and high-carbohydrate diets. In that role, it drives hypoglycaemia, weight gain, and overtreatment—turning a vital hormone into a source of iatrogenic harm.

Mechanism: Restoring Deficiency or Forcing an Overloaded System

Endogenous and injected insulin act through the **insulin receptor (IR)**, a transmembrane tyrosine kinase:

- Insulin binding triggers **IR autophosphorylation** and recruitment of IRS proteins, activating **PI3K → PIP3 → PDK1 → Akt (PKB)** (Saltiel & Kahn, 2001; Boucher et al., 2014).
- Akt then:
 - Phosphorylates TBC1D4/AS160, allowing **GLUT4 vesicle translocation** to the plasma membrane in muscle and adipose tissue → increased glucose uptake.
 - Suppresses hepatic gluconeogenesis and promotes glycogen synthesis.
- Parallel **MAPK cascades** regulate mitogenic pathways, cell growth, and gene expression.

In **type 1 diabetes**, exogenous insulin replaces a missing hormone and is non-negotiable. In **type 2 diabetes**, insulin is often used to **overcome insulin resistance by raising circulating levels** high enough to drive these pathways despite resistance in target tissues.

From a naturopathic standpoint, using insulin to restore a genuine deficiency is fundamentally different from using high doses to prop up a lifestyle and environment that remain metabolically toxic.

Human Risks: Hypoglycaemia, Weight Gain, Overtreatment

Acute Risks

- **Hypoglycaemia** is the principal immediate danger:
 - Triggered by missed/delayed meals, dosing errors, renal/hepatic impairment, or very intensive regimens.
 - Can cause confusion, seizures, arrhythmias, falls, traffic accidents, and death (Philip, 2016).
- **Injection-site problems** (lipohypertrophy, lipoatrophy, local reactions) and the **practical burden** (multiple daily injections, frequent glucose checks, carbohydrate counting) are constant stressors.

Modern basal and rapid-acting analogues reduce severe hypoglycaemia relative to older human insulin when carefully titrated, but **they cannot eliminate it** (Dalal et al., 2017; Melanie et al., 2018).

Chronic Consequences

- **Weight gain** is common, reflecting insulin's anabolic effects and reduced glucosuria; this **worsens insulin resistance**, often leading to yet higher doses and a self-reinforcing loop (UKPDS Group, 1998; Boucher et al., 2014).
- Recurrent hypoglycaemia is linked to:
 - Falls, fractures, and injuries in older adults.
 - Cognitive effects and **fear of hypoglycaemia**, which can cause patients to overeat and avoid physical activity (Philip, 2014).
- Observational studies sometimes show **worse cardiovascular outcomes** in patients on high-dose insulin compared with other regimens—findings heavily confounded

by disease severity, but still a warning that “more insulin” is not automatically “better” (Currie et al., 2013).

Unlike some drugs, insulin itself is not directly hepatotoxic or carcinogenic. The risk comes from **chronic hyperinsulinaemia and glycaemic volatility** imposed by using it to chase high-carb diets and unstable lifestyles, instead of fixing the upstream behaviour and environment.

Pregnancy: Indispensable and Relatively Safe—When Used Wisely

Insulin is **standard of care in pregnancy** for pre-existing diabetes and gestational diabetes:

- The human placenta transports **very little insulin** at therapeutic doses; fetal exposure is low (Hauguel-de Mouzon & Guerre-Millo, 2006; Desoye & Nolan, 2016).
- Long-acting analogues such as **glargine and detemir** have been widely used without clear teratogenic signals; major guidelines accept them as reasonable options (Feig et al., 2018; ADA, 2024).

Fetal risk is driven primarily by **maternal glycaemia**, not direct insulin toxicity:

- **Hyperglycaemia** increases risk of congenital malformations, miscarriage, macrosomia, shoulder dystocia, birth trauma, preeclampsia, and stillbirth.
- **Hypoglycaemia** can cause acute fetal stress (e.g., movement changes, heart rate variability) and maternal harm.

In pregnancy, the goal is near-normal glycaemia achieved through careful titration rather than aggressive overcorrection.

Critical Appraisal: Essential Hormone, Not a License for Metabolic Neglect

Insulin occupies a special status:

- In **type 1 diabetes**, it is an unquestionable hero: non-negotiable, life-saving, and irreplaceable.
- In **advanced type 2 diabetes**, it is often necessary. But it is also too often used as a **pharmacologic crutch** to cover unmodified high-carbohydrate intake, inactivity, poor sleep, and chronic stress.

Key concerns:

- **High-dose insulin regimens in insulin-resistant type 2 diabetes** can trap patients in cycles of weight gain, recurrent hypoglycaemia, and fear of changing diet or exercising.
- Trials like **ACCORD** showed that pushing HbA1c down aggressively with complex regimens (often insulin-heavy) in frail, high-risk patients was associated with **increased mortality**, likely related to hypoglycaemia, weight gain, and treatment burden (ACCORD Study Group, 2008).
- Chronic hyperinsulinaemia may promote **fat storage, sodium retention, and sympathetic activation**, all unfavourable from a cardiometabolic standpoint—even if direct causal proof in humans is complex.

A naturopathic and integrative approach does not question insulin's life-saving role where deficiency exists. It challenges the reflex of **ever-escalating doses to prop up an unchanged lifestyle**. Insulin should be:

- Used as **physiologically as possible** (basal–bolus or simplified basal matched to a realistic, whole-food eating pattern and activity).
- Coupled from the outset with serious, structured efforts to **reduce insulin resistance**: targeted carbohydrate reduction, nutrient-dense whole foods, regular movement, sleep optimisation, stress and trauma-informed care, and toxin reduction.

- **De-intensified** thoughtfully in older or multi-morbid patients to avoid hypoglycaemia and burden, prioritising safety over rigid numerical targets.

Insulin is both **a hero and a hazard: irreplaceable when** deficiency is real, but potentially harmful when used as a blunt instrument to override an unhealthy metabolic environment rather than transforming it.

In forthcoming chapters, we will outline naturopathic strategies—especially therapeutic nutrition, movement, stress work, and careful medication de-prescribing—that can reduce the need for high-dose insulin in type 2 diabetes and support safer, more physiologic insulin use where it remains essential.

References

1. ACCORD Study Group. (2008). Effects of intensive glucose lowering in type 2 diabetes. *New England Journal of Medicine*, 358(24), 2545–2559.
<https://doi.org/10.1056/NEJMoa0802743>
2. American Diabetes Association. (2024). 14. Management of diabetes in pregnancy: Standards of care in diabetes—2024. *Diabetes Care*, 47(Suppl. 1), S254–S267.
<https://doi.org/10.2337/dc24-S014>
3. Boucher, J., Kleinridders, A., & Kahn, C. R. (2014). Insulin receptor signaling in normal and insulin-resistant states. *Cold Spring Harbor Perspectives in Biology*, 6(1), a009191.
<https://doi.org/10.1101/cshperspect.a009191>
4. Currie, C. J., Peters, J. R., Tynan, A., Evans, M., Heine, R. J., Bracco, O. L., Zagar, T., & Poole, C. D. (2013). Survival as a function of HbA1c in people with type 2 diabetes: A retrospective cohort study. *The Lancet*, 375(9713), 481–489.
[https://doi.org/10.1016/S0140-6736\(09\)61969-3](https://doi.org/10.1016/S0140-6736(09)61969-3)
5. Dalal, M. R., Kazemi, M., Ye, F., & Xie, L. (2017). Hypoglycemia After Initiation of Basal Insulin in Patients

- with Type 2 Diabetes in the United States: Implications for Treatment Discontinuation and Healthcare Costs and Utilization. *Advances in therapy*, 34(9), 2083–2092.
<https://doi.org/10.1007/s12325-017-0592-x>
6. Desoye, G., & Nolan, C. J. (2016). The fetal glucose steal: an underappreciated phenomenon in diabetic pregnancy. *Diabetologia*, 59(6), 1089–1094.
<https://doi.org/10.1007/s00125-016-3931-6>
 7. Feig, D. S., Berger, H., Donovan, L., Godbout, A., Kader, T., Keely, E., & Sanghera, R. (2018). Diabetes and pregnancy. *Canadian Journal of Diabetes*, 42, S255–S282.
<https://doi.org/10.1016/j.cjcd.2017.10.038>
 8. Hauguel-de Mouzon, S., & Guerre-Millo, M. (2006). The placenta cytokine network and inflammatory signals. *Placenta*, 27(8–9), 794–798.
<https://doi.org/10.1016/j.placenta.2005.08.009>
 9. Melanie J. Davies, David A. D'Alessio, Judith Fradkin, Walter N. Kernan, Chantal Mathieu, Geltrude Mingrone, Peter Rossing, Apostolos Tsapas, Deborah J. Wexler, John B. Buse; Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care* 1 December 2018; 41 (12): 2669–2701. <https://doi.org/10.2337/dci18-0033>
 10. Philip E. Cryer; Glycemic Goals in Diabetes: Trade-off Between Glycemic Control and Iatrogenic Hypoglycemia. *Diabetes* 1 July 2014; 63 (7): 2188–2195.
<https://doi.org/10.2337/db14-0059>
 11. Saltiel, A. R., & Kahn, C. R. (2001). Insulin signalling and the regulation of glucose and lipid metabolism. *Nature*, 414(6865), 799–806. <https://doi.org/10.1038/414799a>
 12. UK Prospective Diabetes Study (UKPDS) Group. (1998). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of

complications in patients with type 2 diabetes (UKPDS 33).
The Lancet, 352(9131), 837–853.

[https://doi.org/10.1016/S0140-6736\(98\)07019-6](https://doi.org/10.1016/S0140-6736(98)07019-6)

Reframing the Role of Drugs in Diabetes

What this chapter argues is “no drugs,” but a **different hierarchy**:

- These agents should be regarded as **supportive tools**, not as substitutes for changing the **metabolic and social environment** in which diabetes develops.
- In type 2 diabetes, the primary therapeutic goal must shift from “lifelong pharmacologic management” to **maximising the chances of remission or deep medication reduction** through:
 - Nutritional strategies that radically cut ultra-processed foods and excess/refined carbohydrates and prioritise nutrient-dense, whole foods.
 - Regular, structured physical activity and resistance training.
 - Sleep and circadian alignment.
 - Stress reduction, trauma-informed care, and robust psychosocial support.

Within this framework:

- Drugs are used **judiciously, at the lowest effective dose, for the shortest necessary duration**, as **bridges** while root causes are actively treated.
- Success is measured not only by HbA1c, but by **fewer drugs, fewer side-effects, better function and mood, and restored metabolic flexibility and resilience**.

Naturopathic Concept of Diabetes

Early naturopathic medicine, as articulated by Henry Lindlahr, framed most chronic disease (outside trauma) as the consequence of accumulated “morbid matter” obstructing microcirculation and disturbing tissue nutrition and elimination (Lindlahr, 1919). In this view, disease does not “strike” from outside; it **emerges from a chronically disordered internal milieu** created by violations of “natural laws” in lifestyle and environment.

Translated into modern language, three interdependent domains are regarded as fundamental to cellular health:

1. Innervation (Neural Regulation)

Optimal central and autonomic nervous system function is essential for metabolic homeostasis, including glucose regulation and vascular tone. Chronic psychological stress, sleep disruption (e.g., night-shift work), substance use, certain medications, and persistent negative emotional states disturb autonomic balance and HPA-axis activity, reducing “vitality” and promoting metabolic dysregulation (Thayer et al., 2010; Vinik et al., 2011).

2. Nutrition (Quality of the Internal Milieu)

Diet shapes the composition of blood, lymph, and interstitial fluids, which then governs cellular nutrition and signalling. Diets rich in refined carbohydrates, saturated and trans fats, and ultra-processed foods—and poor in fibre and micronutrients—drive systemic inflammation, insulin

resistance, and type 2 diabetes risk (Ley et al., 2014; Mozaffarian, 2016).

3. **Drainage (Elimination and Microcirculation)**

Efficient venous and lymphatic return, along with intact renal and hepatobiliary function, enable removal of metabolic by-products and inflammatory mediators. Sedentary behaviour, excess calories, alcohol overuse, and environmental toxicants fuel low-grade inflammation, oxidative stress, and endothelial dysfunction—central mechanisms in diabetic vascular complications (Donath & Shoelson, 2011; Forbes & Cooper, 2013).

From a naturopathic standpoint, disturbance in any of these domains **erodes cellular resilience** and sets the stage for chronic metabolic disease, including type 2 diabetes. Contemporary data on stress physiology, diet-induced inflammation, and microvascular dysfunction provide partial mechanistic support. The older language of “morbid matter” has effectively evolved into concepts such as **oxidative stress, advanced glycation end products (AGEs), and chronic low-grade inflammation** (Donath & Shoelson, 2011; Rask-Madsen & King, 2013).

Naturopathic Interpretation of Type 2 Diabetes Mellitus

Think of the body as a neighbourhood of homes (cells) served by roads (blood vessels and capillaries), traffic signals and phone lines (innervation), and garbage collection routes (venous and lymphatic drainage). Healthy living requires three basics: reliable communication (innervation), clean delivery of supplies (nutrition), and regular waste removal (drainage).

Type 2 diabetes mellitus (T2DM) is conventionally defined as a chronic metabolic disorder characterised by insulin resistance and progressive β -cell dysfunction, resulting in persistent hyperglycemia (American Diabetes Association [ADA], 2023). A naturopathic

interpretation emphasises how lifestyle-related disturbances in innervation, nutrition, and drainage drive this process:

- **Innervation:** Chronic stress and circadian disruption alter autonomic balance and hypothalamic–pituitary–adrenal (HPA) axis activity, promoting hypercortisolemia, central adiposity, and insulin resistance (Huang et al., 2013; McEwen, 2008).
- **Nutrition:** Excess intake of refined carbohydrates, sugar-sweetened beverages, and energy-dense, nutrient-poor foods contributes to postprandial glucose excursions, lipotoxicity, and chronic inflammation, while diets rich in whole grains, legumes, vegetables, fruits, and unsaturated fats are associated with lower diabetes risk (Ley et al., 2014; Morze et al., 2020).
- **Drainage and microcirculation:** Endothelial dysfunction, impaired capillary recruitment, and altered lymphatic function contribute to reduced tissue perfusion, reduced glucose uptake in skeletal muscle, and accumulation of inflammatory mediators, which further worsen insulin resistance (Rask-Madsen & King, 2013; Meijer et al., 2012).

As the neighbourhood accumulates waste and deliveries become erratic, individual homes (cells) receive poor nourishment and waste removal fails. In response, muscle and fat cells become insulin-resistant (they stop “opening their doors” to glucose), pancreatic beta cells become overworked and eventually lose function, and microvessels suffer damage. Clinically, these processes manifest as fasting and postprandial hyperglycemia, compensatory hyperinsulinemia in early stages, progressive insulin resistance in liver, muscle, and adipose tissue, and long-term microvascular and macrovascular complications (ADA, 2023; DeFronzo et al., 2015).

Naturopathic response follows the same three targets: restore communication (reduce stress, improve sleep, balance autonomic tone), improve nutrition (whole foods, appropriate macronutrient

balance, timing, and removal of dietary toxins), and enhance drainage (reduce inflammation, support liver, kidney, and lymphatic function, encourage movement and hydration). In doing so, restoring these systems unclogs the microcirculation, improves cellular nutrition, and reestablishes waste removal — helping to reverse insulin resistance and protect organ function.

Naturopathic management focuses on:

- Modulating autonomic balance through stress reduction, sleep optimisation, and physical activity.
- Improving diet quality (emphasising minimally processed foods, adequate fibre, and healthy fats).
- Supporting physiological elimination and circulation via movement, hydration, and avoidance of tobacco and excess alcohol.

Some of these strategies are consistent with established guideline-based lifestyle recommendations for diabetes prevention and management (Tuomilehto et al., 2001; Knowler et al., 2002; ADA, 2023).

Molecular Basis of Diabetes

Classical Pathophysiology

Diabetes Mellitus was historically described as a disorder of carbohydrate metabolism because of its defining feature: elevated blood glucose levels. Modern understanding distinguishes:

- Type 1 diabetes: Autoimmune destruction of pancreatic β -cells leading to absolute insulin deficiency.
- Type 2 diabetes: A combination of insulin resistance and progressive β -cell dysfunction. In early T2DM, hyperglycemia is commonly accompanied by compensatory hyperinsulinemia and multiple endocrine alterations (DeFronzo et al., 2015; Kahn et al., 2014).

Insulin resistance does not arise from a defect in the insulin molecule itself, but from impaired responsiveness of target tissues, including skeletal muscle, adipose tissue, and liver. This impairment involves defects in insulin receptor signalling, intracellular signalling intermediates, GLUT4 translocation, and downstream metabolic pathways (Samuel & Shulman, 2016).

Cellular Glucose Transport: Role of GLUT4

Skeletal muscle and adipose tissue account for the majority of insulin-stimulated glucose disposal. The process involves:

1. Insulin receptor activation: Insulin binds to its receptor on the cell surface, leading to autophosphorylation and recruitment of insulin receptor substrates (IRS proteins).
2. Intracellular signalling: Activation of phosphatidylinositol 3-kinase (PI3K) and Akt/protein kinase B pathways.
3. GLUT4 translocation: GLUT4-containing vesicles move from intracellular storage sites to the plasma membrane.
4. Glucose uptake: GLUT4 facilitates glucose entry into the cell by facilitated diffusion; glucose is subsequently metabolised in the cytosol and mitochondria to generate ATP (Huang & Czech, 2007; Bryant et al., 2002).

In insulin-resistant states, multiple defects may occur, including reduced IRS phosphorylation, impaired PI3K/Akt signalling, altered GLUT4 trafficking, and decreased GLUT4 expression, resulting in diminished cellular glucose uptake and elevated blood glucose (Samuel & Shulman, 2016).

Membrane Lipids, Insulin Resistance, and Fatty Acids

Membrane lipid composition influences receptor function, signal transduction, and transporter mobility. The phospholipid bilayer of the plasma membrane contains varying proportions of saturated fatty acids, monounsaturated fatty acids, polyunsaturated fatty acids (PUFAs), and cholesterol. These constituents modulate membrane

fluidity and the organisation of signalling microdomains (e.g., lipid rafts, caveolae) (Simons & Sampaio, 2011).

Several mechanistic links between lipids and insulin resistance are supported by contemporary evidence:

- Intramyocellular and intrahepatic lipids: Accumulation of certain lipid intermediates (e.g., diacylglycerols, ceramides) in muscle and liver interferes with insulin signalling and contributes to insulin resistance (Samuel & Shulman, 2016).
- Fatty acid composition: Diets higher in saturated fatty acids are associated with greater insulin resistance, whereas higher intakes of polyunsaturated and monounsaturated fats, particularly n-6 and n-3 PUFAs, are associated with improved insulin sensitivity and lower diabetes risk (Imamura et al., 2016; Morze et al., 2020).
- Trans fats: Industrially produced trans fatty acids adversely affect lipid profiles, inflammation, and cardiovascular risk and are associated with a higher risk of type 2 diabetes (Mozaffarian et al., 2006; de Souza et al., 2015). Global public health agencies now recommend virtual elimination of industrial trans fats from the food supply.

While early naturopathic explanations emphasised a direct substitution of “unhealthy fats” in cell membranes leading to a “sticky” membrane and blocked sugar entry, current evidence refines this view. Membrane composition is dynamic and influences signalling and transporter behaviour, but insulin does not physically “pass through” the membrane; rather, it binds to surface receptors and initiates intracellular signalling. Insulin resistance is multifactorial, involving genetics, ectopic fat deposition, inflammation, mitochondrial function, and lipid intermediates, rather than a single category of “bad fats” (Kahn et al., 2014; Samuel & Shulman, 2016).

Dietary Fats, Trans Fats, and Type 2 Diabetes

The dietary pattern increasingly common in many countries, including India—high in refined carbohydrates, deep-fried foods, and (until recently) partially hydrogenated oils—has contributed to rising rates of obesity and T2DM (Misra & Khurana, 2008; Mohan et al., 2009). Key points from current evidence include:

- Industrial trans fats (partially hydrogenated oils) are strongly discouraged due to their adverse cardiometabolic effects; many countries are phasing them out.
- Not all vegetable oils are harmful: Oils rich in unsaturated fats (e.g., soybean, canola, sunflower, and olive oils) are associated with improved lipid profiles and lower cardiovascular and diabetes risk when they replace saturated fats (Imamura et al., 2016; Mozaffarian, 2016).
- Omega-3 fatty acids (e.g., from flaxseed, walnuts, fatty fish) contribute to anti-inflammatory effects. They may modestly improve some cardiometabolic risk factors, although they are not a standalone treatment for diabetes (Mori, 2014).

Consequently, evidence-based dietary advice for individuals with or at risk for T2DM emphasises the overall dietary pattern—whole grains, legumes, vegetables, fruits, nuts, seeds, and replacement of saturated and trans fats with unsaturated fats—rather than categorical avoidance of all vegetable oils (ADA, 2023; Morze et al., 2020).

Therefore, from the above understanding, it is beyond dispute that naturopathic care offers a robust framework for addressing the upstream causes and lifestyle drivers of type 2 diabetes. Properly integrated, naturopathy can:

- Improve glycemic control and insulin sensitivity.
- Reduce cardiometabolic risk factors (blood pressure, lipids, weight).
- Enhance patient self-efficacy and adherence through education and counselling.

- Potentially delay disease progression and reduce complications.

In summary, naturopathy has an important active role in diabetes management by delivering structured, patient-centered, lifestyle-based interventions that are consistent with modern evidence on the prevention and treatment of type 2 diabetes, provided it is practised in collaboration with current conventional care (if needed) and grounded in current clinical guidelines and safety standards.

References:

1. American Diabetes Association. (2023). 2. Classification and diagnosis of diabetes: Standards of care in diabetes—2023. *Diabetes Care*, 46(Suppl. 1), S19–S40. <https://doi.org/10.2337/dc23-S002>
2. Bryant, N. J., Govers, R., & James, D. E. (2002). Regulated transport of the glucose transporter GLUT4. *Nature Reviews Molecular Cell Biology*, 3(4), 267–277. <https://doi.org/10.1038/nrm782>
3. DeFronzo, R. A., Ferrannini, E., Groop, L., Henry, R. R., Herman, W. H., Holst, J. J., Hu, F. B., Kahn, C. R., Raz, I., Shulman, G. I., Simonson, D. C., & Weiss, R. (2015). Type 2 diabetes mellitus. *Nature Reviews Disease Primers*, 1, 15019. <https://doi.org/10.1038/nrdp.2015.19>
4. de Souza, R. J., Mente, A., Maroleanu, A., Cozma, A. I., Ha, V., Kishibe, T., Uleryk, E., Budylowski, P., Schünemann, H., Beyene, J., & Anand, S. S. (2015). Intake of saturated and trans unsaturated fatty acids and risk of all cause mortality, cardiovascular disease, and type 2 diabetes: Systematic review and meta-analysis of observational studies. *BMJ*, 351, h3978. <https://doi.org/10.1136/bmj.h3978>
5. Donath, M. Y., & Shoelson, S. E. (2011). Type 2 diabetes as an inflammatory disease. *Nature Reviews Immunology*, 11(2), 98–107. <https://doi.org/10.1038/nri2925>

6. Forbes, J. M., & Cooper, M. E. (2013). Mechanisms of diabetic complications. *Physiological Reviews*, 93(1), 137–188. <https://doi.org/10.1152/physrev.00045.2011>
7. Huang, P. L., & Czech, M. P. (2007). The GLUT4 glucose transporter. *Cell Metabolism*, 5(4), 237–252. <https://doi.org/10.1016/j.cmet.2007.03.006>
8. Huang, C. J., Zourdos, M. C., Jo, E., & Ormsbee, M. J. (2013). Influence of physical activity and nutrition on obesity-related immune function. *TheScientificWorldJournal*, 2013, 752071. <https://doi.org/10.1155/2013/752071>
9. Imamura, F., Micha, R., Wu, J. H. Y., de Oliveira Otto, M. C., Otite, F. O., Abioye, A. I., & Mozaffarian, D. (2016). Effects of saturated fat, polyunsaturated fat, monounsaturated fat, and carbohydrate on glucose-insulin homeostasis: A systematic review and meta-analysis of randomised controlled feeding trials. *PLoS Medicine*, 13(7), e1002087. <https://doi.org/10.1371/journal.pmed.1002087>
10. Kahn, S. E., Cooper, M. E., & Del Prato, S. (2014). Pathophysiology and treatment of type 2 diabetes: Perspectives on the past, present, and future. *Lancet*, 383(9922), 1068–1083. [https://doi.org/10.1016/S0140-6736\(13\)62154-6](https://doi.org/10.1016/S0140-6736(13)62154-6)
11. Knowler, W. C., Barrett-Connor, E., Fowler, S. E., Hamman, R. F., Lachin, J. M., Walker, E. A., & Nathan, D. M. (2002). Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *New England Journal of Medicine*, 346(6), 393–403. <https://doi.org/10.1056/NEJMoa012512>
12. Ley, S. H., Hamdy, O., Mohan, V., & Hu, F. B. (2014). Prevention and management of type 2 diabetes: Dietary components and nutritional strategies. *Lancet*, 383(9933), 1999–2007. [https://doi.org/10.1016/S0140-6736\(14\)60613-9](https://doi.org/10.1016/S0140-6736(14)60613-9)

13. Lindlahr, H. (1919). *Philosophy of Natural Therapeutics*. Nature Cure Publishing. (Public domain: https://archive.org/details/bwb_S0-AEC-168/mode/2up)
14. McEwen, B. S. (2008). Central effects of stress hormones in health and disease: Understanding the protective and damaging effects of stress and stress mediators. *European Journal of Pharmacology*, 583(2–3), 174–185. <https://doi.org/10.1016/j.ejphar.2007.11.071>
15. MEIJER, R.I., DE BOER, M.P., GROEN, M.R., ERINGA, E.C., RATTIGAN, S., BARRETT, E.J., SMULDERS, Y.M. and SERNE, E.H. (2012), Insulin-Induced Microvascular Recruitment in Skin and Muscle are Related and Both are Associated with Whole-Body Glucose Uptake. *Microcirculation*, 19: 494-500. <https://doi.org/10.1111/j.1549-8719.2012.00174.x>
16. Misra, A., & Khurana, L. (2008). Obesity and the metabolic syndrome in developing countries. *Journal of Clinical Endocrinology & Metabolism*, 93(11 Suppl. 1), S9–S30. <https://doi.org/10.1210/jc.2008-1595>
17. Mohan, V., Radhika, G., Sathya, R. M., Tamil, S. R., Ganesan, A., & Sudha, V. (2009). Dietary carbohydrates, glycaemic load, food groups and newly detected type 2 diabetes among urban Asian Indian population in Chennai, India (Chennai Urban Rural Epidemiology Study 59). *The British journal of nutrition*, 102(10), 1498–1506. <https://doi.org/10.1017/S0007114509990468>
18. Mozaffarian, D. (2016). Dietary and policy priorities for cardiovascular disease, diabetes, and obesity: A comprehensive review. *Circulation*, 133(2), 187–225. <https://doi.org/10.1161/CIRCULATIONAHA.115.018585>
19. Mozaffarian, D., Katan, M. B., Ascherio, A., Stampfer, M. J., & Willett, W. C. (2006). Trans fatty acids and cardiovascular disease. *New England Journal of Medicine*, 354(15), 1601–1613. <https://doi.org/10.1056/NEJMra054035>

20. Mori, T. A. (2014). Dietary n-3 PUFA and CVD: a review of the evidence. *Proceedings of the Nutrition Society*, 73(1), 57–64. <https://doi.org/10.1017/S0029665113003583>
21. Rask-Madsen, C., & King, G. L. (2013). Vascular complications of diabetes: Mechanisms of injury and protective factors. *Cell Metabolism*, 17(1), 20–33. <https://doi.org/10.1016/j.cmet.2012.11.012>
22. Samuel, V. T., & Shulman, G. I. (2016). The pathogenesis of insulin resistance: Integrating signaling pathways and substrate flux. *Journal of Clinical Investigation*, 126(1), 12–22. <https://doi.org/10.1172/JCI77812>
23. Morze, J., Danielewicz, A., Hoffmann, G., & Schwingshackl, L. (2020). Diet Quality as Assessed by the Healthy Eating Index, Alternate Healthy Eating Index, Dietary Approaches to Stop Hypertension Score, and Health Outcomes: A Second Update of a Systematic Review and Meta-Analysis of Cohort Studies. *Journal of the Academy of Nutrition and Dietetics*, 120(12), 1998–2031.e15. <https://doi.org/10.1016/j.jand.2020.08.076>
24. Simons, K., & Sampaio, J. L. (2011). Membrane organization and lipid rafts. *Cold Spring Harbor Perspectives in Biology*, 3(10), a004697. <https://doi.org/10.1101/cshperspect.a004697>
25. Thayer, J. F., Åhs, F., Fredrikson, M., Sollers, J. J., & Wager, T. D. (2010). A meta-analysis of heart rate variability and neuroimaging studies: Implications for heart rate variability as a marker of stress and health. *Neuroscience & Biobehavioral Reviews*, 36(2), 747–756. <https://doi.org/10.1016/j.neubiorev.2011.11.009>
26. Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., Salminen, V., & Uusitupa, M. (2001). Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose

- tolerance. *New England Journal of Medicine*, 344(18), 1343–1350. <https://doi.org/10.1056/NEJM200105033441801>
27. Vinik, A. I., Maser, R. E., Mitchell, B. D., & Freeman, R. (2011). Diabetic autonomic neuropathy. *Diabetes Care*, 36(6), 1553–1579. <https://doi.org/10.2337/diacare.26.5.1553>

Metabolism of Glucose: The Crucial Role of Minerals

Note: This section is intended to give conceptual insight into why minerals are indispensable for life and energy metabolism, rather than to provide a detailed biochemical pathway map. Students in MBBS and related systems of medicine (Naturopathy, Unani, Ayurveda, Siddha, Homoeopathy, Sowa-Rigpa) will already study the full chemical reactions in biochemistry.

The Krebs Cycle: Central pathway of Energy Metabolism

The Krebs cycle (also known as the Citric Acid Cycle or Tricarboxylic Acid [TCA] cycle) is a series of enzyme-catalysed reactions in the mitochondrial matrix that represents a central hub of energy metabolism in almost all aerobic organisms (Stryer et al., 2023).

Acetyl-CoA, derived from carbohydrates (via glycolysis), fatty acids (via β -oxidation), and certain amino acids, enters the Krebs cycle. Through a sequence of oxidative reactions, acetyl units are fully oxidised to CO_2 , and high-energy electrons (in the form of NADH and FADH_2) are transferred to the mitochondrial electron transport chain to drive ATP synthesis (Nicholls & Ferguson, 2013).

In classical teaching, oxidation steps in the Krebs cycle and subsequent oxidative phosphorylation are described in terms of ATP yield: for each pair of electrons (originally from hydrogen atoms) transferred via NADH through the electron transport chain, a

theoretical maximum of ~2.5–3 ATP can be generated under ideal conditions (Stryer et al., 2023; Nicholls & Ferguson, 2013).

Several organic acid “salts” used clinically as mineral carriers—citrates, malates, succinates, and to some extent glycines and taurines—are either direct intermediates of the Krebs cycle or related compounds. When minerals are chelated with these organic acids, they may have enhanced gastrointestinal absorption and participate more directly in mitochondrial metabolism (Schuette et al., 1994).

Why Minerals Matter: The Inner Ocean and Electrolytes

Life on Earth is thought to have arisen in a mineral-rich aqueous environment, often described as a “primordial soup” of inorganic and organic molecules (Martin et al., 2008). In mammals, including humans, the extracellular fluid that bathes cells and tissues is sometimes compared—conceptually—to an “internal ocean” with tightly regulated concentrations of ions such as sodium, potassium, calcium, magnesium, chloride, bicarbonate, and phosphate (Guyton & Hall, 2021). Small deviations in this ionic balance can profoundly affect cell function.

Electrolytes and Cell Membrane Potentials

Electrolytes are substances that dissociate into ions in solution and thereby conduct electrical current. Key physiological electrolytes include sodium (Na^+), potassium (K^+), calcium (Ca^{2+}), magnesium (Mg^{2+}), chloride (Cl^-), and bicarbonate (HCO_3^-).

Cell membranes are selectively permeable lipid bilayers that allow water and some small molecules to move relatively freely, while channels and transporters tightly regulate the movement of ions. Cells contain a high concentration of charged organic molecules (e.g., proteins, nucleic acids) that attract inorganic ions and influence water distribution. Without compensatory mechanisms, osmotic

forces would lead to continuous water influx and eventual cell swelling and lysis.

To prevent this, cells expend energy (ATP) to maintain ionic gradients across the plasma membrane. The Na^+/K^+ -ATPase (sodium–potassium pump) uses the energy of ATP hydrolysis (as MgATP) to pump three Na^+ ions out and two K^+ ions into the cell for each cycle, thereby generating and maintaining:

- A high intracellular K^+ and low intracellular Na^+ concentration.
- A negative resting membrane potential essential for nerve impulse conduction and muscle contraction.
- Electrochemical gradients used for secondary active transport of glucose, amino acids, and other solutes (Kaplan, 2002).

Mitochondria also use transmembrane electrochemical gradients (proton gradients) to synthesise ATP—the proton motive force generated by the respiratory chain drives ATP synthase in oxidative phosphorylation (Nicholls & Ferguson, 2013).

Minerals as Cofactors: Enabling Enzymes and Energy Reactions

Enzymes are protein catalysts that lower the activation energy of biochemical reactions. Many enzymes require non-protein cofactors to function, which can be either:

- **Coenzymes:** organic molecules (often derived from vitamins), or
- **Cofactors:** metal ions (e.g., Mg^{2+} , Zn^{2+} , Cu^{2+} , $\text{Fe}^{2+}/\text{Fe}^{3+}$, Se in selenocysteine).

These cofactors can participate in redox reactions, stabilise enzyme–substrate complexes, or serve as transient carriers of chemical groups.

Phosphate groups, particularly in ATP, store and transfer energy via high-energy phosphoanhydride bonds. ATP commonly exists in cells

as a complex with Mg^{2+} (MgATP), which is the true substrate for many kinases and transporters, including the Na^+/K^+ -ATPase (Stryer et al., 2023; Romani, 2011).

Magnesium and other minerals therefore act as indispensable cofactors for hundreds of enzyme systems. Deficiencies can impair multiple metabolic pathways simultaneously, including those central to glucose metabolism and insulin action (Romani, 2011; Barbagallo & Dominguez, 2015).

Selected Minerals in Energy Metabolism and Antioxidant Defense

Copper (Cu)

Copper is distributed in the liver, brain, heart, kidneys, and skeleton and is essential for multiple cuproenzymes involved in oxidative metabolism and antioxidant defence (Lutsenko, 2016):

- Cytochrome c oxidase (Complex IV): The terminal enzyme of the mitochondrial electron transport chain, responsible for >90% of cellular oxygen consumption. It catalyses the reduction of O_2 to water and contributes to the proton gradient used for ATP synthesis.
- Cu/Zn-superoxide dismutase (SOD1): Converts superoxide anions ($\text{O}_2^{\cdot-}$) to hydrogen peroxide (H_2O_2), providing a first-line intracellular defence against reactive oxygen species (ROS).
- Ceruloplasmin: A multicopper oxidase that participates in iron metabolism and also exhibits antioxidant activity.

Copper is involved in collagen and elastin cross-linking, haemoglobin synthesis, and normal pigmentation of hair and skin. Copper deficiency is associated with anaemia, bone abnormalities, impaired connective tissue integrity, and, in severe cases, neurological dysfunction (Lutsenko, 2016; Uauy et al, 1998).

Magnesium (Mg)

Magnesium is a cofactor for more than 300 enzymatic reactions, many of which are fundamental to energy metabolism (Romani, 2011):

- Essential for all reactions involving ATP, since ATP is usually bound to Mg^{2+} (MgATP).
- Required for key glycolytic and Krebs cycle enzymes (e.g., hexokinase, phosphofructokinase, pyruvate dehydrogenase complex components, and various dehydrogenases).
- Provides the energy for the Na^+/K^+ -ATPase, sustaining membrane potentials in nerve and muscle cells.
- Involved in DNA/RNA synthesis, protein synthesis, and fatty acid metabolism.
- Modulates calcium handling and vascular tone; low magnesium status has been linked with insulin resistance, hypertension, and increased risk of type 2 diabetes (Barbagallo & Dominguez, 2015).

Dietary surveys suggest that subclinical magnesium deficiency is common among populations consuming highly refined diets, with implications for metabolic and cardiovascular health (Papagiannidou et al., 2026).

Sodium (Na^+) and Potassium (K^+)

Sodium and potassium are the principal extracellular and intracellular cations, respectively, and are fundamental for:

- Resting membrane potential and action potential generation in excitable tissues (neurons, myocytes).
- Secondary active transport of glucose (e.g., SGLT transporters in the intestine and kidney) and amino acids.
- Regulation of extracellular fluid volume and blood pressure (Guyton & Hall, 2021).

The Na^+/K^+ -ATPase, powered by MgATP, maintains high intracellular K^+ and low intracellular Na^+ , enabling nerve conduction, muscle contraction, and nutrient transport (Kaplan, 2002).

Selenium (Se)

Selenium is incorporated as selenocysteine into several selenoproteins with critical roles in antioxidant defence and redox regulation:

- Glutathione peroxidases (GPx): Reduce hydrogen peroxide and organic hydroperoxides to water or corresponding alcohols using glutathione as an electron donor, thus limiting oxidative damage to lipids, proteins, and DNA (Brigelius-Flohé & Maiorino, 2013).
- Thioredoxin reductases and other redox enzymes: Contribute to cellular redox homeostasis and detoxification.

Glutathione peroxidase activity helps detoxify peroxides and supports the regeneration of other antioxidants, such as vitamin E, indirectly by reducing peroxidised lipids (Brigelius-Flohé & Maiorino, 2013).

Zinc (Zn)

Zinc is required for the structure or catalytic activity of over 300 enzymes and numerous transcription factors (Vallee & Falchuk, 1993; King, 2011). It plays central roles in:

- Carbohydrate and energy metabolism: Components of enzymes in glycolysis, the Krebs cycle, and protein and nucleic acid synthesis.
- Antioxidant defence: Zn is part of Cu/Zn-superoxide dismutase (SOD1), protecting cells from superoxide radicals, and indirectly supports vitamin A and E metabolism.
- Collagen and connective tissue: Cofactor for collagenase and other matrix metalloproteinases; important for wound healing and skin integrity.

- Immune function: Essential for T-cell development and function, antibody production, and maintenance of epithelial barriers (King, 2011).

Zinc deficiency can impair growth, immunity, wound healing, and sense of taste, and may alter glucose and lipid metabolism (King, 2011).

Clinical Relevance in Diabetes and Metabolic Health

Modern agriculture, food processing, and high-heat cooking can reduce dietary intake or bioavailability of several minerals and essential nutrients (Mayer, 1997; Mente et al., 2017). In the context of diabetes and metabolic disorders:

- Suboptimal magnesium and zinc status have been associated with a higher risk of insulin resistance and type 2 diabetes (Barbagallo & Dominguez, 2015; Ranasinghe et al., 2015).
- Adequate selenium, copper, and zinc are important for antioxidant defence systems (GPx, SOD, ceruloplasmin) that counteract the oxidative stress commonly observed in diabetes and its complications (Forbes & Cooper, 2013).
- Preservation of mitochondrial function and Krebs cycle activity is dependent on appropriate availability of these mineral cofactors, as well as vitamins, amino acids, and essential fatty acids.

Thus, while the biochemical details of the Krebs cycle and associated pathways are complex, their efficient operation fundamentally depends on a diverse set of minerals that act as structural elements, electrolytes, enzyme cofactors, and components of antioxidant systems.

Naturopathic Medicine views nutritional correction as the foundation of diabetes management because what we eat directly shapes the “internal environment” in which disease either develops or heals. Thus, creating a health-promoting milieu is the need of the current approach for diabetes management.

References:

1. Barbagallo, M., & Dominguez, L. J. (2015). Magnesium and type 2 diabetes. *World Journal of Diabetes*, 6(10), 1152–1157. <https://doi.org/10.4239/wjd.v6.i10.1152>
2. Stryer, L., Berg, J., Tymoczko, J., Gatto, G., & Hines, J. (2023). *Biochemistry* (10th ed.). New York Macmillan Learning Wh Freeman.
3. Brigelius-Flohé, R., & Maorino, M. (2013). Glutathione peroxidases. *Biochimica et Biophysica Acta (BBA) - General Subjects*, 1830(5), 3289–3303. <https://doi.org/10.1016/j.bbagen.2012.11.020>
4. Forbes, J. M., & Cooper, M. E. (2013). Mechanisms of diabetic complications. *Physiological Reviews*, 93(1), 137–188. <https://doi.org/10.1152/physrev.00045.2011>
5. Guyton, A. C., & Hall, J. E. (2021). *Guyton and Hall textbook of medical physiology* (14th ed.). Elsevier.
6. Kaplan, J. H. (2002). Biochemistry of Na,K-ATPase. *Annual Review of Biochemistry*, 71, 511–535. <https://doi.org/10.1146/annurev.biochem.71.102201.141218>
7. King, J. C. (2011). Zinc: An essential but elusive nutrient. *The American Journal of Clinical Nutrition*, 94(2), 679S–684S. <https://doi.org/10.3945/ajcn.110.005744>
8. Lutsenko S. (2016). Copper trafficking to the secretory pathway. *Metallomics : integrated biometal science*, 8(9), 840–852. <https://doi.org/10.1039/c6mt00176a>
9. Martin, W., Baross, J., Kelley, D., & Russell, M. J. (2008). Hydrothermal vents and the origin of life. *Nature Reviews Microbiology*, 6(11), 805–814. <https://doi.org/10.1038/nrmicro1991>
10. Mayer, A.-M. B. (1997). Historical changes in the mineral content of fruits and vegetables. *British Food Journal*, 99(6), 207–211. <https://doi.org/10.1108/00070709710181540>

11. Mente, A., Mente, A., Dehghan, M., Rangarajan, S., McQueen, M., Dagenais, G., Wielgosz, A., Lear, S., Li, W., Chen, H., Yi, S., Wang, Y., Diaz, R., Avezum, A., Lopez-Jaramillo, P., Seron, P., Kumar, R., Gupta, R., Mohan, V., . . . Mapanga, R. (2017). Association of dietary nutrients with blood lipids and blood pressure in 18 countries: a cross-sectional analysis from the PURE study. *The Lancet Diabetes & Endocrinology*, 5(10), 774–787.
[https://doi.org/10.1016/s2213-8587\(17\)30283-8](https://doi.org/10.1016/s2213-8587(17)30283-8)
12. Nicholls, D. G., & Ferguson, S. J. (2013). *Bioenergetics 4* (4th ed.). Academic Press. Paperback ISBN: 9780123884251
13. Ranasinghe, P., Wathurapatha, W. S., Ishara, M. H., Jayawardana, R., Galappatthy, P., Katulanda, P., & Constantine, G. R. (2015). Effects of Zinc supplementation on serum lipids: a systematic review and meta-analysis. *Nutrition & metabolism*, 12, 26.
<https://doi.org/10.1186/s12986-015-0023-4>
14. Romani, A. M. P. (2011). Cellular magnesium homeostasis. *Archives of Biochemistry and Biophysics*, 512(1), 1–23.
<https://doi.org/10.1016/j.abb.2011.05.010>
15. Papagiannidou, A., Mitropoulou, M., Papantzikos, K. et al. Hypomagnesemia: A Clinical and Nutritional Update. *Curr Nutr Rep* 15, 30 (2026). <https://doi.org/10.1007/s13668-026-00745-5>
16. Schuette, S.A., Lashner, B.A. and Janghorbani, M. (1994), Bioavailability of Magnesium Diglycinate vs Magnesium Oxide in Patients with Ileal Resection. *Journal of Parenteral and Enteral Nutrition*, 18: 430-435.
<https://doi.org/10.1177/0148607194018005430>
17. Uauy, R., Olivares, M., & Gonzalez, M. (1998). Essentiality of copper in humans. *American Journal of Clinical Nutrition*, 67(5), 952S-959S. <https://doi.org/10.1093/ajcn/67.5.952s>

18. Vallee, B. L., & Falchuk, K. H. (1993). The biochemical basis of zinc physiology. *Physiological Reviews*, 73(1), 79–118. <https://doi.org/10.1152/physrev.1993.73.1.79>

Sugar and Health: A Naturopath's Viewpoint

How Much Glucose Is in the Blood?

In a healthy adult, fasting plasma glucose is approximately 70–100 mg/dL (3.9–5.6 mmol/L).. With an average blood volume of about 5 L (50 dL), a person with a glucose level of 100 mg/dL has roughly:

- $100 \text{ mg/dL} \times 50 \text{ dL} = 5,000 \text{ mg} = 5 \text{ g}$ of glucose

This is approximately one teaspoon of glucose circulating in the blood at any given time. By contrast, a typical day's intake of “free sugars” (added sugars, sugar in juices, syrups, honey) in many populations can easily exceed this amount many times over (CDC, 2024; Te Morenga et al., 2013). The body therefore must continually buffer repeated sugar loads by increasing insulin secretion, storing glucose as glycogen and fat, and increasing hepatic de novo lipogenesis.

Metabolic and Hormonal Effects of Excess Sugar

Acute intake of sugar-sweetened beverages and other rapidly absorbed sugars produces a sharp rise in blood glucose, followed by a compensatory rise in insulin. Over time, high intakes of free sugars—especially in liquid form—are associated with:

- Weight gain and visceral adiposity
- Insulin resistance and increased risk of type 2 diabetes
- Elevated triglycerides and non-alcoholic fatty liver disease
- Higher risk of cardiovascular disease

Large prospective studies and meta-analyses consistently link sugar-sweetened beverage consumption with incident type 2 diabetes and cardiometabolic disease, independent of total energy intake (Malik et al., 2010; Imamura et al., 2015; Te Morenga et al., 2013).

Complex carbohydrates from intact or minimally processed foods (e.g., whole grains, legumes, vegetables, whole fruits) are digested more slowly and generally produce a lower and more gradual glycemic response. They also deliver fibre, micronutrients, and bioactive compounds, which support glycaemic control, gut health, and satiety (Jenkins et al., 2002).

From a naturopathic standpoint, the key problem is not carbohydrate per se, but the dominance of rapidly absorbed, nutrient-poor sugars and refined starches in the modern diet.

Sugar, Immunity, and Vitamin C: What Is Known?

Naturopathic and orthomolecular traditions have long proposed that high sugar intake impairs immune function, partly by competing with vitamin C for cellular uptake. Vitamin C is indeed essential for optimal neutrophil function, including chemotaxis and phagocytosis (Carr & Maggini, 2017).

Early experimental work showed that acute consumption of large amounts of simple carbohydrates can transiently reduce neutrophil phagocytic activity in humans (Sanchez et al., 1973). However, the often-quoted numerical claims (e.g., “1 teaspoon of sugar lowers immune resistance by 50% for 24 hours”) are not supported by robust contemporary clinical trials.

What is reasonably supported:

- Chronic diets high in refined sugars contribute to obesity, insulin resistance, and systemic inflammation—all of which are associated with impaired innate and adaptive immunity (Calder et al., 2020).

- Vitamin C is required in high intracellular concentrations in leukocytes, and deficiency impairs host defence; maintaining adequate vitamin C intake from fruits and vegetables is important (Carr & Maggini, 2017).

Thus, while the precise quantitative impact of a single teaspoon of sugar on immune function is uncertain, a high-sugar dietary pattern clearly promotes metabolic states (hyperglycaemia, oxidative stress, inflammation) that weaken immune resilience over time.

Phosphoric Acid, Soft Drinks, and Mineral Balance

Many soft drinks contain phosphoric acid, providing a significant phosphorus load. High phosphorus intake from processed foods and cola beverages, particularly when combined with low calcium intake, has been associated with:

- Lower bone mineral density and, in some studies, a higher fracture risk in adolescents and young adults (Tucker et al., 2006).
- Increased urinary calcium excretion and potential alterations in calcium–phosphate balance (Calvo & Tucker, 2013).

The mechanism proposed is that excessive dietary phosphorus relative to calcium may stimulate parathyroid hormone and fibroblast growth factor-23, promoting bone resorption. However, bone health is influenced by many factors (overall diet quality, vitamin D status, physical activity, hormonal status), and soft drinks are one of several contributors, not the sole cause of osteoporosis.

Naturopathically, regular intake of sugar-sweetened, phosphoric acid–containing beverages is discouraged because it:

- Adds rapidly absorbed sugars and “empty calories”
- Displaces nutrient-dense beverages (e.g., water, milk, unsweetened herbal teas)
- May contribute to dysregulated mineral balance and dental erosion

Refined Sugar, Micronutrient Depletion, and Lipids

Refined sugars provide energy without vitamins, minerals, or fibre. Their metabolism uses vitamins and minerals as cofactors (e.g., B-vitamins, magnesium, chromium), potentially increasing requirements, particularly when overall diet quality is poor (Westman et al., 2008).

High intake of free sugars, especially fructose from sugar-sweetened beverages and high-fructose corn syrup, has been associated with:

- Elevated fasting and postprandial triglycerides
- Increased hepatic fat accumulation and non-alcoholic fatty liver disease
- Unfavourable changes in LDL and HDL cholesterol in some studies

These changes are mechanistically linked to increased hepatic de novo lipogenesis, driven by fructose and energy surplus (Lustig et al., 2012; Te Morenga et al., 2013).

Sugar and Behaviour, Mood, and Neurological Effects

Claims that sugar causes hyperactivity and major behavioural changes in children have been widely circulated. However, controlled trials and meta-analyses have generally not found a consistent causal effect of sugar on hyperactivity or behaviour in children (Wolraich et al., 1995).

Nonetheless:

- Rapid swings in blood glucose (reactive hypoglycaemia after high-sugar loads) may subjectively contribute to fluctuations in energy, mood, and concentration in some individuals.
- Diets high in ultra-processed foods and sugar-sweetened beverages are associated with poorer mental health outcomes in observational studies, although causality is complex (O'Neil et al., 2014).

- From a naturopathic perspective, stabilising blood sugar with low-glycaemic, nutrient-dense foods is considered beneficial for mood and cognitive function, although specific behavioural claims warrant cautious interpretation.

Honey and “Natural” Sweeteners

From a biochemical standpoint, honey is largely composed of simple sugars (primarily fructose and glucose), with minor amounts of enzymes, polyphenols, and trace nutrients, especially in raw, minimally processed varieties (Bogdanov et al., 2008).

Key points:

- **Glycaemic and metabolic effects:** Honey is still a source of free sugars and contributes to glycaemic load and energy intake. It can raise blood glucose and triglycerides, especially in larger amounts.
- **Dental caries:** Like other fermentable sugars, honey can promote dental caries if oral hygiene is poor (Moynihan & Kelly, 2014).
- **Infant botulism:** Honey may contain *Clostridium botulinum* spores and must not be given to infants under 12 months (Centers for Disease Control and Prevention [CDC], 2024).
- **Processing and quality:** Commercial honey is often heated and filtered, which may reduce some enzyme activity and phytonutrients.

Raw, high-quality honey may have modest antioxidant and antimicrobial properties; however, it should still be counted as a free sugar and used sparingly, particularly in people with diabetes or metabolic syndrome (Bogdanov et al., 2008). The statement that one may eat unlimited amounts of “good” honey is inconsistent with current evidence on free sugar and metabolic health.

Sugar, Addiction, and Reward Pathways

Modern neurobiological research supports the idea that highly palatable, sugar-rich foods activate brain reward pathways (dopaminergic mesolimbic circuits) similar to those involved in substance use disorders (Volkow et al, 2011).

In animal models:

- Rats allowed to choose between an intensely sweet solution and intravenous cocaine more often chose the sweet solution, even when they had prior cocaine exposure (Lenoir et al., 2007).
- Repeated intermittent sugar access can induce behaviours and neurochemical changes resembling dependence, including tolerance, withdrawal-like signs, and cross-sensitization with drugs of abuse (Avena et al., 2008).

These findings have led some authors to describe sugar as “addictive” in vulnerable individuals. However, in humans, the concept of “food addiction” is still debated; the term may best be understood as “addiction-like eating” or “highly rewarding food dependence,” rather than equating sugar directly with cocaine in terms of toxicity or social harm (Hebebrand et al., 2014).

Naturopathically, the key insight is that:

- Repeated exposure to high-sugar, ultra-processed foods can strongly condition reward pathways and eating behaviour.
- For some people, this leads to loss of control, overeating, and difficulty adhering to healthier diets—processes that are very real clinically, even if the precise term “addiction” is debated.

Overall Naturopathic Synthesis

From a naturopathic and evidence-informed viewpoint:

- The human body is designed to handle modest amounts of naturally occurring sugars bound within whole foods (fruits, vegetables, whole grains, legumes).
- Modern diets deliver large, repeated boluses of free sugars—often in liquids and ultra-processed foods—far exceeding physiological design.
- This pattern disrupts insulin dynamics, promotes fat storage, strains antioxidant and mineral reserves, alters the gut microbiome, and undermines immune and vascular health.
- Reducing free sugar intake, especially sugar-sweetened beverages and refined sweets, and replacing them with whole, nutrient-dense foods is central to preventing and managing diabetes and other chronic diseases.
- Major health organisations, including the World Health Organization (WHO) and American Heart Association, now recommend limiting free sugars to less than 10% of total energy intake, with further reduction to below 5% (about 25 g/day for an adult) likely to confer additional health benefits (World Health Organization, 2015; Johnson et al., 2009).

References:

1. Avena, N. M., Rada, P., & Hoebel, B. G. (2008). Evidence for sugar addiction: Behavioral and neurochemical effects of intermittent, excessive sugar intake. *Neuroscience & Biobehavioral Reviews*, 32(1), 20–39.
<https://doi.org/10.1016/j.neubiorev.2007.04.019>
2. Bogdanov, S., Jurendic, T., Sieber, R., & Gallmann, P. (2008). Honey for Nutrition and Health: A Review. *Journal of the American College of Nutrition*, 27(6), 677–689.
<https://doi.org/10.1080/07315724.2008.10719745>
3. Calder, P. C., Carr, A. C., Gombart, A. F., & Eggersdorfer, M. (2020). Optimal nutritional status for a well-functioning immune system is an important factor to protect against viral

- infections. *Nutrients*, 12(4), 1181.
<https://doi.org/10.3390/nu12041181>
4. Calvo, M. S., & Tucker, K. L. (2013). Is phosphorus intake that exceeds dietary requirements a risk factor in bone health? *Annals of the New York Academy of Sciences*, 1301(1), 29–35. <https://doi.org/10.1111/nyas.12300>
 5. Carr, A. C., & Maggini, S. (2017). Vitamin C and immune function. *Nutrients*, 9(11), 1211.
<https://doi.org/10.3390/nu9111211>
 6. CDC. (2024). Get the Facts: Added Sugars. In Nutrition. <https://www.cdc.gov/nutrition/php/data-research/added-sugars.html>
 7. CDC. (2024). Infant botulism. <https://www.cdc.gov/botulism/infant-botulism.html>
 8. Hebebrand, J., Albayrak, Ö., Adan, R., Antel, J., Dieguez, C., de Jong, J., ... Dickson, S. L. (2014). “Eating addiction”, rather than “food addiction”, better captures addictive-like eating behavior. *Neuroscience & Biobehavioral Reviews*, 47, 295–306. <https://doi.org/10.1016/j.neubiorev.2014.08.016>
 9. Imamura, F., O’Connor, L., Ye, Z., Mursu, J., Hayashino, Y., Bhupathiraju, S. N., & Forouhi, N. G. (2015). Consumption of sugar sweetened beverages, artificially sweetened beverages, and fruit juice and incidence of type 2 diabetes: Systematic review, meta-analysis, and estimation of population attributable fraction. *BMJ*, 351, h3576.
<https://doi.org/10.1136/bmj.h3576>
 10. Jenkins, D. J., Kendall, C. W., Augustin, L. S., Franceschi, S., Hamidi, M., Marchie, A., Jenkins, A. L., & Axelsen, M. (2002). Glycemic index: Overview of implications in health and disease. *The American Journal of Clinical Nutrition*, 76(1), 266S–273S. <https://doi.org/10.1093/ajcn/76.1.266s>
 11. Johnson, R. K., Appel, L. J., Brands, M., Howard, B. V., Lefevre, M., Lustig, R. H., ... Wylie-Rosett, J. (2009). Dietary sugars intake and cardiovascular health: A scientific

- statement from the American Heart Association. *Circulation*, 120(11), 1011–1020.
<https://doi.org/10.1161/CIRCULATIONAHA.109.192627>
12. Lenoir, M., Serre, F., Cantin, L., & Ahmed, S. H. (2007). Intense sweetness surpasses cocaine reward. *PLoS ONE*, 2(8), e698. <https://doi.org/10.1371/journal.pone.0000698>
 13. Lustig, R. H., Schmidt, L. A., & Brindis, C. D. (2012). Public health: The toxic truth about sugar. *Nature*, 482(7383), 27–29. <https://doi.org/10.1038/482027a>
 14. Malik, V. S., Popkin, B. M., Bray, G. A., Després, J. P., & Hu, F. B. (2010). Sugar-sweetened beverages, obesity, type 2 diabetes mellitus, and cardiovascular disease risk. *Circulation*, 121(11), 1356–1364.
<https://doi.org/10.1161/CIRCULATIONAHA.109.876185>
 15. Moynihan, P. J., & Kelly, S. A. M. (2014). Effect on caries of restricting sugars intake: Systematic review to inform WHO guidelines. *Journal of Dental Research*, 93(1), 8–18.
<https://doi.org/10.1177/0022034513508954>
 16. O’Neil, A., Quirk, S. E., Housden, S., Brennan, S. L., Williams, L. J., Pasco, J. A., Berk, M., & Jacka, F. N. (2014). Relationship between diet and mental health in children and adolescents: A systematic review. *American Journal of Public Health*, 104(10), e31–e42.
<https://doi.org/10.2105/AJPH.2014.302110>
 17. Sanchez, A., Reeser, J. L., Lau, H. S., Yahiku, P. Y., Willard, R. E., McMillan, P. J., & Rice, G. C. (1973). Role of sugars in human neutrophilic phagocytosis. *The American Journal of Clinical Nutrition*, 26(11), 1180–1184.
<https://doi.org/10.1093/ajcn/26.11.1180>
 18. Te Morenga, L., Mallard, S., & Mann, J. (2013). Dietary sugars and body weight: Systematic review and meta-analyses of randomised controlled trials and cohort studies. *BMJ*, 346, e7492. <https://doi.org/10.1136/bmj.e7492>

19. Tucker, K. L., Morita, K., Qiao, N., Hannan, M. T., Cupples, L. A., & Kiel, D. P. (2006). Colas, but not other carbonated beverages, are associated with low bone mineral density in older women: The Framingham Osteoporosis Study. *The American Journal of Clinical Nutrition*, 84(4), 936–942.
<https://doi.org/10.1093/ajcn/84.4.936>
20. Volkow, N. D., Wang, G.-J., Fowler, J. S., & Tomasi, D. (2011). Food and drug reward: Overlapping circuits in human obesity and addiction. *Current Topics in Behavioral Neurosciences*, 11, 1–24.
https://doi.org/10.1007/7854_2011_169
21. Westman, E. C., Yancy, W. S., Jr., & Mavropoulos, J. C. (2008). The effect of a low-carbohydrate, ketogenic diet versus a low-glycemic index diet on glycemic control in type 2 diabetes mellitus. *Nutrition & Metabolism*, 5, 36.
<https://doi.org/10.1186/1743-7075-5-36>
22. Wolraich, M. L., Wilson, D. B., & White, J. W. (1995). The effect of sugar on behavior or cognition in children: A meta-analysis. *JAMA*, 274(20), 1617–1621.
<https://doi.org/10.1001/jama.1995.03530200053037>
23. World Health Organization. (2015). *Guideline: Sugars intake for adults and children*.
<https://www.who.int/publications/i/item/9789241549028>

Sugar and Cancer


Cancer cells frequently exhibit altered energy metabolism compared with most normal cells. This metabolic reprogramming is characterised by increased glucose uptake and preferential conversion of glucose to lactate, even in the presence of oxygen. Understanding these mechanisms is important for appreciating how systemic glucose and insulin levels may influence cancer risk and progression, particularly in individuals with diabetes or insulin resistance.

Although the phrase “sugar feeds cancer” is popular, the relationship between dietary sugar, blood glucose, insulin, and cancer is complex. Current evidence supports reducing excess added sugars and improving metabolic health as part of comprehensive cancer prevention and care. Still, it does not justify extreme carbohydrate elimination or the abandonment of standard oncologic therapies.

The Warburg Effect and Tumour Metabolism

Otto Warburg first described that many malignant tumours demonstrate markedly increased glycolysis and lactate production compared with normal tissues, even under aerobic conditions (Warburg, 1956). This phenomenon, now referred to as the Warburg effect or aerobic glycolysis, reflects a metabolic shift that supports rapid cell proliferation by providing intermediates for biosynthesis and maintaining redox balance (Lunt & Vander Heiden, 2011).

ANAEROBIC GLYCOLYSIS



In cancer cells:

- Glucose uptake is often increased via overexpression of glucose transporters (GLUTs).
- Glycolytic flux is elevated, with substantial conversion of pyruvate to lactate.
- Lactate is exported, contributing to an acidic tumour microenvironment, which may influence invasion, immune evasion, and treatment response (Gatenby & Gillies, 2004).

By contrast, most differentiated normal cells rely predominantly on mitochondrial oxidative phosphorylation under aerobic conditions and use glycolysis primarily as a supplementary pathway.

This altered glucose metabolism is exploited clinically by 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET). FDG is preferentially taken up and phosphorylated by cells with high glycolytic activity, allowing visualization of many (but not all) tumours and metastases (Vlassenko & Mintun et al., 2011). Importantly, PET imaging demonstrates increased glucose utilisation by tumours; it does not, by itself, prove that dietary sugar intake is the direct cause of cancer.

Glucose, Insulin, and Cancer Risk

Chronic hyperglycaemia, hyperinsulinaemia, and insulin resistance—common in obesity and type 2 diabetes—are associated with increased risk of several cancers, including colorectal, postmenopausal breast, endometrial, pancreatic, and liver cancers (Lauby-Secretan et al., 2016; Giovannucci et al., 2010).

Key mechanisms include:

- **Insulin and IGF-1 signalling:** Insulin and insulin-like growth factor-1 (IGF-1) activate pathways (e.g., PI3K–AKT–mTOR, RAS–MAPK) that promote cell proliferation, inhibit apoptosis, and may facilitate tumour progression in susceptible tissues (Pollak, 2012).
- **Obesity-related inflammation:** Adiposity is associated with chronic low-grade inflammation, altered adipokines, and increased oestrogen production, which together may contribute to carcinogenesis (Park et al., 2014).
- **Hyperglycaemia and metabolic stress:** High glucose levels can induce oxidative stress and advanced glycation end-product formation, potentially affecting DNA integrity and cellular signalling.

Some tumour types express increased numbers of insulin and IGF-1 receptors, making them more responsive to these growth signals. However, it is inaccurate to state that cancer cells rely exclusively on sugar or that “insulin and diabetes medications cause cancer” as a general rule. Observational data on antidiabetic drugs and cancer risk are mixed and drug-specific; current guidelines continue to recommend evidence-based diabetes treatment, with ongoing safety monitoring (Johnson & Bowker, 2011; Zhao et al., 2017).

Dietary Sugars, Whole Foods, and Metabolic Health

Not all dietary sugars exert identical metabolic and health effects:

- **Free/added sugars** (e.g., table sugar, high-fructose corn syrup in sugar-sweetened beverages, sweets, and many processed foods) are energy dense and nutrient poor. High intake promotes positive energy balance and weight gain and is strongly linked to overweight, obesity, and type 2 diabetes (Malik & Hu, 2015).
- **Intrinsic sugars in whole foods** (e.g., fruits, vegetables, unsweetened dairy) are accompanied by fibre, micronutrients, and bioactive compounds that slow absorption and support overall metabolic health. High intake of whole fruits and vegetables is associated with reduced risk of several chronic diseases, including some cancers (Aune et al., 2017).

From a cancer and diabetes perspective, the main concern with sugar is its contribution to obesity and metabolic syndrome, rather than sugar acting as a unique carcinogen. The World Cancer Research Fund/AICR recommends limiting intake of sugar-sweetened beverages and energy-dense, ultra-processed foods to prevent weight gain and cancer (World Cancer Research Fund/AICR, 2018).

Sugar, Immune Function, and Hormonal Regulation

Insulin and Growth Hormone (GH) interact in complex ways:

- Chronic hyperinsulinaemia and insulin resistance are associated with alterations in GH and IGF-1 dynamics, which can influence body composition and metabolism (Ho et al., 1996).
- Short-term experimental studies show that acute hyperglycaemia can impair some aspects of neutrophil and lymphocyte function; poor glycaemic control in diabetes is associated with increased infection risk (Turina et al., 2005; Peleg et al., 2007).

However, evidence that typical variations in sugar intake, within an otherwise balanced diet, substantially suppress immune function in healthy individuals remains limited. More robust data link overall

nutritional status, obesity, physical inactivity, and uncontrolled diabetes to impaired immune responses and worse outcomes in infection and cancer.

Low-Carbohydrate and Ketogenic Diets in Cancer

Interest has grown in metabolic interventions, including low-carbohydrate and ketogenic diets, as adjuncts to cancer therapy. The rationale is to:

- Lower circulating glucose and insulin levels.
- Increase ketone body availability, which some preclinical studies suggest may be less readily utilised by certain tumour cells than by normal cells (Seyfried, 2012; Klement & Champ, 2014).

Current evidence:

- Preclinical studies and small early-phase clinical trials suggest potential benefits in specific settings, but findings are heterogeneous and not definitive.
- Large, high-quality randomised controlled trials are limited, and ketogenic diets may be difficult to sustain and potentially contraindicated in some patients (e.g., with cachexia, renal or hepatic impairment) (Barber et al., 2021).
- Thus, while metabolic therapy is promising as a research area, it should be considered experimental and always integrated with—not substituted for—standard oncologic care.

In summary, the adverse effects of excessive sugar intake extend well beyond weight gain and dental caries. High consumption of added sugars contributes to hyperglycaemia, hyperinsulinaemia, insulin resistance, and weight gain, thereby increasing the risk of type 2 diabetes, cardiovascular disease, and several cancers. Conversely, dietary patterns that limit added sugars and refined carbohydrates while emphasising whole, minimally processed foods, healthy fats, and adequate fibre support more favourable insulin and hormone

profiles, reduce chronic inflammation, and help preserve immune and metabolic health. For individuals with or at risk for diabetes, understanding the metabolic impact of sugar and making informed, evidence-based dietary choices are essential components of long-term disease prevention and comprehensive chronic disease management.

References:

1. Aune, D., Giovannucci, E., Boffetta, P., Fadnes, L. T., Keum, N., Norat, T., ... Tonstad, S. (2017). Fruit and vegetable intake and the risk of cardiovascular disease, total cancer and all-cause mortality—a systematic review and dose-response meta-analysis of prospective studies. *International Journal of Epidemiology*, 46(3), 1029–1056.
<https://doi.org/10.1093/ije/dyw319>
<https://academic.oup.com/ije/article/46/3/1029/3039477>
2. Barber, T. M., Hanson, P., Kabisch, S., Pfeiffer, A. F. H., & Weickert, M. O. (2021). The Low-Carbohydrate Diet: Short-Term Metabolic Efficacy Versus Longer-Term Limitations. *Nutrients*, 13(4), 1187. <https://doi.org/10.3390/nu13041187>
3. Gatenby, R. A., & Gillies, R. J. (2004). Why do cancers have high aerobic glycolysis? *Nature Reviews Cancer*, 4(11), 891–899. <https://doi.org/10.1038/nrc1478>
<https://www.nature.com/articles/nrc1478>
4. Giovannucci, E., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel, L. A., ... Yee, D. (2010). Diabetes and cancer: a consensus report. *CA: A Cancer Journal for Clinicians*, 60(4), 207–221.
<https://doi.org/10.3322/caac.20078>
<https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.20078>
5. Ho KK, O'Sullivan AJ, Hoffman DM. Metabolic actions of growth hormone in man. *Endocrine Journal*. 1996 Oct;43

Suppl:S57-63. DOI: 10.1507/endocrj.43.suppl_s57. PMID: 9076343.

6. Huang, S. C., Phelps, M. E., Hoffman, E. J., Sideris, K., Selin, C. J., & Kuhl, D. E. (2000). Noninvasive quantitative imaging of glucose metabolism in tumors. *Nature Medicine*, 6(6), 721–728. <https://doi.org/10.1038/75762>
https://www.nature.com/articles/nm0600_721
7. Johnson, J.A., Bowker, S.L. Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials. *Diabetologia* 54, 25–31 (2011).
<https://doi.org/10.1007/s00125-010-1933-3>
8. Klement, R. J., & Champ, C. E. (2014). Calories, carbohydrates, and cancer therapy with radiation: exploiting the five R's through dietary manipulation. *Cancer metastasis reviews*, 33(1), 217–229. <https://doi.org/10.1007/s10555-014-9495-3>
9. Lauby-Secretan, B., Scoccianti, C., Loomis, D., Grosse, Y., Bianchini, F., & Straif, K. (2016). Body fatness and cancer — Viewpoint of the IARC Working Group. *New England Journal of Medicine*, 375(8), 794–798.
<https://doi.org/10.1056/nejmsr1606602>
10. Lunt, S. Y., & Vander Heiden, M. G. (2011). Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. *Annual Review of Cell and Developmental Biology*, 27, 441–464. <https://doi.org/10.1146/annurev-cellbio-092910-154237>
<https://www.annualreviews.org/doi/10.1146/annurev-cellbio-092910-154237>
11. Malik, V. S., & Hu, F. B. (2015). Fructose and cardiometabolic health: what the evidence from sugar-sweetened beverages tells us. *Journal of the American College of Cardiology*, 66(14), 1615–1624.
<https://doi.org/10.1016/j.jacc.2015.08.025>
<https://www.jacc.org/doi/10.1016/j.jacc.2015.08.025>

12. Zhao, M., Chen, J., Yuan, Y. et al. Dipeptidyl peptidase-4 inhibitors and cancer risk in patients with type 2 diabetes: a meta-analysis of randomized clinical trials. *Sci Rep* 7, 8273 (2017). <https://doi.org/10.1038/s41598-017-07921-2>
13. Park, J., Morley, T. S., Kim, M., Clegg, D. J., & Scherer, P. E. (2014). Obesity and cancer—mechanisms underlying tumour progression and recurrence. *Nature Reviews Endocrinology*, 10(8), 455–465.
<https://doi.org/10.1038/nrendo.2014.94>
<https://www.nature.com/articles/nrendo.2014.94>
14. Peleg, A. Y., Weerarathna, T., McCarthy, J. S., & Davis, T. M. E. (2007). Common infections in diabetes: pathogenesis, management and relationship to glycaemic control. *Diabetes/Metabolism Research and Reviews*, 23(1), 3–13.
<https://doi.org/10.1002/dmrr.682>
<https://onlinelibrary.wiley.com/doi/10.1002/dmrr.682>
15. Pollak, M. (2012). The insulin and insulin-like growth factor receptor family in neoplasia: an update. *Nature Reviews Cancer*, 12(3), 159–169. <https://doi.org/10.1038/nrc3215>
<https://www.nature.com/articles/nrc3215>
16. Seyfried, T. N. (2012). *Cancer as a metabolic disease: on the origin, management, and prevention of cancer*. Hoboken, NJ: Wiley-Blackwell.
Publisher link: <https://www.wiley.com/en-us/Cancer+as+a+Metabolic+Disease-p-9780470584927>
17. Vlassenko, A.G., Mintun, M.A. (2012). Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET). In: Choi, IY., Gruetter, R. (eds) *Neural Metabolism In Vivo*. Advances in Neurobiology, vol 4. Springer, Boston, MA.
https://doi.org/10.1007/978-1-4614-1788-0_10
18. Warburg, O. (1956). On the origin of cancer cells. *Science*, 123(3191), 309–314.
<https://doi.org/10.1126/science.123.3191.309>
<https://www.science.org/doi/10.1126/science.123.3191.309>

19. World Cancer Research Fund/American Institute for Cancer Research. (2018). *Diet, nutrition, physical activity and cancer: a global perspective*. Continuous Update Project Expert Report 2018.
<https://doi.org/10.21955/amrcopenres.1114946.1>

Diabetic Nephropathy

Diabetic nephropathy (DN), also called diabetic kidney disease (DKD), is one of the most common causes of chronic kidney disease (CKD) and end-stage kidney disease (ESKD) worldwide. It is a progressive complication of both type 1 and type 2 diabetes and is characterised clinically by persistent albuminuria, declining glomerular filtration rate (GFR), and an increased risk of cardiovascular disease and mortality (Alicic et al., 2017; de Boer et al., 2011).

Pathophysiology

Central Role of Hyperglycaemia and Haemodynamic Changes

The primary drivers of diabetic nephropathy are chronic hyperglycaemia and intraglomerular hypertension, not immune complex-mediated injury.

Long-standing hyperglycaemia leads to:

- Formation of advanced glycation end products (AGEs)
- Activation of protein kinase C and other intracellular signalling pathways
- Increased oxidative stress and inflammatory mediator release

These processes cause structural and functional changes in the kidney, including:

- Glomerular basement membrane (GBM) thickening
- Mesangial matrix expansion

- Podocyte injury and loss
- Nodular glomerulosclerosis (Kimmelstiel–Wilson nodules) in advanced disease

Concurrently, systemic and intraglomerular hypertension contribute to glomerular capillary hypertension and hyperfiltration, which accelerate glomerular damage (Alicic et al., 2017; Tuttle et al., 2014).

Role of the Renin–Angiotensin–Aldosterone System (RAAS)

Activation of the RAAS increases intraglomerular pressure and promotes fibrosis.

Angiotensin II:

- Constricts efferent arterioles, raising glomerular capillary pressure
- Stimulates production of transforming growth factor- β (TGF- β), which promotes extracellular matrix accumulation and scarring

RAAS blockade with ACE inhibitors or angiotensin receptor blockers (ARBs) is a cornerstone of therapy because it lowers intraglomerular pressure and slows progression of DN (KDIGO, 2022; ADA, 2024).

Inflammation and Immune Mechanisms

Inflammation and immune system activation contribute to the progression of DN, but classic immune complex–mediated glomerulonephritis is not the primary mechanism in typical diabetic nephropathy.

Key points:

- In DN, glomerular injury is predominantly due to metabolic (hyperglycaemia), haemodynamic, and fibrotic pathways.
- Immune cells (e.g., macrophages, T cells) and inflammatory cytokines (e.g., IL-6, TNF- α) are involved in disease progression.

- True immune complex deposition (as seen in IgA nephropathy, lupus nephritis, etc.) represents a different category of kidney disease and may coexist with diabetes, but it is not the hallmark of DN (Fiorentino et al., 2018).

Thus, while inflammation is important, the concept that most diabetic kidney failure is initiated by immune complex deposition in the glomeruli is not supported by current evidence.

Clinical Features and Histopathology

Diabetic nephropathy typically progresses through the following stages:

1. **Hyperfiltration stage** – Increased GFR and kidney enlargement, often asymptomatic.
2. **Microalbuminuria (moderately increased albuminuria)** – 30–300 mg/day of albumin excretion.
3. **Macroalbuminuria (severely increased albuminuria)** – >300 mg/day of albumin excretion.
4. **Progressive decline in GFR** – Leading to CKD stages 3–5.
5. **End-stage kidney disease** – Requiring dialysis or kidney transplantation (de Boer et al., 2011).

Typical histological findings in DN include:

- GBM thickening
- Diffuse mesangial expansion
- Nodular glomerulosclerosis (Kimmelstiel–Wilson nodules)
- Arteriolar hyalinosis
- Tubulointerstitial fibrosis and atrophy in later stages (Fiorentino et al., 2018)

Drugs, NSAIDs, and Acute Kidney Injury

Certain medications, including non-steroidal anti-inflammatory drugs (NSAIDs), can cause:

- Haemodynamically mediated acute kidney injury (e.g., by inhibiting prostaglandins and reducing renal blood flow)
- Allergic interstitial nephritis (an immune-mediated process) in susceptible individuals

These events are generally acute or subacute, not the main mechanism of chronic diabetic nephropathy. Routine therapeutic use of insulin and standard oral glucose-lowering agents is not established as a cause of chronic immune complex deposition in the kidneys (KDIGO, 2022, KDIGO, 2020).

Why Is Diabetic Kidney Disease Often Progressive?

Diabetic kidney disease is challenging to fully reverse, especially when advanced, because:

- Structural changes (glomerulosclerosis, interstitial fibrosis) are largely irreversible.
- Hyperglycaemia, hypertension, dyslipidaemia, and ongoing RAAS activation continue to drive progression unless intensively managed.
- Many patients are diagnosed late, after significant nephron loss has already occurred (Alicic et al., 2017; KDIGO, 2022).

However, DN is not “incurable” in the sense that nothing can be done:

- Early stages can be stabilised or progression significantly slowed.
- Even in later stages, optimal management improves survival and quality of life.
- Kidney transplantation can be avoided with early detection and correct intervention, which does not further put the situation in a vicious cycle of the progression of damage.

Current Management

Standard, guideline-based treatment of diabetic nephropathy is aimed at slowing or preventing further decline in kidney function.

Core elements include:

1. Glycaemic Control

- Individualised HbA1c targets (often around 7%)
- Insulin for type 1 diabetes and many with type 2; oral and injectable agents (e.g., metformin, SGLT2 inhibitors, GLP-1 receptor agonists) for type 2 diabetes (ADA, 2024).

2. Blood Pressure Control

- Target generally <130/80 mmHg in patients with diabetes and CKD, if tolerated.
- ACE inhibitors or ARBs are first-line agents when albuminuria is present, due to renal protective effects (KDIGO, 2022).

3. SGLT2 Inhibitors and Other Kidney-Protective Agents

- SGLT2 inhibitors (e.g., empagliflozin, dapagliflozin) reduce the risk of CKD progression and cardiovascular events in type 2 diabetes with CKD (Heerspink et al., 2020).
- Non-steroidal mineralocorticoid receptor may provide additional kidney and cardiovascular benefit in selected patients (Bakris et al., 2020).

4. Lifestyle and Dietary Measures

- Smoking cessation
- Weight management and regular physical activity
- Individualised dietary advice (appropriate protein intake, sodium restriction, attention to potassium according to kidney function).

- Overly restrictive or unbalanced diets (e.g., indiscriminate “toxin-rich” or “potassium-depleted” regimens) are not recommended; diet should follow evidence-based nutritional guidance from a renal dietitian.

5. *Avoidance of Nephrotoxins*

- Cautious use or avoidance of NSAIDs and other nephrotoxic drugs in patients with CKD.
- Appropriate adjustment of drug doses according to GFR.

6. *Management of Comorbidities*

- Lipid-lowering therapy (e.g., statins) to reduce cardiovascular risk.
- Treatment of anaemia, bone and mineral disorders, and metabolic acidosis when indicated

In summary, a clear understanding of the mechanisms underlying diabetic kidney disease underscores that early identification of kidney involvement and timely, evidence-based intervention offer the most realistic and effective strategy for preventing or slowing its progression.

References:

1. Alicic, R. Z., Rooney, M. T., & Tuttle, K. R. (2017). Diabetic kidney disease: Challenges, progress, and possibilities. *Clinical Journal of the American Society of Nephrology*, 12(12), 2032–2045. <https://doi.org/10.2215/CJN.11491116>
2. American Diabetes Association. (2024). 11. Chronic kidney disease and risk management: Standards of care in diabetes—2024. *Diabetes Care*, 47(Supplement 1), S196–S213. <https://doi.org/10.2337/dc24-S011>
3. Bakris, G. L., Agarwal, R., Anker, S. D., Pitt, B., Ruilope, L. M., Rossing, P., ... Filippatos, G. (2020). Effect of finerenone on chronic kidney disease outcomes in type 2

- diabetes. *New England Journal of Medicine*, 383(23), 2219–2229. <https://doi.org/10.1056/NEJMoa2025845>
4. de Boer, I. H., Rue, T. C., Hall, Y. N., Heagerty, P. J., Weiss, N. S., & Himmelfarb, J. (2011). Temporal trends in the prevalence of diabetic kidney disease in the United States. *JAMA*, 305(24), 2532–2539. <https://doi.org/10.1001/jama.2011.861>
 5. Fiorentino, M., Bolignano, D., Tesar, V., Pisano, A., Biesen, W. V., Tripepi, G., D'Arrigo, G., Gesualdo, L., & Group, C.-E. G. (2018). Renal biopsy in patients with diabetes: A pooled meta-analysis of 48 studies. *Nephrology Dialysis Transplantation*, 32(1), 97–110. <https://doi.org/10.1093/ndt/gfw070>
 6. Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F. F., ... DAPA-CKD Trial Committees and Investigators. (2020). Dapagliflozin in patients with chronic kidney disease. *New England Journal of Medicine*, 383(15), 1436–1446. <https://doi.org/10.1056/NEJMoa2024816>
 7. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. (2022). KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. *Kidney International*, 102(4S), S1–S127. <https://kdigo.org/guidelines/diabetes-ckd/>
 8. Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. (2020). *Kidney International Supplements*, 3(1), 1–150. <https://kdigo.org/guidelines/ckd-evaluation-and-management/>
 9. Tuttle, K. R., Bakris, G. L., Bilous, R. W., Chiang, J. L., de Boer, I. H., Goldstein-Fuchs, J., Hirsch, I. B., Kalantar-Zadeh, K., Narva, A. S., Navaneethan, S. D., Neumiller, J. J., Patel, U. D., Ratner, R. E., Whaley-Connell, A., & Molitch, M. E. (2014). Diabetic kidney disease: A report from an

ADA consensus conference. *Diabetes Care*, 37(10), 2864–2883. <https://doi.org/10.2337/dc14-1296>

Heating of Food and AGE Products in Diabetes

Effects of Heating on Food Components

Heating food alters the structure of macronutrients and micronutrients through processes such as protein denaturation, starch gelatinisation, lipid oxidation, and vitamin degradation. These effects depend on temperature, duration, moisture, and food matrix:

- **Proteins:** Denaturation begins well below boiling temperatures and is generally *reversible or functionally neutral* for digestion; in many cases it increases digestibility by exposing peptide bonds to digestive enzymes (van Boekel, 2001).
- **Carbohydrates:** Heating gelatinises starch, often improving digestibility and glycaemic response compared with raw starches, although high-temperature dry-heat methods can promote formation of AGEs (Nowotny et al., 2015).
- **Vitamins:** Heat-labile vitamins (e.g., vitamin C, some B vitamins, folate) can be partially lost with prolonged or high-temperature cooking, especially in water (Miglio et al., 2008). Fat-soluble vitamins are relatively more stable.
- **Overall nutrient “usability”:** There is no evidence that food heated above a specific threshold (e.g., 42 °C) becomes 95% unusable or that raw food has 90–100% bioavailability. In fact, for several nutrients (e.g., lycopene, carotenoids, some proteins and starches), *moderate* cooking improves bioavailability (Miglio et al., 2008; van Boekel, 2001).

In contrast, **sustained core body temperatures above ~41–42 °C** in humans can cause systemic protein denaturation, enzyme dysfunction, multi-organ failure and death (Bouchama & Knochel, 2002). This is a clinical issue related to hyperthermia, not to the digestive “usability” of heated foods.

Advanced Glycation End Products (AGEs)

Advanced Glycation End Products (AGEs) are heterogeneous compounds formed when reducing sugars react non-enzymatically with amino groups on proteins, lipids, or nucleic acids (Maillard reaction). In diabetes, chronic hyperglycaemia accelerates AGE formation and accumulation in vascular, renal, neural, and other tissues (Singh et al., 2001; Nowotny et al., 2015).

AGEs act primarily via:

- RAGE (Receptor for Advanced Glycation End Products) activation, which:
 - Increases oxidative stress and NF-κB-mediated inflammation
 - Impairs insulin signalling and contributes to insulin resistance
 - Promotes endothelial dysfunction and atherogenesis
 - Induces pancreatic β-cell stress and apoptosis
 - Triggers epigenetic alterations that may perpetuate metabolic dysfunction (Goldin et al., 2006; Nowotny et al., 2015)

This overall burden is often described as carbonyl stress, reflecting excess reactive carbonyl intermediates driving AGE formation and toxicity.

Sources of AGEs

Endogenous (Within the Body)

- Formed physiologically at low levels and increase with ageing
- Markedly accelerated in chronic hyperglycaemia (type 1 and type 2 diabetes)
- Further increased in diabetic nephropathy, cardiovascular disease, and other complications (Singh et al., 2001; Nowotny et al., 2015)

Exogenous (Dietary and Other External Sources)

- High-temperature cooking (especially dry heat): grilling, broiling, roasting, frying, and baking substantially increase AGE content compared with boiling, steaming, or stewing (Uribarri et al., 2010).
- Animal products (meats, high-fat cheeses, butter, cream, egg yolks) tend to have a higher AGE load, particularly when cooked at high temperatures.
- Highly processed foods (fast foods, baked goods, deep-fried snacks) frequently contain large amounts of AGEs and related oxidised lipids.

Reducing dietary AGE intake appears to lower circulating AGE levels and inflammatory markers and may improve insulin sensitivity and endothelial function in people with diabetes (Uribarri et al., 2010; de Vos et al., 2016).

Dietary and Lifestyle Approaches to Reduce AGE Burden

1. Cooking Methods and Food Choices

- Prefer low- to moderate-temperature, moist-heat methods:

- Steaming, boiling, stewing, poaching, and using slow cookers generate substantially fewer AGEs than grilling, frying, or broiling (Uribarri et al., 2010).
- Shorter cooking times and lower surface browning (less charring/crusting) further reduce AGE formation.
- Marinades containing acidic ingredients (e.g., vinegar, lemon juice, wine, yoghurt) can decrease AGE formation in meats during cooking (Goldin et al., 2006; Uribarri et al., 2010).
- Emphasise a plant-forward pattern (e.g., Mediterranean-style): vegetables, fruits, whole grains, legumes, nuts, and seeds generally contain fewer AGEs and more antioxidants and fibre than energy-dense, highly processed foods (Evert et al., 2019; de Vos et al., 2016).

2. Natural Glycation Inhibitors and Phytochemicals

A range of phytochemicals exhibit antiglycation properties in vitro and in animal models, although human data are more limited:

- **Flavonoids and polyphenols:**
 - Quercetin, citrus flavonoids, green tea catechins, resveratrol, and various coumarins show inhibitory effects on AGE formation and RAGE-mediated signalling in experimental systems (Wang et al., 2025; Nowotny et al., 2015).
- **Curcumin (from *Curcuma longa*):**
 - Demonstrates antiglycation and antioxidant effects in vitro; small human trials suggest benefits on glycaemic control and inflammatory markers in type 2 diabetes, though evidence is still emerging (Panahi et al., 2016).
- **Boswellic acids and ginsenosides:**
 - Show anti-inflammatory and potential antiglycation effects in preclinical studies, but robust clinical data in diabetes and AGE endpoints remain limited.

These agents should be viewed as adjuncts—for standard medical and nutritional care.

3. *Antioxidant Support*

Oxidative stress amplifies carbonyl stress and AGE-related injury:

- **Vitamin C:** Potent water-soluble antioxidant that may reduce oxidative modification of proteins and lipids and has modest antiglycation activity in vitro. Supplementation can improve some oxidative stress markers in diabetes, but routine high-dose use is not universally recommended and should be individualised (Ceriello et al., 2013).
- **Vitamin E:** Lipid-soluble antioxidant; high-dose supplementation has mixed results and potential risks in some populations. Food-based sources (nuts, seeds, plant oils) are generally preferred (Evert et al., 2019).
- **Polyphenol-rich foods:** Berries, green tea, cocoa (unsweetened), herbs, and spices provide antioxidants that may mitigate AGE-induced oxidative stress (Nowotny et al., 2015).

4. *Specific Botanicals and Lifestyle Measures*

- **Turmeric / Curcumin:** May inhibit glycation and improve glycaemic and inflammatory markers in type 2 diabetes when used in standardised preparations; monitor for drug–herb interactions and hepatobiliary issues (Panahi et al., 2017).
- **Green tea:** Catechins show antiglycation and antioxidant activity; regular consumption is associated with lower cardiometabolic risk in observational studies (Nowotny et al., 2015).
- **Amla (*Emblica officinalis* / Indian gooseberry):** Rich in vitamin C and polyphenols; small human studies suggest improvements in fasting glucose and lipid profile, but high-quality trials are limited.
- **Fenugreek (*Trigonella foenum-graecum*):** Seeds contain soluble fibre and 4-hydroxyisoleucine; several clinical trials show improved fasting glucose and HbA1c in type 2

diabetes, possibly reducing glycation load indirectly through better glycaemic control (Neelakantan et al., 2014).

Lifestyle factors that reduce endogenous AGE formation include:

- **Regular physical activity:** Improves insulin sensitivity, lowers chronic hyperglycaemia, and reduces oxidative stress (American Diabetes Association [ADA], 2024).
- **Weight management:** Weight loss in overweight/obese individuals with type 2 diabetes improves glycaemic control, thereby reducing endogenous AGE formation (ADA, 2024).
- **Stress reduction and sleep optimisation:** May attenuate sympathetic activation and inflammatory pathways that interact with RAGE signalling (Evert et al., 2019).

Key Nutrients in Diabetes Management (and Their Relation to AGEs)

While not specific “AGE antidotes,” several nutrients are important for metabolic control and may indirectly reduce AGE burden by improving glycaemia and oxidative balance:

- **Vitamin D:** Low vitamin D status is associated with insulin resistance and type 2 diabetes; supplementation in deficient individuals can modestly improve glycaemic indices in some studies (Pittas et al., 2010).
- **Magnesium:** Cofactor for many enzymes in glucose metabolism and insulin signalling; low magnesium intake is linked to higher diabetes risk and poorer glycaemic control (Fang et al., 2016).
- **Chromium:** May have small effects on fasting glucose and HbA1c in some people with type 2 diabetes, though evidence is heterogeneous and not sufficient for routine high-dose use (Evert et al., 2019).

- **B vitamins:** Important for energy metabolism; metformin therapy can reduce vitamin B12 levels, so monitoring and replacement may be necessary (ADA, 2024).

Dietary patterns supportive of glycaemic control and lower AGE intake include:

- **Dark green leafy vegetables:** Sources of vitamins A, C, K, folate, magnesium, and iron.
- **Beans and legumes:** High in fibre, plant protein, folate, potassium, and trace minerals (including zinc and magnesium); associated with improved glycaemic control and cardiovascular risk reduction.
- **Fatty fish (e.g., salmon, sardines, mackerel):** Provide marine omega-3 fatty acids; recommended at least twice weekly for cardioprotection (Evert et al., 2019).
- **Nuts and seeds:** Provide magnesium, healthy fats, fibre, and vitamin E.
- **Berries:** Rich in fibre and polyphenols with antioxidant and potential antiglycation effects.
- **Whole grains:** Supply B vitamins, magnesium, and fibre; lower post-prandial glycaemic impact compared with refined grains.
- **Traditional herbs and spices** (e.g., turmeric, fenugreek, curry leaves) used within evidence-based integrative frameworks can complement, but not replace, standard medical therapy.

References:

1. American Diabetes Association. (2024). 3. Prevention or delay of diabetes and associated comorbidities: Standards of care in diabetes—2024. *Diabetes Care*, 47(Supplement_1), S48–S63. <https://doi.org/10.2337/dc24-S003>
2. Wang, S., Zhang, Y., Li, W., Zhao, X., Zhang, M., Wang, M., & Xie, J. (2025). Effects and mechanisms of dietary

- polyphenols in ameliorating glycolipid metabolic disorders: Inhibition of advanced glycation end products. *Fitoterapia*, 184, 106668. <https://doi.org/10.1016/j.fitote.2025.106668>
3. Bouchama, A., & Knochel, J. P. (2002). Heat stroke. *New England Journal of Medicine*, 346(25), 1978–1988. <https://doi.org/10.1056/NEJMra011089>
 4. Ceriello, A., Esposito, K., Piconi, L., Ihnat, M. A., Thorpe, J. E., Testa, R., Boemi, M., & Giugliano, D. (2013). Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. *Diabetes*, 57(5), 1349–1354. <https://doi.org/10.2337/db08-0063>
 5. de Vos, L. C., Lefrandt, J. D., Dullaart, R. P. F., Zeebregts, C. J., & Smit, A. J. (2016). Advanced Glycation End Products: An Emerging Biomarker for Adverse Outcome in Patients with Peripheral Artery Disease. *Atherosclerosis*, 254, 291–299. <https://doi.org/10.1016/j.atherosclerosis.2016.10.012>
 6. Evert, A. B., Dennison, M., Gardner, C. D., Garvey, W. T., Lau, K. H. K., MacLeod, J., Mitri, J., Pereira, R. F., Rawlings, K., Robinson, S., Saslow, L., Uelmen, S., & Urbanski, P. (2019). Nutrition therapy for adults with diabetes or prediabetes: A consensus report. *Diabetes Care*, 42(5), 731–754. <https://doi.org/10.2337/dci19-0014>
 7. Fang, X., Han, H., Li, M., Liang, C., Fan, Z., Aaseth, J., He, J., & Cao, Y. (2016). Dose–response relationship between dietary magnesium intake and type 2 diabetes mellitus: A systematic review and meta-regression analysis of prospective cohort studies. *Nutrients*, 8(11), 739. <https://doi.org/10.3390/nu8110739>
 8. Goldin, A., Beckman, J. A., Schmidt, A. M., & Creager, M. A. (2006). Advanced glycation end products: Sparking the development of diabetic vascular injury. *Circulation*, 114(6),

597–605.

<https://doi.org/10.1161/CIRCULATIONAHA.106.621854>

9. Miglio, C., Chiavaro, E., Visconti, A., Fogliano, V., & Pellegrini, N. (2008). Effects of different cooking methods on nutritional and physicochemical characteristics of selected vegetables. *Journal of Agricultural and Food Chemistry*, 56(1), 139–147. <https://doi.org/10.1021/jf072304b>
10. Neelakantan, N., Narayanan, M., de Souza, R. J., & van Dam, R. M. (2014). Effect of fenugreek (*Trigonella foenum-graecum* L.) intake on glycemia: A meta-analysis of clinical trials. *Nutrition Journal*, 13, 7. <https://doi.org/10.1186/1475-2891-13-7>
11. Nowotny, K., Jung, T., Höhn, A., Weber, D., & Grune, T. (2015). Advanced glycation end products and oxidative stress in type 2 diabetes mellitus. *Biomolecules*, 5(1), 194–222. <https://doi.org/10.3390/biom5010194>
12. Panahi, Y., Hosseini, M. S., Khalili, N., Naimi, E., Simental-Mendía, L. E., Majeed, M., & Sahebkar, A. (2016). Effects of curcumin on serum cytokine concentrations in subjects with metabolic syndrome: A post-hoc analysis of a randomized controlled trial. *Biomedicine & Pharmacotherapy*, 82, 578–582. <https://doi.org/10.1016/j.biopha.2016.05.037>
13. Pittas, A. G., Chung, M., Trikalinos, T., Mitri, J., Brendel, M., Patel, K., Lichtenstein, A. H., Lau, J., & Balk, E. M. (2010). Systematic review: Vitamin D and cardiometabolic outcomes. *Annals of Internal Medicine*, 152(5), 307–314. <https://doi.org/10.7326/0003-4819-152-5-201003020-00009>
14. Singh, R., Barden, A., Mori, T., & Beilin, L. (2001). Advanced glycation end-products: A review. *Diabetologia*, 44(2), 129–146. <https://doi.org/10.1007/s001250051591>
15. Uribarri, J., Woodruff, S., Goodman, S., Cai, W., Chen, X., Pyzik, R., Yong, A., Striker, G. E., & Vlassara, H. (2010). Advanced glycation end products in foods and a practical guide to their reduction in the diet. *Journal of the American*

Dietetic Association, 110(6), 911–916.e12.

<https://doi.org/10.1016/j.jada.2010.03.018>

16. van Boekel, M.A.J.S. (2001), Kinetic aspects of the Maillard reaction: a critical review. *Nahrung*, 45: 150-159.

<https://doi.org/10.1002/1521->

[3803\(20010601\)45:3<150::AID-FOOD150>3.0.CO;2-9](https://doi.org/10.1002/1521-3803(20010601)45:3<150::AID-FOOD150>3.0.CO;2-9)

Artificial Sweeteners and Diabetes: Helpful Substitutes or Metabolic Distractions?

Before examining naturopathic strategies for type 2 diabetes, it is crucial to look squarely at artificial sweeteners—because many people try to “fix” diabetes simply by swapping sugar for “diet” products, while leaving the rest of their diet and lifestyle unchanged.

What Are Artificial (Non-Nutritive) Sweeteners?

Artificial sweeteners, more accurately **non-nutritive sweeteners (NNS)** or low-/no-calorie sweeteners, provide intense sweetness with little or no energy and no direct glycaemic load. Common examples include:

- Saccharin
- Aspartame
- Sucralose
- Acesulfame potassium (acesulfame-K)
- Neotame
- Advantame

In addition, there are high-intensity sweeteners **derived from natural sources**, such as:

- **Steviol glycosides** (e.g., rebaudioside A) from *Stevia rebaudiana*

Several of these (saccharin, aspartame, sucralose, acesulfame-K, neotame, advantame, steviol glycosides) are approved by the U.S. Food and Drug Administration and other authorities, each with an

acceptable daily intake (ADI) based on toxicology data (FDA, 2024; Gardner et al., 2012).

Regulatory approval means “unlikely to cause classic toxic effects at or below the ADI.” It **does not mean** they improve metabolic health or are neutral when used chronically in a highly processed food environment.

Do Artificial Sweeteners Help with Weight Loss and Diabetes Control?

The simplistic assumption— “switch from sugar to artificial sweeteners and you automatically lose weight and control diabetes”—is not supported consistently.

Randomised controlled trials (RCTs):

- When NNS **replace sugar-sweetened beverages/foods within a calorie-reduced plan**, they can modestly lower energy intake and body weight (Miller & Perez, 2014; Laviada-Molina et al., 2020).

Observational studies:

- High intake of artificially sweetened beverages is often **associated** with weight gain, metabolic syndrome, type 2 diabetes, and cardiovascular disease (Azad et al., 2017; Debras et al., 2022).
- These findings may reflect **reverse causality and confounding** (people with metabolic risk choose “diet” products), but they are not reassuring.

For people with diabetes, NNS can:

- Lower intake of **free sugars**.
- Reduce **post-prandial glucose spikes** when they genuinely **displace** caloric sweeteners.

However, they **do not replace the need** for an overall dietary pattern built on **minimally processed, fibre-rich, nutrient-dense foods** and

appropriate energy balance (ADA, 2024). Swapping to “diet” drinks while keeping the same ultra-processed, high-refined-carb diet is a metabolic illusion, not a cure.

Appetite, Energy Regulation, and the “Sweetness–Calorie” Mismatch

Naturopathic concern extends beyond calories: it asks what constant exposure to intense, non-caloric sweetness does to **appetite regulation and taste wiring**.

- **Animal data** are cautionary:
 - In a widely cited rat study, animals consuming yogurt sweetened with a non-nutritive sweetener ate **more total calories, gained more weight, and accumulated more fat** than rats given sugar-sweetened yogurt—suggesting that **“uncoupling” sweetness from calories** can disturb energy regulation (Swithers & Davidson, 2008).
- **Human data** are mixed:
 - Some short-term trials show **neutral or modestly beneficial** effects on appetite and energy intake when NNS replace sugar (Rogers et al., 2016).
 - Other research and WHO reviews raise concern that frequent use of intensely sweet, non-caloric products may **maintain or heighten a preference for sweetness**, making it harder to reduce overall sweet-tasting intake (WHO, 2023).

Conclusion: current evidence does **not** prove that artificial sweeteners inevitably increase appetite in humans. But from a naturopathic perspective, **training the palate to expect intense sweetness without nutritional value** risks prolonging dependence on sweet tastes and on processed products rather than retraining taste toward naturally sweet, whole foods.

Glycemic Control and Insulin Response

Most NNS **do not contain carbohydrate** and do not acutely raise blood glucose. However, possible **indirect effects** on glucose metabolism and the microbiome are under investigation:

- Several studies find **no meaningful effect** of aspartame, sucralose, or saccharin on insulin secretion or blood glucose at typical doses in healthy volunteers or people with diabetes (Renwick & Molinary, 2010; Romo-Romo et al., 2018).
- Other small, mechanistic studies suggest that **certain sweeteners at high doses (e.g., saccharin)** may alter the gut microbiota and **impair glucose tolerance** in susceptible individuals (Suez et al., 2014).

Major organisations currently view approved NNS as:

- **Safe at or below the ADI**, and
- **Generally neutral for glycaemic control** when used to substitute for sugars,

but **not essential** or mandatory for weight loss or diabetes prevention (ADA, 2024; WHO, 2023).

A naturopathic stance accepts occasional, targeted use but questions routine daily exposure to intense sweeteners when the real therapeutic target should be **resetting taste, reducing dependence on sweetness, and shifting the overall diet**.

Safety and Adverse Effects

Regulatory Overview

Agencies such as FDA, EFSA, and JECFA have repeatedly reviewed toxicologic, carcinogenic, reproductive, and neurological data:

- **Saccharin**
 - Early rat studies linked high-dose saccharin to bladder tumours. Later mechanistic work showed this was a **species- and dose-specific mechanism** not relevant to

humans. Saccharin was removed from the U.S. National Toxicology Program's carcinogen list in 2000 (Reuters, 2000)

- **Aspartame**

- EFSA and others have concluded aspartame is **safe at current consumption levels within the ADI** for the general population, except for individuals with phenylketonuria (PKU), who must avoid it (EFSA, 2013).
- In 2023, IARC classified aspartame as “possibly carcinogenic to humans” (Group 2B) based on **limited observational evidence**, while JECFA and WHO **maintained the existing ADI**, judging that current intakes are unlikely to pose a cancer risk for most consumers (World Health Organization, 2023).

Regulatory toxicology asks “Is it acutely or clearly carcinogenic at realistic doses?” It does **not** ask “Does it support long-term metabolic healing in a person with diabetes?”

Aspartame: Composition and Reported Symptoms

Aspartame is approximately **180–200 times sweeter than sucrose** and is composed of:

- Aspartic acid (an amino acid)
- Phenylalanine (an amino acid)
- Methanol (in small amounts)

These components are also present in larger amounts in many common foods (e.g., protein-containing foods and certain fruits and vegetables) (Magnuson et al., 2007).

Claims that aspartame commonly causes a very wide range of severe adverse effects (e.g., brain tumours, Alzheimer's disease, Parkinson's disease, multiple neurologic or systemic conditions) are not supported by high-quality evidence. Large systematic reviews and regulatory assessments do not confirm a causal relationship between

aspartame, at typical intake levels, and these conditions (EFSA, 2013; Magnuson et al., 2007).

Nevertheless:

- A subset of individuals report symptoms such as headache, dizziness, or gastrointestinal discomfort temporally related to aspartame or other non-nutritive sweeteners. Controlled challenge studies show mixed results but suggest that some people may be sensitised (Humphries et al., 2008).
- People with PKU must avoid aspartame because of its phenylalanine content.

Clinically, if a patient consistently reports symptoms shortly after consuming specific sweeteners that resolve with avoidance, individualised restriction is reasonable.

Professional and Guideline Perspectives

Recent WHO guidance and diabetes guidelines converge on a cautious, pragmatic position:

- **NNS can help reduce free sugar and total energy intake** when they **replace** sugar-sweetened products, particularly in people with overweight/obesity or diabetes who habitually drink sugary beverages.
- **Long-term health impacts**, especially with high habitual intake from early childhood, remain uncertain. Observed associations with cardiometabolic outcomes in cohorts warrant **caution and moderation**, not enthusiastic promotion (WHO, 2023).
- NNS are **not required** for a healthy diet. Water, unsweetened beverages (e.g., herbal teas), and minimally processed foods should be the **primary focus**.
- “Sugar-free” on a label **does not guarantee** that a product is good for weight or glycaemic control; many sugar-free items are high in **refined starches, fats, or total calories**.

Common NNS-containing products that deserve critical evaluation in diabetes care include:

1. Diet or “zero” sodas
2. Sugar-free sports and energy drinks
3. Sugar-free snacks and desserts
4. Sugar-free ice cream
5. Sugar-free jams and spreads
6. Sugar-free gum
7. Sugar-free confectionery

From a naturopathic viewpoint, the goal is not to **swap one set of industrial products for another**, but to help patients **step out of the sugar / artificial-sweetener loop altogether**—moving toward whole foods, naturally modest sweetness, and genuine palate retraining.

In the next sections, we will build on this perspective to outline naturopathic nutritional strategies for type 2 diabetes that reduce dependence on both sugar and artificial sweeteners, and prioritise real, unprocessed foods as the foundation of metabolic healing.

References

1. American Diabetes Association. (2024). *Standards of medical care in diabetes—2024*. *Diabetes Care*, 47(Suppl. 1). <https://doi.org/10.2337/dc24-SINT>
2. Azad, M. B., Abou-Setta, A. M., Chauhan, B. F., Rabbani, R., Lys, J., Copstein, L., Mann, A., Jeyaraman, M. M., Reid, A. E., Fiander, M., MacKay, D. S., McGavock, J. M., Wicklow, B., & Zarychanski, R. (2017). Nonnutritive sweeteners and cardiometabolic health: A systematic review and meta-analysis of randomized controlled trials and prospective cohort studies. *CMAJ*, 189(28), E929–E939. <https://doi.org/10.1503/cmaj.161390>
3. Debras, C., Chazelas, E., Srour, B., Druet-Pecollo, N., Esseddik, Y., de Edelenyi, F. S., Agaësse, C., De Sa, A., Luchia, R., Gigante, B., Zelek, L., Agaësse, C., Galan, P.,

- Hercberg, S., Latino-Martel, P., Deschasaux, M., & Touvier, M. (2022). Artificial sweeteners and risk of cardiovascular diseases: Results from the NutriNet-Santé cohort. *BMJ*, 378, e071204. <https://doi.org/10.1136/bmj-2022-071204>
4. European Food Safety Authority (EFSA) Panel on Food Additives and Nutrient Sources Added to Food. (2013). Scientific opinion on the re-evaluation of aspartame (E 951) as a food additive. *EFSA Journal*, 11(12), 3496. <https://doi.org/10.2903/j.efsa.2013.3496>
 5. Food and Drug Administration. (2024). *Additional information about high-intensity sweeteners permitted for use in food in the United States*. U.S. FDA. <https://www.fda.gov/food/food-additives-petitions/additional-information-about-high-intensity-sweeteners-permitted-use-food-united-states>
 6. Gardner, C., Wylie-Rosett, J., Gidding, S. S., Steffen, L. M., Johnson, R. K., Reader, D., & Lichtenstein, A. H. (2012). Nonnutritive sweeteners: Current use and health perspectives: A scientific statement from the American Heart Association and the American Diabetes Association. *Circulation*, 126(4), 509–519. <https://doi.org/10.1161/CIR.0b013e31825c42ee>
 7. Humphries, P., Pretorius, E., & Naudé, H. (2008). Direct and indirect cellular effects of aspartame on the brain. *European Journal of Clinical Nutrition*, 62(4), 451–462. <https://doi.org/10.1038/sj.ejcn.1602866>
 8. Laviada-Molina, H., Molina-Segui, F., Pérez-Gaxiola, G., Cuello-García, C., Arjona-Villicaña, R., Espinosa-Marrón, A., & Martínez-Portilla, R. J. (2020). Effects of nonnutritive sweeteners on body weight and BMI in diverse clinical contexts: Systematic review and meta-analysis. *Obesity Reviews*, 21(8), e13020. <https://doi.org/10.1111/obr.13020>
 9. Magnuson, B. A., Burdock, G. A., Doull, J., Kroes, R. M., Marsh, G. M., Pariza, M. W., Spencer, P. S., Waddell, W. J., Walker, R., & Williams, G. M. (2007). Aspartame: A safety

evaluation based on current use levels, regulations, and toxicological and epidemiological studies. *Critical Reviews in Toxicology*, 37(8), 629–727.

<https://doi.org/10.1080/10408440701516184>

10. Miller, P. E., & Perez, V. (2014). Low-calorie sweeteners and body weight and composition: A meta-analysis of randomized controlled trials and prospective cohort studies. *American Journal of Clinical Nutrition*, 100(3), 765–777.
<https://doi.org/10.3945/ajcn.113.082826>
11. Renwick, A. G., & Molinary, S. V. (2010). Sweet-taste receptors, low-energy sweeteners, glucose absorption and insulin release. *British Journal of Nutrition*, 104(10), 1415–1420. <https://doi.org/10.1017/S0007114510002540>
12. Reuters. (2000, May 16). Saccharin Deleted From U.S. List of Carcinogens. Los Angeles Times.
<https://www.latimes.com/archives/la-xpm-2000-may-16-mn-30578-story.html>
13. Rogers, P. J., Hogenkamp, P. S., de Graaf, C., Higgs, S., Lluch, A., Ness, A. R., Penfold, C., Perry, R., Putz, P., Yeomans, M. R., & Mela, D. J. (2016). Does low-energy sweetener consumption affect energy intake and body weight? A systematic review, including meta-analyses, of the evidence from human and animal studies. *International Journal of Obesity*, 40(3), 381–394.
<https://doi.org/10.1038/ijo.2015.177>
14. Romo-Romo, A., Aguilar-Salinas, C. A., Brito-Córdova, G. X., Gómez-Díaz, R. A., & Almeda-Valdés, P. (2018). Sucralose decreases insulin sensitivity in healthy subjects: a randomized controlled trial. *American Journal of Clinical Nutrition*, 108(3), 485–491.
<https://doi.org/10.1093/ajcn/nqy152>
15. Suez, J., Korem, T., Zilberman-Schapira, G., Segal, E., & Elinav, E. (2014). Non-caloric artificial sweeteners and the microbiome: Findings and challenges. *Gut Microbes*, 6(2),

- 149–155. <https://doi.org/10.1080/19490976.2015.1017700>
(See also: Suez, J. et al. (2014). Artificial sweeteners induce glucose intolerance by altering the gut microbiota. *Nature*, 514(7521), 181–186. <https://doi.org/10.1038/nature13793>)
16. Swithers, S. E., & Davidson, T. L. (2008). A role for sweet taste: Calorie predictive relations in energy regulation by rats. *Behavioral Neuroscience*, 122(1), 161–173. <https://doi.org/10.1037/0735-7044.122.1.161>
17. U.S. Food and Drug Administration. (2024). *Additional information about high-intensity sweeteners permitted for use in food in the United States*. <https://www.fda.gov/food/food-additives-petitions/additional-information-about-high-intensity-sweeteners-permitted-use-food-united-states>
18. World Health Organization. (2023). Aspartame Hazard and Risk Assessment Results Released. In [www.who.int](https://www.who.int/news/item/14-07-2023-aspartame-hazard-and-risk-assessment-results-released). <https://www.who.int/news/item/14-07-2023-aspartame-hazard-and-risk-assessment-results-released>
19. World Health Organization. (2023). *WHO guideline: Use of non-sugar sweeteners*. World Health Organization. <https://www.who.int/publications/i/item/9789240073616>

Healthy Sweeteners: Realistic Expectations

From a naturopathic perspective, sweeteners are not just “calories” but bioactive substances that can either burden or support metabolism. Even “healthier” sweeteners still add a sugar load; the goal is less overall sweetness, with better-quality choices where sweetness is used.

Below is evidence-aligned discussion of three commonly recommended options—raw honey, coconut-sap crystals, and stevia—followed by a brief comment on recommendations in diabetes care.

Raw Honey

Honey is one of the oldest recorded sweeteners, used for at least 3,000 years in many cultures—including ancient Egypt—for food, wound care, and as a general tonic. Modern analysis helps separate **romantic claims** from **documented properties**.

What Makes Raw Honey Distinct?

“Raw” honey is:

- Taken straight from the extractor, **unheated, unpasteurised, and minimally filtered**.
- Contains small amounts of **enzymes (e.g., invertase, amylase, glucose oxidase)**, organic acids, vitamins, minerals, and a wide array of **polyphenols and antioxidants** (Alvarez-Suarez et al., 2010; Burlando & Cornara, 2013).

- Often includes traces of **pollen, propolis, wax**, and other bee-hive components.

Heating, ultra-filtration, and industrial blending can:

- Reduce enzyme activity and antioxidant capacity.
- Strip pollen and hive components.

Commercial, heavily processed honey is therefore **closer to “flavoured sugar syrup”** than to a complex, bioactive food.

Metabolic and Clinical Considerations

Nutritionally, honey is still a **high-sugar carbohydrate** (mostly fructose and glucose) and will raise blood glucose, though some studies suggest a slightly **lower glycaemic response** than equivalent amounts of sucrose or glucose and modest benefits on lipids and inflammatory markers in some populations (Bahrami et al., 2009; Erejuwa et al., 2012).

Documented properties:

- **Antimicrobial and wound-healing effects:** Particularly with medical-grade honeys like Manuka; used in chronic wounds and burns (Mandal & Mandal, 2011).
- **Antioxidant and anti-inflammatory actions:** Via polyphenols and flavonoids, potentially relevant for cardiometabolic health (Alvarez-Suarez et al., 2010; Burlando & Cornara, 2013).

Key points for people with (or at risk for) diabetes:

- Honey is **not “free” metabolically**: it must be counted within total carbohydrate, and portions must be small.
- As a sweetener, **raw, local, minimally processed honey** is more nutrient-dense than white sugar, but it will still raise blood glucose.

In a naturopathic program, raw honey is best used:

- Sparingly, in **small amounts**,

- Preferably with protein/fat/fibre-rich foods (not alone),
- As an occasional, higher-quality alternative to refined sugar—not as an unlimited “healing sugar.”

Coconut Sap Crystals

“Coconut sugar” or coconut-sap crystals are made from the **evaporated sap of coconut flower buds**, not from coconut flesh.

The fresh sap:

- Is lightly sweet, with a near-neutral pH.
- Contains modest amounts of **minerals (especially potassium), some B-vitamins (including inositol), amino acids, and prebiotic fructooligosaccharides (FOS)** (Asghar et al., 2019).

The marketed crystals:

- Are typically **low-processed, gently dehydrated** to preserve some of this nutrient content.
- Have a **lower glycaemic index** than table sugar in some studies, though still clearly **glycaemic**
- Provide **more minerals and some prebiotic FOS** than refined sucrose, but **most of their calories still come from sugar** (largely sucrose with some glucose and fructose).

Naturopathically, coconut-sap crystals are:

- Preferable to refined white sugar in terms of **micronutrient density and GI**,
- Still not suitable for large-scale, unmeasured use in people with insulin resistance or diabetes.

Stevia (*Stevia rebaudiana*)

Stevia has a long history of use by the Guaraní people of Paraguay as a **sweet herb and medicinal plant**. Modern preparations isolate its intense, non-caloric glycosides:

- Main glycosides: **stevioside, rebaudioside A (Reb-A), and others.**
- These are **hundreds of times sweeter than sucrose**, with negligible calories.

Metabolic and Clinical Evidence

Stevia glycosides:

- Do **not raise blood glucose or insulin** when used in typical amounts (Farhat et al., 2019; Zare et al., 2024).
- In some trials, may modestly **improve post-prandial insulin and glucose responses**, and have been explored for potential **blood-pressure-lowering** and **insulin-sensitising** effects (Jeppesen et al., 2002; Gregersen et al., 2004).
- Are considered safe at current intake levels by major regulators (JECFA, EFSA).

Whole-leaf extracts and traditional preparations are more complex mixtures that:

- Have been studied less rigorously but are used traditionally in some countries for **diabetes, hypoglycaemia, candidiasis, digestive support, and hypertension.**
- Appear generally safe, though regulatory approvals usually focus on **purified glycosides** (e.g., Reb-A).

For people with diabetes, stevia:

- Provides a **non-glycaemic sweetener option.**
- May help **wean off sugar** when used mindfully.
- Should still be used in the context of **reducing overall sweetness** and not simply replacing sugar in a highly processed diet.

Naturopathic Recommendations and Cautions

From a strict naturopathic perspective, “healthy sweeteners” are:

- **Raw, unpasteurised organic honey**
- **Coconut-sap crystals (minimally processed)**
- **High-quality stevia (whole-leaf or purified glycosides)**
- (Raw agave powder is often mentioned, but many commercial agave products are high in **free fructose**, which is problematic in excess for liver and metabolic health; they must be chosen and used with great care.)

However, for individuals with type 2 diabetes or marked insulin resistance:

- All caloric sweeteners—including raw honey and coconut crystals—should be **tightly limited and carefully counted** within an overall carbohydrate budget.
- Stevia (and small amounts of other non-nutritive natural sweeteners) may be **preferable** for sweetness where needed, but the **long-term goal** is to **reduce the palate’s demand for intense sweetness altogether**.

In the naturopathic framework presented in this textbook, “healthy sweeteners” are therefore:

- **Occasional tools**, not staples.
- Chosen for **purity, minimal processing, and added nutrient/phytochemical value**,
- Integrated into a **whole-food, low-ultra-processed diet**, rather than layered on top of the same high-glycaemic, high-refined-carb pattern.

In the next sections, we will build on this by outlining comprehensive naturopathic nutritional approaches to type 2 diabetes that minimise both sugar and artificial sweeteners, and prioritise whole, naturally flavoured foods.

References:

1. Alvarez-Suarez, J. M., Tulipani, S., Díaz, D., Estevez, Y., Romandini, S., Giampieri, F., Damiani, E., Astolfi, P.,

- Bompadre, S., & Battino, M. (2010). Antioxidant and antimicrobial capacity of several monofloral Cuban honeys and their correlation with color, polyphenol content and other chemical compounds. *Food and Chemical Toxicology*, 48(8–9), 2490–2499. <https://doi.org/10.1016/j.fct.2010.06.021>
2. Asghar, M. T., Yusof, Y. A., Mokhtar, M. N., Ya'acob, M. E., Mohd Ghazali, H., Chang, L. S., & Manaf, Y. N. (2019). Coconut (*Cocos nucifera* L.) sap as a potential source of sugar: Antioxidant and nutritional properties. *Food science & nutrition*, 8(4), 1777–1787. <https://doi.org/10.1002/fsn3.1191>
 3. Bahrami, M., Ataie-Jafari, A., Hosseini, S., Foruzanfar, M. H., Rahmani, M., & Pajouhi, M. (2009). Effects of natural honey consumption in diabetic patients: an 8-week randomized clinical trial. *International journal of food sciences and nutrition*, 60(7), 618–626. <https://doi.org/10.3109/09637480801990389>
 4. Burlando, B., & Cornara, L. (2013). Honey in dermatology and skin care: A review. *Journal of Cosmetic Dermatology*, 12(4), 306–313. <https://doi.org/10.1111/jocd.12058>
 5. Erejuwa, O. O., Sulaiman, S. A., & Wahab, M. S. A. (2012). Honey: A novel antioxidant. *Molecules*, 17(4), 4400–4423. <https://doi.org/10.3390/molecules17044400>
 6. Farhat, G., Berset, V., & Moore, L. (2019). Effects of Stevia Extract on Postprandial Glucose Response, Satiety and Energy Intake: A Three-Arm Crossover Trial. *Nutrients*, 11(12), 3036. <https://doi.org/10.3390/nu11123036>
 7. Gregersen, S., Jeppesen, P. B., Holst, J. J., & Hermansen, K. (2004). Antihyperglycemic effects of stevioside in type 2 diabetic subjects. *Metabolism*, 53(1), 73–76. <https://doi.org/10.1016/j.metabol.2003.07.013>
 8. Jeppesen, P. B., Gregersen, S., Rolfsen, S. E., Jepsen, M., Colombo, M., Agger, A., Xiao, J., Kruhøffer, M., Ørntoft, T., & Hermansen, K. (2002). Antihyperglycemic and blood pressure-lowering effects of stevioside in the diabetic

- Goto-Kakizaki (GK) rat. *Metabolism*, 52(3), 372–378.
<https://doi.org/10.1053/meta.2003.50058>
9. Mandal, M. D., & Mandal, S. (2011). Honey: Its medicinal property and antibacterial activity. *Asian Pacific Journal of Tropical Biomedicine*, 1(2), 154–160.
[https://doi.org/10.1016/S2221-1691\(11\)60016-6](https://doi.org/10.1016/S2221-1691(11)60016-6)
10. Zare, M., Mobina Zeinalabedini, Soraiya Ebrahimpour-Koujan, Bellissimo, N., & Azadbakht, L. (2024). Effect of Stevia on Blood Glucose and HbA1c: A Meta-Analysis. *Diabetes & Metabolic Syndrome Clinical Research & Reviews*, 18(7), 103092–103092.
<https://doi.org/10.1016/j.dsx.2024.103092>

Refined Foods

From a naturopathic standpoint, the modern diet's obsession with **refined, shelf-stable, ultra-processed foods** is one of the most powerful drivers of insulin resistance and type 2 diabetes. Refining strips away vitamins, minerals, fibre, and phytochemicals, leaving behind rapidly absorbed starch and sugar plus chemical residues. What remains is “food” only in the narrow sense of delivering calories, not in the sense of **truly nourishing human physiology**.

What Refining Does to Grains

Whole grains contain:

- **Bran** (outer layer): fibre, B-vitamins, minerals, antioxidants.
- **Germ** (embryo): healthy fats, vitamin E, B-vitamins, phytonutrients.
- **Endosperm**: mostly starch with some protein.

“Refined” or “white” flour (“wheat flour,” “enriched wheat flour”) is made by removing the bran and germ:

- This strips away **most of the fibre, B-vitamins (thiamine, riboflavin, niacin, folate), vitamin E, magnesium, zinc, and many phytochemicals** (Slavin, 2004; Jones, 2012).
- What remains is a **rapidly digestible starch** that behaves metabolically like sugar, driving sharp post-prandial glucose and insulin spikes.

Industrial enrichment adds back a handful of synthetic B-vitamins and iron, but:

- It **does not restore the full matrix** of nutrients, fibre, and bioactives.
- Refined products still promote **higher glycaemic and insulinaemic responses** and are strongly associated with type 2 diabetes and cardiovascular disease (Aune et al., 2013; Hu, 2011).

Health Consequences of Refined Grain–Based Diets

Micronutrient Depletion

High intakes of white flour products crowd out nutrient-dense foods, contributing to:

- **B-vitamin inadequacy**, including folate, B6, and B12 (the latter more tied to low animal-source foods, age, and malabsorption than to flour per se). In many populations, large proportions of adults fail to meet the minimum micronutrient requirements (Passarelli et al., 2024).
- **Iron, magnesium, zinc, and fibre deficits**, all of which affect energy metabolism, mood, and glycaemic control.

Chronic subclinical deficiency states can manifest as **fatigue, irritability, low mood, impaired cognition, and vulnerability to chronic disease**.

Digestive and Immune Issues

Aggressive breeding, gluten content changes, and modern baking (fast-rise yeast, short fermentation, additives) have altered wheat products:

- Higher intake of refined wheat is associated with **greater risk of obesity, type 2 diabetes, and non-alcoholic fatty liver disease** (Aune et al., 2013; Schwingshackl et al., 2017).

- Celiac disease and non-celiac gluten sensitivity diagnoses have increased; while multiple factors are involved, **high intake of refined wheat products and rapid-rise processing** likely play a role in symptom burden (Fasano et al., 2015).
- Occupational and environmental exposure to **baking enzymes** (including amylases) can cause respiratory allergy and baker's asthma (Baur et al., 1998).

Pesticides and Chemical Load

Modern conventional wheat is often exposed to:

- **Seed fungicides**,
- Multiple passes of **herbicides and insecticides**,
- Occasionally **desiccants** prior to harvest,
- Pesticides/insecticides in storage facilities.

Residues from these chemicals contribute to the **total toxic load**, which naturopathic medicine regards as a key amplifier of chronic inflammation and oxidative stress—central mechanisms in diabetes and its complications (Donath & Shoelson, 2011; Trasande et al., 2016). While levels may fall below regulatory thresholds, cumulative and synergistic effects over decades are not well studied.

Industrial Milling and Bleaching

Traditional stone-milling:

- Grinds slowly, with **lower heat**, preserving more nutrients and lipids.

Modern roller milling:

- Uses **high-speed steel rollers**, generating more heat and oxidation.
- Often followed by chemical **bleaching and “maturing”** (e.g., chlorine dioxide, benzoyl peroxide) to whiten flour and alter baking properties (Shewry & Hey, 2015).

Although typical bleaching agents are removed or transformed before consumption, their use reflects an industrial priority for **appearance and processability over nutritional integrity**.

*Note: Claims that standard white flour treatments generate clinically significant amounts of alloxan in human food are not supported by high-quality data. However, the broader point remains valid: refining plus chemical treatment yields a **nutrient-poor, high-GI product** that undermines metabolic health.*

Metabolic Impact: Fast Carbohydrate, Slow Damage

Frequent intake of refined-grain foods (white bread, biscuits, noodles, pastries, many breakfast cereals):

- Produces **rapid glucose absorption and high insulin responses**, followed by reactive dips that can drive hunger, irritability, and cravings.
- Promotes **visceral fat accumulation, hepatic fat deposition, and insulin resistance**.
- Is strongly linked with higher risk of **type 2 diabetes, cardiovascular disease, and all-cause mortality**, in contrast to whole-grain intake (Aune et al., 2013; Schwingshackl et al., 2017).

Over time, diets centred on refined starches:

- Make people feel tired, moody, and hungry,
- Encourage overeating and weight gain,
- Worsen glycaemic variability and increase drug requirements in people with diabetes.

From a naturopathic lens, such diets are the **opposite of therapeutic nutrition**: they deliver calories stripped of context, intensify toxic load, and erode the body's capacity to self-regulate.

Naturopathic Implications

For people with, or at risk for, type 2 diabetes, core nutritional priorities include:

- **Eliminating or sharply reducing refined grain products** (white breads, refined flours, most packaged baked goods).
- Replacing them with:
 - **Whole, intact grains** (in those who tolerate grains),
 - **Legumes, nuts, seeds,**
 - **Non-starchy and low-glycaemic vegetables,**
 - Targeted amounts of **whole fruit.**
- Choosing **organic or low-pesticide sources** where possible to reduce chemical burden.
- Favouring **traditional or slow-fermented breads** (e.g., whole-grain sourdough) if bread is included at all.

This is the nutritional foundation on which naturopathic protocols for diabetes are built. Without addressing the dominance of refined grains and ultra-processed foods, no supplement or drug can reliably restore metabolic health.

In the next section, we will move from critique to construction: outlining step-by-step naturopathic food plans for type 2 diabetes that minimise refined starches and focus on restoring nutrient density, fibre, and metabolic stability.

References:

1. Aune, D., Norat, T., Romundstad, P., & Vatten, L. J. (2013). Whole grain and refined grain consumption and the risk of type 2 diabetes: A systematic review and dose–response meta-analysis of cohort studies. *European Journal of Epidemiology*, 28(11), 845–858.
<https://doi.org/10.1007/s10654-013-9852-5>

2. Baur, X., Degens, P. O., & Sander, I. (1998). Baker's asthma: still among the most frequent occupational respiratory disorders. *The Journal of allergy and clinical immunology*, 102(6 Pt 1), 984–997. [https://doi.org/10.1016/s0091-6749\(98\)70337-9](https://doi.org/10.1016/s0091-6749(98)70337-9)
3. Donath, M. Y., & Shoelson, S. E. (2011). Type 2 diabetes as an inflammatory disease. *Nature Reviews Immunology*, 11(2), 98–107. <https://doi.org/10.1038/nri2925>
4. Fasano, A., Sapone, A., Zavallos, V., & Schuppan, D. (2015). Nonceliac gluten sensitivity. *Gastroenterology*, 148(6), 1195–1204. <https://doi.org/10.1053/j.gastro.2014.12.049>
5. Hu, F. B. (2011). Globalization of diabetes: The role of diet, lifestyle, and genes. *Diabetes Care*, 34(6), 1249–1257. <https://doi.org/10.2337/dc11-0442>
6. Passarelli, S., Free, C. M., Shepon, A., Beal, T., Batis, C., & Golden, C. D. (2024). Global estimation of dietary micronutrient inadequacies: a modelling analysis. *The Lancet. Global health*, 12(10), e1590–e1599. [https://doi.org/10.1016/S2214-109X\(24\)00276-6](https://doi.org/10.1016/S2214-109X(24)00276-6)
7. Schwingshackl, L., Schwedhelm, C., Hoffmann, G., Knüppel, S., Iqbal, K., Andriolo, V., Bechthold, A., Schlesinger, S., & Boeing, H. (2017). Food groups and risk of type 2 diabetes mellitus: A systematic review and meta-analysis of prospective studies. *European Journal of Epidemiology*, 32(5), 363–375. <https://doi.org/10.1007/s10654-017-0246-y>
8. Shewry, P. R., & Hey, S. J. (2015). The contribution of wheat to human diet and health. *Food and Energy Security*, 4(3), 178–202. <https://doi.org/10.1002/fes3.64>
9. Slavin, J. (2004). Whole grains and human health. *Nutrition Research Reviews*, 17(1), 99–110. <https://doi.org/10.1079/NRR200374>

10. Trasande, L., Zoeller, R. T., Hass, U., Kortenkamp, A., Grandjean, P., Myers, J. P., DiGangi, J., Bellanger, M., Hauser, R., Legler, J., Skakkebaek, N. E., Heindel, J. J., & Heindel, J. J. (2016). Estimating burden and disease costs of exposure to endocrine-disrupting chemicals in the European Union. *Journal of Clinical Endocrinology & Metabolism*, 100(4), 1245–1255. <https://doi.org/10.1210/jc.2014-4324>

Why a High-Carb Diet Can Be Disastrous to Metabolic Health?

From a naturopathic, metabolic perspective, **chronic overconsumption of rapidly absorbed carbohydrates**—especially refined grains and sugars—is a major driver of insulin resistance, type 2 diabetes, and obesity. Decades of advice to eat “high-carb, low-fat” while underplaying carbohydrate quality have left many people heavier, more insulin-resistant, and confused about why they are “doing everything right” yet getting sicker.

How Excess Carbohydrate Drives Fat Storage and Insulin Resistance

Step 1: Rapid Glucose Spikes

Meals rich in refined starches and sugars (white bread, biscuits, rice, noodles, sweet drinks):

- Are digested quickly, producing a **rapid rise in blood glucose**.
- The pancreas responds by secreting a **large pulse of insulin** to push glucose into cells.

Step 2: Insulin as a Storage Hormone

Insulin is not only a glucose-lowering hormone; it is a **storage hormone**:

- It promotes **glycogen synthesis** in liver and muscle, but glycogen storage capacity is limited.

- Once glycogen stores are relatively full, **excess glucose is converted into fat** (de novo lipogenesis), particularly in the liver and adipose tissue (Samuel & Shulman, 2016).
- High insulin **blocks lipolysis** (fat breakdown), making it very difficult to access stored fat for energy.

In practical terms, a high-carb, high-insulin pattern tells the body, **“Store fat and don’t burn it.”**

Step 3: Hormonal Effects and Hunger

Chronically high insulin and glucose swings:

- Suppress **glucagon**, which normally promotes the release and burning of stored fuel.
- Interfere with **growth hormone** dynamics, reducing support for lean-mass maintenance.
- Lead to a characteristic **roller-coaster of energy and hunger**:
 - Rapid rise in glucose → high insulin → overshoot drop in glucose → **hunger and cravings** within 1–3 hours (Ludwig, 2002).

This pattern drives people to **eat more frequently**, often reaching for more refined carbs, creating a **self-reinforcing cycle** of overeating and fat gain.

Clinical and Epidemiologic Evidence

High intakes of **refined grains, added sugars, and high-glycaemic-load diets** are consistently linked to:

- **Higher risk of type 2 diabetes** (Bhupathiraju et al., 2014; Aune et al., 2013).
- **Greater weight gain and obesity**, particularly when combined with sugary beverages (Hu, 2013).
- **Non-alcoholic fatty liver disease** and other cardiometabolic disturbances (Vos et al., 2017).

By contrast, lower-carbohydrate and low-glycaemic-load patterns:

- Often lead to **greater improvements in HbA1c, weight, and triglycerides** than high-carb, low-fat diets in people with type 2 diabetes (Feinman et al., 2015; Goldenberg et al., 2021).
- Can reduce or even eliminate the need for some glucose-lowering medications when applied rigorously and safely.

Summary

Chronic overconsumption of **grain-based and sugar-rich carbohydrates** is a central driver of **insulin resistance, fat storage, and hunger dysregulation**.

- High-insulin states:
 - Promote **fat accumulation**,
 - Block access to stored fat,
 - Disrupt hunger and satiety signals,
 - Increase the need for medications to control glucose.
- Simply “cutting fat” while **keeping carbohydrate load high** is a recipe for metabolic frustration.

In the naturopathic framework presented in this book, restoring metabolic health requires:

- **Reducing total and especially refined carbohydrate load,**
- Prioritising **non-starchy vegetables, fibre, and adequate protein,**
- Using healthy fats strategically, and
- Restructuring meal patterns to stabilise glucose and insulin.

In the next sections, we will outline specific naturopathic dietary patterns for type 2 diabetes—focusing on lower-glycaemic, whole-food approaches that reduce insulin demand and support fat

loss, while integrating with (and gradually reducing) pharmacologic therapy where appropriate.

References:

1. Aune, D., Norat, T., Romundstad, P., & Vatten, L. J. (2013). Whole grain and refined grain consumption and the risk of type 2 diabetes: A systematic review and dose–response meta-analysis of cohort studies. *European Journal of Epidemiology*, 28(11), 845–858.
<https://doi.org/10.1007/s10654-013-9852-5>
2. Bhupathiraju, S. N., Tobias, D. K., Malik, V. S., Pan, A., Hruby, A., Manson, J. E., Willett, W. C., & Hu, F. B. (2014). Glycemic index, glycemic load, and risk of type 2 diabetes: Results from 3 large US cohorts and an updated meta-analysis. *American Journal of Clinical Nutrition*, 100(1), 218–232. <https://doi.org/10.3945/ajcn.113.079533>
3. Feinman, R. D., Pogozelski, W. K., Astrup, A., Bernstein, R. K., Fine, E. J., Westman, E. C., Accurso, A., Frassetto, L., Gower, B. A., McFarlane, S. I., Nielsen, J. V., Krarup, T., Saslow, L., Roth, K. S., Vernon, M. C., Volek, J. S., Wilshire, G. B., Dahlqvist, A., Sundberg, R., ... Worm, N. (2015). Dietary carbohydrate restriction as the first approach in diabetes management: Critical review and evidence base. *Nutrition*, 31(1), 1–13.
<https://doi.org/10.1016/j.nut.2014.06.011>
4. Goldenberg, J. Z., Day, A., Brinkworth, G. D., Sato, J., Yamada, S., Jönsson, T., Beardsley, J., Johnson, J. A., & Thabane, L. (2021). Efficacy and safety of low and very low carbohydrate diets for type 2 diabetes remission: Systematic review and meta-analysis. *BMJ*, 372, m4743.
<https://doi.org/10.1136/bmj.m4743>
5. Hu, F. B. (2013). Resolved: There is sufficient scientific evidence that decreasing sugar-sweetened beverage consumption will reduce the prevalence of obesity and

- obesity-related diseases. *Obesity Reviews*, 14(8), 606–619.
<https://doi.org/10.1111/obr.12040>
6. Ludwig, D. S. (2002). The glycemic index: Physiological mechanisms relating to obesity, diabetes, and cardiovascular disease. *JAMA*, 287(18), 2414–2423.
<https://doi.org/10.1001/jama.287.18.2414>
 7. Samuel, V. T., & Shulman, G. I. (2016). The pathogenesis of insulin resistance: Integrating signaling pathways and substrate flux. *Journal of Clinical Investigation*, 126(1), 12–22. <https://doi.org/10.1172/JCI77812>
 8. Vos, M. B., Lavine, J. E., & Fisher, E. A. (2017). Sugar and the health of children: An endocrine society scientific statement. *Endocrine Reviews*, 38(1), 1–20.
<https://doi.org/10.1097/MPG.0000000000001733>

HFCS – High Fructose Corn Syrup: Cheap Sweetness, expensive Metabolism

High-fructose corn syrup (HFCS) is one of the clearest examples of how industrial food chemistry has sabotaged metabolic health. It is **not a traditional food**; it is a highly processed, corn-derived sweetener designed to be cheap, intensely sweet, and easy to blend into almost every packaged product. Its rise parallels—and plausibly contributes to—the explosion of obesity, fatty liver, and type 2 diabetes.

What HFCS Is (and Isn't)

HFCS is:

- Produced from **corn starch**, enzymatically broken down to glucose and then partially converted to fructose (via glucose isomerase).
- Typically a mixture of **≈55% fructose and 45% glucose** in soft drinks (HFCS-55), and **≈42% fructose** in many foods (HFCS-42).
- **Not present in nature** as such; it is an industrial ingredient, similar in “naturalness” to refined table sugar.

Because U.S. and global corn production is heavily subsidised and HFCS is cheap and stable, it has flooded:

- Soft drinks and fruit drinks
- Sweetened yogurts and flavoured milks

- Baked goods, condiments, salad dressings, sauces, snack foods

This ubiquity means many people consume large amounts of added fructose and glucose **without realising it**, often in liquid form, which is particularly problematic metabolically.

HFCS, Sugary Drinks, and Metabolic Fallout

Sugary drinks (soft drinks, “energy” drinks, sweetened juices) are a major HFCS delivery system:

- A single 330–355 mL can of soda typically contains **≈35–40 g of sugar**, often from HFCS—around **9–10 teaspoons**. Many adolescents consume much more than one per day.
- Regular intake of sugary drinks is strongly associated with **weight gain, type 2 diabetes, and cardiovascular disease** (Malik et al., 2010; Hu, 2013).

Meta-analyses show that:

- Each additional daily serving of sugar-sweetened beverage is associated with a **≈26% higher risk of type 2 diabetes**, independent of body weight (Malik et al., 2010).
- Liquid sugars are **poorly satiating**, leading to higher total calorie intake (Pan & Hu, 2011).

For many people, simply cutting **one sugary drink per day** can translate into **measurable weight loss** over a year—without any other change.

How HFCS and High Fructose Loads Damage Metabolism

While sucrose (table sugar) and HFCS are both roughly half glucose, half fructose, large, rapid doses of fructose—**especially in liquid form and as added sugar**—have specific harms:

1. Liver Overload and Fatty Liver

- Fructose is taken up primarily by the **liver**, where it is rapidly phosphorylated and shunted into pathways that favour **de novo lipogenesis (fat production)**.
- Over time, this contributes to **non-alcoholic fatty liver disease (NAFLD)** and hepatic insulin resistance (Tappy & Lê, 2010).
- Controlled feeding trials show that high-fructose diets increase **intrahepatic fat, triglycerides, and liver fat production** compared with isocaloric low-fructose diets (Stanhope et al., 2009).

2. Visceral Fat and Atherogenic Lipids

- In a key trial where 25% of energy came from fructose vs glucose-sweetened beverages for 10 weeks, both groups gained weight, but the **fructose group gained significantly more visceral (abdominal) fat**, had higher post-prandial triglycerides, and more small, dense LDL particles (Stanhope et al., 2009).
- Visceral fat and these lipid patterns are tightly linked to **metabolic syndrome and cardiovascular risk**.

3. Insulin Resistance and Glucose Control

- Chronic high-fructose intake worsened **insulin sensitivity and glycaemic control** in the same study (Stanhope et al., 2009).
- Over time, this drives the classic progression to **type 2 diabetes**.

4. Appetite Regulation

- Fructose does **not stimulate insulin and leptin** to the same extent as glucose and may fail to suppress ghrelin (hunger hormone) adequately, potentially promoting **over-eating** (Tappy & Lê, 2010; Teff et al., 2004).

- This blunted hormonal response helps explain why sugary drinks leave people hungry soon after consumption.

5. Kidney and Other Organ Effects

- High intake of sugar-sweetened beverages has been associated with increased risk of **chronic kidney disease**, independent of other risk factors (Dai et al., 2024).
- High fructose loads may increase **uric acid**, promote endothelial dysfunction, and contribute to hypertension (Johnson et al., 2017).

Animal studies consistently show that HFCS or very high-fructose diets:

- Promote **more weight gain, greater adiposity, and worse metabolic profiles** than equivalent calories from other carbohydrates (Bocarsly et al., 2010; Parker, 2010).

Human data, taken together, support a clear conclusion: **large amounts of added fructose—especially as HFCS in beverages—drive fatty liver, visceral obesity, dyslipidaemia, and insulin resistance.**

“Natural” Does Not Mean Safe

Key clarifications:

- HFCS and refined sucrose are both **highly processed, concentrated sweeteners**; both are harmful in excess.
- Fructose in **whole fruits and vegetables** behaves differently:
 - It is **diluted by water and fibre**,
 - Comes packaged with **vitamins, minerals, antioxidants, and phytochemicals**,
 - Is absorbed more slowly and in **much smaller doses** than in sweetened drinks.

The problem is dose, speed, and context:

- HFCS delivers **large, rapid fructose loads** without fibre or micronutrients, mainly via beverages and ultra-processed foods.
- The body is **not designed** to handle repeated boluses of free sugar and fructose in this form.

Naturopathic Perspective: HFCS as a Non-Negotiable “Stop”

From a naturopathic and integrative standpoint:

- HFCS and other **added sugars** (including table sugar, inverted sugar, many syrups) are among the **most important dietary toxins** to remove in type 2 diabetes, fatty liver, and metabolic syndrome.
- Their elimination (especially in sugary drinks) is a **first-line intervention**, often yielding rapid improvements in:
 - Energy and appetite control
 - Weight trajectory
 - Triglycerides and liver enzymes
 - Glucose and insulin requirements

In practical terms:

- Careful label reading is essential: HFCS and other added sugars hide in condiments, breads, snack foods, flavoured yogurts, and many “health” products.
- Sweetness, when used at all, should come primarily from **whole foods** (e.g., whole fruits) and, secondarily and sparingly, from **higher-quality sweeteners** (e.g., small amounts of raw honey or coconut crystals) within a structured plan.

In the next sections, we will integrate this understanding into comprehensive naturopathic nutrition plans that sharply reduce

added sugars (including HFCS) and focus on restoring liver and insulin sensitivity through whole foods, lower-glycaemic patterns, and targeted lifestyle change.

References:

1. Bocarsly, M. E., Powell, E. S., Avena, N. M., & Hoebel, B. G. (2010). High-fructose corn syrup causes characteristics of obesity in rats: Increased body weight, body fat and triglyceride levels. *Pharmacology Biochemistry and Behavior*, 97(1), 101–106.
<https://doi.org/10.1016/j.pbb.2010.02.012>
2. Dai X-Y, Chen X-Y, Jia L-N, Jing X-T, Pan X-Y, Zhang X-Y, Jing Z, Yuan J-Q, He Q-S and Yang L-L (2024) Sugary beverages intake and risk of chronic kidney disease: the mediating role of metabolic syndrome. *Front. Nutr.* 11:1401081. <https://doi.org/10.3389/fnut.2024.1401081>
3. Hu, F. B. (2013). Resolved: There is sufficient scientific evidence that decreasing sugar-sweetened beverage consumption will reduce the prevalence of obesity and obesity-related diseases. *Obesity Reviews*, 14(8), 606–619.
<https://doi.org/10.1111/obr.12040>
4. Johnson, R. J., Sánchez-Lozada, L. G., Andrews, P., & Lanaspa, M. A. (2017). Perspective: A Historical and Scientific Perspective of Sugar and Its Relation with Obesity and Diabetes. *Advances in nutrition* (Bethesda, Md.), 8(3), 412–422. <https://doi.org/10.3945/an.116.014654>
5. Malik, V. S., Popkin, B. M., Bray, G. A., Després, J.-P., Willett, W. C., & Hu, F. B. (2010). Sugar-sweetened beverages and risk of metabolic syndrome and type 2 diabetes: A meta-analysis. *Diabetes Care*, 33(11), 2477–2483. <https://doi.org/10.2337/dc10-1079>
6. Pan, A., & Hu, F. B. (2011). Effects of carbohydrates on satiety: differences between liquid and solid food. *Current*

- opinion in clinical nutrition and metabolic care, 14(4), 385–390. <https://doi.org/10.1097/MCO.0b013e328346df36>
7. Parker, H. (2010). A sweet problem: Princeton researchers find that high-fructose corn syrup prompts considerably more weight gain. In Princeton University.
<https://www.princeton.edu/news/2010/03/22/sweet-problem-princeton-researchers-find-high-fructose-corn-syrup-prompts>
 8. Stanhope, K. L., Schwarz, J.-M., Keim, N. L., Griffen, S. C., Bremer, A. A., Graham, J. L., Hatcher, B., Cox, C. L., Dyachenko, A., Zhang, W., McGahan, J. P., Seibert, A., Krauss, R. M., Chiu, S., Schaefer, E. J., Ai, M., Otokozawa, S., Nakajima, K., Nakano, T., ... Havel, P. J. (2009). Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. *Journal of Clinical Investigation*, 119(5), 1322–1334.
<https://doi.org/10.1172/JCI37385>
 9. Tappy, L., & Lê, K.-A. (2010). Metabolic effects of fructose and the worldwide increase in obesity. *Physiological Reviews*, 90(1), 23–46.
<https://doi.org/10.1152/physrev.00019.2009>
 10. Teff, K. L., Elliott, S. S., Tschöp, M., Kieffer, T. J., Rader, D., Heiman, M., Townsend, R. R., Keim, N. L., D'Alessio, D., & Havel, P. J. (2004). Dietary fructose reduces circulating insulin and leptin, attenuates postprandial suppression of ghrelin, and increases triglycerides in women. *Journal of Clinical Endocrinology & Metabolism*, 89(6), 2963–2972. <https://doi.org/10.1210/jc.2003-031855>

Trans Fats, Vegetable Oils, Margarine, and Vanaspati: Industrial Fats in a Metabolically Vulnerable Population

“The central problem is not fat alone, but the interaction between industrial processing, repeated heating, ultra-processed food patterns, and the metabolic vulnerability of the Indian population.”

India carries a massive burden of type 2 diabetes and cardiovascular disease. Alongside the shift from traditional fats and cooking methods to industrial fats, deep-frying, and packaged foods, the rise of refined carbohydrates and sugars has quietly intensified metabolic risk. This section examines **trans fats, vanaspati, margarine, and commonly used vegetable oils** in the Indian context, with a naturopathic focus on real-world cooking practices rather than isolated nutrients.

What Are Trans Fats and Vanaspati?

Trans fats are unsaturated fats in which at least one double bond has been flipped from the natural *cis* configuration to the *trans* form—most often during **industrial hydrogenation**:

- Historically abundant in **partially hydrogenated vegetable oils, bakery shortenings, some margarines, and vanaspati**.
- They improve **texture, shelf life, and frying stability**, but at a steep cardiovascular cost.

Vanaspati is a semi-solid, hydrogenated vegetable fat widely used in India because it is:

- **Low-cost availability, shelf-stable, transportable, and highly suitable for frying.**
- Attractive to the food industry and street vendors—but historically a **major source of industrial trans fatty acids.**

Many commercial **margarines and bakery fats** have also contained trans fats when produced with partially hydrogenated oils. The key lesson:

*It is not enough to ask “Is it plant-based?” or “Is it solid or liquid?”
We must ask: “How was this fat processed, and how is it being used?”*

Repeated Heating and Oil Degradation

A common lay statement is that “reheating oil turns it into trans-fat.” Scientifically:

- **Repeated high-temperature frying and prolonged heating:**
 - Increase **oxidation**,
 - Generate **polar compounds, aldehydes, polymers**,
 - And can modestly **increase trans-fat formation** depending on the oil, temperature, and duration (Stier, 2013; Rossell, 2001).
- Reused oil accumulates degradation products that have been associated with **inflammation, endothelial dysfunction, and altered lipid profiles** in experimental settings (Ng et al., 2014).

In India, where frying oils in homes, restaurants, and street stalls may be **reused many times** for economic reasons, even oils that begin with a relatively acceptable fatty-acid profile can become **metabolically undesirable** when repeatedly overheated.

Why Industrial Trans Fats Are Harmful

The evidence against industrial trans fats is among the strongest in nutrition science:

- They **raise LDL-cholesterol and lipoprotein(a)** and **lower HDL-cholesterol**, creating a highly atherogenic lipid profile (Mozaffarian et al., 2006; Brouwer et al., 2010).
- High trans-fat intake is robustly associated with **increased risk of coronary heart disease and mortality** (Mozaffarian et al., 2006).
- Several studies suggest that trans fats are linked to **systemic inflammation, insulin resistance, and possibly type 2 diabetes**, though the evidence is most consistent for cardiovascular outcomes (de Souza et al., 2015).

Proposed mechanisms include:

- Incorporation of trans fatty acids into **cell membranes**, altering fluidity and receptor function.
- Promotion of a **pro-inflammatory internal milieu**.
- Interference with normal intracellular signalling, potentially including insulin pathways.

In a dietary pattern already heavy in **refined carbohydrates, fried foods, and low in protective nutrients**, trans fats act as force multipliers for metabolic damage.

Why the Indian Population May Be More Vulnerable

Indian and South Asian populations show:

- High rates of **central obesity, dyslipidaemia, insulin resistance**, and type 2 diabetes **at comparatively lower BMI**—the so-called “thin-fat Indian” or “South Asian phenotype” (Misra & Khurana, 2011).

This “metabolic susceptibility” means:

- The same quantity and quality of industrial fats and reheated oils may trigger **more severe metabolic consequences** in Indian populations than in groups with lower baseline risk.
- Trans fats and degraded frying oils do not “cause” diabetes in isolation, but they **aggravate** an already vulnerable system shaped by:
 - Refined carbs and sugars,
 - Low physical activity,
 - Chronic stress and sleep disruption,
 - Air and water pollution,
 - Ultra-processed food patterns.

Practices to Avoid

Risks rise sharply with:

- **Frequent consumption of foods made with partially hydrogenated fats** (vanaspati, older margarines, bakery shortenings).
- Regular intake of **bakery items, biscuits, sweets, and fried snacks** prepared with industrial fats.
- **Repeated deep-frying and reuse of the same oil** multiple times.
- High dependence on **ultra-processed foods** where oil type and frying practices are unknown or poorly regulated.

India’s regulator (FSSAI) has moved to **limit industrial trans fats to $\leq 2\%$** in oils and fats, reflecting robust evidence of harm. But regulation cannot fully counteract **street-food practices, small-scale manufacturers, and home re-use of oil**.

Better Practices to Adopt

Naturopathic and public-health-aligned measures include:

- **Eliminate or strictly avoid vanaspati and hydrogenated fats.**
- **Minimise deep-fried foods, commercial bakery items, and packaged snacks.**
- **Do not reuse frying oil** multiple times; discard oil that has darkened, thickened, or smells rancid.
- Use **fresh oil for cooking**, keep total added fats moderate, and avoid heating oil to the smoking point.
- **Rotate oils** reasonably (e.g., mustard/groundnut/rice-bran in line with regional traditions and affordability), instead of over-relying on any single oil as a “miracle fat.”
- Increase **pulses, vegetables, whole grains, nuts, and seeds**, which dilute the metabolic load from fats and refined carbs and provide fibre, antioxidants, and anti-inflammatory nutrients.

From a naturopathic standpoint, oils should be:

- **Fresh, minimally oxidised, and used sparingly,**
- Embedded in a whole-food dietary pattern,
- Never seen as a substitute for broad lifestyle change.

Conclusion: Industrial Fat + Modern Pattern + Metabolic Susceptibility

In the Indian diabetes context, **trans fats, vanaspati, and poor frying practices** are not minor details; they are important amplifiers of risk. The strongest evidence links **industrial trans fats to cardiovascular harm**, with growing but somewhat less uniform evidence for worsening insulin resistance and diabetes risk.

A balanced, evidence-based conclusion is:

- The central problem is **not all fats**, nor all vegetable oils.
- It is the **convergence** of:
 - Industrial hydrogenation and trans fats,

- Repeated high-temperature frying and oil reuse,
- High intake of ultra-processed, fried, and bakery foods,
- And the **high metabolic vulnerability** of the Indian population.

Naturopathic and integrative diabetes care therefore emphasises:

- **Eliminating trans fats and reheated oils,**
- Prioritising **fresh, modest amounts of suitable oils** in home cooking,
- And, above all, **transforming the whole dietary pattern** away from ultra-processed, fried foods toward nutrient-dense, minimally processed, plant-rich meals.

In the following sections, we will understand the impact of Trans fats, Soft Drinks, Sweetened Beverages, Commercial Pasteurized Dairy and more such parameters on insulin sensitivity and vascular health.

References:

1. Brouwer, I. A., Wanders, A. J., & Katan, M. B. (2010). Effect of animal and industrial trans fatty acids on HDL and LDL cholesterol levels in humans—A quantitative review. *PLoS ONE*, 5(3), e9434. <https://doi.org/10.1371/journal.pone.0009434>
2. de Souza, R. J., Mente, A., Maroleanu, A., Cozma, A. I., Ha, V., Kishibe, T., Uleryk, E., Budylowski, P., Schünemann, H., Beyene, J., & Anand, S. S. (2015). Intake of saturated and trans unsaturated fatty acids and risk of all-cause mortality, cardiovascular disease, and type 2 diabetes: Systematic review and meta-analysis of observational studies. *BMJ*, 351, h3978. <https://doi.org/10.1136/bmj.h3978>
3. Misra, A., & Khurana, L. (2011). Obesity and the metabolic syndrome in developing countries. *Journal of Clinical Endocrinology & Metabolism*, 93(11 Suppl. 1), S9–S30. <https://doi.org/10.1210/jc.2008-1595>

4. Ng, C. Y., Leong, X. F., Masbah, N., Adam, S. K., Kamisah, Y., & Jaarin, K. (2014). Heated vegetable oils and cardiovascular disease risk factors. *Vascular pharmacology*, 61(1), 1-9. <https://doi.org/10.1016/j.vph.2014.02.004>
5. Mozaffarian, D., Katan, M. B., Ascherio, A., Stampfer, M. J., & Willett, W. C. (2006). Trans fatty acids and cardiovascular disease. *New England Journal of Medicine*, 354(15), 1601–1613. <https://doi.org/10.1056/NEJMra054035>
6. Stier, R.F. (2000), Chemistry of frying and optimization of deep-fat fried food flavour — An introductory review. *Eur. J. Lipid Sci. Technol.*, 102: 507-514.
[https://doi.org/10.1002/1438-9312\(200009\)102:8/9<507::AID-EJLT507>3.0.CO;2-V](https://doi.org/10.1002/1438-9312(200009)102:8/9<507::AID-EJLT507>3.0.CO;2-V)

Soft Drinks, Sweetened Beverages, and Juices: Liquid Sugar in Disguise

“Whole foods and unsweetened beverages are safer choices than liquid sugar in almost any form.”

Introduction

In India, soft drinks, sweetened beverages, and packaged juices are not just “refreshments”; they are **status symbols, convenience foods, and, too often, default daily drinks**. From a metabolic perspective, they are also among the most efficient ways to deliver rapid, poorly satiating sugar loads to an already insulin-resistant population.

Why Liquid Sugar Is So Problematic

The debate is not only about **how much sugar** these drinks contain, but **how they behave in the body**:

- Liquid sugars **require almost no chewing or digestion**.
- They are absorbed **rapidly**, creating steep rises in blood glucose and **sharp insulin demands**.
- They **lack fibre and bulk**, so they do not trigger normal satiety signals.

Compared with the same sugar eaten in a solid, fibre-rich food, a sugary drink delivers a **faster, harder metabolic hit** and does a much poorer job of making you feel full.

Soft Drinks: The Clearest Red Flag

Regular sugar-sweetened soft drinks (colas, flavoured sodas):

- Are consistently linked to **weight gain, insulin resistance, type 2 diabetes, and cardiovascular disease** in large cohort studies and meta-analyses (Malik et al., 2010; Hu, 2013).
- Do more than add calories: they **normalise frequent exposure to intense sweetness**, training the palate to expect sugary flavours and making it harder to move toward lower-sugar patterns.

The harm is **metabolic and behavioural**: blood sugar spikes plus a persistent preference for sweet taste.

“Sweetened Beverages” Beyond Soda

Sugar-sweetened beverages also include:

- Sweetened energy and sports drinks
- Flavoured milk drinks and bottled teas
- Sweet lassi, sherbets, “fruit” drinks
- “Natural” or “traditional” drinks made with **jaggery, honey, cane juice, or fruit concentrates**

Labels may emphasise “natural,” “traditional,” or “fortified,” but from a glycaemic and insulin standpoint, **added sugar is still added sugar**, regardless of whether it comes from jaggery, honey, or HFCS. The pancreas does not care about marketing.

Fruit Juices: Health Halo, Hidden Problem

Fruit juice—especially packaged juice—is often assumed to be healthy. In reality:

- **Juicing removes most of the fibre**, concentrating natural sugars into a fast-absorbed liquid.
- A glass of juice can deliver the sugar of **several pieces of fruit** in a form that is easy to overconsume and **less satiating** than whole fruit (Mozaffarian et al., 2011).
- Even 100% juice is **not equivalent to whole fruit**, particularly when taken daily or in large portions.

Packaged juices can be worse:

- Many contain **added sugar, glucose syrup, or fruit concentrates**, pushing the sugar load even higher.
- The category “juice” should **never be assumed safe for diabetes**, unless intake is small, infrequent, and carefully counted.

Key Debates (and Practical Answers)

Common questions include:

- **Is fruit juice healthier than soft drinks?**
 - Nutrient content is higher, but sugar load and glycaemic impact can be similar. For diabetes, **juice is not benign**.
- **Are sweetened beverages harmful only because of sugar, or also because they are liquid?**
 - Both: **sugar load plus liquid form** (low satiety, rapid absorption) are harmful.
- **Are “natural” sweeteners (jaggery, honey, fruit syrup) safer in drinks?**
 - Not metabolically. They still raise glucose and insulin; their “natural” label does not make them protective.
- **Are diet drinks harmless?**
 - They reduce sugar exposure but are **not health foods** and may perpetuate a preference for intense sweetness. Occasional use may be better than sugary drinks, but water and unsweetened beverages are better still.
- **Do small daily intakes matter?**
 - Yes. A “small” glass every day can add up to large weekly sugar loads, particularly in an insulin-resistant person.

Better Public and Clinical Advice

For diabetes prevention and management, practical counsel is:

- **Prefer:**
 - Plain water (including infused with herbs/lemon without sugar)
 - Plain buttermilk
 - Unsweetened tea (herbal, black, green)
 - Unsweetened coffee
- **Limit/avoid:**
 - Soft drinks and sweetened beverages—keep them as **rare treats, not daily habits**.
 - Fruit juice as an everyday drink; choose **whole fruit instead**.
 - “Health” and “energy” drinks unless labels are carefully checked and sugar-free.
- **Read labels for:**
 - Sugar, sucrose, glucose, fructose, HFCS, **jaggery**, honey, fruit concentrate, glucose/fructose syrup, syrup blends.
- **Do not let a drink replace a balanced meal:** liquid calories almost never provide the protein, fibre, and micronutrients needed for metabolic stability.

Summary

Soft drinks, sweetened beverages, and juices are **major, often hidden contributors** to excess sugar intake in India. Their risk lies in their **liquid form, rapid absorption, low fibre, poor satiety, and cultural normalisation**, not just in the grams of sugar on the label.

Within a naturopathic framework, reducing or eliminating these drinks is a **non-negotiable first step** toward reversing insulin resistance and lowering medication needs.

In the following sections, we will show how to construct naturopathic meal and beverage patterns for type 2 diabetes that replace liquid sugar with water, unsweetened traditional drinks, and whole foods that support stable glucose and insulin dynamics.

References:

1. Hu, F. B. (2013). Resolved: There is sufficient scientific evidence that decreasing sugar-sweetened beverage consumption will reduce the prevalence of obesity and obesity-related diseases. *Obesity Reviews*, 14(8), 606–619. <https://doi.org/10.1111/obr.12040>
2. Malik, V. S., Popkin, B. M., Bray, G. A., Després, J.-P., Willett, W. C., & Hu, F. B. (2010). Sugar-sweetened beverages and risk of metabolic syndrome and type 2 diabetes: A meta-analysis. *Diabetes Care*, 33(11), 2477–2483. <https://doi.org/10.2337/dc10-1079>
3. Mozaffarian, D., Hao, T., Rimm, E. B., Willett, W. C., & Hu, F. B. (2011). Changes in diet and lifestyle and long-term weight gain in women and men. *New England Journal of Medicine*, 364(25), 2392–2404. <https://doi.org/10.1056/NEJMoa1014296>

Commercial Pasteurised Dairy Products: Industrial Milk vs. Real Food

Milk is widely promoted as a universal health food. In reality, there is a major difference between:

- Milk from healthy, grass-fed animals handled hygienically and minimally processed, and
- Commercial, pasteurised, homogenised milk from high-yield industrial systems.

From a naturopathic and integrative point of view, the central concerns are:

1. How the animal is raised and treated (feed, hormones, antibiotics, infection burden).
2. How the milk is processed (pasteurisation, homogenisation, ultra-high-temperature treatment).
3. How dairy fits into an individual's immune, digestive, and metabolic context (lactose tolerance, allergy, insulin resistance, acne, etc.).

What Pasteurisation Is (and Is Not)

Pasteurisation was introduced in the early 1900s to reduce milk-borne infections in settings with **poor hygiene and animal health**. Standard low-temperature, long-time (LTLT) pasteurisation:

- Heats milk to $\approx 63\text{--}65\text{ }^{\circ}\text{C}$ ($145\text{--}150\text{ }^{\circ}\text{F}$) for ≥ 30 minutes, then cools quickly.
- Kills most vegetative pathogens and extends shelf life.

This process:

- **Reduces some vitamins** (notably vitamin C, some B-vitamins) and enzyme activity (heat-sensitive enzymes),
- Alters some protein structures modestly,
- But **does not “destroy” all proteins** or render milk “95% unusable” in a literal sense (FDA, 2018; Claeys et al., 2013).

From a strict safety standpoint, pasteurisation **has reduced outbreaks** of brucellosis, tuberculosis, and other infections in high-income settings. The naturopathic concern is that it is now used to **compensate for industrial farming and poor husbandry**, rather than to complement high-quality, pasture-based production.

Industrial Dairy: How the System Shapes the Milk

Modern high-intensity dairy often involves:

- **High-yield breeds** pushed to produce far more milk than in traditional systems.
- Diets heavily based on **grain/concentrates** rather than pasture, altering milk fat composition (typically **lower omega-3 and CLA**, higher ω -6) (Butler et al., 2008).
- Routine or frequent **antibiotic use** for mastitis and other infections; misuse contributes to antibiotic residues and resistance (Tang et al., 2017).
- Possible use of **recombinant bovine somatotropin (rBST/rBGH)** in some countries to increase yield (banned in the EU and not used in many regions, but historically used in the U.S.). rBST increases mastitis rates, thereby increasing antibiotic use (Dohoo et al., 2003).

Milk from such systems can contain:

- **Residues** of veterinary drugs, pesticides from feed, and environmental contaminants—though regulated limits aim to keep these low.

- Increased **somatic cell counts** (reflective of udder inflammation/mastitis).

While regulatory monitoring reduces acute toxicity, a naturopathic view questions the long-term effect of **chronic, low-level chemical and inflammatory exposure**, especially in vulnerable individuals.

Pasteurised Commercial Milk and Health: What Is Actually Known?

Dairy is **complex**: some evidence suggests benefits (e.g., for bone density or lower T2DM risk in some cohorts), while other data link certain dairy patterns with acne, some cancers, and digestive or immune symptoms. Extreme claims that pasteurised milk “plays a key role” in almost every major disease are **not supported by strong evidence**.

Reasonably supported concerns include:

Lactose intolerance and digestive symptoms

- Many adults—especially in Asian and African populations—have low lactase activity, leading to bloating, gas, and diarrhoea with regular milk (Bayless et al., 2017). Pasteurisation does not cause this; it simply does not fix it.

Cow’s milk protein allergy and hypersensitivity

- Casein and whey can provoke immune reactions in susceptible people (IgE-mediated and non-IgE). Heat treatment can modify antigenicity but does not eliminate it.

Acne and possible hormonal effects

- Several observational studies link higher intake of skim milk and some dairy products to acne in adolescents and young adults (Adebamowo et al., 2005; Ulvestad et al., 2017). Mechanisms may involve **insulin, IGF-1, and hormone-like signalling**.

Potential link to certain cancers

- Data on prostate and ovarian cancers are mixed; some large cohorts suggest a modest association between **high dairy/calcium intake and prostate cancer**, while evidence for ovarian cancer is less consistent (Aune et al., 2015). Causality is not firmly established.

On the other hand, several meta-analyses report that **moderate dairy intake** (especially fermented dairy) is associated with **neutral or slightly beneficial** cardiometabolic outcomes in general populations (Guo et al., 2017). This underscores that **not all dairy, and not all people, are the same**.

From a naturopathic standpoint, the problem is **how dairy is produced and processed, and who is consuming it**, rather than “all dairy is poison” vs “all dairy is perfect.”

Pasteurisation, Nutrients, and Enzymes

Heat treatment of milk:

- **Reduces vitamin C** substantially (often >50%) and lowers some B-vitamins (water-soluble) to varying degrees (Claeys et al., 2013).
- Inactivates many **native enzymes** (e.g., alkaline phosphatase as the safety marker, some lipases, and certain proteases).
- Has modest effects on most amino acids at pasteurisation temperatures; severe denaturation occurs more with **UHT (ultra-high temperature)** processing than with standard pasteurisation.

The claim that foods heated above 42 °C are only “5% usable” and “95% clog your system” is **not evidence-based**. Humans have always consumed cooked foods; digestive physiology is well adapted to a range of cooking temperatures. However:

- Over-processing and high-temperature treatment can **reduce bioavailability of some micronutrients**,

- Remove or inactivate beneficial enzymes and bacteria, and
- Promote forms of protein and fat that may be **less physiologically favourable**, especially when combined with industrial farm conditions.

In diabetology and naturopathy, the concern is less about any single enzyme and more about **how ultra-processed dairy products displace whole foods, add extra calories, and deliver hormone-active proteins in a metabolically fragile population.**

Homogenisation: Structure and Possible Immune Effects

Homogenisation mechanically forces milk through small orifices at **2,000–3,000 psi (or higher):**

- Breaks down fat globules into much smaller droplets,
- Alters the structure of the **fat–protein interface**,
- Changes physical properties: increased viscosity, whiter appearance, altered heat stability and oxidation sensitivity.

Some hypotheses and animal studies suggest:

- Homogenised milk may be **more allergenic** in some models, possibly due to protein-coated fat globules having different immune visibility.
- However, human data are limited, and strong causal claims remain speculative.

From a conservative, naturopathic perspective, **minimally processed, non-homogenised dairy** from healthy animals is preferred for those who tolerate dairy, while industrial homogenised products are lower on the priority list.

Factory Farming, Animal Health, and Ethics

Industrial dairy production raises serious **ethical and health** questions:

- Confinement, repeated pregnancies, high-yield demands, and poor environments can lead to **lameness, chronic mastitis, and early culling** (Fraser, 2014).
- This system tends to rely heavily on **drugs, concentrates, and mechanisation** to maintain output.
- Many consumers (and naturopathic clinicians) object not only on ethical grounds but because **chronic animal illness and stress** are unlikely to produce optimally nourishing food.

A naturopathic model prioritises:

- **Pasture-based, low-input systems,**
- Animals allowed to graze naturally,
- Clean milking and handling practices,
- Transparent sourcing, ideally local or regional.

Calcium, Bones, and Diabetes Context

The idea that “more milk = stronger bones” is overly simplistic:

- Some large prospective cohorts found **no reduction in fracture risk**—and in some cases higher fracture rates—with higher milk intake in adults (Feskanich et al., 2014).
- Bone health depends on **overall diet (vegetables, protein, minerals), vitamin D, vitamin K2, physical activity, hormonal status,** and avoidance of smoking and heavy alcohol, not dairy alone.

For people with diabetes:

- Extra commercial dairy may contribute **calories, insulinotropic load (especially from some proteins), and saturated fat,** without providing unique benefits that cannot be obtained from **leafy greens, nuts/seeds, small fish with bones, and fermented foods.**

Practical Guidance on Commercial Pasteurised Dairy

For individuals with insulin resistance, chronic inflammation, or suspected dairy sensitivity:

- **Avoid or minimise:**
 - Mass-produced, pasteurised, homogenised milk (even if labelled “organic”).
 - Sweetened and flavoured milks, chocolate milk.
 - Processed cheeses, ice cream, and many commercial yogurts laden with sugar and stabilisers.
- Consider trial **elimination of all commercial dairy for 4–6 weeks**, then structured re-challenge to assess symptoms (GI, skin, respiratory, fatigue, joint pain, glycaemia).

For those who tolerate dairy and wish to include some:

- Prefer **small amounts of fermented, minimally processed dairy** from **known, pasture-based sources** (e.g., plain yoghurt, kefir, traditional buttermilk, non-homogenised full-fat milk) where safely available.
- Avoid relying on dairy as the primary calcium or protein source; focus on **diverse whole-food sources**.

In a naturopathic diabetes protocol, **no commercial pasteurised dairy product is “essential”**. Many people do better metabolically and symptomatically with **little or no industrial dairy**, particularly when moving toward lower-carbohydrate, anti-inflammatory, whole-food eating.

*The key is not to replace one ultra-processed item with another, but to build a diet around **vegetables, legumes, nuts, seeds, high-quality proteins, and traditional fats**, adding carefully selected dairy only if it clearly agrees with the individual.*

References:

1. Adebamowo, C. A., Spiegelman, D., Berkey, C. S., Danby, F. W., Rockett, H. H., Colditz, G. A., Willett, W. C., & Holmes,

- M. D. (2006). Milk consumption and acne in adolescent girls. *Dermatology online journal*, 12(4), 1. PMID: 17083856
2. Aune, D., Navarro Rosenblatt, D. A., Chan, D. S. M., Vingeliene, S., Abar, L., Vieira, A. R., Greenwood, D. C., Bandera, E. V., & Norat, T. (2015). Dairy products, calcium, and prostate cancer risk: A systematic review and meta-analysis of cohort studies. *American Journal of Clinical Nutrition*, 101(1), 87–117.
<https://doi.org/10.3945/ajcn.113.067157>
 3. Bayless, T. M., Brown, E., & Paige, D. M. (2017). Lactase non-persistence and lactose intolerance. *Current Gastroenterology Reports*, 19(4), 23.
<https://doi.org/10.1007/s11894-017-0558-9>
 4. Butler, G., Nielsen, J. H., Slots, T., Seal, C., Eyre, M. D., Sanderson, R., & Leifert, C. (2008). Fatty acid and fat-soluble antioxidant concentrations in milk from high- and low-input conventional and organic systems: Seasonal variation. *Journal of the Science of Food and Agriculture*, 88(8), 1431–1441. <https://doi.org/10.1002/jsfa.3235>
 5. Claeys, W. L., Cardoen, S., Daube, G., De Block, J., Dewettinck, K., Dierick, K., De Zutter, L., Huyghebaert, A., Imberechts, H., Thiange, P., Vandenplas, Y., & Herman, L. (2013). Raw or heated cow milk consumption: Review of risks and benefits. *Food Control*, 31(1), 251–262.
<https://doi.org/10.1016/j.foodcont.2012.09.035>
 6. Dohoo, I. R., Leslie, K., DesCôteaux, L., Fredeen, A., Dowling, P., Preston, A., & Shewfelt, W. (2003). A meta-analysis review of the effects of recombinant bovine somatotropin. 1. Methodology and effects on production. *Canadian journal of veterinary research = Revue canadienne de recherche veterinaire*, 67(4), 241–251. PMID: [14620860](https://pubmed.ncbi.nlm.nih.gov/14620860/)
 7. Feskanich, D., Willett, W. C., & Colditz, G. A. (2014). Calcium, vitamin D, milk consumption, and hip fractures: A prospective study among postmenopausal women. *American*

Journal of Clinical Nutrition, 77(2), 504–511.

<https://doi.org/10.1093/ajcn/77.2.504>

8. Fraser, D. (2014). *Understanding animal welfare: The science in its cultural context* (2nd ed.). Wiley-Blackwell. ISBN: 978-1-119-62640-4
9. Guo, J., Astrup, A., Lovegrove, J. A., Gijsbers, L., Givens, D. I., & Soedamah-Muthu, S. S. (2017). Milk and dairy consumption and risk of cardiovascular diseases and all-cause mortality: Dose–response meta-analysis of prospective cohort studies. *European Journal of Epidemiology*, 32(4), 269–287.
<https://doi.org/10.1007/s10654-017-0243-1>
10. Tang, K. L., Caffrey, N. P., Nóbrega, D. B., Cork, S. C., Ronksley, P. E., Barkema, H. W., Polachek, A. J., Ganshorn, H., Sharma, N., Kellner, J. D., & Ghali, W. A. (2017). Restricting the use of antibiotics in food-producing animals and its associations with antibiotic resistance in food-producing animals and human beings: A systematic review and meta-analysis. *The Lancet Planetary Health*, 1(8), e316–e327. [https://doi.org/10.1016/S2542-5196\(17\)30141-9](https://doi.org/10.1016/S2542-5196(17)30141-9)
11. Ulvestad, M., Bjertness, E., Dalgard, F., & Halvorsen, J. A. (2017). Acne and dairy products in adolescence: results from a Norwegian longitudinal study. *Journal of the European Academy of Dermatology and Venereology : JEADV*, 31(3), 530–535. <https://doi.org/10.1111/jdv.13835>
12. U.S. Food and Drug Administration. (2018). *Grade “A” pasteurized milk ordinance 2017 revision*. FDA.
<https://www.fda.gov/food/milk-guidance-documents-regulatory-information/pasteurized-milk-ordinance-centennial>

Raw Organic Grass-Fed Dairy and Diabetes

From a naturopathic perspective, raw, organic, grass-fed, unhomogenised milk is a very different product from ultra-processed, industrial dairy. Traditionally produced raw milk can be nutrient-dense and biologically active; at the same time, it carries real microbiological risks if animal health or hygiene is poor. A responsible discussion has to hold both truths together.

What “Raw Organic Grass-Fed Dairy” Means

In this context, “raw organic grass-fed dairy” refers to milk that is:

- **Raw:** Not pasteurised or ultra-heat-treated.
- **Unhomogenised:** Fat globules remain in their natural size and structure.
- **Grass-fed / pasture-based:** Cows graze primarily on pasture, with minimal or no grain concentrates.
- **Organic** (where certified): Without routine synthetic pesticides, fertilisers, or growth hormones, and with stricter rules on antibiotic use.

When produced under **high-hygiene, pasture-based conditions**, raw milk can offer:

- A broad spectrum of **proteins** (casein and whey),
- **Natural enzymes** and bioactive peptides,
- **Immune proteins** (lactoferrin, lysozyme, lactoperoxidase, immunoglobulins),
- Beneficial **microbes**,

- Higher levels of **omega-3 fats and CLA** compared with conventional grain-fed milk (Butler et al., 2008; Benbrook et al., 2013).

Proteins, Enzymes, and Immune Factors

Raw milk contains:

- **Casein (≈80% of protein)** and **whey (≈20%)**, both providing essential amino acids.
- **Lactoferrin**: An iron-binding protein with antimicrobial, antiviral, and immune-modulating properties; it may improve iron absorption and inhibit certain pathogens (Guns et al., 2015).
- **Lysozyme and lactoperoxidase**: Enzymes that can damage bacterial cell walls or inhibit bacterial growth.
- **Immunoglobulins (antibodies)**: Contribute to local immune defence and may support mucosal immunity, particularly in early-lactation milk (colostrum) (Korhonen, 2009).

Heat treatment (especially high-temperature processes) **reduces or inactivates** many of these proteins and enzymes. That is one reason some individuals report better **digestive tolerance** with carefully produced raw milk than with commercial ultra-processed dairy.

Lactose, Fermentation, and Digestibility

Lactose is the main carbohydrate in milk. Many adults have **low lactase activity and experience lactose intolerance when consuming** standard milk. Raw milk:

- Naturally contains **lactic-acid bacteria** and **bacterial lactase** (especially if slightly soured or fermented),
- Is commonly fermented into **kefir, yoghurt, buttermilk, and soft cheeses**, which further reduce lactose content and increase lactic acid and enzymes.

Pasteurisation modestly reduces some vitamins and does not change the absolute amount of calcium, but may affect some **protein–mineral interactions** and enzyme activity. Bone health, however, depends on **many factors** beyond milk alone: total diet (vegetables, protein, vitamin K2), vitamin D, activity, and hormones.

Some people who are sensitive to commercial pasteurised milk find they **tolerate fermented raw dairy** (e.g., kefir from grass-fed milk) much better. This is not universal, and anyone with a history of severe allergy or immune compromise must be cautious, but it is a clinically observed pattern that aligns with the biology of fermentation.

From a naturopathic viewpoint, raw, grass-fed dairy can be a **useful nutrient source** for some people—but it is **not indispensable**, and equivalent or better nutrient patterns can be constructed without dairy if needed.

Milk Fat, CLA, and Fat-Soluble Nutrients

In grass-fed raw milk:

- A significant portion of fat is **saturated**, which supports cell structure and serves as a carrier for **fat-soluble vitamins (A, D, E, K)**.
- Levels of **omega-3 fatty acids and conjugated linoleic acid (CLA)** are higher than in grain-fed milk. CLA has been studied for potential benefits on body composition, inflammation, and insulin sensitivity, though human evidence is modest and mixed (Benjamin & Spener, 2009).
- Dietary fat stimulates **cholecystokinin (CCK)**, a hormone that promotes satiety and supports digestion—one reason very low-fat or “fat-free” dairy can feel less satisfying.

A key naturopathic point: **whole-fat, minimally processed dairy from grass-fed animals** tends to have a more favourable fatty-acid and micronutrient profile than ultra-processed low-fat products with added sugars.

Cholesterol and Metabolic Context

Raw whole milk contains cholesterol and saturated fat. In isolation, these are not toxins:

- **Cholesterol** is essential for cell membranes, bile acids, and steroid hormones.
- The body adjusts its own cholesterol synthesis according to intake.

Current evidence suggests that for many people, **dietary cholesterol has a modest impact** on blood cholesterol compared with overall dietary pattern, genetics, and metabolic health (Berger et al., 2015). In an anti-inflammatory, whole-food diet with controlled refined carbohydrates, small amounts of cholesterol-containing foods like high-quality raw dairy are often well tolerated.

Raw Milk vs. Safety: A Necessary Balance

While carefully produced raw milk can be nutrient-dense, it is not risk-free:

- Raw milk can transmit **pathogenic bacteria** (e.g., *Campylobacter*, *Salmonella*, *STEC*, *Listeria*) if animals are infected or hygiene is inadequate.
- Outbreaks have been documented in several countries; risk is higher for **infants, pregnant women, older adults, and immunocompromised individuals** (Claeys et al., 2013; CDC, 2017).

Key naturopathic and public-health principles:

- If raw milk is used, it should come **only from farms with excellent pasture-based management, meticulous hygiene, and transparent testing practices**, and be handled cold and clean.
- Even then, **high-risk individuals** may be safer with **fermented, low-temperature-pasteurised, or non-dairy alternatives**.

- Legal availability and regulation vary by country and state; clinicians must tailor advice to local law and patient vulnerability.

It is inaccurate to say “stories of illness from raw milk are unfounded”; they are documented. Equally, it is inaccurate to claim all pasteurised milk is “toxic.” The reality is nuanced: **production conditions, processing level, and individual tolerance** all matter.

Practical Guidance

In a diabetes- and metabolic-focused naturopathic program:

- **Raw, grass-fed dairy is never mandatory.** Many people do well without dairy.
- For people who tolerate dairy and wish to include it:
 - Prioritise **fermented, full-fat, grass-fed products** (e.g., kefir, yoghurt, traditional buttermilk) from trusted, hygienic sources.
 - Keep portions moderate and **integrated into a low-glycaemic, whole-food plan.**
 - Monitor for changes in digestion, skin, respiratory symptoms, and glycaemic control.
- For those with autoimmunity, significant allergies, recurrent sinus/respiratory issues, or severe insulin resistance, a **time-limited dairy elimination** followed by structured re-challenge can clarify whether any form of dairy (raw or processed) is helpful, neutral, or harmful.

The core naturopathic message is not that “raw milk alone can sustain life,” but that **when dairy is used**, the closer it is to:

- **Pasture-based, low-input farming,**
- **Minimal, gentle processing, and**
- **Appropriate for the individual’s immune and metabolic state,**

the more likely it is to behave as a **food** rather than a **stressor**.

References:

1. Benbrook, C. M., Butler, G., Latif, M. A., Leifert, C., & Davis, D. R. (2013). Organic production enhances milk nutritional quality by shifting fatty acid composition: A United States–wide, 18-month study. *PLoS ONE*, 8(12), e82429. <https://doi.org/10.1371/journal.pone.0082429>
2. Benjamin, S., & Spener, F. (2009). Conjugated linoleic acids as functional food: An insight into their health benefits. *Nutrition & Metabolism*, 6, 36. <https://doi.org/10.1186/1743-7075-6-36>
3. Berger, S., Raman, G., Vishwanathan, R., Jacques, P. F., & Johnson, E. J. (2015). Dietary cholesterol and cardiovascular disease: a systematic review and meta-analysis. *The American journal of clinical nutrition*, 102(2), 276–294. <https://doi.org/10.3945/ajcn.114.100305>
4. Butler, G., Nielsen, J. H., Slots, T., Seal, C., Eyre, M. D., Sanderson, R., & Leifert, C. (2008). Fatty acid and fat-soluble antioxidant concentrations in milk from high- and low-input conventional and organic systems: Seasonal variation. *Journal of the Science of Food and Agriculture*, 88(8), 1431–1441. <https://doi.org/10.1002/jsfa.3235>
5. Centers for Disease Control and Prevention. (2017). *Food safety and raw milk*. CDC. <https://www.cdc.gov/food-safety/foods/raw-milk.html>
6. Claeys, W. L., Cardoen, S., Daube, G., De Block, J., Dewettinck, K., Dierick, K., De Zutter, L., Huyghebaert, A., Imberechts, H., Thiange, P., Vandenplas, Y., & Herman, L. (2013). Raw or heated cow milk consumption: Review of risks and benefits. *Food Control*, 31(1), 251–262. <https://doi.org/10.1016/j.foodcont.2012.09.035>
7. Superti F. (2020). Lactoferrin from Bovine Milk: A Protective Companion for Life. *Nutrients*, 12(9), 2562. <https://doi.org/10.3390/nu12092562>

8. Korhonen, H. (2009). Milk-derived bioactive peptides: From science to applications. *Journal of Functional Foods*, 1(2), 177–187. <https://doi.org/10.1016/j.jff.2009.01.007>

Energy and Protein Bars and Diabetes: Ultra-Processed “Health Foods” in Clinical Disguise

“Prioritise whole foods, minimise dependence on packaged bars, and treat protein bars as occasional tools rather than dietary necessities.”

Conventional, allopathic nutrition guidance has been remarkably tolerant of **ultra-processed, health-branded snack bars**—often recommending them in clinic handouts, hospital canteens, and “diabetes education” materials as if a shiny wrapper and a “high-protein” claim could compensate for industrial formulations. This is metabolic theatre, not metabolic medicine.

A naturopathic framework refuses that illusion. It insists on asking a blunt question: **does this bar behave more like real food in a living body, or like a cleverly marketed confectionery product?**

What Is Really Hiding on the Label?

Front-of-pack slogans (“high protein,” “low sugar,” “diabetic-friendly,” “no added sugar”) routinely obscure:

Hidden sugars:

- Glucose, fructose, sucrose, malt syrup, rice syrup, jaggery syrup, date syrup, honey.

Sugar alcohols:

- Sorbitol, maltitol, xylitol, erythritol—poorly absorbed, frequently causing **bloating, gas, diarrhoea** in sensitive people.

Refined and sometimes chemically modified fats:

- Palm oil, interesterified fats, occasionally residual trans fats.

Additive cocktails:

- Emulsifiers (e.g., polysorbates, carrageenan), stabilisers, artificial flavours and colours linked in some data to **microbiota disruption and low-grade inflammation** (Chassaing et al., 2015).

Disappointing protein reality:

- Bars loudly branded “PROTEIN” often provide only **6–8 g per bar**, far below what their marketing implies.

On paper they sound like therapeutic tools; in the bloodstream they often behave like **ultra-processed sweets with a health halo** (Monteiro et al., 2019; Srouf et al., 2019).

A genuinely critical, integrative approach teaches patients (and clinicians) to **read the ingredient list and nutrition panel, not the advertising copy**.

Why This Matters Metabolically

The clash is between marketing and metabolism:

- A bar can deliver **10–20 g of protein** and still carry a **substantial sugar/refined-starch load**, spiking glucose and insulin.
- Most bars are firmly within the **ultra-processed (NOVA 4)** category, and high intake of ultra-processed foods is strongly linked to **obesity, type 2 diabetes, and cardiovascular**

disease (Monteiro et al., 2019; Srouf et al., 2019; Hall et al., 2019).

Yet conventional counselling often reduces the conversation to **“calories” and “macros”**, ignoring:

- Degree of processing and **additive burden**.
- Effects on **gut microbiota, appetite regulation, reward pathways**, and long-term food patterns.
- The simple fact that bars keep patients **chained to packets**, not to kitchens, markets, and real ingredients.

From a naturopathic standpoint, this is a profound failure: the system that should be dismantling junk-food culture is quietly endorsing its “diabetes-friendly” versions.

Diabetes Perspective: Why “High-Protein” Does Not Equal Safe

For a person with diabetes, a bar is **never automatically safe** because of a front-of-pack claim:

Glycaemic and metabolic impact depend on:

- **Total and net carbohydrates** (including sugar, starch, and sugar alcohols).
- **Type of sweeteners** (sugars, syrups, polyols, artificial sweeteners) and their downstream effects.
- **Fibre content and quality** (isolated fibres vs whole-food sources).
- **Fat quality** (nuts, seeds vs palm oil/interestified fats).
- Overall **portion size** and frequency of use.

Bars:

- **Rarely match real meals** for micronutrient density, phytonutrients, or digestive balance.

- Can be **useful in narrow contexts** (travel, delays, hypoglycaemia backup, post-exercise when no real food is available).
- Become **misleading and harmful** when positioned as **daily staples or meal replacements**, a pattern often normalised in conventional dietetic practice.

There is also a growing concern—barely acknowledged in mainstream guidelines—about:

- Long-term effects of **artificial sweeteners, sugar alcohols, and emulsifiers** on **gut microbiota, intestinal permeability, appetite, and metabolic risk** (Suez et al., 2014; Chassaing et al., 2015; WHO, 2023).

Naturopathy does not pretend all answers are in; it simply applies a **precautionary principle**: if a product looks, feels, and is manufactured like junk food, treat it as junk food until proven otherwise.

When Bars May Be a Justifiable “Plan B”

Bars are not inherently useless. Even naturopathic practice recognises scenarios where they can be the **least bad option**:

- While travelling, when no real food is available.
- When a meal is unavoidably delayed, and hypoglycaemia is a real risk.
- Immediately after **intense physical activity**, when quick protein plus some carbohydrate is required, and whole foods are temporarily inaccessible.
- As an **emergency backup** in a bag or car for people prone to severe hypos.

Even here, however:

- Bars must be seen as **Plan B**, not the dietary foundation.
- Their role is to **bridge a gap temporarily**, not to legitimise a lifetime subscription to ultra-processed eating.

Naturopathic care insists that **true metabolic healing** requires patients to reclaim their kitchens, not just their bar selection.

Naturopathic Guidance: From Packets Back to Food

For diabetes care in India—and anywhere else—naturopathic, evidence-aligned guidance is starkly different from allopathic “snack advice”:

Whole foods first, always:

- Nuts and seeds (almonds, walnuts, sunflower/pumpkin seeds)
- Roasted chana and peanuts
- Sprouts, boiled eggs, paneer cubes
- Fresh fruit with nuts or seeds
- Plain curd/yoghurt with seeds or a little fruit

Bars only occasionally, not as a daily habit.

When a bar is truly needed:

- **Read the label end-to-end.**
- Avoid products high in **sugars, syrups, refined starches, and low-quality fats.**
- Be cautious with heavy loads of **sugar alcohols and artificial sweeteners.**
- Aim for **≥10–15 g of clearly defined protein** (e.g., whey, casein, egg, or properly identified plant protein) with **modest carbs and real fats** (nuts, seeds, not just palm oil).
- Prefer **short, recognisable ingredient lists**: nuts, seeds, straightforward protein sources, minimal sweetener, real fibres (e.g., chicory root, inulin), not a chemistry set.

Whenever possible, teach and support patients to prepare **simple home snacks** that beat bars on every metric:

- Roasted nut–seed mixes,
- Chana + peanuts,

- Curd with seeds,
- Lentil-based chillas/dosas,
- Vegetable sticks with hummus or chutney.

This is exactly where naturopathic practice excels, and allopathic clinics often fail: **hands-on skill-building, kitchen literacy, and food culture restoration**, not just prescribing more products.

Conclusion: Bars as a Symptom of a Sick Food Culture

Energy and protein bars are **processed convenience foods**, not inherently healthy “diabetes snacks.” Some have a narrow, legitimate role in emergencies or very specific situations. Many are **marketed far more healthfully than they deserve**, and their normalisation in conventional diabetes care reflects a broader failure to confront ultra-processed food systems head-on.

In a naturopathic, diabetes-focused framework:

- **Whole, minimally processed foods are the default.**
- Bars are **occasional, carefully chosen tools**, not substitutes for real meals or the deep, uncomfortable lifestyle work needed to reverse insulin resistance.
- Success is measured not by how many “diabetic-friendly” packets a person can stack in their pantry, but by how much they can **transition back to real food, real cooking, and real metabolic flexibility.**

In subsequent chapters, we will move beyond critique and detail naturopathic dietary frameworks for type 2 diabetes that eliminate dependence on ultra-processed products—including bars—and use whole foods, therapeutic meal structure, and sustained lifestyle change to reduce medication needs and improve long-term outcomes.

References:

1. Chassaing, B., Koren, O., Goodrich, J. K., Poole, A. C., Srinivasan, S., Ley, R. E., & Gewirtz, A. T. (2015). Dietary

- emulsifiers impact the mouse gut microbiota promoting colitis and metabolic syndrome. *Nature*, 519(7541), 92–96. <https://doi.org/10.1038/nature14232>
2. Hall, K. D., Ayuketah, A., Brychta, R., Cai, H., Cassimatis, T., Chen, K. Y., Chung, S. T., Costa, E., Courville, A., Darcey, V., Fletcher, L. A., Gharib, A. M., Guo, J., Howard, R., Joseph, P. V., McGehee, S., Ouwerkerk, R., Raisinger, K., ... Zhou, M. (2019). Ultra-processed diets cause excess calorie intake and weight gain: An inpatient randomized controlled trial of ad libitum food intake. *Cell Metabolism*, 30(1), 67–77.e3. <https://doi.org/10.1016/j.cmet.2019.05.008>
 3. Monteiro, C. A., Cannon, G., Levy, R. B., Moubarac, J.-C., Louzada, M. L. C., Rauber, F., Khandpur, N., Cediel, G., Neri, D., Martinez-Steele, E., Baraldi, L. G., & Jaime, P. C. (2019). Ultra-processed foods: What they are and how to identify them. *Public Health Nutrition*, 22(5), 936–941. <https://doi.org/10.1017/S1368980018003762>
 4. Srour, B., Fezeu, L. K., Kesse-Guyot, E., Allès, B., Méjean, C., Andrianasolo, R. M., Chazelas, E., Deschasaux, M., Hercberg, S., Galan, P., Monteiro, C. A., Julia, C., & Touvier, M. (2019). Ultra-processed food intake and risk of type 2 diabetes: Results from the NutriNet-Santé prospective cohort. *JAMA Internal Medicine*, 180(2), 283–291. <https://doi.org/10.1001/jamainternmed.2019.5942>
 5. Suez, J., Korem, T., Zilberman-Schapira, G., Segal, E., & Elinav, E. (2014). Non-caloric artificial sweeteners and the microbiome: Findings and challenges. *Gut Microbes*, 6(2), 149–155. <https://doi.org/10.1080/19490976.2015.1017700>
 6. World Health Organization. (2023). *Use of non-sugar sweeteners: WHO guideline*. WHO. <https://www.who.int/publications/i/item/9789240073616>

Genetically Modified Soy and Diabetes: Industrial Ingredient or Real Food?

“Soy should be evaluated by its form, processing, quantity, and role in the full diet, rather than by a single label such as “GMO” or “natural.”

Conventional nutrition has a habit of reducing complex food questions to **single labels and single nutrients**: “high-protein,” “low-fat,” “GMO-free,” “fortified.” Soy is one of the worst casualties of this reductionism. Instead of asking **how soy is grown, processed, and inserted into a junk-food system**, conventional advice is content to tick regulatory boxes—while the same system quietly pumps refined soybean oil and soy isolates into an ultra-processed food environment that is already wrecking metabolic health.

A naturopathic perspective refuses this kind of nutritional tunnel vision. It asks how soy, in all its very different forms, actually behaves inside a living, stressed, insulin-resistant body—and how it fits into a **whole dietary pattern**, not into an industry-designed “protein bar.”

Introduction: Soy in the Indian Metabolic Cauldron

In India, “soy” is not one thing:

- It appears as **tofu, soy chunks, soy milk**, and a few fermented products.
- It floods the food system as **refined soybean oil**, cheap filler in snacks, and **imported soy ingredients** grafted into biscuits, bars, and ready-to-eat foods.

- It enters invisibly as **genetically modified (GM) soy or soy oil** in industrial formulations.

The conventional medical establishment too often responds with **binary slogans**: “GMO vs non-GMO,” “plant-based vs animal,” while ignoring the much more immediate problems:

- Massive intake of **refined oils**,
- Deep-fried and ultra-processed foods,
- Pesticide-dependent monocultures, and
- Zero investment in teaching people to cook simple, whole, protein-rich meals at home.

A more scientifically defensible, naturopathically aligned view is:

- **Whole and minimally processed soy foods** can have a limited, useful role in some diets.
- The true danger zone lies in **industrial refinement, extraction, repeated frying, pesticide-heavy cultivation, and uncritical acceptance of GM commodity crops** in a deeply unhealthy food system.

Soy as Food vs Soy as Industrial Input

Traditional or minimally processed soy foods:

- **Tofu, plain soy chunks, unsweetened soy milk, fermented soy (e.g., tempeh, miso in other cuisines)** can provide decent plant protein, fibre, and phytoestrogens that may offer modest cardiometabolic benefits when used to **replace** red/processed meat in balanced diets (Messina, 2016; Li et al., 2018).

Highly processed soy derivatives:

- **Textured vegetable protein (TVP)**, soy protein isolates/concentrates, flavoured soy snacks and “mock meats,” and especially **refined soybean oil**, are **nutritionally and metabolically different substances**.

- These are designed to **boost protein claims and lower cost**, not to support human physiology.

Conventional nutrition often lumps these together under “soy protein,” ignoring that:

- A bowl of **home-cooked tofu with vegetables** is not remotely equivalent to:
 - A bar of **soy-isolate candy with glucose syrup and palm oil**, or
 - A **deep-fried snack** soaked in repeatedly heated soybean oil.

Naturopathy insists on this distinction, because the **body certainly does**.

Soy and Diabetes: Not the Prime Villain, But Not Innocent in its Industrial Form

Right now, GM soy itself is **not the primary engine** of India’s diabetes epidemic. The main drivers remain:

- Excess **refined carbohydrates and sugars**,
- Low **fibre and plant diversity**,
- **Unhealthy fats** (refined, reheated oils, trans fats),
- Ultra-processed foods,
- Sedentarism, abdominal obesity, chronic stress, poor sleep.

But it is a serious error to stop there. Even if soy is not “the” problem, the **industrial ways soy is used** can still:

- Amplify overall intake of **refined oils** (including soybean oil), often used in **deep-frying and repeated heating**—linked to oxidative stress and worsened lipids (Ng et al., 2014).
- Encourage reliance on **soy-based ultra-processed products**—bars, shakes, snacks—marketed as “plant-based”

and “high-protein,” while smuggling in sugar, emulsifiers, and cheap fats.

- Support an agricultural model that **normalises huge chemical inputs**, soil degradation, and loss of biodiversity—indirect but powerful contributors to chronic disease.

From a naturopathic standpoint, soy in its **simplest forms** can be acceptable in moderation. Soy as a **commodity ingredient in junk food** is just another cog in the metabolic disaster machine.

Hidden Issues in the Soy Debate

A careful, naturopathic reading surfaces several points that are commonly never discussed:

- **GM soy ≠ soybean oil ≠ whole soy food:**
 - A block of plain tofu and a vat of refined, repeatedly heated soybean oil are not metabolically equivalent, even if both started as GM beans.
- **Genetics vs processing vs pattern:**
 - Public and policy debates obsess over “GMO vs non-GMO,” while leaving the **bigger, better-documented threat**—ultra-processed, oil-heavy, sugar-heavy dietary patterns—largely intact (Monteiro et al., 2019; Srouf et al., 2019).
- **Residues, labelling, and traceability:**
 - Imported soy ingredients may carry **pesticide residues** and have opaque supply chains. Labelling is often incomplete or misleading.
- **Soy-based “health foods”:**
 - Bars, energy drinks, and “mock meats” that trumpet “plant-based” on the front often deliver **refined starches, syrups, cheap oils, and additives** in the back. Their risk to metabolic health is driven far more by

processing and pattern than by whether the soy gene was introduced by *Agrobacterium*.

- **Total diet > single ingredient:**

- In real-world counselling, people do not get diabetes because they ate tofu twice a week; they get diabetes because the **entire food environment is built on refined grains, sugar, oils, and convenience products.**

Naturopathy uses soy to make a broader point: when debates fixate on a single crop, they often protect the **industrial food system itself** from scrutiny.

Evidence-Aligned Advice

For people with or at risk of diabetes in India, aggressive but balanced guidance looks like this:

- **Prioritise whole and minimally processed protein sources:**
 - Local pulses and dals (tuar, masoor, chana, moong),
 - Chickpeas, rajma, lobia, sprouts,
 - Nuts and seeds,
 - Eggs, fish, or other animal proteins for those who choose them,
 - **Simple soy foods** (e.g., plain tofu, simple soy chunks, fermented soy) in moderation if well tolerated.
 - **Do not lean heavily on refined oils**, including soybean oil, especially for deep-frying and repeated heating.
- **Scrutinise processed soy products:**
 - Read labels for **sugars, syrups, refined starches, flavour enhancers, and long additive lists.**
 - Treat “plant-based” and “soy-protein” marketing with deep suspicion.

- **Remember that “plant-based” is not automatically “healthy”:**
 - A home-cooked bowl of dal and sabzi is metabolically superior to a **soy-protein candy bar** with glucose syrup and palm oil, regardless of GMO status.
- **Build diets around diversity and moderation:**
 - No single food—even soy—should dominate. A resilient metabolic pattern is built on **variety**, colour, fibre, traditional recipes, and minimal industrial interference.

This is exactly where naturopathic care has been **systematically sidelined and mocked**: in its insistence that food must be judged as **lived patterns and cooking practices**, not as isolated laboratory constructs.

Conclusion: GM Soy is a Symptom, Not the Core Disease

Genetically modified soy, by itself, is **not currently proven** to be a primary driver of diabetes in India. That fact should kill both the **apocalyptic GMO propaganda** and the **complacent “it’s all safe, don’t worry” narrative** pushed by agribusiness-friendly voices in conventional nutrition.

The more defensible, clinically relevant message is:

Diabetes prevention and reversal depend above all on:

- **Improving overall diet quality,**
- **Severely limiting refined carbohydrates and ultra-processed foods,**
- **Reducing excessive intake of poor-quality fats and reheated oils,**
- **Rebuilding whole-food, plant-rich, culturally grounded eating patterns.**

Within that framework, soy can be:

- **A minor, optional ally** in whole or minimally processed form, or

- A dangerous distraction when it is used to **greenwash ultra-processed products**.

Naturopathic medicine refuses to let the debate stop at GM vs non-GM. It demands a deeper reckoning with how we grow, process, and eat food—and it offers concrete, lifestyle-centred paths to pull metabolic care out of the hands of industrial formulators and back into kitchens, farms, and communities.

In the chapters that follow, we will set aside the marketing noise and build naturopathic dietary frameworks for type 2 diabetes that rely on diverse whole foods—pulses, vegetables, nuts, seeds, modest whole soy where appropriate—rather than on any single commodity crop or “fortified” product.

References:

1. Li, W., Ruan, W., Peng, Y., & Wang, D. (2018). Soy and the risk of type 2 diabetes mellitus: A systematic review and meta-analysis of observational studies. *Diabetes research and clinical practice*, 137, 190-199.
<https://doi.org/10.1016/j.diabres.2018.01.010>
2. Messina, M. (2016). Soy and health update: Evaluation of the clinical and epidemiologic literature. *Nutrients*, 8(12), 754.
<https://doi.org/10.3390/nu8120754>
3. Monteiro, C. A., Cannon, G., Levy, R. B., Moubarac, J.-C., Louzada, M. L. C., Rauber, F., Khandpur, N., Cediel, G., Neri, D., Martinez-Steele, E., Baraldi, L. G., & Jaime, P. C. (2019). Ultra-processed foods: What they are and how to identify them. *Public Health Nutrition*, 22(5), 936–941.
<https://doi.org/10.1017/S1368980018003762>
4. Ng, C. Y., Leong, X. F., Masbah, N., Adam, S. K., Kamisah, Y., & Jaarin, K. (2014). Heated vegetable oils and cardiovascular disease risk factors. *Vascular pharmacology*, 61(1), 1-9. <https://doi.org/10.1016/j.vph.2014.02.004>
5. Srour, B., Fezeu, L. K., Kesse-Guyot, E., Allès, B., Méjean, C., Andrianasolo, R. M., Chazelas, E., Deschasaux, M., Hercberg, S., Galan, P., Monteiro, C. A., Julia, C., &

Touvier, M. (2019). Ultra-processed food intake and risk of type 2 diabetes: Results from the NutriNet-Santé prospective cohort. *JAMA Internal Medicine*, 180(2), 283–291.
<https://doi.org/10.1001/jamainternmed.2019.5942>

Animal Products and Farm-Raised Fish: When “Protein” Becomes a Metabolic Trap

*“Food quality, processing, portion size, and dietary pattern matter more than the broad category **ANIMAL PRODUCTS** label”.*

Allopathic nutrition loves blunt categories: “animal vs plant,” “lean vs fatty,” “non-veg vs veg.” This flattening lets the system dodge the real questions: **How was this animal raised? What was it fed? How was the product processed? What is it eaten with?** A deep-fried chicken bucket with a cola and a salad of pulses are both “meals,” but their metabolic impact is not even in the same universe.

A naturopathic framework refuses to treat “animal products” as a single entity. It demands that we dissect quality, processing, portion, and pattern—and then rebuild diets around whole, minimally processed foods rather than whatever the industrial meat and aquaculture complex wants to sell.

Why the Debate Is So Confused

Two unhelpful extremes dominate public and even clinical discourse:

- “Animal protein is inherently toxic.”
- “Animal protein is inherently superior.”

Both ignore a large body of evidence:

- **Red and processed meats** are consistently associated with higher risk of **type 2 diabetes, cardiovascular disease, and mortality** (Pan et al., 2011; Micha et al., 2010).

- **Fish, eggs, and plain dairy** show **more mixed or neutral patterns**, with some fermented dairy (e.g., yoghurt/curd) associated with **lower diabetes risk** (Guo et al., 2017).

A grilled egg, a bowl of plain curd, a chemically cured sausage, and a farm-raised, antibiotic-laden fish fillet are not metabolically equivalent just because they all fall under “animal products.” Allopathic advice that lumps them together is lazy and dangerous.

Red and Processed Meats: Clear Signal, Ignored in Practice

The strongest, most consistent caution signal exists for:

- **Red meat** (especially in high quantities), and
- **Processed meats** (sausages, bacon, salami, many deli meats).

These foods often combine:

- High **saturated fat and heme iron**,
- **Sodium, nitrites/nitrates**, and other curing agents,
- High loads of **advanced glycation end products (AGEs)** from high-temperature cooking,
- And a surrounding diet typically low in fibre and vegetables.

Meta-analyses show:

- Each daily serving of processed meat is associated with a significantly **higher risk of type 2 diabetes** and coronary heart disease (Micha et al., 2010; Pan et al., 2011).

Yet conventional diabetes clinics still hand out “lean meat and cold-cut” lists as if these products were benign. Naturopathic care calls this what it is: **clinical complicity with the processed-meat industry**.

Fish: Nuance Lost in the Farmed vs Wild Reality

Fish is often recommended reflexively as “heart-healthy protein.” Compared with processed meat, this is more defensible—but only if we ask **which fish and how raised**.

- **Wild, low-contaminant, oily fish** (e.g., sardines, mackerel, some wild salmon) provide **long-chain omega-3s (EPA/DHA)** with benefits for triglycerides, blood pressure, and cardiovascular risk (Mozaffarian & Rimm, 2006).
- **Farm-raised fish** are a different story:
 - Crowded pens, **grain- or soy-based feeds**, less natural movement.
 - Often **higher total fat**, disturbed omega-3:omega-6 ratio, and variable nutrient profiles.
 - Frequent use of **antibiotics and parasiticides** in some systems.
 - Certain farmed salmon samples have shown **higher levels of PCBs and dioxins** than wild salmon (Hites et al., 2004), though practices vary by region and species.

Indian risk assessments suggest that **mercury levels in farmed fish are generally within tolerable limits**, but that does not make all farmed fish metabolically or toxicologically equivalent. Feed composition and farming standards directly shape:

- **Fatty-acid profile,**
- Contaminant burden,
- And overall health impact of the final product.

Naturopathic guidance therefore distinguishes:

- **Occasional, well-sourced fish** as a potentially useful protein and omega-3 source,
- From routine intake of **low cost, intensively farmed fish** in deep-fried, ultra-processed forms.

Dairy, Eggs, and the Mixed Evidence

Lumping dairy and eggs with red and processed meat under “animal foods are bad” is scientifically sloppy:

- **Dairy:**
 - Several umbrella reviews suggest that **moderate intake of milk and yoghurt** is associated with **neutral or slightly lower risk** of type 2 diabetes; cheese and butter show more variable results (Guo et al., 2017; Gijssbers et al., 2016).
 - Effects depend heavily on **processing (plain vs flavoured), fat content, and sugar addition.**
- **Eggs:**
 - Large cohort studies show **neutral or modestly increased diabetes risk** at higher intakes, often confounded by co-consumption of processed meat and refined carbs (Drouin-Chartier et al., 2020).

For India, this nuance matters:

- Curd/yoghurt and buttermilk are **culturally entrenched and nutritionally dense**, especially in rural and semi-urban diets.
- Eggs are an affordable, high-quality protein for many low- and middle-income families.

Naturopathy does not blindly demonise these foods; it asks how they are **produced, processed, and combined** within the larger diet.

The Indian Context: What Animal Foods Replace (and What They Come With)

In India, the real metabolic question is:

When people add animal products, what disappears from the plate—and what else comes with them?

Common patterns:

- Animal dishes served with **refined white rice, maida-based breads, fried batters, sugary drinks, and packaged snacks.**

- Pulses, millets, vegetables, and salads pushed to the side—or off the plate entirely.

In that environment:

- It is absurd to blame a single boiled egg or small portion of fish for diabetes,
- And equally absurd to declare meat “harmless” when it is routinely paired with **deep-fried carbs and sugar-sweetened beverages**.

Naturopathic practice forces a **whole-pattern view**:

- Animal foods in **small, high-quality portions**, eaten with **vegetables, pulses, whole or lower-GI grains**, are vastly different from industrial meat eaten with **white bread, fries, and cola**.

Practical Guidance:

For diabetes prevention and management, aggressive but nuanced recommendations are:

- **Limit or avoid red and processed meats**, especially industrially cured, smoked, or heavily processed products.
- **Prefer less-processed protein foods**:
 - Pulses, dals, chickpeas, lentils, sprouts, nuts, seeds,
 - Eggs, fresh fish, and modest amounts of high-quality poultry or meat (if used at all).
- **Use fish in moderate amounts**, paying attention to:
 - Source (wild vs farmed),
 - Farming/aquaculture standards,
 - Avoidance of deep-fried preparations.
- **Include eggs and dairy selectively**, based on:
 - Individual tolerance (lactose, casein),
 - Overall diet quality,

- Preference for **plain, minimally processed forms** (e.g., curd, buttermilk, paneer, boiled/poached eggs).
- **Avoid pairing animal foods with metabolic “landmines”:**
 - Refined white bread, deep-fried batters, sugary drinks, dessert-like “celebration meals.”
- **Favour traditional, minimally processed preparations:**
 - Light curries, stews, grilled/steamed dishes, instead of batter-fried, heavily sauced, or ultra-processed meat products.

In other words, a naturopathic approach does not simply shout “animal foods are evil” or “plant-based is magic.” It demands that **every animal product be interrogated on its quality, processing, portion, and companions on the plate**, and always subordinated to a whole-food, plant-rich foundation.

In the chapters that follow, we will outline naturopathic dietary patterns for type 2 diabetes that are predominantly plant-based, but show precisely how—if at all—small amounts of carefully chosen animal products or fish can be integrated without sabotaging metabolic healing.

References:

1. Drouin-Chartier, J.-P., Chen, S., Wei, Y., Li, Y., Bhupathiraju, S. N., Souza, R. J., Spiegelman, D., Hu, F. B., & Bhatt, D. L. (2020). Egg consumption and risk of type 2 diabetes: A prospective study and dose–response meta-analysis. *BMJ*, 368, m513.
<https://doi.org/10.1136/bmj.m513>
2. Gijsbers, L., Ding, E. L., Malik, V. S., de Goede, J., Geleijnse, J. M., & Soedamah-Muthu, S. S. (2016). Consumption of dairy foods and diabetes incidence: A dose–response meta-analysis of observational studies. *American Journal of Clinical Nutrition*, 103(4), 1111–1124.
<https://doi.org/10.3945/ajcn.115.123216>

3. Guo, J., Astrup, A., Lovegrove, J. A., Gijsbers, L., Givens, D. I., & Soedamah-Muthu, S. S. (2017). Milk and dairy consumption and risk of cardiovascular diseases and all-cause mortality: Dose–response meta-analysis of prospective cohort studies. *European Journal of Epidemiology*, 32(4), 269–287.
<https://doi.org/10.1007/s10654-017-0243-1>
4. Hites, R. A., Foran, J. A., Carpenter, D. O., Hamilton, M. C., Knuth, B. A., & Schwager, S. J. (2004). Global assessment of organic contaminants in farmed salmon. *Science*, 303(5655), 226–229. <https://doi.org/10.1126/science.1091447>
5. Micha, R., Wallace, S. K., & Mozaffarian, D. (2010). Red and processed meat consumption and risk of incident coronary heart disease, stroke, and diabetes mellitus: A systematic review and meta-analysis. *Circulation*, 121(21), 2271–2283.
<https://doi.org/10.1161/CIRCULATIONAHA.109.924977>
6. Mozaffarian, D., & Rimm, E. B. (2006). Fish intake, contaminants, and human health: Evaluating the risks and the benefits. *JAMA*, 296(15), 1885–1899.
<https://doi.org/10.1001/jama.296.15.1885>
7. Pan, A., Sun, Q., Bernstein, A. M., Schulze, M. B., Manson, J. E., Willett, W. C., & Hu, F. B. (2011). Red meat consumption and risk of type 2 diabetes: 3 cohorts of US adults and an updated meta-analysis. *American Journal of Clinical Nutrition*, 94(4), 1088–1096.
<https://doi.org/10.3945/ajcn.111.018978>

Butter, Coconut Oil, and Hemp Oil: Natural Fats vs Industrial Chemistry

Modern allopathic advice has spent decades scapegoating “**saturated fat and cholesterol**”—while giving a free pass to **industrial seed oils, hydrogenated fats, and ultra-processed junk** that actually drive inflammation, oxidative stress, and insulin resistance. Naturopathic nutrition takes a different line: **the real question is not “fat yes or no?” but “which fat, from what source, how processed, and in what dietary pattern?”**

Fats: Natural vs Industrial

All fats are built from **fatty acids**—chains of carbon, hydrogen, and oxygen:

- **Saturated fats:** no double bonds; generally solid or semi-solid at room temperature (e.g., butter, coconut oil).
- **Monounsaturated fats:** one double bond (e.g., olive oil).
- **Polyunsaturated fats (PUFAs):** multiple double bonds (e.g., omega-3 and omega-6 in nuts, seeds, fish, hemp oil).

Most fats in food and in our bodies are stored as **triglycerides**—three fatty acids attached to a glycerol backbone. Elevated blood triglyceride levels are tightly linked to cardiometabolic risk, but are driven **far more by excess refined carbohydrates and sugars** than by unprocessed natural fats (Parks & Hellerstein, 2000).

The Industrial Detour: Hydrogenation and Trans Fats

To make low cost plant oils behave like butter and lard, the food industry invented **hydrogenation**:

- Unsaturated oils are heated to high temperatures under pressure, with **hydrogen gas and a nickel or other metal catalyst**, to force extra hydrogen atoms onto double bonds.
- This process hardens the fat and creates **trans-fatty acids**, which have distorted molecular shapes and **no evolutionary precedent** in human physiology.

Trans fats:

- **Raise LDL cholesterol and lower HDL,**
- **Promote systemic inflammation and endothelial dysfunction,**
- **Strongly increase risk of coronary heart disease and mortality,** even at low intakes (Mozaffarian et al., 2006; de Souza et al., 2015).

Despite this, for decades allopathic cardiology and industry marketing blessed margarines and shortenings as “heart-healthy” while demonising traditional fats like butter and coconut oil—a historic failure that naturopathy has criticised from the beginning.

Butter: Demonised Traditional Fat vs Synthetic Spreads

Butter vs Margarine

Butter: minimally processed fat from cream. When from **grass-fed, well-raised cows**, it contains:

- **Vitamin A, D, E, K2,**
- **Short- and medium-chain fats** (e.g., butyrate),
- **Conjugated linoleic acid (CLA),**
- A better **omega-3: omega-6 ratio** than grain-fed butter (Butler et al., 2008).

- **Margarine/shortening:** historically made from **partially hydrogenated oils** with trans fats and multiple additives; even newer “trans-free” versions remain highly refined, often based on cheap seed oils with inflammatory ω -6 excess.

Large meta-analyses now show:

- **Industrial trans fats** are clearly linked to **heart disease and death** (Mozaffarian et al., 2006).
- For **natural saturated fats**, the picture is more nuanced: within whole-food patterns (e.g., Mediterranean, traditional diets), modest saturated fat intake is **much less harmful** than once claimed and often neutral when refined carbs are low (de Souza et al., 2015; Mensink, 2016).

Naturopathic implication:

- If a patient consumes dairy, **small amounts of butter from grass-fed, minimally processed sources** are vastly preferable to margarine and industrial spreads, especially in a **low-sugar, whole-food diet**.
- Butter is **not a free-for-all**—portion control and overall pattern still matter—but it is not the metabolic villain that trans fats and ultra-processed oils are.

Coconut Oil: Natural Saturated Fat and Medium-Chain Triglycerides

Coconut oil has been a staple in many traditional cultures (South Pacific, Kerala, coastal Asia) where:

- Saturated fats from coconut can contribute **30–60% of calories**,
- Yet historical rates of **cardiovascular disease were low** under traditional, unprocessed dietary patterns (Prior et al., 1981).

Key features:

- Rich in **medium-chain triglycerides (MCTs)**—especially **lauric acid** (≈50% of fat), plus caprylic and capric acids.
- MCTs are:
 - Absorbed rapidly,
 - Transported directly to the **liver**,
 - **Oxidised for energy rather than preferentially stored** as fat,
 - May modestly increase **energy expenditure and fat oxidation** (St-Onge & Jones, 2002).

Evidence:

- Small trials suggest MCT-rich diets can promote **modest weight loss and improved body composition** when they replace long-chain fats, within calorie-controlled contexts (Mumme & Stonehouse, 2015).
- Systematic reviews show coconut oil tends to **raise LDL-cholesterol but also raise HDL**, with net effects more complex than “good” or “bad” (Eyres et al., 2016).

Naturopathic stance, in contrast to blanket allopathic condemnation:

- **Unrefined, cold-pressed coconut oil** can be used in **moderation** as part of a whole-food, low-sugar diet, particularly in traditional cuisines.
- It should **not** be seen as a miracle cure or licence to ignore overall energy balance and diet quality.
- It is still preferable to **trans-fat-laden shortenings and repeatedly heated industrial seed oils** that dominate modern frying.

Hemp Oil: Electron-Rich, Omega-3–Balanced Plant Fat

Hemp (*Cannabis sativa* L., low-THC industrial varieties) is one of the **most nutrient-balanced oilseeds** known:

Hemp seed oil typically provides:

- Around **75–80% polyunsaturated fat**,
- An **omega-6: omega-3 ratio around 3:1**, considered favourable for human physiology (Callaway, 2004; Simopoulos, 2010).
- Small amounts of **gamma-linolenic acid (GLA)**, an anti-inflammatory ω -6 derivative.

Benefits supported by emerging evidence:

- A balanced ω -6: ω -3 intake (roughly 2–4:1) is linked to **lower inflammation, better endothelial function, and improved metabolic profiles**, compared with the ~15–20:1 ratios common in Westernised diets overloaded with soy, corn, and sunflower oil (Simopoulos, 2010).
- Hemp oil provides **both LA (omega-6) and ALA (omega-3)** in a near-ideal ratio, plus minor GLA, making it a **useful adjunct** for restoring essential fatty acid balance (Callaway, 2004).
- It should be used **cold** (salads, dressings), as high-temperature cooking damages its delicate PUFAs.

Naturopathic integration:

- Hemp oil is **not a magic bullet**, but in small, cold-used amounts it can help correct the **omega-3 deficit and ω -6 excess** driving many inflammatory conditions.
- It offers an alternative for those who cannot or will not use **fish oil**, and fits well into **plant-centred, anti-inflammatory meal plans**.

Naturopathic Verdict on Fats in Diabetes and Metabolic Health

Allopathic guidelines have spent decades telling patients to:

- Avoid saturated fats and cholesterol,
- Consume “heart-healthy” refined seed oils and low-fat products,

while metabolic disease exploded. Naturopathic care, grounded in both tradition and emerging science, takes a different route:

Primary villains:

- **Trans fats and hydrogenated oils,**
- **Refined, repeatedly heated seed oils (soy, corn, sunflower, safflower, etc.),**
- **Ultra-processed foods** overloaded with these fats and refined carbs.

Conditionally beneficial or neutral when used appropriately:

- **Butter** from grass-fed, minimally processed sources—in small amounts, within a plant-rich, low-sugar diet.
- **Coconut oil**, unrefined, in modest amounts and preferably within traditional cuisines, not as a universal “superfood.”
- **Cold-pressed hemp oil**, as a **balanced EFA source**, used unheated in salads, chutneys, or dressings.

Non-negotiable requirements for metabolic healing:

- A diet **low in refined carbohydrates and ultra-processed foods**,
- High in **vegetables, pulses, nuts, seeds, and whole foods**,
- With fats chosen for **naturalness, minimal processing, and context**, not for corporate slogans.

In the chapters that follow, we will translate this critical view into concrete naturopathic fat-use guidelines for type 2 diabetes—showing how to replace industrial oils and spreads with small

amounts of traditional, minimally processed fats (including butter, coconut, and hemp), embedded in whole-food, plant-rich eating patterns that reduce medication dependence and improve long-term outcomes.

References:

- Butler, G., Nielsen, J. H., Slots, T., Seal, C., Eyre, M. D., Sanderson, R., & Leifert, C. (2008). Fatty acid and fat-soluble antioxidant concentrations in milk from high- and low-input conventional and organic systems: Seasonal variation. *Journal of the Science of Food and Agriculture*, 88(8), 1431–1441. <https://doi.org/10.1002/jsfa.3235>
- Callaway, J. C. (2004). Hempseed as a nutritional resource: An overview. *Euphytica*, 140(1–2), 65–72. <https://doi.org/10.1007/s10681-004-4811-6>
- de Souza, R. J., Mente, A., Maroleanu, A., Cozma, A. I., Ha, V., Kishibe, T., Uleryk, E., Budyłowski, P., Schünemann, H., Beyene, J., & Anand, S. S. (2015). Intake of saturated and trans unsaturated fatty acids and risk of all-cause mortality, cardiovascular disease, and type 2 diabetes: Systematic review and meta-analysis. *BMJ*, 351, h3978. <https://doi.org/10.1136/bmj.h3978>
- Eyres, L., Eyres, M. F., Chisholm, A., & Brown, R. C. (2016). Coconut oil consumption and cardiovascular risk factors in humans. *Nutrition Reviews*, 74(4), 267–280. <https://doi.org/10.1093/nutrit/nuw002>
- Mensink, R. P., & World Health Organization. (2016). *Effects of saturated fatty acids on serum lipids and lipoproteins: a systematic review and regression analysis*. World Health Organization. <https://paperzz.com/doc/7798372/effects-of-saturated-fatty-acids-on-serum-lipids-and-lipo...>

- Mozaffarian, D., Katan, M. B., Ascherio, A., Stampfer, M. J., & Willett, W. C. (2006). Trans fatty acids and cardiovascular disease. *New England Journal of Medicine*, 354(15), 1601–1613. <https://doi.org/10.1056/NEJMr054035>
- Mumme, K. D., & Stonehouse, W. (2015). Effects of medium-chain triglycerides on weight loss and body composition: A meta-analysis of randomized controlled trials. *Journal of the Academy of Nutrition and Dietetics*, 115(2), 249–263. <https://doi.org/10.1016/j.jand.2014.10.022>
- Parks, E. J., & Hellerstein, M. K. (2000). Carbohydrate-induced hypertriacylglycerolemia: Historical perspective and review of biological mechanisms. *American Journal of Clinical Nutrition*, 71(2), 412–433. <https://doi.org/10.1093/ajcn/71.2.412>
- Prior, I. A., Davidson, F., Salmond, C. E., & Czochanska, Z. (1981). Cholesterol, coconuts, and diet on Polynesian atolls: A natural experiment: The Pukapuka and Tokelau Island studies. *American Journal of Clinical Nutrition*, 34(8), 1552–1561. <https://doi.org/10.1093/ajcn/34.8.1552>
- Simopoulos, A. P. (2010). The omega-6/omega-3 fatty acid ratio: health implications. *Oléagineux, Corps gras, Lipides*, 17(5), 267-275. <https://doi.org/10.1051/ocl.2010.0325>
- St-Onge, M.-P., & Jones, P. J. H. (2002). Physiological effects of medium-chain triglycerides: Potential agents in the prevention of obesity. *Journal of Nutrition*, 132(3), 329–332. <https://doi.org/10.1093/jn/132.3.329>

Oils in Your Kitchen: Stop Frying Your Metabolism

Conventional nutrition has spent decades telling people to “use vegetable oil instead of saturated fat” and then watched, apparently without alarm, as type 2 diabetes, fatty liver, and heart disease exploded in populations drowning in **refined seed oils and deep-fried starch**. From a naturopathic standpoint, your choice of kitchen fats is not a cosmetic detail; it is a **major driver of inflammation, oxidative stress, and insulin resistance**.

The goal is simple: **get industrial oils and overheated fats out of your kitchen, and replace them with a short, well-chosen list of natural fats used correctly.**

Which Fats Belong in a Naturopathic Kitchen?

A realistic, evidence-aligned naturopathic kitchen needs only a few core fats:

- **Butter or ghee (preferably from grass-fed, minimally processed milk)**
- **Coconut oil (unrefined, cold-pressed)**
- **Extra-virgin, cold-pressed olive oil**
- **Cold-pressed hemp oil and flaxseed oil (for cold use only, not cooking)**

These fats:

- Are **minimally processed**,

- Provide **stable saturated or monounsaturated fats** for cooking, or balanced PUFAs for cold use,
- And fit naturally into **whole-food, plant-rich, low-sugar meal patterns** that improve insulin sensitivity.

In contrast, most commonly recommended “heart-healthy” seed oils in the conventional world are:

- **Refined, chemically extracted, deodorised,**
- Very high in **omega-6 polyunsaturated fats,**
- Frequently **reheated to high temperatures,** creating oxidation products.

What Should *Not* Be in Your Frying Pan

For cooking—especially at high heat—**do not use:**

- Refined **corn oil, soybean oil, sunflower oil, safflower oil, cottonseed oil,** generic “vegetable oil,” or **canola oil** for frying.

Reasons:

1. They are rich in **omega-6 PUFAs**, which are:
 - Highly susceptible to **oxidation** at cooking temperatures,
 - Produce **toxic aldehydes and oxidation products** when heated or reheated (Guillén & Goicoechea, 2008).
2. High, chronic ω -6 intake (especially with low ω -3 and low antioxidant intake) is associated with:
 - **Systemic** inflammation,
 - Higher cardiometabolic risk (Simopoulos, 2010).
3. In real-world Indian kitchens and street-food stalls, these oils are:
 - Used for **deep-frying and repeatedly reheated,**
 - Producing a stew of **oxidised lipids** and polar compounds, which correlate with endothelial dysfunction and atherogenic changes.

4. A large share of global soy and corn oil is derived from **GM, herbicide-intensive crops**, which raises additional concerns about **residues and ecosystem damage**, even if direct clinical toxicity at low doses is still debated. (Ng et al., 2014).

Allopathic guidelines that still recommend “any vegetable oil” for frying in diabetic patients, without regard to **fatty acid profiles, processing, and frying practices, are not aligned with current evidence on lipid oxidation and the harms of ultra-processed foods.**

For Heat: Coconut Oil, Butter, and Ghee

When you do cook (ideally at **moderate** rather than extreme temperatures):

- **Coconut oil** and **ghee/clarified butter** are the most heat-stable staples:
 - Their **saturated and monounsaturated fat composition** makes them more resistant to oxidation than PUFA-rich seed oils (Eyres et al., 2016).
 - Traditional cuisines that use these fats within whole-food patterns and low sugar intake historically show **low rates of CVD and diabetes**, until refined flours, sugars, and industrial oils enter the picture (Prior et al., 1981).
- **Butter** (from grass-fed cows) can be used at lower to medium heat or as a finishing fat:
 - Provides fat-soluble vitamins (A, D, K2) and short-/medium-chain fats, but the **milk solids** are less heat-stable than pure fat (ghee).

Used judiciously within a **plant-rich diet**, these fats are preferable to reheated seed oils and trans-fat-containing shortenings.

For Cold Use: Olive, Hemp, and Flax Oils

For salads, chutneys, finishing dishes (not high-heat frying):

Extra-virgin olive oil

- High in **monounsaturated fat (oleic acid)** and polyphenols.
- Core component of the **Mediterranean pattern**, repeatedly associated with lower cardiovascular and diabetes risk (Schwingshackl & Hoffmann, 2014).

Cold-pressed hemp seed oil and flaxseed oil

- Rich in **ALA (omega-3)** and, in hemp's case, a near-ideal **ω-6:ω-3 balance** (~3:1) (Callaway, 2004; Simopoulos, 2010).
- Must be kept **refrigerated and used unheated**; heating destroys their benefits and promotes oxidation.

These oils support **anti-inflammatory fatty acid profiles when used in small amounts as part of a diet rich** in vegetables, pulses, nuts, seeds, and whole foods.

Raw vs Cooked: Metabolism, Not Extremism

Claims that the human body is “defenceless against cooked food” or that one “can never gain weight from raw foods” are overstated and unsupported by controlled trials: people can and do gain weight on both cooked and raw diets, depending on energy balance and food choices.

However, a naturopathic critique of **overcooking and frying** is still valid:

- High-temperature cooking (especially grilling, frying) increases **AGEs and advanced lipid oxidation products**, which can worsen **insulin resistance, endothelial dysfunction, and inflammation** (Uribarri et al., 2010).
- Ultra-processed cooked foods (refined flours, sugars, and oils) **bypass normal satiety mechanisms**, are digested rapidly, and **overwhelm metabolic safeguards**, unlike intact, fibre-rich raw foods.

A pragmatic naturopathic stance:

- **Increase:** raw or lightly cooked vegetables, fresh fruit, nuts, seeds, sprouts, minimally processed foods.
- **Reduce:** deep-fried foods, overcooked meats, charred items, reheated oils.
- Aim for a plate where **most of the bulk and colour** comes from plants in as close to their natural state as practical.

Raw Nuts and Seeds: High-Fat, High-Protection

Raw, unroasted, unsalted nuts and seeds are **nutrient-dense, not fattening “cheats”**:

- Provide **monounsaturated and polyunsaturated fats**, protein, fibre, vitamin E, magnesium, folate, copper, and phytochemicals.
- Large cohorts and meta-analyses show that regular nut consumption is associated with:
 - **Lower coronary heart disease risk,**
 - Improved lipid profiles (lower LDL, modestly higher HDL),
 - **Lower all-cause and cardiovascular mortality**—often **without weight gain**, and sometimes with better weight control (Sabaté & Ang, 2009; Aune et al., 2016).

Examples:

- **Almonds:** rich in magnesium and monounsaturated fats; can improve LDL and glycaemic control in type 2 diabetes when substituted for refined carbs (Jenkins et al., 2011).
- **Walnuts:** high in ALA (omega-3) and antioxidants; associated with lower CVD risk.
- **Pistachios:** beneficial for lipids and may support eye health via lutein and zeaxanthin.

- **Brazil nuts:** concentrated selenium source; 1–3 nuts can meet daily needs, but doses must be moderate.

Nuts may be best:

- Eaten as **daytime snacks** (not huge portions late at night),
- Replacing **biscuits, namkeen, and fried snacks**, rather than being “added on” to an already excess-calorie diet.

For people with diabetes, **30–60 g/day of mixed nuts** in place of refined-carbohydrate snacks is both realistic and evidence-based.

Naturopathic Summary: Rebuild the Fat Environment Around Your Food

A naturopathic, diabetes-focused oil and fat strategy looks like this:

- **Eliminate or drastically reduce:**
 - Hydrogenated fats, margarines, shortenings,
 - Generic “vegetable oils” for frying,
 - Repeatedly heated oils in home, restaurant, and street-food settings.
- **Cook, when necessary, with:**
 - Coconut oil, ghee, or small amounts of butter—at **moderate temperatures**.
- **Dress and finish with:**
 - Extra-virgin olive oil, cold-pressed hemp or flax oil (unheated).
- **Base snacks on:**
 - Raw or dry-roasted **nuts and seeds**, not chips, fried mixtures, or “baked” ultra-processed snacks.
- **Shift plate composition:**
 - More **raw or lightly cooked plant foods**, fewer fried, overcooked, and heavily processed items.

This is the opposite of the old allopathic “low-fat, high-refined-carb plus any vegetable oil” advice that helped trap millions in cycles of hyperinsulinaemia, fatty liver, and drug escalation.

In the following chapters, we will integrate these fat guidelines into full naturopathic meal plans for type 2 diabetes—showing exactly how to combine oils, nuts, and cooking methods with vegetables, pulses, and whole foods to normalise insulin sensitivity and reduce medication dependence.

References:

1. Aune, D., Keum, N., Giovannucci, E., Fadnes, L. T., Boffetta, P., Greenwood, D. C., Tonstad, S., Vatten, L. J., Riboli, E., & Norat, T. (2016). Nut consumption and risk of cardiovascular disease, total cancer, all-cause and cause-specific mortality: A systematic review and dose-response meta-analysis of prospective studies. *BMC Medicine*, 14, 207. <https://doi.org/10.1186/s12916-016-0730-3>
2. Callaway, J. C. (2004). Hempseed as a nutritional resource: An overview. *Euphytica*, 140(1–2), 65–72. <https://doi.org/10.1007/s10681-004-4811-6>
3. Eyres, L., Eyres, M. F., Chisholm, A., & Brown, R. C. (2016). Coconut oil consumption and cardiovascular risk factors in humans. *Nutrition Reviews*, 74(4), 267–280. <https://doi.org/10.1093/nutrit/nuw002>
4. Guillén, M. D., & Goicoechea, E. (2008). Formation of oxygenated α,β -unsaturated aldehydes and other toxic compounds in sunflower oil oxidation at room temperature in closed receptacles. *Food Chemistry*, 111(1), 157–164. <https://doi.org/10.1016/j.foodchem.2008.03.052>
5. Jenkins, D. J. A., Kendall, C. W. C., Marchie, A., Parker, T. L., Connelly, P. W., Qian, W., Haight, J. S., Faulkner, D., Vidgen, E., & Lapsley, K. G. (2011). Dose response of almonds on coronary heart disease risk factors: Blood lipids,

- oxidized low-density lipoproteins, lipoprotein(a), homocysteine, and pulmonary nitric oxide: A randomized, controlled, crossover trial. *Circulation*, 106(11), 1327–1332. <https://doi.org/10.1161/01.CIR.0000028421.91733.20>
6. Ng, C. Y., Leong, X. F., Masbah, N., Adam, S. K., Kamisah, Y., & Jaarin, K. (2014). Heated vegetable oils and cardiovascular disease risk factors. *Vascular pharmacology*, 61(1), 1-9. <https://doi.org/10.1016/j.vph.2014.02.004>
 7. Prior, I. A., Davidson, F., Salmond, C. E., & Czochanska, Z. (1981). Cholesterol, coconuts, and diet on Polynesian atolls: A natural experiment: The Pukapuka and Tokelau Island studies. *American Journal of Clinical Nutrition*, 34(8), 1552–1561. <https://doi.org/10.1093/ajcn/34.8.1552>
 8. Sabate, J., & Ang, Y. (2009). Nuts and health outcomes: New epidemiologic evidence. *American Journal of Clinical Nutrition*, 89(5), 1643S–1648S. <https://doi.org/10.3945/ajcn.2009.26736Q>
 9. Schwingshackl, L., & Hoffmann, G. (2014). Monounsaturated fatty acids, olive oil and health status: A systematic review and meta-analysis of cohort studies. *Lipids in Health and Disease*, 13, 154. <https://doi.org/10.1186/1476-511X-13-154>
 10. Simopoulos, A. P. (2010). The omega-6/omega-3 fatty acid ratio: health implications. *Oléagineux, Corps gras, Lipides*, 17(5), 267-275. <https://doi.org/10.1051/ocl.2010.0325>
 11. Uribarri, J., Woodruff, S., Goodman, S., Cai, W., Chen, X., Pyzik, R., Yong, A., Striker, G. E., & Vlassara, H. (2010). Advanced glycation end products in foods and a practical guide to their reduction in the diet. *Journal of the American Dietetic Association*, 110(6), 911–916.e12. <https://doi.org/10.1016/j.jada.2010.03.018>

Organic Dark Leafy Greens: The Missing Pharmacology in Diabetes Care

Allopathic diabetes care will spend hours titrating drugs and almost no time insisting that patients eat the **most nutrient-dense, disease-modifying food on the planet**: organic dark leafy greens. Milligram for milligram, no tablet on the market can match what a plate of spinach, kale, mustard greens, or methi delivers to an inflamed, insulin-resistant body.

From a naturopathic standpoint, **dark leafy greens are frontline therapy**, not decorative side dishes.

Why Dark Leafy Greens Are Metabolic Gold

Pound for pound, dark leafy vegetables are among the **most concentrated sources of nutrients** available:

- **Minerals**: calcium, magnesium, potassium, iron, manganese, selenium.
- **Vitamins**: K, C, E, many B-vitamins, provitamin A (beta-carotene), and small amounts of other fat-solubles depending on variety.
- **Phytonutrients**: carotenoids (lutein, zeaxanthin, β -carotene), flavonoids, glucosinolates, chlorophyll, and other antioxidants.
- **Fibre**: soluble and insoluble, crucial for glycaemic control, satiety, and microbiome health.
- **Plant omega-3 (ALA)**: especially in some leafy greens like purslane and spinach (Simopoulos, 2010).

High intake of green leafy vegetables is consistently associated with:

- Lower risk of **type 2 diabetes** (Carter et al., 2010),
- Reduced cardiovascular events and overall mortality in population studies (Boeing et al., 2012),
- Improved markers of inflammation and oxidative stress.

Naturopathic nutrition treats dark greens as **non-negotiable daily medicine** for anyone with, or at risk for, diabetes.

Phytochemicals and Chlorophyll: More Than “Vitamins”

Phytochemicals

Leafy greens are loaded with thousands of **bioactive plant compounds**—many still being characterised. Key groups include:

- **Carotenoids** (e.g., lutein, zeaxanthin, β -carotene): antioxidant and anti-inflammatory, support eye and cardiovascular health.
- **Flavonoids and phenolic acids**: help modulate oxidative stress, endothelial function, and inflammation (Scalbert et al., 2011).
- **Glucosinolates** (in brassicas: kale, collards, cabbage): precursors to isothiocyanates with **anticarcinogenic and detoxification-supporting** effects.

Epidemiologic data show that higher intake of green leafy and cruciferous vegetables is associated with a lower risk of cancer, improved vascular health, and reduced all-cause mortality (Boeing et al., 2012).

Chlorophyll

Chlorophyll and its derivatives:

- Exhibit **antioxidant, anti-inflammatory, and anti-mutagenic** properties (Ferruzzi & Blakeslee, 2007).

- Can bind certain dietary carcinogens (e.g., heterocyclic amines from grilled meats) and reduce their absorption and DNA damage in experimental models (Egner et al., 2001).

For people with diabetes—who live in a body bathed in oxidative stress and glycation by-products—this **continuous antioxidant and detoxification support** is not optional; it is core therapy.

Lutein, Zeaxanthin, and Eye Protection

Lutein and zeaxanthin, concentrated in dark greens (kale, spinach, mustard, collards):

- Accumulate in the **macula and lens of the eye**, functioning as **blue-light filters and antioxidants**.
- Higher dietary and plasma levels are associated with **lower risk of age-related macular degeneration and cataracts** (Moeller et al., 2006; Ma et al., 2012).

Given that **diabetic retinopathy and accelerated eye ageing** are major threats in diabetes, it is astonishing how rarely conventional care prescribes the one “supplement” most patients can afford: **a daily mountain of organic dark leafy greens**.

Greens, Cancer, and Cardiometabolic Protection

Studies across populations show:

- More intake of **green leafy and cruciferous vegetables** is linked to **lower stomach, colorectal, breast, and lung cancer risk** (Boeing et al., 2012; Aune et al., 2017).
- Greens (and other non-starchy vegetables) are central components of dietary patterns that **reduce blood pressure, improve lipids, lower weight, and improve glycaemic control** (e.g., DASH, Mediterranean, plant-forward diets).

Broccoli sprouts and certain brassicas provide unique compounds like **sulforaphane**, which induces phase-II detox enzymes and may confer protection against carcinogens and oxidative injury (Fahey et al., 2012).

For a person with type 2 diabetes, who carries elevated risks of cancer and cardiovascular disease, **daily high-density green intake** is not a wellness trend; it is risk-reduction strategy.

Whole Greens vs Green Powders

Green powders have exploded in the supplement market. From a naturopathic and practical standpoint:

- **Whole organic greens** (spinach, kale, methi, amaranth leaves, mustard greens, coriander, dill, etc.) are **superior**:
 - Intact water content,
 - Full fibre matrix,
 - Volatile phytonutrients that degrade with drying and storage,
 - More complete synergy of nutrients.
- **High-quality, organic green powders** can be:
 - A **useful backup**, especially for patients who cannot reliably access or prepare fresh greens daily.
 - Helpful for travel or for adding to smoothies.

But:

- Powders can **never fully replace** chewing, blending, or lightly cooking actual leaves.
- Many cheap products contain contaminants, fillers, or under-dosed ingredients.

Naturopathic guidance:

- Strive for **large daily servings of fresh, organic greens**;
- Use **green powders** as **supplemental insurance**, not as permission to avoid vegetables.

How to Actually Eat Enough Greens: Salads, Light Cooking, and Green Smoothies

Most people drastically **overestimate** how many greens they eat. A sprinkling of iceberg lettuce on a plate is not therapeutic. A realistic diabetes-healing target often means:

- **2–4 cups (or more)** of raw leafy greens per day, or
- Equivalent volume when lightly cooked or blended.

Raw and Lightly Cooked Greens

- Use **dark lettuces, baby greens, spinach, kale, coriander, methi, dill** in large mixed salads.
- Light steaming or sautéing with a bit of healthy fat (e.g., ghee, olive oil) can:
 - Improve **palatability and absorption** of fat-soluble nutrients,
 - Reduce oxalate content in some leafy greens.

Even in a raw-leaning naturopathic approach, some **light cooking** can increase nutrient accessibility and tolerability for certain individuals (e.g., thyroid issues with large amounts of raw crucifers).

Green Smoothies

One of the most practical ways to secure therapeutic doses of greens is **blending**:

- High-speed blenders can **rupture plant cell walls**, improving access to intracellular nutrients while preserving fibre.
- A base recipe:
 - 40–60% **organic greens** (spinach, kale, coriander, mixed leaves),
 - 40–60% **whole fruit** (e.g., low-GI: berries, green apple, guava),
 - Optional: **seeds (chia, flax), hemp protein, sprouts, herbs.**

For people with diabetes:

- Keep fruit portions moderate and emphasise **non-starchy greens and fibre**, adjusting fruit types based on glycaemic response.
- 1–2 green smoothies per day can dramatically increase intake of:
 - **Magnesium, potassium, folate, carotenoids, vitamin K1,**
 - Chlorophyll and polyphenols.

Blending is generally superior to juicing for diabetics:

- **Juicing** removes fibre, concentrating sugars (even “natural” ones).
- **Blending** retains fibre, slowing absorption and improving satiation.

Naturopathic Guidance for People with Diabetes

In a naturopathic diabetes protocol, organic dark leafy greens are not decoration; they are a **daily prescription**:

- Aim for **at least 2–4 heaped cups of dark greens daily**, via:
 - Big salads,
 - Lightly cooked greens,
 - Green smoothies or blended soups.
- Rotate varieties:
 - Spinach, methi, sarson (mustard greens), amaranth leaves, kale, coriander, dill, radish leaves, drumstick leaves, etc.
- Combine with:
 - **Healthy fats** (nuts, seeds, olive oil, ghee) for absorption of fat-soluble nutrients,
 - **Protein and fibre** for glycaemic stability.

- Use **green powders**:
 - Only as backup when fresh greens are limited,
 - Ensuring they are **organic and from reputable producers**.

Allopathic management will continue to chase HbA1c targets with ever more expensive drugs. Naturopathy insists that no medication regimen is complete—or truly rational—if the patient’s plate does not carry a large, daily quota of **organic, dark green leaves**.

In subsequent chapters, we will integrate dark leafy greens into full naturopathic meal plans for type 2 diabetes, showing how to build breakfasts, lunches, dinners, and smoothies that push drug-centred management into the background and put food-centred metabolic healing at the core.

References:

1. Aune, D., Giovannucci, E., Boffetta, P., Fadnes, L. T., Keum, N., Norat, T., Greenwood, D. C., Riboli, E., Vatten, L. J., & Tonstad, S. (2017). Fruit and vegetable intake and the risk of cardiovascular disease, total cancer and all-cause mortality—A systematic review and dose-response meta-analysis of prospective studies. *International Journal of Epidemiology*, 46(3), 1029–1056. <https://doi.org/10.1093/ije/dyw319>
2. Boeing, H., Bechthold, A., Bub, A., Ellinger, S., Haller, D., Kroke, A., Leschik-Bonnet, E., Müller, M. J., Oberritter, H., Schulze, M., Stehle, P., & Watzl, B. (2012). Critical review: Vegetables and fruit in the prevention of chronic diseases. *European Journal of Nutrition*, 51(6), 637–663. <https://doi.org/10.1007/s00394-012-0380-y>
3. Carter, P., Gray, L. J., Troughton, J., Khunti, K., & Davies, M. J. (2010). Fruit and vegetable intake and incidence of type 2 diabetes mellitus: Systematic review and meta-analysis. *BMJ*, 341, c4229. <https://doi.org/10.1136/bmj.c4229>

4. Egner, P. A., Muñoz, A., & Kensler, T. W. (2003). Chemoprevention with chlorophyllin in individuals exposed to dietary aflatoxin. *Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis*, 523, 209-216. [https://doi.org/10.1016/S0027-5107\(02\)00337-8](https://doi.org/10.1016/S0027-5107(02)00337-8)
5. Fahey, J. W., Holtzclaw, W. D., Wehage, S. L., Wade, K. L., Stephenson, K. K., & Talalay, P. (2015). Sulforaphane bioavailability from glucoraphanin-rich broccoli: control by active endogenous myrosinase. *PloS one*, 10(11), e0140963.. <https://doi.org/10.1371/journal.pone.0140963>
6. Ferruzzi, M. G., & Blakeslee, J. (2007). Digestion, absorption, and cancer preventive activity of dietary chlorophyll derivatives. *Nutrition Research*, 27(1), 1–12. <https://doi.org/10.1016/j.nutres.2006.12.003>
7. Ma, L., Dou, H., & Huang, Y. (2012). Lutein and zeaxanthin intake and the risk of age-related macular degeneration: A systematic review and meta-analysis. *British Journal of Nutrition*, 107(3), 350–359. <https://doi.org/10.1017/S0007114511004260>
8. Moeller, S. M., Volland, R., Tinker, L., Blodi, B., Klein, M. L., Gehrs, K. M., Johnson, E. J., Snodderly, D. M., Wallace, R. B., Chappell, R. J., Parekh, N., Ritenbaugh, C., Wallace, R., Mares, J. A., & CAREDS Research Group. (2008). Associations between age-related nuclear cataract and lutein and zeaxanthin in the diet and serum in the Carotenoids in the Age-Related Eye Disease Study. *Archives of Ophthalmology*, 126(3), 354–364. <https://doi.org/10.1001/archophth.126.3.354>
9. Scalbert, A., Johnson, I. T., & Saltmarsh, M. (2005). Polyphenols: Antioxidants and beyond. *American Journal of Clinical Nutrition*, 81(1 Suppl.), 215S–217S. <https://doi.org/10.1093/ajcn/81.1.215S>

10. Simopoulos, A. P. (2010). The omega-6/omega-3 fatty acid ratio: health implications. *Oléagineux, Corps gras, Lipides*, 17(5), 267-275. <https://doi.org/10.1051/ocl.2010.0325>

Sprouted Grains: What Industrial Diabetes Care Forgot to Tell You About Wheat and Rice

Conventional Nutrition has spent decades handing out “whole-wheat” and “multi-grain” advice while ignoring a brutal agricultural and processing shift: **we stopped letting grains sprout, and we started grinding them into ultra-fine flour and heat-damaged products.** Naturopathic care brings back what the industrial food system discarded—**sprouting**—because it transforms grains from dense, hard-to-digest starch pellets into living, enzyme-rich, low-glycaemic foods.

Why Sprouting Changes Everything

The metabolic impact of wheat, rye, rice, quinoa, and other grains depends dramatically on **how they are prepared**:

- **Unsprouted, refined flour** → high glycaemic load, low micronutrient density, more phytic acid and enzyme inhibitors, easier overconsumption, tighter link with obesity and type 2 diabetes.
- **Sprouted (germinated) grains** →
 - Lower starch load and altered carbohydrate profile,
 - Improved **vitamin, mineral, and antioxidant content**,
 - Reduced **anti-nutrients** (phytic acid, enzyme inhibitors),
 - Enhanced **digestibility** and often lower glycaemic index.

Multiple studies show that **germination**:

- Increases **B-vitamins (especially B2, B3, B6), vitamin C, vitamin E, and carotenoids**,
- Boosts **free amino acids and antioxidant capacity**,
- Reduces **phytate and protease inhibitors**, making minerals and proteins more bioavailable (Benincasa et al., 2019; Maldonado-Alvarado et al., 2023).

In other words, sprouting turns “diabetes fuel” into something much closer to a functional, slow-burn carbohydrate-and-protein source.

What Sprouting Does Biochemically

During germination, the grain’s own enzymes wake up:

- **Starches → simpler sugars**
 - Amylases break down complex starch, reducing dense carbohydrate load and making grains easier to digest (Benincasa et al., 2019).
- **Proteins → peptides and free amino acids**
 - Proteases increase the pool of free amino acids, sometimes improving digestibility and antioxidant peptide formation.
- **Fats → free fatty acids**
 - Lipases begin to mobilise fats, modestly altering lipid profile.
- **Vitamins and antioxidants increase**
 - Studies report increases in **vitamin C**, several **B-vitamins**, and **antioxidant compounds** such as phenolics and carotenoids (Laus et al., 2017).
- **Anti-nutrients decrease**
 - **Phytic acid** and **enzyme inhibitors** fall, improving absorption of **iron, zinc, magnesium, calcium** (Gibson et al., 2010).

This is exactly what naturopathy demands: **activate the grain's life processes before you eat it**, instead of relying on synthetic fortification and huge drug budgets to patch up the damage from dead flour.

Sprouted Grain Products and Glycaemic Impact

Sprouted-grain breads and flours:

- Tend to have **higher fibre, more protein, and a different starch structure** than standard refined breads.
- Often show a **lower glycaemic response and improved satiety** compared with white bread, and sometimes with conventional whole-wheat bread (Jenkins et al., 1983).
- Can help blunt post-prandial glucose spikes and insulin swings when replacing refined breads in otherwise whole-food diets.

For people with diabetes:

- Sprouted grains are still **carbohydrate sources**—they must be portion-controlled and monitored.
- But they are vastly preferable to **maida-based breads, biscuits, and polished white rice**, especially when combined with **protein, fat, and vegetables**.

Importantly, some individuals who react badly to conventional wheat find that they **tolerate sprouted wheat or other sprouted grains better**, because proteolysis and lower antinutrient content can reduce gut stress (though not in true coeliac disease, where gluten remains a problem).

What Can Be Sprouted?

Virtually all **edible grains, seeds, and legumes** can be sprouted:

- **Grains:** Wheat, spelt, rye, barley, millet, ragi, bajra, oats (whole), brown rice, quinoa, amaranth, buckwheat, maize.

- **Legumes:** Mung beans, lentils, chickpeas, peas, horse gram, etc.
- **Seeds:** Alfalfa, fenugreek, radish, broccoli, clover, sesame, pumpkin, sunflower, flax, etc.

Key examples:

- **Alfalfa sprouts:** Provide vitamins A, C, E, K, some B-vitamins, minerals (including manganese), and phytoestrogens; widely studied for antioxidant and lipid-lowering properties (Tlahig & Elfalleh., 2025).
- **Sesame seeds:** High in lignans (sesamin, sesamolin), calcium, vitamin E, and healthy fats; sprouting can modestly increase bioavailability of calcium and iron.
- **Mung sprouts:** Common in Indian cuisines; germination increases vitamin C and antioxidant activity and reduces flatulence-causing oligosaccharides.

From a naturopathic standpoint, sprouts are **living multivitamins**, not garnish.

How to Make Sprouts (and Actually Eat Them)

Home sprouting is simple:

1. **Choose** whole, intact grains/legumes/seeds (preferably organic, non-irradiated).
2. **Rinse and soak** in clean water for several hours or overnight.
3. **Drain and spread** in a jar, tray, or sprouter; keep moist (rinsing 1–2×/day) but not submerged.
4. Allow **1–3 days** for small sprouts (~1–3 mm) to appear.
5. Rinse, drain, and **refrigerate** for a few days, using promptly.

Ways to use:

- As the **base** of salads (e.g., sprouted mung + chopped vegetables + lemon + herbs).
- Sprinkled on soups, curries, and stir-fries **after** cooking.

- Mixed into **parathas, dosas, chillas** made with sprouted-grain or sprouted-pulse batters.
- Combined with nuts, seeds, and raw vegetables as a **high-protein snack**.

For people with diabetes, sprouted grains/legumes should:

- Replace **refined rice and flour products**,
- Be **paired with fats and vegetables** for optimal glycaemic control,
- Introduced gradually in those with sensitive digestion.

Organic vs “Natural”: Why It Matters for Sprouts

Sprouting **concentrates** not only nutrients, but whatever residues are present:

- Chemicals on conventional grains/seeds (pesticides, fungicides) can remain in sprouted products.
- “Natural” on a label does **not** guarantee freedom from pesticides, heavy metals, or processing chemicals.

Organic (when genuinely certified):

- Implies adherence to standards that restrict synthetic pesticides and fertilisers,
- Encourages **soil health and ecological balance**,
- Reduces chemical burden in a person already dealing with **detoxification stress from diabetes, medications, and urban pollution**.

From a naturopathic perspective:

- Ideally choose **organic seeds/grains** for sprouting.
- If not available, still sprout—but rinse meticulously and prioritise varieties with lower pesticide loads.

Naturopathic Summary for Diabetes Care

In the allopathic model, grains are often simply “carbs” to be limited or swapped out for **pharmaceuticals and fortified low-GI products**. Naturopathy takes a more radical stance:

- If grains are used at all, **they should be sprouted, fermented, or otherwise traditionally processed** to activate enzymes, increase vitamins, and reduce anti-nutrients.
- Sprouted grains and legumes can:
 - Improve micronutrient intake and mineral bioavailability,
 - Lower glycaemic impact compared with refined grain products,
 - Support microbiome and gut health,
 - Replace nutrient-poor staples like white bread, biscuits, and polished rice.

For people with type 2 diabetes:

- Sprouted foods are **not a licence to binge on carbohydrate**,
- But they are a powerful tool to **rebuild starch-based meals with higher nutrient density, better digestibility, and less metabolic damage**.

In the chapters that follow, we will integrate sprouted grains and legumes into specific naturopathic meal plans—showing how to construct breakfasts, lunches, and dinners that replace refined flour and rice with germinated, enzyme-rich options to stabilise blood sugar and support medication reduction.

References:

1. Benincasa, P., Falcinelli, B., Lutts, S., Stagnari, F., & Galieni, A. (2019). Sprouted grains: A comprehensive review. *Nutrients*, 11(2), 421.
<https://doi.org/10.3390/nu11020421>
2. Gibson, R. S., Bailey, K. B., Gibbs, M., & Ferguson, E. L. (2010). A review of phytate, iron, zinc, and calcium

concentrations in plant-based complementary foods used in low-income countries and implications for bioavailability.

Food and nutrition bulletin, 31(2_suppl2), S134-S146.

<https://doi.org/10.1177/15648265100312S20>

3. Jenkins, D. J., Wolever, T. M., Jenkins, A. L., Thorne, M. J., Lee, R., Kalmusky, J., Reichert, R., & Wong, G. S. (1983). The glycaemic index of foods tested in diabetic patients: a new basis for carbohydrate exchange favouring the use of legumes. *Diabetologia*, 24(4), 257–264.
<https://doi.org/10.1007/BF00282710>
4. Laus, M. N., Cataldi, M. P., Robbe, C., D'Ambrosio, T., Amodio, M. L., Colelli, G., ... & Pastore, D. (2017). Antioxidant capacity, phenolic and vitamin C contents of quinoa (*Chenopodium quinoa* willd.) as affected by sprouting and storage conditions. *Italian Journal of Agronomy*, 12(1).
<https://doi.org/10.4081/ija.2017.816>
5. Maldonado-Alvarado, P., Pavón-Vargas, D. J., Abarca-Robles, J., Valencia-Chamorro, S., & Haros, C. M. (2023). Effect of Germination on the Nutritional Properties, Phytic Acid Content, and Phytase Activity of Quinoa (*Chenopodium quinoa* Willd). *Foods* (Basel, Switzerland), 12(2), 389.
<https://doi.org/10.3390/foods12020389>
6. Tlahig, S., & Elfalleh, W. (2025). Alfalfa as a nutritional and functional food resource: applications and health benefits. *Food Bioscience*, 68, 106762.
<https://doi.org/10.1016/j.fbio.2025.106762>

Herbal Medicines for Diabetes Management

Allopathic diabetology has normalised lifelong polypharmacy while largely sidelining **plant medicines that have been used for centuries to target glucose, lipids, inflammation, and vascular damage**. When phytotherapy appears in conventional guidelines, it is often relegated to a token paragraph, despite an expanding body of in-vitro, animal, and human data. This chapter re-centres **evidence-supported herbal medicines** as active tools for type 2 diabetes management—**always in addition to, not in reckless replacement of, essential drugs such as insulin, where indicated—with a clear agenda: to reduce drug burden, side effects, and progression wherever possible.**

Below is an overview of key botanicals used, with a focus on mechanisms relevant to diabetes and cardiometabolic health.

1. *Terminalia arjuna* (Arjuna)

T. arjuna is highly relevant in diabetes, where cardiovascular disease is the major killer.

Key actions relevant to diabetes:

- **Cardioprotective and antihypertensive effects:** Clinical and experimental work suggests improvements in left ventricular function, angina, and blood pressure (Dwivedi, 2007).
- **Antioxidant and anti-inflammatory activity:** Rich in tannins, flavonoids, and triterpenoids that help counter oxidative stress and endothelial dysfunction seen in diabetes.

- Some preclinical data indicate **lipid-lowering and anti-atherosclerotic effects**, which can indirectly support glycaemic management by improving overall cardiometabolic risk.

In a naturopathic formulation, *T. arjuna* is a **cardiometabolic scaffold herb**—targeting the vasculature and myocardium that allopathic care often protects only with statins and ACE inhibitors.

2. *Terminalia chebula* (Haritaki)

- **Antioxidant and anti-glycation** properties: In vitro and animal data show inhibition of advanced glycation end product (AGE) formation and strong free-radical scavenging, relevant to micro- and macrovascular complications (Saha et al., 2016; Wang et al., 2024).
- **Mild hypoglycaemic effects** have been reported in animal models, likely via improved insulin sensitivity and glucose utilisation.

3. *Boerhavia diffusa* (Punarnava)

Used as a **diuretic, hepatoprotective, and anti-inflammatory** herb.

Diabetes-relevant actions:

- **Nephroprotective effects:** Important in diabetic nephropathy—studies show protective effects against drug-induced and metabolic renal damage (Viswanath et al., 2004).
- **Hepatoprotective:** Supports liver detoxification and glucose–lipid handling, crucial in insulin resistance and NAFLD.
- Some preclinical work suggests **modest hypoglycaemic and lipid-modulatory effects**.

In polyherbal diabetes formulas, *B. diffusa* helps protect the **kidneys and liver, the organs that bear the brunt of** both hyperglycaemia and allopathic polypharmacy.

4. *Seseli indicum*

Data on *Seseli indicum* per se are limited; several *Seseli* species contain **coumarins and essential oils** with reported antioxidant, anti-inflammatory, and antispasmodic effects. In a diabetes context, such herbs are typically used:

- As **circulatory and digestive adjuvants**,
- To support vascular tone and microcirculation,
- To enhance absorption and synergy of other active herbs.

Formulators often include such botanicals in **small proportions** to modulate the “vehicle” of the formula rather than as primary hypoglycaemics.

5. *Trigonella foenum-graecum* (Fenugreek)

One of the **best studied** antidiabetic herbs.

Mechanisms:

- **Soluble fibre (galactomannans)** slows gastric emptying and carbohydrate absorption → lower postprandial glucose.
- **4-hydroxyisoleucine** and other alkaloids stimulate pancreatic insulin secretion and improve insulin sensitivity.
- Clinical trials show **significant reductions in fasting and postprandial glucose, HbA1c, and triglycerides** when fenugreek is used as seeds or standardised extracts (Neelakantan et al., 2014).

6. *Bauhinia variegata* (Kanchanar)

Traditionally used for **thyroid, lymphatic, and glandular disorders**, *B. variegata* has shown:

- **Antihyperglycaemic, antihyperlipidemic, antioxidant activity** in animal models fed diabetogenic diets or given alloxan/streptozotocin, likely via improved insulin secretion and antioxidant defence (Tripathi et al., 2019).
- Potential to support **weight and lipid balance**, indirectly relevant to insulin resistance.

7. *Asphaltum* (Shilajit)

It is a mineral-rich exudate

- **Mitochondrial and antioxidant support:** fulvic acids and trace minerals support mitochondrial function and reduce oxidative stress. (Kiran et al., 2019)
- A combination of Asphaltum with *Berberis arastata* was shown to improve the management of type 2 diabetes mellitus with no reported side effects. (Singh et al., 2025).
- Often used to **enhance bioavailability** and systemic effect of co-administered herbs.

8. *Syzygium cumini* (Jamun)

A classic Indian antidiabetic plant.

Mechanisms:

- Seed extracts contain **jamboline, ellagic acid, and other polyphenols** with insulinomimetic and insulin-sensitising effects.
- Human and animal studies show **reduced fasting glucose, improved OGTT, and some HbA1c benefit** with seed powder or extracts (Sharma et al., 2016).
- Also exhibits **antioxidant and anti-glycation** properties relevant to microvascular complication risk.

9. *Cinnamomum verum* (True Cinnamon)

Cinnamon is one of the few spice-herbs to have multiple human trials in diabetes.

Mechanisms and evidence:

- Improves **insulin receptor signalling and GLUT4 translocation**, possibly via polyphenolic polymers that act as insulin sensitisers.
- Meta-analyses of RCTs show **modest but significant reductions in fasting plasma glucose, and sometimes HbA1c and lipids**, particularly in poorly controlled type 2 diabetes (Allen et al., 2013).

10. *Berberis aristata* (Daruharidra)

Source of **berberine**, an isoquinoline alkaloid with striking metabolic effects.

Mechanisms:

- **AMP-activated protein kinase (AMPK) activation**, similar to metformin, increasing insulin sensitivity and reducing hepatic gluconeogenesis.
- Clinical trials of berberine in type 2 diabetes show **reductions in fasting glucose, postprandial glucose, and HbA1c comparable to metformin**, along with improvements in triglycerides and LDL (Yin et al., 2008).
- Also demonstrates **antimicrobial and gut-microbiota-modulating** actions.

In a naturopathic framework, *B. aristata*/berberine is a **bridge herb** that targets the same nodes as allopathic drugs but with broader, pleiotropic effects.

11. *Chlorophytum borivillianum* (Safed Musli)

Traditionally used as an **adaptogen, aphrodisiac, and tonic**.

Diabetes-related actions:

- Animal studies suggest **antihyperglycaemic and antihyperlipidaemic effects** in diabetic models, likely via improved insulin secretion and antioxidant activity (Giribabu et al., 2014).
- Supportive role in **fatigue, sexual dysfunction, and stress**—common in chronic diabetes.

12. *Pterocarpus marsupium* (Vijaysar)

One of the most respected traditional **blood sugar herbs**.

Mechanisms and evidence:

- Contains **pterostilbene, liquiritigenin, and other flavonoids** with β -cell regenerative, insulin-secretagogue, and antioxidant effects in animal models.
- Animal Studies showed the **modulation of cytokine TNF- α** by *P. marsupium*, relating to the potential antidiabetic activity. (Halagappa et al., 2010)

13. *Gymnema sylvestre* (Gudmar)

Nicknamed “sugar-destroyer,” one of the **most important antidiabetic botanicals**.

Mechanisms:

- **Gymnemic acids** temporarily block sweet taste receptors and may reduce sugar cravings.
- Enhance **insulin secretion** and possibly promote **β -cell regeneration** in animal models.
- Decrease intestinal glucose absorption and improve peripheral glucose utilisation.

Human studies:

- Supplementation in type 2 diabetes has shown **reduced fasting glucose and HbA1c**, and in some cases allowed

reduction or withdrawal of oral hypoglycaemic drugs under supervision (Baskaran et al., 1990).

14. *Tribulus terrestris* (Gokshura)

Known more for **urogenital and androgen-modulating effects**, but also relevant in metabolic syndrome.

Relevance:

- In an animal study, a combined herbal formulation extract of *T. terrestris* and *Curcuma amada* was found to be effective against diabetes by lowering blood glucose, urea, and creatinine and increasing the restoration of insulin and glycogen levels in diabetic animals. (Kaliaperumal et al., 2024).
- Supports **blood pressure control, libido, and kidney function**, all compromised in long-standing diabetes.

Integrative, Naturopathic Use

The herbs listed here:

- Target **multiple metabolic pathways** simultaneously: insulin secretion, insulin sensitivity, intestinal absorption, lipid metabolism, oxidative stress, inflammation, cardiovascular and renal protection.
- Can be combined in **polyherbal formulations** designed to:
 - Lower glucose and HbA1c,
 - Improve lipids and blood pressure,
 - Protect the heart, kidneys, eyes, and nerves,
 - Reduce cravings and support weight loss,
 - And **reduce dependence on high-dose pharmaceuticals** when implemented alongside intensive diet and lifestyle change.

In the sections that follow, we will map specific polyherbal combinations and dosing strategies—showing how to integrate these

botanicals safely with standard drugs, and how to use them within a full naturopathic plan (nutrition, movement, stress work, sleep, detoxification) to move patients from perpetual “management” toward true metabolic recovery.

References:

1. Allen, R. W., Schwartzman, E., Baker, W. L., Coleman, C. I., & Phung, O. J. (2013). Cinnamon use in type 2 diabetes: An updated systematic review and meta-analysis. *Annals of Family Medicine*, 11(5), 452–459.
<https://doi.org/10.1370/afm.1517>
2. Baskaran, K., Kizar Ahamath, B., Radha Shanmugasundaram, K., & Shanmugasundaram, E. R. B. (1990). Antidiabetic effect of a leaf extract from *Gymnema sylvestre* in non-insulin-dependent diabetes mellitus patients. *Journal of Ethnopharmacology*, 30(3), 295–300.
[https://doi.org/10.1016/0378-8741\(90\)90108-6](https://doi.org/10.1016/0378-8741(90)90108-6)
3. Dwivedi, S. (2007). Terminalia arjuna Wight & Arn.—A useful drug for cardiovascular disorders. *Journal of Ethnopharmacology*, 114(2), 114–129.
<https://doi.org/10.1016/j.jep.2007.08.003>
4. Giribabu, N., Kumar, K. E., Rekha, S. S., Muniandy, S., & Salleh, N. (2014). Chlorophytum borivilianum root extract maintains near normal blood glucose, insulin and lipid profile levels and prevents oxidative stress in the pancreas of streptozotocin-induced adult male diabetic rats. *International journal of medical sciences*, 11(11), 1172–1184.
<https://doi.org/10.7150/ijms.9056>
5. Halagappa, K., Girish, H. N., & Srinivasan, B. P. (2010). The study of aqueous extract of Pterocarpus marsupium Roxb. on cytokine TNF- α in type 2 diabetic rats. *Indian journal of pharmacology*, 42(6), 392–396. <https://doi.org/10.4103/0253-7613.71922>

6. Kaliaperumal, K., Bhat, B. A., Subramanian, K., Ramakrishnan, T., Chakravarthy, E., Al-Keridis, L. A., ... & Karunakaran, R. (2024). In-vivo anti-hyperglycemic effect of herbal extracts *Tribulus terrestris* (L) and *Curcuma amada* (R) on streptozotocin-induced diabetic rats and its associated histopathological studies. *Heliyon*, 10(1).
<https://doi.org/10.1016/j.heliyon.2024.e24009>
7. Kiran, R., Hussain, S., Ahmad, A., Javed, M., Riaz, M., Hanif, M. A., ... & BASHIR, M. S. (2019). Review; chemical characteristics and therapeutic potential of *Asphaltum punjabianum* (shilajit). *Postepy Biol Komorki*, 4, 437-46.
8. Neelakantan, N., Narayanan, M., de Souza, R. J., & van Dam, R. M. (2014). Effect of fenugreek (*Trigonella foenum-graecum* L.) intake on glycemia: A meta-analysis of clinical trials. *Nutrition Journal*, 13, 7.
<https://doi.org/10.1186/1475-2891-13-7>
9. Pandey, M., & Khan, A. (2002). Hypoglycaemic effect of defatted seeds and water soluble fibre from the seeds of *Syzygium cumini* (Linn.) skeels in alloxan diabetic rats. *Indian journal of experimental biology*, 40(10), 1178–1182.
10. Patel, N., Mishra, R., Rajput, D., & Gupta, A. (2025). A comprehensive review of the phytochemistry, pharmacology, pharmacokinetics, and green nanotechnological significance of *Boerhavia diffusa* Linn. *Fitoterapia*, 184, 106599.
<https://doi.org/10.1016/j.fitote.2025.106599>
11. Saha, S., & Verma, R. J. (2016). Antioxidant activity of polyphenolic extract of *Terminalia chebula* Retzius fruits. *Journal of taibah university for science*, 10(6), 805-812.
<https://doi.org/10.1016/j.jtusci.2014.09.003>
12. Singh, R., Yadav, P., Patel, A., & Prajapati, P. K. (2025). The synergy between Shilajatu (*Asphaltum punjabinum*) and Daruharidra (*Berberis aristata* DC.), curtails the glycaemic indicators and alleviates the symptoms of type 2 diabetes: a

- case report. *Journal of Medical Case Reports*, 19(1), 598.
<https://doi.org/10.1186/s13256-025-05572-w>
13. Srivastava, S., & Chandra, D. (2013). Pharmacological potentials of *Syzygium cumini*: a review. *Journal of the science of food and agriculture*, 93(9), 2084–2093.
<https://doi.org/10.1002/jsfa.6111>
 14. Tripathi, A. K., Gupta, P. S., & Singh, S. K. (2019). Antidiabetic, anti-hyperlipidemic and antioxidant activities of *Bauhinia variegata* flower extract. *Biocatalysis and agricultural biotechnology*, 19, 101142.
<https://doi.org/10.1016/j.bcab.2019.101142>
 15. Wang, C., Zhang, H., Wang, X., Wang, X., Li, X., Li, C., ... & Zhang, M. (2024). Comprehensive review on fruit of *Terminalia chebula*: traditional uses, phytochemistry, pharmacology, toxicity, and pharmacokinetics. *Molecules*, 29(23), 5547. <https://doi.org/10.3390/molecules29235547>
 16. Yin, J., Xing, H., & Ye, J. (2008). Efficacy of berberine in patients with type 2 diabetes mellitus. *Metabolism*, 57(5), 712–717. <https://doi.org/10.1016/j.metabol.2008.01.013>

Nutraceuticals for Diabetes Management: Filling the Gaps Conventional Care Ignores

Drug-centric diabetes care rarely asks: **what raw materials does the body need to repair insulin signalling, quell inflammation, and reverse micronutrient bankruptcy?** Naturopathic practice does. Nutraceuticals are not a substitute for food or essential drugs (e.g., insulin where required), but they are powerful levers to:

- Improve **insulin sensitivity and glycaemic control**
- Reduce **oxidative stress and low-grade inflammation**
- Support **vascular, nerve, and immune function**
- Compensate for losses driven by **poor diet, medications, and urban living**

The supplements below are typically **spread evenly through the day** and used alongside an aggressive, whole-food, low-ultra-processed diet and herbal protocols.

Doses mentioned here reflect an intensive, naturopathic-medicine-style approach and should be individualised, especially for patients with renal, hepatic, or complex multimorbid conditions.

1. Green Superfood Powder

Use: Add a scoop to smoothies daily.

High-quality green powders (organic blends of dried greens, algae, grasses, herbs) are **condensed plant nutrition**:

- Provide **minerals (magnesium, potassium, trace elements)**, chlorophyll, carotenoids, flavonoids, and sometimes added probiotics or fibres.
- Help compensate for **low vegetable intake**, especially in urban and hospital environments.

While evidence is heterogeneous (formulas vary), trials on concentrated fruit–vegetable–herb powders show:

- Improved **efficacy in reducing cardiometabolic risks** (Kiyimba et al., 2023).
- Potential reductions in **blood pressure and oxidative DNA damage** in high-risk populations.

They **do not replace whole greens**, but are far superior to the near-zero phytonutrient intake tolerated in most allopathic clinics.

2. Vitamin C (Ascorbic Acid) – 1–5 g/day

Vitamin C is **chronically depleted** in diabetes due to oxidative stress and increased renal loss.

- Short-term studies showed that vitamin C supplementation may improve glycemic control and BP in people with type 2 diabetes. (Mason et al., 2021).
- Research also revealed a significant decrease in levels of serum HbA1c, fasting insulin, and fasting blood glucose (FBG) in vitamin C-treated T2DM patients compared with their untreated counterparts. (Nosratabadi et al., 2023)
- High-dose oral vitamin C (up to several grams/day) is generally safe in normal renal function, but caution is required in **renal impairment or oxalate stone history**.

3. Vitamin E – ~800 IU/day (with Caution)

Vitamin E (mixed tocopherols/tocotrienols) protects **lipid membranes** from peroxidation:

- In diabetes, oxidative stress accelerates **atherosclerosis and neuropathy**. Vitamin E can modulate inflammation and oxidative stress in diabetes (Es-Sai et al., 2025).

However:

- High-dose α -tocopherol (≥ 400 IU/d) in general populations has shown **mixed or neutral outcomes**, with concerns about haemorrhagic stroke risk in some meta-analyses. (Khanna et al., 2015)
- Any 800 IU regimen should be **monitored**, especially in those on anticoagulants.

Naturopathic use focuses on **short- to medium-term antioxidant support** with **mixed forms** and always in synergy with vitamin C and other antioxidants.

4. Vitamin D3 – ~6000 IU/day

Vitamin D deficiency is extremely common in diabetes and metabolic syndrome.

- Low vitamin D is associated with **higher risk of type 2 diabetes, insulin resistance, and CVD** (Pittas et al., 2010).
- Supplementation improves **insulin sensitivity and β -cell function** in some RCTs, particularly in deficient individuals (Mitri et al., 2011).

Doses of 4000–6000 IU/day are often required to reach **serum 25(OH)D ~40–60 ng/mL**, but:

- Must be tailored, with **periodic monitoring of 25(OH)D, ionized calcium, and renal function**.
- Rather than a blind “one-dose-fits-all” approach typical of supplement marketing.

5. Vitamin B12 – 1000 mcg/day

Metformin, PPIs, and poor diet make **B12 deficiency extremely common** in diabetes.

- Deficiency contributes to **neuropathy, anaemia, cognitive decline**, and elevated homocysteine. (Out et al., 2013).
- Supplementation (oral 1000–2000 mcg/day or parenteral, depending on status) can **improve neuropathic symptoms and correct biochemical deficits**. (Pratama et al., 2022).

For any metformin-treated patient, high-dose B12 is almost non-negotiable.

6. Chromium (Ionic) – ~250 mcg/day

Chromium is a trace element involved in **insulin signalling and glucose tolerance**.

- Supplementation with chromium picolinate or other forms (~200–1000 mcg/day) has shown **modest improvements in fasting glucose and HbA1c** in some type 2 diabetes RCTs and meta-analyses (Balk et al., 2007).
- Greatest benefit seems in people with **poor control and low baseline chromium**.

Ionic forms may offer better bioavailability; however, doses should remain well below the tolerable upper limit (typically ≤ 1000 mcg/day).

7. Vanadium (Ionic) – ~250 mcg/day

Vanadium compounds exhibit **insulin-mimetic** activity.

- Small studies with vanadyl sulfate (typically 50–150 mg elemental vanadium/day) report **improved fasting glucose and insulin sensitivity** in type 2 diabetes, but with frequent GI side-effects and narrow therapeutic windows (Smith et al., 2008).

At **microgram-level doses** (e.g., 250 mcg ionic), vanadium may offer **gentle insulin-sensitising support** with lower risk, but human data at this range are limited; it should be treated as an **adjunct under professional supervision**, not a primary therapy.

8. Digestive Enzymes

Hypochlorhydria (low stomach acid), pancreatic insufficiency, and dysbiosis are common in chronic diabetics.

- Broad-spectrum **digestive enzyme blends** (amylase, protease, lipase, sometimes lactase and cellulase) can:
 - Improve digestion and nutrient absorption,
 - Reduce post-meal bloating and malabsorption,
 - Indirectly support better glycaemic control by improving utilisation of whole foods.

Specific dosing depends on the product; they are typically taken **with meals**.

Evidence for enzymes in diabetes is indirect (better nutrient status, less GI distress), but clinically significant in naturopathic practice.

9. Zinc – ~50 mg/day

Zinc is:

- Cofactor for **over 300 enzymes**, including many in insulin synthesis, secretion, and signalling.
- Often low in people with diabetes due to increased urinary loss and poor diet.

Supplementation (15–50 mg/day) has been shown to:

- Improve **glycaemic control** and lipid profiles,
- Reduce **oxidative stress and inflammatory markers** (Jayawardena et al., 2012).

At 50 mg/day, monitor **copper status** long-term, as high zinc can deplete copper.

10. B-Complex

Beyond B12, a **broad B-complex** (B1, B2, B3, B5, B6, folate, etc.) supports:

- **Mitochondrial energy production**
- Homocysteine metabolism
- Nerve function and mood

Thiamine (B1) at higher doses has shown benefit in **dyslipidemia and vascular complications** (Thornalley, 2005). A balanced complex covers multiple small insufficiencies that are seldom addressed in allopathic practice.

11. Bioflavonoids including Quercetin – ~150 mg/day

Quercetin:

- Has shown similar effects as that of Metformin. Supplementation stimulates **insulin sensitivity and glucose uptake** in preclinical models (Dhanya., 2022).
- Human data are still emerging, but small trials show improved **blood pressure and vascular function** in metabolic syndrome.

Quercetin is particularly relevant for **capillary protection (retinal, renal, and nerve capillaries)** and as a synergist with vitamin C.

12. Borage Oil – 1000 mg 3×/day

Borage oil is rich in **gamma-linolenic acid (GLA)**, an anti-inflammatory omega-6 derivative.

- GLA can be converted to **dihomo-γ-linolenic acid (DGLA)**, which yields anti-inflammatory eicosanoids.
- Trials in diabetic neuropathy with GLA-rich oils (often evening primrose) show **improvements in nerve conduction and neuropathic symptoms** (Keen et al., 1993).

Borage must be **certified free of pyrrolizidine alkaloids** (a hepatotoxic contaminant in poor-quality products).

13. Iodine – 2 Drops/Day (Lugol's/Iodoral)

Iodine and iodide support:

- **Thyroid hormone synthesis**, which governs metabolic rate and insulin sensitivity.
- Iodine also has roles in **breast and immune health**.

In diabetes, subclinical hypothyroidism is common and worsens lipid and glucose metabolism. Supplementation:

- Must be used carefully in populations with **autoimmune thyroid disease** or high baseline iodine intake.
- Is best paired with **vitamin C, selenium, magnesium**, and clinical monitoring (TSH, free T4/T3, thyroid antibodies).

14. MSM (Methylsulfonylmethane) – 5–10 g/day

MSM is an organosulfur compound:

- Supports **sulphur pools** needed for connective tissue, glutathione synthesis, and detoxification.
- Human trials mainly document benefits for **osteoarthritis pain and function**, with good safety up to ~6 g/day (Kim et al., 2006).

In a diabetes context:

- MSM is used naturopathically to support **cell-membrane flexibility, joint health, and detoxification capacity**, especially in those on multiple medications.
- Direct antidiabetic data are limited; its role is more **supportive** than primary.

Integrative Perspective

A drug-only diabetes model pretends that:

- **Micronutrient depletion, chronic oxidative stress, mitochondrial dysfunction, and inflammatory lipids** can be left to chance;

- As long as HbA1c hits target, the job is done.

Naturopathic medicine rejects this. It uses nutraceuticals to:

- Rebuild **intracellular environment and signalling**,
- Support organs under pharmaceutical and glycaemic assault,
- And create conditions in which **medication doses can be safely reduced** as diet, movement, sleep, and herbal therapy are optimised.

In the next sections, we will show how to phase nutraceuticals into a structured naturopathic diabetes protocol—prioritising those with the strongest evidence and greatest individual need, and coordinating them with herbal medicines, dietary patterns, and the judicious use of allopathic drugs, rather than blind polypharmacy.

References:

1. Dhanya, R. (2022). Quercetin for managing type 2 diabetes and its complications, an insight into multitarget therapy. *Biomedicine & Pharmacotherapy*, 146, 112560. <https://doi.org/10.1016/j.biopha.2021.112560>
2. Es-Sai, B., Wahnou, H., Benayad, S., Rabbaa, S., Laaziouez, Y., El Kebbaj, R., ... & Duval, R. E. (2025). Gamma-tocopherol: a comprehensive review of its antioxidant, anti-inflammatory, and anticancer properties. *Molecules*, 30(3), 653. <https://doi.org/10.3390/molecules30030653>
3. Jayawardena, R., Ranasinghe, P., Galappatthy, P., Malkanthi, R. L. S., Constantine, G. R., & Katulanda, P. (2012). Effects of zinc supplementation on diabetes mellitus: A systematic review and meta-analysis. *Diabetology & Metabolic Syndrome*, 4, 13. <https://doi.org/10.1186/1758-5996-4-13>
4. Keen, H., Payan, J., Allawi, J., Walker, J., Jamal, G. A., Weir, A. I., Brange, J., & Gale, E. A. (1993). Treatment of diabetic neuropathy with γ -linolenic acid. The gamma-Linolenic Acid Multicenter Trial Group. *Diabetes Care*, 16(1), 8–15. <https://doi.org/10.2337/diacare.16.1.8>

5. Khanna, S., Heigel, M., Weist, J., Gnyawali, S., Teplitsky, S., Roy, S., Sen, C. K., & Rink, C. (2015). Excessive α -tocopherol exacerbates microglial activation and brain injury caused by acute ischemic stroke. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*, 29(3), 828–836.
<https://doi.org/10.1096/fj.14-263723>
6. Kim, L. S., Axelrod, L. J., Howard, P., Buratovich, N., & Waters, R. F. (2006). Efficacy of methylsulfonylmethane (MSM) in osteoarthritis pain of the knee: A pilot clinical trial. *Osteoarthritis and Cartilage*, 14(3), 286–294.
<https://doi.org/10.1016/j.joca.2005.10.003>
7. Kiyimba, T., Yiga, P., Bamuwamye, M., Ogwok, P., Van der Schueren, B., & Matthys, C. (2023). Efficacy of dietary polyphenols from whole foods and purified food polyphenol extracts in optimizing cardiometabolic health: A meta-analysis of randomized controlled trials. *Advances in Nutrition*, 14(2), 270-282.
<https://doi.org/10.1016/j.advnut.2023.01.002>
8. Mason, S. A., Keske, M. A., & Wadley, G. D. (2021). Effects of vitamin C supplementation on glycemic control and cardiovascular risk factors in people with type 2 diabetes: a GRADE-assessed systematic review and meta-analysis of randomized controlled trials. *Diabetes care*, 44(2), 618-630.
<https://doi.org/10.2337/dc20-1893>
9. Mitri, J., Muraru, M. D., & Pittas, A. G. (2011). Vitamin D and type 2 diabetes: A systematic review. *European Journal of Clinical Nutrition*, 65(9), 1005–1015.
<https://doi.org/10.1038/ejcn.2011.118>
10. Nosratabadi, S., Ashtary-Larky, D., Hosseini, F., Namkhah, Z., Mohammadi, S., Salamat, S., ... & Asbaghi, O. (2023). The effects of vitamin C supplementation on glycemic control in patients with type 2 diabetes: A systematic review and meta-analysis. *Diabetes & Metabolic Syndrome: Clinical*

- Research & Reviews*, 17(8), 102824.
<https://doi.org/10.1016/j.dsx.2023.102824>
11. Out, M., Kooy, A., Leher, P., Schalkwijk, C. A., Stehouwer, C. D. A., & Smulders, Y. M. (2013). Long-term treatment with metformin in type 2 diabetes and vitamin B12 deficiency: A randomized placebo-controlled trial. *BMJ Open Diabetes Research & Care*, 1(1), e000007.
<https://doi.org/10.1136/bmjdrc-2013-000007>
 12. Paiva, A. N., de Lima, J. G., de Medeiros, A. C., Figueiredo, H. A., de Andrade, R. L., Ururahy, M. A., ... & Almeida, M. D. G. (2015). Beneficial effects of oral chromium picolinate supplementation on glycemic control in patients with type 2 diabetes: a randomized clinical study. *Journal of Trace Elements in Medicine and Biology*, 32, 66-72.
<https://doi.org/10.1016/j.jtemb.2015.05.006>
 13. Pittas, A. G., Lau, J., Hu, F. B., & Dawson-Hughes, B. (2007). The role of vitamin D and calcium in type 2 diabetes: A systematic review and meta-analysis. *Journal of Clinical Endocrinology & Metabolism*, 92(6), 2017–2029.
<https://doi.org/10.1210/jc.2007-0298>
 14. Pratama, S., Lauren, B. C., & Wisnu, W. (2022). The efficacy of vitamin B12 supplementation for treating vitamin B12 deficiency and peripheral neuropathy in metformin-treated type 2 diabetes mellitus patients: A systematic review. *Diabetes & Metabolic Syndrome: Clinical Research & Reviews*, 16(10), 102634.
<https://doi.org/10.1016/j.dsx.2022.102634>
 15. Smith, D. M., Pickering, R. M., & Lewith, G. T. (2008). A systematic review of vanadium oral supplements for glycaemic control in type 2 diabetes mellitus. *QJM: An International Journal of Medicine*, 101(5), 351-358.
<https://www.ncbi.nlm.nih.gov/books/NBK76434/>
 16. Thornalley, P. J. (2005). The potential role of thiamine (vitamin B1) in diabetic complications. *Current Diabetes*

Reviews, 1(3), 287–298.

<https://doi.org/10.2174/157339905774574249>

17. Zimmermann, M. B., & Boelaert, K. (2015). Iodine deficiency and thyroid disorders. *The Lancet Diabetes & Endocrinology*, 3(4), 286–295.

[https://doi.org/10.1016/S2213-8587\(14\)70225-6](https://doi.org/10.1016/S2213-8587(14)70225-6)

Scientific and Curative Treatment of Diabetes: From Lifelong “Management” to Genuine Remission

Conventional diabetology has largely normalised a bleak script: diagnose late, stack drugs, escalate doses, add insulin, treat complications surgically—and call this “scientific management.” For type 2 diabetes in particular, this is inaccurate and defeatist. High-quality evidence now shows that **diabetes can often be put into remission** and that the underlying metabolic dysfunction is, to a significant degree, **reversible** rather than inexorable (Lean et al., 2018; Hallberg et al., 2018).

A naturopathic and integrative approach calls this what it is: **curative intent**—aiming to restore normal glucose regulation and drastically reduce or even eliminate medication where safely possible.

Type 1 vs Type 2 Diabetes: What “Curative” Can Realistically Mean

Type 1 diabetes (≈5% of cases): Autoimmune β -cell destruction.

- Current standard of care requires **lifelong insulin**.
- Early intensive immunomodulatory strategies and β -cell preservation are active research areas (e.g., teplizumab), but **no widely accepted cure exists yet** (Lucier, 2024).
- Lifestyle and naturopathic measures can **reduce insulin requirements, stabilise glucose, and protect organs**, but withdrawal of insulin is unsafe for most people with established T1D.

Type 2 diabetes ($\approx 90\text{--}95\%$ of cases): Insulin resistance plus relative β -cell dysfunction.

- Here, a large and growing body of evidence supports **remission**—sustained normal or near-normal glycaemia without glucose-lowering medications—through **intensive lifestyle and weight-loss interventions** (Lean et al., 2018; Hallberg et al., 2018; Gregg et al., 2012).
- Naturopathic medicine goes further by systematically addressing **diet quality, toxic fats, stress, sleep, environmental load, and gut health**, not just calories or weight.

In this chapter, “curative treatment” refers primarily to **type 2 diabetes remission and deep de-escalation of pharmacotherapy**, plus **maximal prevention of complications and organ protection in both type 1 and type 2 diabetes**.

Core Goal: Repair the Body’s Own Blood-Sugar Control System

A truly scientific, curative programme does not aim merely to “cover” high glucose with more medication; it aims to **restore the native regulatory system**:

- Improve **insulin sensitivity** (muscle, liver, adipose tissue).
- Reduce **glucotoxicity and lipotoxicity**.
- Allow **β -cells to rest and, where possible, partially recover**.
- Protect and rehabilitate **vasculature, kidneys, liver, nerves, and retina**.

That requires aggressive change in:

- **Food environment** (especially carbohydrates and fats).
- **Movement patterns**.
- **Sleep and circadian rhythm**.

- **Psychosocial stress.**
- **Toxin and inflammatory load.**

Medications are used **strategically and temporarily**, not as a substitute for this work.

Dietary and Fat-Quality Overhaul: Rewiring the Controller

Correcting Macronutrient Load and Glycaemic Burden

Multiple rigorous interventions show that **intensive dietary change** can drive type 2 diabetes into remission:

- **Calorie-restricted, low-energy diets** (~800 kcal/day for several months) in primary care achieved **46% remission at 12 months** and 36% at 24 months in DiRECT (Lean et al., 2018).
- **Low-carbohydrate (<130 g/day) and ketogenic diets** delivered high rates of medication de-prescribing and HbA1c reductions, with ~60% of participants achieving diabetes remission or reversal in some trials (Hallberg et al., 2018; Goldenberg et al., 2021).

The common denominator:

- Rapid reduction in **liver and pancreatic fat**,
- Improved insulin sensitivity,
- Reduced demand on β -cells.

A naturopathic programme typically emphasises:

- Strong **reduction of refined carbohydrates and sugars**,
- Emphasis on **low-glycaemic vegetables, pulses, nuts, seeds, quality proteins**,
- Structured eating patterns (time-restricted feeding, consistent meal timing).

Replacing Toxic Fats with Therapeutic Fats

The standard diet in many urban Indian populations is dominated by:

- **Refined seed oils (soy, corn, sunflower, safflower, generic “vegetable oil”),**
- **Frequent deep-frying and oil reuse,**
- **High omega-6, oxidised fat intake, which drives inflammation and endothelial dysfunction** (Anjana et al., 2025; Kalra et al., 2023).

Naturopathic practice aggressively **removes**:

- Hydrogenated fats, shortenings, margarines,
- Deep-fried and ultra-processed foods,
- Reused and overheated oils.

And **replaces** them with:

- **Extra-virgin olive oil,**
- **Unrefined coconut oil, ghee/butter** (in moderation, within an anti-inflammatory context),
- **Omega-3-rich fats** (flax, hemp, chia, fatty fish),
- **Natural whole-food sources** (nuts, seeds, avocado).

This shift:

- **Lowers systemic inflammation,**
- **Improves lipid patterns,**
- **May enhance insulin sensitivity** and endothelial function when integrated with carbohydrate control.

Manual Blood-Sugar Control During Recovery (With Medical Supervision)

As diet and lifestyle interventions intensify, **medication needs fall quickly**. Without guidance, this can lead to hypoglycaemia. A scientific, integrative protocol focuses on:

- **Frequent home glucose monitoring** (pin-prick glucometer or CGM).
- **Immediate medication review** as carbohydrates are reduced and weight falls.
- Gradual **de-prescribing of sulfonylureas, meglitinides, and insulin** as appropriate, under physician supervision (Hallberg et al., 2018).
- Use of **non-hypoglycaemic agents (e.g., metformin, SGLT2 inhibitors, GLP-1 RAs)** selectively while lifestyle takes effect, then reassessing.

Behavioural strategies:

- Smaller, less frequent eating windows instead of constant grazing; however, time-restricted feeding or fasting under supervision is more suggested as a tool for Diabetes Reversal.
- Fibre-rich, protein-containing meals to blunt glucose spikes.
- Short **post-meal walks**, which significantly improve post-prandial glycaemia (Colberg et al., 2016).
- Elimination of **alcohol and sugary drinks** during the active reversal phase.

This is **real-time manual control** designed to give the pancreas and liver a chance to reset.

Restoring and Monitoring Insulin Dynamics

As glycaemia normalises:

- **Fasting insulin and C-peptide** often fall gradually, reflecting reduced resistance and β -cell stress.
- In some people with early or mild type 2 diabetes, insulin levels return to near-normal ranges as **hepatic and pancreatic fat is cleared** (Taylor, 2013).

Monitoring:

- HbA1c, fasting glucose, and where possible **fasting insulin, HOMA-IR, and liver fat** (via imaging or surrogate markers) can objectively track reversal.
- Remission is typically defined as **HbA1c <6.5% (48 mmol/mol) for ≥ 3 months without glucose-lowering medications** (Riddle et al., 2021).

Naturopathic emphasis:

- Does not stop at “normal HbA1c on three drugs”; it demands **normal glycaemia with minimal or no medication**, if biologically achievable.

Repairing Complications: What Can and Cannot Self-Heal

Vascular and Nerve Damage

Intensive lifestyle change and improved glycaemic control can:

- Stabilise or improve **neuropathy, nephropathy, and retinopathy** in many patients, especially when caught early (Diabetes Control and Complications Trial Research Group, 1993; UKPDS Group, 1998).
- Reduce progression of **macrovascular disease**, particularly when combined with blood-pressure and lipid improvements.

However:

- Long-standing structural damage (e.g., advanced glomerulosclerosis in kidneys, large-vessel atherosclerosis) may only **partially reverse** or stabilise.
- Early intervention remains critical.

Diabetic Retinopathy and Laser Treatment

A responsible, integrative position:

- **Do everything possible to reverse hyperglycaemia and correct systemic drivers** early, to prevent or regress retinopathy.
- **Do not withhold sight-saving laser or intravitreal therapies** when indicated by an ophthalmologist, especially in advanced or proliferative disease.
- Use naturopathic strategies as **adjuncts**, not as a reason to delay evidence-based sight-preserving treatments.

Time Course of Recovery

Evidence from DiRECT and other intensive interventions:

- People with **shorter diabetes duration (<6 years)** and greater weight loss had higher remission rates and faster recovery (Lean et al., 2018).
- Many achieved normal glycaemia within **3–6 months** of aggressive diet and weight loss.
- Those with **long-standing diabetes** can still improve dramatically, but full remission is less frequent and may take longer.

Naturopathic clinical reality:

- **3–6 months:** substantial improvements in HbA1c, fasting glucose, blood pressure, lipids, energy, and medication burden.
- **6–12+ months:** continued body-composition change, stabilisation of insulin dynamics, and deeper complication healing.
- The earlier the intervention, the **higher the probability of full remission**.

Truly Scientific, Curative Diabetes Care: An Integrative Blueprint

A genuinely scientific programme for type 2 diabetes with curative intent includes:

1. **Radical food restructuring**

- Removal of refined carbohydrates, sugars, ultra-processed foods, and toxic fats.
- Replacement with **whole, low-glycaemic, plant-rich patterns and therapeutic fats.**

2. **Structured movement** throughout the day (especially post-prandial).

3. **Sleep and circadian repair**, systematically addressed.

4. **Stress and trauma work**, to reduce cortisol-driven insulin resistance.

5. **Targeted nutraceuticals and herbal medicines** to support insulin sensitivity, β -cells, liver, kidney, nerves, and vascular beds.

6. **Judicious, temporary pharmacotherapy**, adjusted dynamically as lifestyle treatment takes effect.

7. **Continuous monitoring** (glucose/CGM, labs, complications) to confirm remission and guide de-prescribing.

This is what naturopathy has been advocating for decades, long before weight-loss-induced remission trials gave it the language of “evidence-based.”

In the pages that follow, we will outline practical protocols and step-by-step implementation plans for this integrative, curative approach—showing how it can safely coexist with and often surpass purely allopathic regimens to achieve long-term freedom from diabetic medication and complications.

References:

1. Colberg, S. R., Sigal, R. J., Yardley, J. E., Riddell, M. C., Dunstan, D. W., Dempsey, P. C., Horton, E. S., Castorino, K., & Tate, D. F. (2016). Physical activity/exercise and diabetes: A position statement of the American Diabetes Association. *Diabetes Care*, 39(11), 2065–2079.
<https://doi.org/10.2337/dc16-1728>
2. Diabetes Control and Complications Trial Research Group. (1993). The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *New England journal of medicine*, 329(14), 977-986.
<https://doi.org/10.1056/NEJM199309303291401>
3. Kalra, A., Jose, A. P., Prabhakaran, P., Kumar, A., Agrawal, A., Roy, A., ... & Prabhakaran, D. (2023). The burgeoning cardiovascular disease epidemic in Indians—perspectives on contextual factors and potential solutions. *The Lancet Regional Health-Southeast Asia*, 12.
<https://doi.org/10.1016/j.lansea.2023.100156>
4. Goldenberg, J. Z., Day, A., Brinkworth, G. D., Sato, J., Yamada, S., Jönsson, T., Beardsley, J., Johnson, J. A., & Thabane, L. (2021). Efficacy and safety of low and very low carbohydrate diets for type 2 diabetes remission: Systematic review and meta-analysis. *BMJ*, 372, m4743.
<https://doi.org/10.1136/bmj.m4743>
5. Gregg, E. W., Chen, H., Wagenknecht, L. E., Clark, J. M., Delahanty, L. M., Bantle, J., Pownall, H., & Look AHEAD Research Group. (2012). Association of an intensive lifestyle intervention with remission of type 2 diabetes. *JAMA*, 308(23), 2489–2496.
<https://doi.org/10.1001/jama.2012.67929>
6. Hallberg, S. J., McKenzie, A. L., Williams, P. T., Bhanpuri, N. H., Peters, A. L., Campbell, W. W., Hazbun, T. L., Volk, B. M., McCarter, J. P., Phinney, S. D., & Volek, J. S. (2018). Effectiveness and safety of a novel care model for the

- management of type 2 diabetes at 1 year: An open-label, non-randomized, controlled study. *Diabetes Therapy*, 9(2), 583–612. <https://doi.org/10.1007/s13300-018-0373-9>
7. Lean, M. E. J., Leslie, W. S., Barnes, A. C., Brosnahan, N., Thom, G., McCombie, L., Peters, C., Zhyzhneuskaya, S., Al-Mrabeh, A., Hollingsworth, K. G., Rodrigues, A. M., Rehackova, L., Adamson, A. J., Sniehotta, F. F., Mathers, J. C., Ross, H., McIlvenna, Y., Stefanetti, R., Trenell, M., ... Taylor, R. (2018). Primary care-led weight management for remission of type 2 diabetes (DiRECT): An open-label, cluster-randomised trial. *The Lancet*, 391(10120), 541–551. [https://doi.org/10.1016/S0140-6736\(17\)33102-1](https://doi.org/10.1016/S0140-6736(17)33102-1)
 8. Anjana, R. M., Sudha, V., Abirami, K., Gayathri, R., Manasa, V. S., Deepa, M., ... & Mohan, V. (2025). Dietary profiles and associated metabolic risk factors in India from the ICMR–INDIAB survey-21. *Nature Medicine*, 31(11), 3813–3824. <https://doi.org/10.1038/s41591-025-03949-4>
 9. Riddle, M. C., Cefalu, W. T., Evans, P. H., Gerstein, H. C., Nauck, M. A., Oh, W. K., Rothberg, A. E., Taylor, R., & Integrated Working Group on Remission of Type 2 Diabetes. (2021). Consensus report: Definition and interpretation of remission in type 2 diabetes. *Diabetes Care*, 44(10), 2438–2444. <https://doi.org/10.2337/dci21-0034>
 10. Simopoulos, A. P. (2010). The omega-6/omega-3 fatty acid ratio: Health implications. *World Review of Nutrition and Dietetics*, 102, 10–22. <https://doi.org/10.1159/000319088>
 11. Lucier J, Mathias PM. Type 1 Diabetes. [Updated 2024 Oct 5]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK507713/?report=classic>
 12. Taylor, R. (2013). Type 2 diabetes: Etiology and reversibility. *Diabetes Care*, 36(4), 1047–1055. <https://doi.org/10.2337/dc12-1805>

13. UK Prospective Diabetes Study (UKPDS) Group. (1998). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). *The Lancet*, 352(9131), 837–853.
[https://doi.org/10.1016/S0140-6736\(98\)07019-6](https://doi.org/10.1016/S0140-6736(98)07019-6)

Diabetes Eating Plan: Food as First-Line, Not Afterthought

A drug-centred approach to diabetes quietly tolerates the same ultra-processed, high-sugar, toxic-fat food environment that created the disease in the first place. A naturopathic, curative approach does the opposite: it **rebuilds the food environment from the ground up**. Medication, if used, becomes a bridge—not the foundation.

Below is a refined, evidence-aligned eating plan that is deliberately strict in the reversal phase, then liberalised as metabolic health improves.

Core “No” Principles (Reversal Phase)

Eliminate Junk Fats and Industrial Oils

This is one of the **central drivers** of insulin resistance and vascular damage.

Avoid completely:

- Trans fats and hydrogenated fats (shortening, many margarines, “vanaspati,” partially hydrogenated oils).
- Deep-fried/fast foods and anything fried in **reused** oil.
- Generic “vegetable oil,” refined soybean, corn, sunflower, safflower, cottonseed oil used for frying.

These fats:

- Promote **systemic inflammation, oxidative stress, and endothelial dysfunction,**

- Are strongly associated with higher risk of cardiovascular disease and mortality (de Souza et al., 2015),
- Worsen the very complications diabetes patients are trying to avoid.

Eliminate Refined “White” Carbs and Added Sugars

Avoid:

- White sugar, jaggery/sugar syrups, confectionery, sugary drinks.
- White flour (maida), white bread, biscuits, most commercial baked goods.
- Regular pasta and most commercial noodles.
- Large portions of potatoes and high-GI starches during the active reversal phase.

Refined carbohydrates:

- Spike blood glucose and insulin,
- Drive **fatty liver, visceral obesity, and β -cell exhaustion**,
- Strongly correlate with type 2 diabetes risk (Bhupathiraju et al., 2014).

Note on “natural” sweeteners:

Even raw honey, coconut sugar, or agave **raise blood glucose** and must be treated as **occasional, small-portion extras**, not “eat as much as you like.” For diabetics in a reversal programme, the safest assumption is: **no free sugars** beyond what comes naturally in whole fruits and vegetables.

Strongly Restrict Animal Products (Especially Red and Processed Meat, Industrial Dairy)

Large cohort studies repeatedly show:

- **Red and processed meats** are linked to higher risk of type 2 diabetes, cardiovascular disease, and mortality (Pan et al., 2011; Micha et al., 2010).
- High intake of **pasteurised, high-fat dairy and cheese** is associated with some cancers and cardiometabolic risk, though fermented dairy and yoghurt are more neutral or slightly protective in some analyses (Gijssbers et al., 2016).

For an intensive diabetes-reversal phase:

- **Avoid completely:**
 - Processed meats (sausages, bacon, kebabs made from processed mince, etc.).
 - Red meat and high-fat industrial dairy (cheese, cream, butter from feedlot systems).
- **Minimise or temporarily exclude** (depending on your programme design and beliefs):
 - Poultry, eggs, and fish—even though evidence for moderate amounts in whole-food diets is more neutral.

A later chapter can outline how to reintroduce **small amounts of high-quality fish, eggs, or fermented dairy** if desired, but the fastest reversal usually happens with a **predominantly or fully whole-food, plant-based diet** (Barnard et al., 2009).

Avoid Ultra-Processed Convenience Foods and “Diabetic” Packaged Products

- “Sugar-free” biscuits, “diabetic” sweets, protein bars, processed snacks, flavoured yoghurts, instant mixes, etc., typically contain **refined starches, seed oils, artificial sweeteners, and emulsifiers**.
- High intake of **ultra-processed foods** is strongly associated with obesity and type 2 diabetes (Monteiro et al., 2019; Srouf et al., 2019).

If it comes in a packet with **more than a few recognisable ingredients**, assume it is not part of a serious reversal programme.

Core “Yes” Principles (Reversal Phase)

Raw and Lightly Cooked Vegetables (Especially Dark Leafy Greens)

Aim for **at least half your plate** at each meal to be vegetables, with a strong bias toward **dark leafy greens**:

- Spinach, methi, mustard greens, kale, amaranth leaves, coriander, dill, drumstick leaves.
- Plus, crucifers and other non-starchy veg: broccoli, cauliflower, cabbage, cucumbers, tomatoes, peppers, radishes, gourds, carrots, beans, etc.

Benefits:

- Low glycaemic load, high fibre.
- Rich in **magnesium, potassium, folate, carotenoids, vitamin K, antioxidants**—all protective for vessels, nerves, eyes, and liver (Carter et al., 2010; Boeing et al., 2012).

Organic is preferable where possible, but quantity and diversity matter most.

Therapeutic Fats and Oils (Used Properly)

To restore **cell-membrane function and insulin sensitivity**, use:

For cooking (moderate heat):

- Unrefined coconut oil, ghee, or small amounts of butter—from grass-fed sources if possible.

For cold use (dressings, finishing):

- Extra-virgin olive oil.
- Cold-pressed flaxseed oil and hemp oil (never heated).

These fats:

- Support a healthier **omega-3 : omega-6** balance,

- Are less prone to oxidation when used correctly (Simopoulos, 2010),
- Improve satiety and help replace junk fats, not add to them.

Whole, Gluten-Free or Sprouted Grains (In Controlled Portions)

For most people with type 2 diabetes, some starchy foods can remain—but must be:

- Whole, **preferably sprouted or minimally processed**, and
- Consumed in **moderate portions**, not as the dominant plate share.

Options:

- **Gluten-free grains:** amaranth, buckwheat, millet, quinoa, sorghum, brown/red rice, wild rice.
- **Sprouted grain products:** sprouted millet, sprouted moong + rice dosas, sprouted multigrain rotis (for those who tolerate wheat).

Keep total carbohydrate load modest, and **test the effect of each grain** on your own blood glucose with a meter/CGM.

Green Smoothies and Shakes

Green smoothies are one of the most efficient ways to deliver therapeutic doses of greens:

- Base: 40–60% **greens** (spinach, kale, methi, coriander) + 40–60% **low-GI fruit** (berries, green apple, guava, unsweetened amla, etc.).
- Optional: **seeds (chia, flax), hemp protein, sprouts.**

For patients with diabetes:

- Limit high-sugar fruits (bananas, mangoes, grapes) especially early in reversal.
- Focus on **volume of greens and fibre**, with fruit only as needed for palatability.

Blending (not juicing) retains fibre, slows absorption, and improves satiety.

Raw Nuts and Seeds

Nuts and seeds are high-fat but **strongly protective**:

- Almonds, walnuts, pistachios, cashews, hazelnuts, pumpkin, sunflower, chia, flax, sesame.
- Unroasted or dry-roasted, **unsalted**, no sugar or frying.
- Regular nut intake is associated with **lower CVD and diabetes risk, better lipids, and no weight gain, often better weight control** (Aune et al., 2016).

Use as:

- Between-meal snacks to replace biscuits and fried namkeen.
- Toppings for salads and smoothies.

Big Salads and Mixed Platters

At least once or twice daily:

Large salad bowls or mixed vegetable platters with:

- Leafy greens + colourful veg + herbs + seeds + a small amount of healthy fat (olive oil, lemon, tahini (ground sesame seeds)).

Can be combined with:

- A portion of **pulses/legumes** (dal, chickpeas, sprouts) for protein and fibre.

These can substitute for **grain-heavy meals**, especially in the evening, thereby improving overnight glucose levels.

Cinnamon as a Functional Spice

Cinnamon (preferably **true cinnamon**, *Cinnamomum verum*) has:

- Polyphenols such as **MHCP-like polymers** that may improve insulin receptor function and **glucose uptake** in cells.
- RCTs and meta-analyses show **modest reductions in fasting glucose** in type 2 diabetes (Allen et al., 2013).

Practical use:

- 1–3 g/day spread across meals (e.g., in smoothies, herbal teas, sprinkled on fruit or yoghurt).
- Avoid megadoses or long-term heavy use of cassia cinnamon (*C. cassia*) due to potential **coumarin-related liver toxicity**.

Microwaves: A Note

Claims that microwaves “destroy 60–90% of the vital-energy field” or that microwaved food uniquely causes cancers and organ failure are **not supported by human clinical evidence**. The main, real concerns with modern cooking are:

- **Overheating and charring** (regardless of method), which create AGEs and oxidised fats.
- **Poor food choices** (ultra-processed, high-sugar, high-fat combinations).

From a naturopathic standpoint, the priority is to:

- Minimise **any high-temperature, high-dry-heat cooking** (grilling, deep-frying, repeated reheating),
- Prefer steaming, light sautéing, and raw dishes,
- Focus on **food quality and pattern** more than the specific appliance.

Putting It Together: A Day on the Diabetes-Reversal Eating Plan

Morning

- Large green smoothie (mostly greens + small amount of low-GI fruit + seeds).
- Handful of nuts/seeds if needed.

Midday

- Big salad (leafy greens, mixed veg, sprouts, seeds) with olive or flax/hemp oil.
- Portion of dal/chickpeas or sprouted grain for protein/carbs if appropriate.

Evening

- Non-starchy vegetable curry or stir-fry cooked in coconut oil/ghee, with a small portion of gluten-free/sprouted grain if tolerated.
- Raw or lightly cooked greens on the side.

Throughout the day

- Herbal teas, water, unsweetened beverages.
- Cinnamon, herbs, and spices liberally.
- Nuts/seeds as snacks instead of processed foods.

This pattern is **aggressive by design**. It is the nutritional equivalent of an intensive drug regimen—but aimed at *remission*, not perpetual “control.”

In subsequent chapters, we will show how to phase this eating plan into real life, how to personalise carbohydrate and fat levels, and how to coordinate dietary change with de-prescribing of medications so that blood sugar normalisation actually means healing, not just more pills.

References:

- Allen, R. W., Schwartzman, E., Baker, W. L., Coleman, C. I., & Phung, O. J. (2013). Cinnamon use in type 2 diabetes: An updated systematic review and meta-analysis. *Annals of Family Medicine*, 11(5), 452–459.
<https://doi.org/10.1370/afm.1517>
- Aune, D., Keum, N., Giovannucci, E., Fadnes, L. T., Boffetta, P., Greenwood, D. C., Tonstad, S., Vatten, L. J., Riboli, E., & Norat, T. (2016). Nut consumption and risk of cardiovascular disease, total cancer, all-cause and cause-specific mortality: A systematic review and dose-response meta-analysis of prospective studies. *BMC Medicine*, 14, 207. <https://doi.org/10.1186/s12916-016-0730-3>
- Barnard, N. D., Cohen, J., Jenkins, D. J. A., Turner-McGrievy, G., Gloede, L., Jaster, B., Seidl, K., Green, A. A., & Talpers, S. (2009). A low-fat vegan diet and a conventional diabetes diet in the treatment of type 2 diabetes: A randomized, controlled, 74-week clinical trial. *American Journal of Clinical Nutrition*, 89(5), 1588S–1596S.
<https://doi.org/10.3945/ajcn.2009.26736H>
- Bhupathiraju, S. N., Tobias, D. K., Malik, V. S., Pan, A., Hruby, A., Manson, J. E., Willett, W. C., & Hu, F. B. (2014). Glycemic index, glycemic load, and risk of type 2 diabetes: Results from 3 large US cohorts and an updated meta-analysis. *American Journal of Clinical Nutrition*, 100(1), 218–232. <https://doi.org/10.3945/ajcn.113.079533>
- Boeing, H., Bechthold, A., Bub, A., Ellinger, S., Haller, D., Kroke, A., Leschik-Bonnet, E., Müller, M. J., Oberritter, H., Schulze, M., Stehle, P., & Watzl, B. (2012). Critical review: Vegetables and fruit in the prevention of chronic diseases. *European Journal of Nutrition*, 51(6), 637–663.
<https://doi.org/10.1007/s00394-012-0380-y>

- Carter, P., Gray, L. J., Troughton, J., Khunti, K., & Davies, M. J. (2010). Fruit and vegetable intake and incidence of type 2 diabetes mellitus: Systematic review and meta-analysis. *BMJ*, 341, c4229. <https://doi.org/10.1136/bmj.c4229>
- de Souza, R. J., Mente, A., Maroleanu, A., Cozma, A. I., Ha, V., Kishibe, T., Uleryk, E., Budylowski, P., Schünemann, H., Beyene, J., & Anand, S. S. (2015). Intake of saturated and trans unsaturated fatty acids and risk of all-cause mortality, cardiovascular disease, and type 2 diabetes: Systematic review and meta-analysis of observational studies. *BMJ*, 351, h3978. <https://doi.org/10.1136/bmj.h3978>
- Gijssbers, L., Ding, E. L., Malik, V. S., de Goede, J., Geleijnse, J. M., & Soedamah-Muthu, S. S. (2016). Consumption of dairy foods and diabetes incidence: A dose–response meta-analysis of observational studies. *American Journal of Clinical Nutrition*, 103(4), 1111–1124. <https://doi.org/10.3945/ajcn.115.123216>
- Micha, R., Wallace, S. K., & Mozaffarian, D. (2010). Red and processed meat consumption and risk of incident coronary heart disease, stroke, and diabetes mellitus: A systematic review and meta-analysis. *Circulation*, 121(21), 2271–2283. <https://doi.org/10.1161/CIRCULATIONAHA.109.924977>
- Monteiro, C. A., Cannon, G., Levy, R. B., Moubarac, J.-C., Louzada, M. L. C., Rauber, F., Khandpur, N., Cediël, G., Neri, D., Martinez-Steele, E., Baraldi, L. G., & Jaime, P. C. (2019). Ultra-processed foods: What they are and how to identify them. *Public Health Nutrition*, 22(5), 936–941. <https://doi.org/10.1017/S1368980018003762>
- Pan, A., Sun, Q., Bernstein, A. M., Schulze, M. B., Manson, J. E., Willett, W. C., & Hu, F. B. (2011). Red meat consumption and risk of type 2 diabetes: 3 cohorts of US adults and an updated meta-analysis. *American Journal of*

Clinical Nutrition, 94(4), 1088–1096.

<https://doi.org/10.3945/ajcn.111.018978>

- Simopoulos, A. P. (2010). The omega-6/omega-3 fatty acid ratio: health implications. *Oléagineux, Corps gras, Lipides*, 17(5), 267-275.
- Srour, B., Fezeu, L. K., Kesse-Guyot, E., Allès, B., Méjean, C., Andrianasolo, R. M., Chazelas, E., Deschasaux, M., Hercberg, S., Galan, P., Monteiro, C. A., Julia, C., & Touvier, M. (2019). Ultra-processed food intake and risk of type 2 diabetes: Results from the NutriNet-Santé prospective cohort. *JAMA Internal Medicine*, 180(2), 283–291.
<https://doi.org/10.1001/jamainternmed.2019.5942>

The Diabetes Protocol: Naturopathic Framework

This protocol is designed as an intensive, time-limited intervention to reverse insulin resistance, normalise blood glucose, and reduce medication burden wherever medically possible. It must be implemented under professional supervision, especially if you are on insulin or oral hypoglycaemic drugs, because requirements can fall rapidly.

Food: Daily, Non-Negotiable Foundations

At Least 50% Raw Plant Foods

- Make **half of everything you eat** raw or very lightly cooked **vegetables and low-GI fruits**.
- Prioritise dark leafy greens (spinach, methi, mustard greens, kale), crucifers (broccoli, cabbage, cauliflower), cucumbers, peppers, radishes, sprouts, herbs.

Benefits:

- High **fibre** → slows glucose absorption, feeds gut microbiota.
- Dense in **magnesium, potassium, folate, carotenoids, vitamin C, K, antioxidants** → supports insulin sensitivity, vascular and nerve protection.

Green Smoothies – At Least One Daily

- Blend **greens + small amount of low-GI fruit + seeds** (e.g., chia, flax, hemp).

- Example: spinach + coriander + cucumber + ½ green apple + chia.

Why:

- High volume of greens in a **palatable, easily digested form**.
- Retains fibre (unlike juice), moderates glycaemic response, and supplies phytonutrients.

Baking Soda

- The proposed mixture: 1 tsp baking soda in hot water, then diluted with cool water and taken on an empty stomach.

Caveats:

- While systemic acid–base balance is tightly regulated by the kidneys and lungs, **small amounts of sodium bicarbonate** can relieve dyspepsia or support exercise in specific cases.
- In diabetes, especially with hypertension or kidney disease, **sodium load must be considered**.
- This is **not essential** for reversal and should only be used under clinical guidance.

Focus first on alkalinising the body through **vegetable-rich, low-sugar eating**, not through chronic bicarbonate use.

Healing Practices: Daily and Monthly

Exercise

- Minimum: **15–30 minutes brisk walking outdoors daily**, preferably **after meals**.
- Aim toward at least **150 minutes/week** of moderate exercise plus resistance training 2–3×/week.

Post-meal movement:

- Reduces **post-prandial glucose spikes**,
- Improves insulin sensitivity and cardiovascular fitness.

Oil Pulling

- Swishing oil (e.g., coconut or sesame) in the mouth for 5–20 minutes, then spitting it out.

Benefits:

- May improve **oral health and reduce oral bacterial load**, indirectly supporting systemic inflammation, which is relevant in diabetes.
- Use as a **supportive detox ritual**.

Fasting

- Options:
 - **Time-restricted eating** (e.g., 10–12-hour eating window).
 - Occasional **24-hour water fast** for experienced, stable individuals.

Benefits:

- Reduces **insulin levels and liver fat**,
- Enhances **autophagy and metabolic flexibility**.

Always:

- Coordinate fasting with medication (if on any) adjustments to **avoid hypoglycaemia**, especially on insulin or sulfonylureas.

Sunshine

- Target: **10–20 minutes of direct sun exposure daily** on as much skin as culturally and practically acceptable.
- Avoid glass barriers; UVB is blocked by glass.

Benefits:

- Supports endogenous **vitamin D synthesis**, mood, and circadian alignment.

Sauna (If Available)

- Once weekly (or as tolerated) **infrared or traditional sauna**.

Benefits:

- Supports **sweat-mediated excretion** of some xenobiotics and heavy metals.
- May improve **vascular function and blood pressure** when combined with hydration and electrolyte balance.

Supplements (Distributed Across the Day)

These are adjuncts to, not replacements for, food and lifestyle. Doses are intensive and should be individualised.

1. Green Superfood Powder

- 1 scoop in a smoothie daily to boost phytonutrient and mineral intake.

2. Vitamin C – 1–5 g/day (ascorbic acid)

- Split doses; consider lower end if prone to GI upset or kidney stones.
- L-lysine and L-proline can be added to support **vascular collagen**.

3. Vitamin E – ~800 IU/day

- Prefer **mixed tocopherols/tocotrienols**; monitor if on anticoagulants.

4. Vitamin D3 – ~6000 IU/day

- Adjust to maintain **25(OH)D ~40–60 ng/mL**, with lab monitoring.

5. Vitamin B12 – 1000 mcg/day

- Especially critical for those on **metformin** or with plant-based diets.

6. Chromium (ionic) – 250 mcg/day

- Supports **insulin signalling**; avoid exceeding ~1000 mcg/day cumulatively.

7. **Vanadium (ionic)** – 250 mcg/day
 - Mild insulin-mimetic; use cautiously and always under supervision.
8. **Digestive Enzymes**
 - Per product instructions, with meals to aid digestion and nutrient uptake.
9. **Zinc** – 50 mg/day
 - Take with food; add **copper** if using long term to avoid depletion.
10. **B-Complex**
 - Once or twice daily to support **energy metabolism, nerve health, and homocysteine metabolism.**
11. **Bioflavonoids (incl. Quercetin)** – ~150 mg/day
 - Antioxidant and endothelial support; combine with vitamin C.
12. **Borage Oil** – 1000 mg, 3×/day
 - Source of **GLA**; choose PA-free products; supports neuropathy and inflammation.
13. **Iodine (Lugol's/Iodoral)** – ~2 drops/day in water
 - Only with thyroid monitoring; co-supplement vitamin C, selenium, magnesium.
14. **Cinnamon** – up to 5 g/day
 - Divide across meals; prefer **C. verum**; adjust for GI tolerance and coumarin exposure.
15. **MSM** – 5–10 g/day
 - Split doses; supports sulphur pools, connective tissue, and detoxification.
16. **Herbal Blend - Powder**
 - Contains **cinnamon, Terminalia arjuna, Andrographis paniculata, Tribulus terrestris, etc.**

- Use as per dosing guidelines; these herbs support **glycaemia, lipids, cardiovascular and hepatic function** and have been discussed in the herbal chapter.

How to Use This Protocol Clinically

Baseline Assessment

- HbA1c, fasting and post-prandial glucose, lipid profile, liver/kidney function, 25(OH)D, B12, TSH, medications, complications (eyes, kidneys, nerves, heart).

Initiation (First 2–4 Weeks)

- Implement food and movement changes.
- Begin key supplements (D3, B12, magnesium, zinc, chromium, green powder, omega-3/GLA).
- **Intensify glucose monitoring** and start medication tapering where indicated.

Consolidation (Months 2–6)

- Increase raw plant intake, refine green smoothie use, integrate fasting carefully.
- Optimise nutraceutical and herbal regimen.
- Continue stepwise **de-prescribing** as HbA1c and CGM profiles improve.

Maintenance and Fine-Tuning (After 6 Months)

- Once stable HbA1c (<6.5% without medications, if achievable) and improved body composition are reached, **liberalise diet modestly** while preserving core principles.
- Reassess the need for high-dose supplements; maintain a **core set** (e.g., D3, B12, magnesium, omega-3, zinc) long term.

This protocol is deliberately more intensive than standard care because its goal is not simply to manage numbers but to **rebuild metabolic resilience and, where biology allows, achieve remission.**

30 Day Diabetes Protocol— Take the Challenge

This 30-day protocol is written as an **activity-based learning challenge** for readers who want to experience, in their own bodies, how aggressively applied naturopathic principles can change blood sugar, energy, and medication needs. It is not a substitute for medical care. If you are on insulin or oral diabetes drugs, you must work with your clinician to adjust doses as your numbers improve.

Think of this as a **30-day experiment**, not a promise of cure. Many people will see dramatic improvements; some may reach remission; others will need longer. The point is to **engage fully and observe**.

Ground Rules for the 30 Days

Commit to the Experiment

- Treat these 30 days as **laboratory time**.
- Track **fasting and post-meal glucose** daily, and keep a simple journal: foods, movement, sleep, symptoms, mood.
- Coordinate with your doctor, especially if you're on **insulin or sulfonylureas**—medications may need to be reduced quickly as carbs fall.

Safety First

- Do **not** stop prescribed medications abruptly.
- If fasting glucose routinely drops below ~80 mg/dL (4.4 mmol/L) or you experience hypo symptoms, contact your clinician promptly.

- If you have kidney, heart, or severe GI conditions, some elements (fasting, sauna, colon hydrotherapy, high-dose supplements) may need to be modified or skipped.

Food Challenge: 30 Days of Raw-Centred Eating

For 30 days, the core experiment is **radical simplification**: remove metabolic noise so the body can reset.

100% Raw, Whole Plant Foods (Reversal Intensive Phase)

For this 30-day challenge:

- All foods are **raw, uncooked, and unprocessed** (or minimally processed, like cold-pressed oils).
- Allowed categories:
 - Fresh fruits (emphasise low–moderate GI, watch portions if glucose remains high).
 - Fresh vegetables (especially leafy greens and non-starchy veg).
 - Green smoothies (greens + modest fruit + seeds).
 - Raw nuts and seeds.
 - Sprouted grains and legumes.
 - Dehydrated fruits/veg (no added sugar/oil).

Avoid completely:

- All meats and eggs.
- All flour products, breads, baked goods, pastas, crackers.
- All pasteurised dairy.
- All cooked, fried, or packaged/ultra-processed foods.

This is intentionally strict. After 30 days, a more flexible, sustainable pattern can be crafted.

Daily Therapeutic Practices

Design a **daily checklist** you can literally tick off:

Movement — Minimum 30 Minutes

- Choose any combination: brisk walk, light jog, cycling, yoga, gym, sports.
- At least **10–15 minutes after the largest meal** whenever possible to blunt glucose spikes.

Activity task:

- Log what you did, for how long, and your pre- and post-activity glucose (if using a meter or CGM).

Green Smoothie — At Least One per Day

- Blend 40–60% greens (spinach, kale, methi, coriander) + 40–60% low-GI fruit + seeds (chia/flax/hemp).
- Drink slowly, ideally earlier in the day.

Activity task:

- Each day, write down:
 - Which greens you used,
 - Which fruits,
 - How your energy and hunger felt 2–3 hours later.

Hydration and Baking Soda

- Start the day with 200–500 mL warm water.
- The suggested baking soda drink (1 tsp in hot, then cooled water) is optional and should not be used if you have kidney, heart, or hypertension issues without medical oversight.
- Focus primarily on **2–3 L/day of plain water and herbal teas**.

Weekly Fasting (Advanced Learners)

Once per week (if medically appropriate and supervised):

- Either:
 - A **24-hour water fast**, or

- A **green-smoothie/vegetable-juice-only day** (no fruit juices).

Activity task:

- Record hunger, mood, glucose trends, and how you break the fast (first meal after).

Sunshine and Sauna

- **Sunshine:** Aim for ~15 minutes/day on uncovered skin (avoid burning; no glass barriers).
- **Sauna:** Up to 2×/week if available and tolerated; hydrate well.

Activity task:

- Note how your sleep, mood, and joint pain respond across the month.

Rebounder and Lymph Flow

- 5–10 minutes/day of gentle bouncing on a mini-trampoline, or equivalent low-impact movement (skipping, dancing).

Focus: **joyful movement**, not performance.

Colon Hydrotherapy / Enemas

- These are **advanced detox tools**, not mandatory.
- If used, work with a qualified practitioner; monitor for dehydration/electrolyte changes.
- For most readers, focusing on **raw fibre, hydration, and movement** will be more than enough for this 30-day experiment.

30-Day Sample Daily Routine (Activity Map)

Morning

1. Hydrate

- 200–500 mL warm water (with or without a small pinch of baking soda, if cleared).
- 2. Green Smoothie + Core Supplements**
 - Green smoothie with a scoop of green superfood powder.
 - Take:
 - Vitamin C (e.g., 3 g split over day),
 - Vitamin B12,
 - B-complex,
 - A portion of cinnamon if using.
 - 3. Breakfast (1 hour later)**
 - Raw fruits, vegetables, nuts, seeds, sprouts.
 - Take chromium, vanadium, MSM (as tolerated), and digestive enzymes if using.
 - Take Vitamin D3 (portion of daily dose),
 - 4. Activity task:**
 - Check and write down fasting glucose and 1–2h post-smoothie/post-breakfast glucose.

Midday (Lunch)

- 1. Supplements**
 - MSM dose, borage oil, herbal mix powder, zinc, bioflavonoids, enzymes.
- 2. Big Salad**
 - Large mixed greens + vegetables + sprouts + seeds + olive/flax/hemp oil + herbs/spices + sea salt.
- 3. Iodine + Vitamin C**
 - 2 drops iodine in water (if appropriate), +/- vitamin C.
- 4. Movement**
 - 10–20-minute post-meal walk.

Evening (Dinner)

1. Herbal Mix Powder

- e.g., prescribed herbal formula, 20 minutes before eating.

2. Meal

- Big salad or another green smoothie; raw nuts/seeds if needed.

3. Supplements

- Take magnesium, vitamin C, vitamin E, borage oil as planned.

4. Reflection

- Brief note: energy, mood, cravings, glucose, bowel movements.

Snacks (Any Time)

- Raw fruits, vegetables, nuts, seeds, unsweetened dried fruits (moderation), as needed.
- Avoid constant grazing; give the body windows without food.

Dealing with “Healing Reactions” (Herxheimer-like Responses)

As diet and lifestyle change, some people experience:

- Headaches, fatigue, skin eruptions, flu-like symptoms, bowel changes, mood swings.

These may reflect **withdrawal from sugar/caffeine**, microbiome shifts, or simple adjustment stress—not necessarily “toxins leaving,” but real physiological change.

If symptoms are intense:

- **Slow down**, don’t double down.
- Emphasise:
 - Hydration (2–3 L/day),

- Simple raw foods (greens, cucumber, lightly sweet fruits),
- Green smoothies and herbal support,
- Gentle walking,
- Shorter sauna sessions if tolerated.
- Avoid:
 - Enemas or colon treatments if very weak/dehydrated.
 - Over-fasting when already unstable.

Resume the full protocol when you feel steadier. If symptoms are severe or persistent, consult a clinician.

If You Can't Access All Supplements or Therapies

The **core drivers of improvement** are:

- The **food pattern** (high raw, low-GI, unprocessed, no refined sugars/flours/industrial oils).
- **Movement, sleep, sunshine, and stress reduction.**

If you cannot source every supplement or herbal mix:

- Do the protocol with **what you have**—you will still see results.
- View nutraceuticals as **accelerators, not absolute requirements.**

Learning Outcomes for the Reader

By the end of 30 days, if you've engaged fully and tracked your data, you should be able to:

- Describe how **your own glucose profile** responds to raw, plant-rich eating and movement.
- Recognise the difference between **true hunger and habitual cravings.**
- Identify which foods and practices most strongly stabilise or destabilise your readings.

- Bring **structured, lived experience** to discussions with your healthcare team about reducing medication and building a long-term plan.

This is activity-based learning at its most radical: the laboratory is your body; the outcome is your health.

Epilogue

Health is not the absence of disease; it is the steady return of your body to the conditions in which it knows how to thrive.

Remember that you are always on a **health–disease continuum**.

Where you stand on that line depends, to a profound degree, on **you and your lifestyle**—on what you eat, how you move, how you sleep, how you manage stress, and what you allow into your environment.

If this book has offered you anything, let it be this conviction:
diabetes is not simply managed in a prescription pad; it is transformed at your table, in your kitchen, in your sleep, in your breath, and in the way you live each ordinary day.

May you use what you have read here to ask better questions, to challenge habits that no longer serve, and to build care plans that do more than control numbers—plans that restore strength, clarity, and joy.

The work ahead is demanding, but it is also simple:
less of what injures, more of what heals.
Walk that line with patience and courage, and the body will do the rest.
